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ABSTRACT 
Background: Post-discharge Medicines Use Reviews (dMURs) were introduced into the 
English community pharmacy contract in 2011, with the aim of improving understanding and 
use of medication by patients who have experienced changes to their medicines in hospital.  
Early evidence showed uptake of dMURs to be poor.  Furthermore, despite being a 
nationally commissioned service, there is little evidence of the benefit of dMURs to patients. 
In light of the documented medication problems that occur in older people on transfer of 
care, a randomised controlled feasibility study was devised to investigate the feasibility and 
potential outcomes of a transitional care service for older patients which utilises community 
pharmacists via the dMUR service 
 
Methods: Hospital pharmacists identified in-patients aged over 65 years who could 
potentially benefit from a dMUR.   Participants were randomised to be referred for a dMUR 
with their usual community pharmacist or to receive standard discharge care.   
 
Results and Contribution: This study is the first to report on patient outcomes following 
dMUR referrals.  Through interventions made by community pharmacists, referrals may 
provide a 4-fold return on investment to the NHS in terms of improved quality of care.  
There were trends towards a shorter length of stay on readmission and reduction in A&E 
visits in the months following dMUR, and they may also prevent medication related 
admissions and deterioration in medication adherence and physical health over time.  
However this work revealed significant challenges in providing dMUR referral services to 
older patients.  Being housebound due to poor mobility or health is a major barrier, due to 
difficulties experienced by community pharmacists with providing domiciliary dMURs.   
Carer management of medication is another.  It is proposed that the provision of 
domiciliary dMURs should be facilitated by simplifying and clarifying the process for 
community pharmacists.  Proxy dMURs with carers should be allowed in certain cases.   
Another key proposal is that the dMUR service should be re-designed to involve at least 
two parts.  Remuneration should reflect the complexity and time needed for dMURs 
compared to ‘standard’ MURs.  
Lack of time of hospital pharmacists is a barrier to recruiting appropriate patients for dMUR 
referral and making good quality referrals.  Electronic referral from hospital to community 
pharmacy may assist and should be implemented more widely.  It is also suggested that 
hospital pharmacies should be remunerated for making referrals.    
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CHAPTER 1: INTRODUCTION 
In recent years there has been increased recognition of the problems faced by 
older people on discharge from hospital, including those related to medication (1-
8).  In late 2011, I had been a qualified pharmacist for four years and, having 
recently completed my post-graduate diploma in clinical pharmacy, was working on 
the care of the elderly ward and the emergency admissions unit at Southport 
District General Hospital.  I became frustrated by the frequency with which I saw 
recently discharged, elderly patients re-admitted without the changes to their 
medication from the original admission having been enacted properly or followed 
up in the community.   
At this time, post-discharge Medicines Use Reviews (dMURs) had recently been 
introduced into the English national community pharmacy contract, with the aim of 
improving the understanding and use of medication by patients who had 
experienced changes to their medicines in hospital (9).   Shortly after this, the 
Royal Pharmaceutical Society (RPS) early implementer sites for medicines related 
transfer of care were established.  Early feedback from these sites showed minimal 
uptake of dMURs, even after signposting by hospitals (10).  Furthermore, despite 
being a nationally commissioned service, there was no evidence of the benefit of 
such reviews to patients.  In fact, previous research on the role of pharmacists in 
transitional care generally has shown inconsistent effects on outcomes and at the 
time there was little published research on the contribution community pharmacists 
could make (11).  I therefore became determined to set up a service that would 
refer patients directly to their nominated community pharmacist for a dMUR, and to 
evaluate this service in terms of both its feasibility and the potential benefits on 
specific patient orientated outcomes.   
Overall Aim of thesis: To investigate the feasibility and potential outcomes of a 
transitional care service for older patients which utilises community pharmacists via 
the dMUR service 
My specialism in care of the elderly led me to focus my research on older patients, 
as I was acutely aware of the potential for medication related problems in this 
group.  These problems are related not only to the polypharmacy which has 
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become an inevitable consequence of the prevalence of multiple long-term 
conditions in the older population, but the changes in the ability of the aging body 
to handle many medications, and the impact of changes in manual dexterity, visual 
acuity, mobility and cognition, on the day-to-day management of medicines by a 
larger proportion of older people then in the general population (12,13). 
Despite having taken over seven years to complete, the work represented in this 
thesis is as important now as it was when it began.  Over this period of time, many 
relevant primary research reports, review articles and national policy documents 
and guidelines have been published.  Indeed, the findings in this thesis have 
already resulted in the publication of three papers in peer reviewed journals, which 
themselves form part of the current pool of knowledge on the subject of medicines 
related transfer of care: 
Ramsbottom HF, Fitzpatrick R, Rutter P. Post discharge medicines use review 
service for older patients: recruitment issues in a feasibility study. International 
Journal of Clinical Pharmacy 2016 Apr;38(2):208-212. 
Rutter P, Ramsbottom H, Fitzpatrick R. Community pharmacist perceptions of 
delivering post-hospital discharge Medicines Use Reviews for elderly patients. 
International Journal of Clinical Pharmacy 2017 Feb;39(1):33-36. 
Ramsbottom H, Rutter P, Fitzpatrick R. Post discharge medicines use review 
(dMUR) service for older patients: Cost-savings from community pharmacist 
interventions. Research In Social & Administrative Pharmacy 2018 
February;14(2):203-206.  
In terms of current health policy, this thesis focuses closely on the aims of the 2014 
government document Transforming Primary Care, part of a national strategy to 
provide proactive, joined-up care for older people, co-ordinating services and 
providing proactive follow-up support on discharge (14).  Many of the themes 
explored within this thesis also receive special mention in the 2018 government 
document Prevention is Better than Cure and the 2019 NHS Long Term Plan, the 
latter published only weeks before this thesis was submitted for examination 
(15,16).  These include the need to make greater use of community pharmacists’ 
skills, to better support patients to take control of their own care and get the best 
from their medicines and to reduce delayed discharges from hospital.  These 
documents include a special focus on the aging population, reiterating that people 
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are living longer now than ever before, but that these extra years are not always 
spent in good health.  The need to improve the support given to carers of older 
people is mentioned specifically in the Long Term Plan, which is also a finding of 
this thesis. 
Other projects are being undertaken around the UK to improve the transfer of 
medicines related discharge information to community pharmacies and increase 
the uptake of dMURs.  This PhD study was ongoing at the same time as several of 
these were being implemented and/or evaluated, including electronic referral 
systems in East Lancashire, North-East England and Wessex and the Welsh 
Discharge Medicines Review (DMR) service (17-20).  However the findings 
contained within this thesis make a unique contribution to this body of work, 
through the focus on patient experience and outcomes, laying a foundation for 
future service improvements and evaluation.  
The chapters to follow start with a contextual Chapter 2, which defines the target 
population for this research in more detail and provides a background to the 
problem this work addresses.  Chapter 3 then discusses the specific problems that 
can occur with medicines when older people are discharged from hospital, why 
they happen and their consequences.  The need for mechanisms to improve 
medicines related transfer of care in the elderly is identified and some possible 
mechanisms to achieve this are introduced.  This is followed by the formal 
literature review, Chapter 4, which defines previous and ongoing research into 
interventions that support medicines related transfer of care for older people 
discharged from hospital, either led by or involving pharmacists.  Methodological 
considerations, including the rationale behind selecting a mixed methods 
approach, potential study designs, operational aspects and ethical considerations 
are discussed in Chapter 5, before the final methods chosen for recruitment, data 
collection and analysis are presented in Chapter 6.  Chapter 7 presents the results 
of the data collected during this PhD project, relating both to process measures 
and participant outcomes.  These are then discussed in the context of other recent 
and ongoing research and national health policy in Chapter 8.  Chapter 9 presents 
the conclusions of this thesis, the implications of which are embodied in the 
recommendations for both research and practice in Chapter 10.  
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CHAPTER 2: CONTEXT 
This chapter defines the target population for this research and provides a 
background to the problem it addresses.  The changing demographics of the 
United Kingdom (UK)’s population and the increasing ‘medicalisation’ of healthcare 
are placing significant demands on the country’s health and social care systems.  
Consequences such as medication errors and emergency hospital admissions are 
more common in older people and contribute to an increasing pressure on hospital 
beds.  This has led to a national drive towards increased collaboration between 
secondary and primary care, and supporting people to self-care and stay well in 
the community following discharge from hospital.  The role the pharmacy 
profession can play in this integrated care is under-developed and this highlights a 
gap for evidence based services to be introduced to support medicines-related 
transitional care of older people. 
 
2.1 WHAT CONSTITUTES OLD AGE? 
For over a century, the chronological age of 65 years has been accepted as a 
definition of an 'elderly' or older person in developed countries.  This somewhat 
arbitrary value is often associated with the age at which one can begin to receive 
pension benefits (21). However, with advances in medical and health science 
during the late 20th and early 21st centuries, the average population lifespan has 
increased rapidly.  The increasing life expectancy across the Western world has 
led to a recognition that there may be a need to re-define what constitutes old age 
(22).  
To add further complexity to the challenge of defining who is elderly, the use of a 
calendar age to mark the threshold of old age assumes that this is equivalent to 
biological age.  However, it is now generally accepted that these two are not 
necessarily synonymous (21,22).  The ageing process is not uniform across the 
population due to differences in genetics, lifestyle, and overall health (22).  In 1975, 
Norman Ryder was the first to use the concept of remaining life expectancy, rather 
than years lived, to re-consider the measurement of old age, selecting the arbitrary 
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period of 10 years of remaining life expectancy to define the point of entry into old 
age (23).   
More recently, the concept of frailty, a distinctive health state related to the ageing 
process in which multiple body systems gradually lose their in-built reserves, has 
emerged (24).  An older person living with frailty is at a higher risk of a sudden 
deterioration in their physical and mental health.  The British Geriatrics Society 
(BGS) reports that around 10% of people aged over 65 years have frailty, rising to 
between a quarter and a half of those aged over 85 years (24). 
Taking all this into account, it is not surprising that both researchers and various 
national organisations such as the Office for National Statistics, the Health and 
Social Care Information Centre (HSCIC), the National Health Service (NHS) and 
the DoH use different age values in publications and policy when discussing older 
people.  This makes it difficult to compare data from different publications.  For 
example, when discussing prescription medication use, figures are presented for 
those aged below 60 and for those aged 60 years and over, as 60 is the age at 
which a person becomes eligible for free NHS prescriptions.  Figures for other 
statistics, such as population demographics and hospital admissions, commonly 
use two ‘age-bands’ for older people, differentiating those aged between 65 and 84 
from those aged 85+, although there are sometimes differences in the ranges 
used.  The definition of an older or elderly person in the academic research 
reviewed in this thesis also varied. 
A review of 20 Australian clinical practice guidelines relating to the use of 
pharmacotherapy found that three guidelines defined ‘elderly’ using chronological 
age, with two defining ‘elderly’ as being 65 years or older and one using the age of 
75 years or more. The remaining 17 guidelines did not define ‘elderly’ by any 
specific measure (25).  In England and Wales, the latest National Institute for 
Health and Care Excellence (NICE) guidelines for Hypertension, and for 
Cardiovascular Disease: Risk Assessment and Reduction, recommend different 
approaches to care for people aged 80 or 85 and over, respectively (26,27).  NICE 
has, however, started to recognise the heterogeneity of the older population.  For 
example NICE CG181 states that patient preference, co-morbidities, 
polypharmacy, general frailty and life expectancy should be taken into account 
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when making treatment decisions regarding lipid lowering therapy, as well as 
chronological age (27).   
As no one definition of old age exists, the decision was made that, for the purposes 
of the work presented in this thesis, the most established convention of age 65 
would be used as the cut-off for defining a person as ‘older’.  This may be a slightly 
conservative definition in today’s society, but if not elderly, it may still be assumed 
that the majority of this population are at least ‘approaching’ old age.  Providing 
support for medication use at this stage may therefore establish behaviours which 
will endure and remain with the person as they make the transition into ‘old age’ or 
‘frailty’, possibly even delaying the point at which the transition occurs. 
 
2.2: THE CHANGING DEMOGRAPHICS OF THE UK POPULATION 
The UK has an ageing population.  In 2012 there were over 7.8 million people in 
England aged between 65 and 84; by 2032 this number is set to increase by 39% 
to 10.9 million.  The population aged 85+ is predicted to more than double, from 
1.3 million to 2.6 million (28).  This compares to an increase of 11% in the 
population aged 0-14, (from 9.3 million to 10.4 million) and just 7% in those aged 
15-64 (from 34.7 million to 37.2 million) (28).  The old age dependency ratio (the 
number of people over the national state pension age (SPA) for every 1000 people 
of working age) rose from 230 per 1000 in 1971 to 314 per 1000 in 2009, and is 
likely to continue to rise over the next 20 years.  By 2037 there is expected to be 
349 people over the SPA for every 1000 people of working age.  This means that 
there will be fewer people of working age to support the population over the SPA 
(28,29).  
These changes can be attributed both to ageing of the large number of people born 
during the post 2nd World War baby boom, and increasing life expectancy 
compared to previous generations (28,29).  A boy born in the UK in 1981 could 
expect to live 84.6 years on average.  For a boy born in 2017, the figure is 90.8 
years and, based on current assumptions, by 2037 it is projected to be 93.6 years.  
Similarly, a girl born in 1981 could expect to live 88.3 years on average, rising to 
93.6 years for those born in 2017 and, 96.3 years for those born in 2037 (29).   
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However, healthy life expectancy is not increasing as quickly; although people are 
living longer, they are not necessarily living these extra years in better health, 
resulting in proportionately greater demands on health systems including the NHS 
(15,29-32).     
Whilst the population aged 85 and over grew by 68% between 1990 and 2010, the 
number of non-elective hospital admissions for this age group increased by 189% 
(28).  With further increases expected in population within this age group during the 
next fifteen years, hospital workload seems likely to increase further. 
Given the above, it is not surprising that the costs of health and social care are 
significantly greater for older people (28).  
 
2.3 THE INCREASING MEDICALISATION OF HEALTHCARE 
‘Long-term conditions’ (LTC) or ‘chronic diseases’ are conditions for which there is 
currently no cure, which are managed with medicines and other treatment, for 
example diabetes, chronic obstructive pulmonary disease (COPD), depression and 
hypertension (33).  The prevalence of LTC is increasing; in 2012 the DoH 
estimated that around 15 million people in England were living with a long-term 
condition, accounting for 70% of the NHS budget (33).  In October 2014, the Five-
Year Forward View (5YFV), NHS England’s five year strategy for the NHS, stated 
that growing demand, if met by no further annual efficiencies and flat real terms 
funding, would produce a mismatch between resources and patient needs of nearly 
£30 billion a year by 2020/21 (32).   
The increasing prevalence of LTC is at least partly due to improvements in 
technology, transforming our ability to predict and diagnose disease, thereby 
leading to the earlier recognition of LTC, as well as the introduction of new clinical 
guidelines for their treatment (31-34).  However, two key risk factors for developing 
a long-term condition are ageing and lifestyle (32).  Given that ageing of the 
population is inevitable, the 5YFV stated that the sustainability of the NHS and the 
economic prosperity of Britain depended on a radical upgrade in prevention and 
public health, and the engagement of the public to tackle risk factors for poor 
health (32).  This was reinforced in November 2018 by the publication of the 
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government policy paper Prevention is Better than Cure, which emphasised the 
need to support everyone to manage their health issues earlier and more 
effectively (15). 
Notwithstanding the push towards lifestyle changes to prevent or delay the 
progression of chronic disease, once developed, many LTC are almost exclusively 
managed with medication.  It is therefore not surprising that prescribing rates 
continue to rise, with prescribing a medication being the most common intervention 
in the NHS.  For example, in 2015, just over 1 billion prescription items were 
dispensed by community pharmacies in England, representing a 50% increase in 
the 10 years since 2005 (31).  
The Quality and Outcomes Framework, the annual reward and incentive 
programme for general practice in the UK, has resulted in more consistent 
adherence to evidence-based treatment guidelines (35,36).  While this is in many 
ways positive, with the intention of encouraging high quality care and reducing 
variations in practice, it also encourages greater use of medicines (35,36).   
Other factors driving up prescribing rates may include patient expectation, biased 
reporting in medical journals and a lack of understanding of health statistics and 
risk (36).   It is easy to misunderstand health statistics, and doctors can find 
themselves needing to manage unrealistic expectations of patients who may find it 
difficult to obtain reliable information. Communicating relative risks as opposed to 
absolute risk or numbers needed to treat can unintentionally lead both doctors and 
patients to overestimate the benefits of a treatment (36).  The UK’s Academy of 
Royal Medical Colleges suggests that the onus on doctors to “do something” at 
each consultation may have bred unbalanced decision making (36).  This could 
result in patients sometimes being offered treatments that have only minor benefit 
and minimal evidence despite the potential for substantial harm and expense.   
 
2.4: LONG TERM CONDITIONS AND OLDER PEOPLE 
Age is a major non-modifiable risk factor for a number of LTC.  Fifty-eight per-cent 
of people aged over 60, and 70% aged over 80, have at least one long-term 
condition, compared to 14% of those aged under 40 (33).    
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In 2013, the global burden of disease study concluded that ageing of the world’s 
population is leading to a substantial increase in the numbers of individuals living 
with sequelae of diseases and injuries (30).  Chronic disease is now so common 
that healthcare systems are increasingly focused on people with more than one 
long-term condition (36,37).  The presence of two or more LTC is referred to as 
‘multi-morbidity’.  In this context, LTC include symptom complexes such as frailty 
and chronic pain and sensory problems such as sight and hearing loss, as well as 
clinical conditions (37).  Whilst not exclusively a condition of the elderly, the 
presence of multi-morbidity increases with age, with a quarter of people aged 60 or 
over, and a third of people aged 80 or over living with multi-morbidity (30).     
 
2.5: POLYPHARMACY AND ITS RELATIONSHIP WITH AGE 
As a population, older people take more medications than younger ones.  This 
situation is unsurprising when we consider that, if each one of their LTC is treated 
according to national guidelines, older people may end up taking a complex 
combination of medicines, a situation termed polypharmacy (38).  The 
management of risk factors for future disease can also contribute to polypharmacy 
and be a major treatment burden for older people with multi-morbidity (37). 
Studies indicate that almost half of people aged 65 or older in England take 5 or 
more regular medicines, a figure which has quadrupled over the last two decades 
(34).  An analysis of more than 300,000 patients in Scotland found that 16.4% of 
patients aged 65 years and above took 10 or more regular medications, compared 
to 5.8% of the population as a whole (39).   
Polypharmacy is even more prevalent in older patients admitted to hospital, with 
one British study finding that 60% of an inpatient population with an average age of 
65 were taking five or more medicines concurrently (40).  A study of six different 
hospitals across Western Europe found the average number of medications taken 
by an older inpatient population (median age 82 years) to be six (41). 
Older people are particularly vulnerable to adverse drug reactions due to changes 
in the handling of, and sensitivity to, many medications in the ageing body.  
Polypharmacy, leading to interactions between medications, may exacerbate this 
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problem further.  In fact, older age and greater number of medicines are two of the 
strongest predictors of potentially harmful medication errors and hospitalisation for 
preventable adverse drug events, as discussed below.   
In England, the PRACtICe Study, published in 2012, conducted a detailed 
examination of the prescribing records of 1,777 patients in general practice with the 
aim of identifying and learning from medication prescribing and monitoring errors 
(42).  In this study, a prescribing error was defined as an unintentional, significant 
reduction in the probability of treatment being timely and effective, or increase in 
the risk of harm, as a result of a prescribing decision or prescription-writing 
process. A monitoring error was said to occur when a prescribed medicine was not 
monitored in the way which would be considered acceptable in routine general 
practice. 
The PRACtICe study found a higher prevalence of prescribing and monitoring 
errors in elderly patients.  Of patients who had received at least one medication, 
38% of those aged 75 years or older experienced an error, compared to 20% of all 
patients.  The study also found that 30 and 47% of patients receiving respectively 5 
or more and 10 or more medications had prescribing or monitoring errors in the 12-
month study period.  Thus both older age and polypharmacy were associated with 
a higher rate of unsafe or inappropriate prescribing.   
A meta-analysis of 68 studies reporting adverse drug reaction (ADR) related 
hospital admissions included 17 studies where participants were elderly (age over 
65 in most cases, over 70 in one and over 75 in another) (43).  In those studies, 
ADRs were associated with 17% of admissions, compared to 4% in the non-elderly 
population.  Twelve of the 68 studies reported data on the preventability of 
admissions, two of which were studies of elderly patients.  Overall, 88% of elderly 
admissions were judged to be preventable. The authors concluded that ADRs in 
the elderly result in a significant number of unnecessary hospital admissions and 
associated waste of money (43).  A later systematic review of 25 prospective 
studies found that in the five studies involving older patients (aged over 60), 11% of 
admissions were ADR related, compared to 6% for non-elderly adults (44).   
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A further study conducted after these two reviews found that 6.5% of elderly 
admissions where related to ADRs, with almost three-quarters of the ADRs 
suffered classified as avoidable (45).  Medications commonly reported to be 
involved in ADRs in elderly patients include those used to treat cardiovascular and 
central nervous system disorders, as well as non-steroidal anti-inflammatory drugs 
(NSAIDs) (43-45). 
Other studies have used broader definitions when identifying hospital admissions 
related to medication.  A review of 15 studies from seven countries reporting 
preventable drug related admissions (PDRA) found that where the average age of 
patients was over 70 years, the rate of PDRA was approximately twice that of 
studies where patients were younger (7.6% vs 3.9%) (46).  A further recent large 
prospective study conducted in two hospitals in England found very similar results: 
7% of admissions in patients aged 65 or over were PDRA, nearly twice the 
proportion found in younger adult patients (4%) (40).   
 
2.6: PRESSURE ON HOSPITAL BEDS 
Rates of emergency hospital admission (those which are not planned and happen 
at short notice because of perceived clinical need) continue to rise.  In response to 
the growth in emergency admissions, the ‘emergency marginal rate’ rule was 
introduced into the national tariff of payment to NHS hospitals (Payment by 
Results, PbR) in 2010/11, in an attempt to lower the rates of emergency admission 
and encourage acute providers to work with other stakeholders to reduce demand 
for emergency care (47). This rule sets a baseline monetary value for emergency 
admissions at provider level.  A provider is then paid only a percentage of the 
national price for any increases above this baseline. 
In October 2013, the National Audit Office (NAO) produced a report examining 
emergency hospital admissions (48).  Despite the adjustments to the national 
payment tariff, the report stated that in 2012-13, there were 5.3 million emergency 
admissions to hospitals in England.  These admissions costed approximately £12.5 
billion and represented an increase of 47% in the number of emergency 
admissions over the preceding 15 years. 
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The NAO report identified that the main factor in the increase in long-stay 
admissions is the increasingly frail elderly population who are living with one or 
multiple LTC (48).  This population are far more likely to have immediate or chronic 
health problems, to need urgent care and to go to an accident and emergency 
(A&E) department.  Once in A&E they are more likely to be admitted into hospital, 
and once admitted, typically spend much longer in hospital, thereby costing the 
NHS more under the PbR system (48).   The King’s Fund Report, Older People 
and Emergency Bed Use: Exploring Variation found the average emergency length 
of stay increased with age, from 7 days for those aged 65–74 to 11 days for those 
aged 85 and over (49).   This compares to the overall average length of stay 
following emergency admission of 5.8 days (48). 
In light of the increase in emergency admissions and the increase in the elderly 
population, the DoH commissioned the Centre for Health Service Economics and 
Organisation (CHSEO) to conduct a study of recent trends in emergency hospital 
admissions of older people, aged 65 and over, and factors associated with these 
trends (50).  This study found that emergency admissions for people aged 65 and 
above in England increased by 46% between 2001/02 and 2012/13, from 1.5 
million to 2.2 million.  Even when demographic population changes were taken in 
to account, the rate of emergency admissions of older people per thousand older 
population increased by almost 26% over this 11-year period.   
Similar to the NAO, the CHSEO report found that all age groups had seen 
considerable increases in the number of short-stay admissions over their study 
period.  When looking at emergency hospital spells of at least 2 days, they found a 
reasonably stable picture for people aged 20 to 84.  However, amongst people 
aged 85 and over they found a substantial increase of 52% (50). 
The CHSEO report states that the underlying demand for emergency inpatient care 
in old age has been affected by rising numbers of older people and by changes in 
the health state of the older population, but these factors explain only around one-
third of the rise.  It may therefore be that changes in attitudes, including rising risk 
aversion among the public and health and social care staff, have affected demand 
by lowering the threshold for seeking emergency care.  The increased scope for 
urgent and emergency care to diagnose and treat health conditions, and 
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associated greater awareness may also have put upward pressure on demand 
(50).   
All parts of the health system have a role to play in managing emergency 
admissions and ensuring that patients are treated in the most appropriate setting.  
Hospital based factors such as accessibility and internal processes can influence 
the likelihood of patients aged over 65 being admitted as an emergency and their 
subsequent speed of discharge (49).  However, the current movement towards full 
service provision seven days a week in hospitals is not matched by community 
services, which can compromise attempts to prevent emergency admissions and 
prolong the length of stay for patients unable to access pathways out of hospital 
seven days a week (48,51).  Older people are more likely to be affected by this as 
they are more likely to need support in the community (51).  This is a particular 
concern for older people as a long length of stay is associated with poor outcomes 
for the elderly, especially those who are frail and suffer from dementia.  With 
prolonged length of stay comes an increased risk of complications such as falls, 
delirium and hospital acquired infection.  All this lowers the likelihood of a 
successful return to independent living (51). 
Relationships between services in primary and secondary care and the extent to 
which they co-ordinate and work collaboratively are important.  Interestingly, the 
King’s Fund found that areas with higher proportions of people aged over 65 have 
lower rates of acute bed use.  This suggests that in areas with a relatively high 
proportion of older people, more attention may have been paid to service 
improvements such as the development of more integrated care models.  Indeed 
areas with well-developed, integrated services for older people (in terms of both 
integration between health and social care and between hospital and community 
care), had lower rates of hospital bed use. 
 
2.7: NATIONAL HEALTH POLICY: THE DRIVE TOWARDS CARE IN THE 
COMMUNITY 
Avoiding unnecessary emergency hospital admissions and managing those that 
are admitted more effectively is a major concern for the NHS (48).  According to 
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the DoH, approximately 20% of emergency admissions are for known conditions 
that could be managed effectively in the community (14).  Transforming Primary 
Care, published by the DoH in April 2014, is part of the national strategy to provide 
proactive, joined-up care for older people and those with complex needs.  The plan 
states that providing these patients with personalised support outside of hospital 
will be critical in achieving a reduction in unplanned hospital admissions. This 
includes co-ordinating services and providing proactive follow up support on 
discharge to prevent readmission.  This document makes reference to the part that 
pharmacy services can play, by supporting older people to use their medicines 
safely and effectively and to make decisions about how they can maximise their 
health (14).   
This vision is echoed both in the 5YFV and in Prevention is Better than Cure, which 
advocate that patients with LTC should be empowered to take control of their own 
care, and that more care must be delivered outside of hospitals (15,32).  Barriers 
between primary, secondary and community healthcare, and between health and 
social care, must be broken down. Options presented by the 5YFV to achieve this 
include integrated hospital and primary care providers known as Primary and Acute 
Care Systems, which combine general practice and hospital services, and 
Multidisciplinary Community Providers, combining General Practitioner (GP) 
services with nurses, other community health services, hospital specialists and 
perhaps mental health and social care to create integrated out-of-hospital care 
(32).  The 5YFV recognises the particular challenge of providing support for frail 
older patients, who are more likely to have multiple LTC and increased health and 
social care needs (32).   
The DoH’s Shared Delivery Plan, published in February 2016, outlines its own 
main objectives for 2015-2020, and endorses NHS England’s 5YFV.  The plan 
focuses on the importance of supporting people to take an active role and make 
their own decisions regarding their health and care.  A key objective is to reduce 
emergency hospital admissions by improving out of hospital care, with more 
preventative and person centred care, especially for people with LTC (52).  To 
support the achievement of these objectives, NHS England, the Department for 
Communities and Local Government, the DoH and the Local Government 
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Association (a politically-led, cross-party organisation that works on behalf of 
councils to support, promote and improve local government) have set up a single 
pooled budget for health and social care services to work more closely together in 
local areas.  Individual clinical commissioning groups (CCGs) and local authorities 
are required to pool budgets and to agree an integrated spending plan for how they 
will use their allocation.  Now called the Better Care Fund and totalling £5.3bn, key 
aims of this initiative include preventing non-elective hospital admissions, reducing 
inappropriate admissions of older people into residential care, supporting 
vulnerable older people discharged from hospital through reablement or 
rehabilitation programmes to prevent readmissions, and reducing delayed transfers 
of care from hospital (53). 
Delayed transfers of care and barriers to collaboration and co-ordination of care 
across local health economies were identified as major challenges faced by 
hospital trusts in the Carter Report on productivity and efficiency in English acute 
hospitals (54).  The report states that hospital trusts, and their local health and 
social care partners, are currently working within a system where the incentives 
and processes around transfers of care are not always clear and rarely fully 
aligned.  Greater collaboration to establish a daily cycle of early and proactive 
transfer out of hospital could lead to both efficiency and quality improvement 
opportunities but time and effort is needed to engage local health and social care 
partners and communities.  Optimising information technology systems to allow the 
capture of patient data across a variety of care settings in the acute sector and the 
community was identified as key to delivering timely and co-ordinated transfer of 
care. 
Pharmacy was recognised as one of the key resource areas within NHS hospitals 
by the Carter Report, which recommended that pharmacists and clinical pharmacy 
technicians should spend more time on patient facing clinical services such as 
medicines reconciliation, prescribing and discharge support as this increases the 
likelihood that medicines use is optimised (54).   
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2.8: SUMMARY 
There is a need for pharmacy services to adopt the ethos of the national strategy to 
encourage integration between providers of care in different sectors.  This is 
particularly important given the increasing number of elderly people with multiple 
LTC, prescribed multiple medicines.  Pharmacists have the potential to support 
these patients and their carers to become empowered to manage their medication 
and make their own decisions regarding drug treatments.  However, the role the 
pharmacy profession can play in collaborative care is under-developed and this 
highlights a gap for evidence based services to be introduced to support 
medicines-related transitional care of older people. 
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CHAPTER 3: MEDICINES RELATED TRANSFER OF CARE OF 
OLDER PEOPLE 
This chapter discusses the problems that can occur with medicines when older 
people are discharged from hospital, why they happen and their consequences.  
The need for mechanisms to improve medicines related transfer of care in the 
elderly is identified and some possible methods to achieve this are introduced. 
Transfer (or transition) of care occurs whenever patients move between care 
providers (55).  It includes admission to and discharge from hospital, shift changes 
on a ward, transfers between departments in a hospital, and transition from a 
patient’s own home to a long-term care facility (1).  Moving between inpatient and 
outpatient settings is a routine part of patient care and is the most extensively 
studied transfer of care to date (1).   
Hospital discharge is a period of transition from hospital to home that involves 
transfer in responsibility for care from the inpatient provider to the patient and the 
primary care team (56).  Inadequate communication and insufficient care co-
ordination are common challenges during transfers of care.  Poor communication 
between inpatient and outpatient providers, together with the lack of an effective 
communication infrastructure, contributes to poor patient outcomes (1). 
 
3.1: PROBLEMS WITH MEDICINES OCCURING ON DISCHARGE FROM 
HOSPITAL 
Adverse drug events (ADEs) are adverse outcomes experienced by patients, which 
are caused by medication (2).  A slightly broader term, drug related problem (DRP) 
has been used by some researchers to encompass all events or circumstances 
involving drug therapy that actually or potentially interfere with desired health 
outcomes (57).  DRPs include issues with treatment effectiveness, adverse drug 
reactions (ADRs), and others such as patient dissatisfaction with treatment and 
non-adherence (57).  Using these definitions, all ADEs are DRPs, but not all DRPs 
ultimately lead to ADEs. 
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Although they may occur at any time, there is a greater risk of DRPs and ADEs 
during care transitions (1).  ADEs are the most common type of adverse event 
reported following discharge from hospital, occurring in 10-20% of patients after 
discharge (3).  In one study, almost half of ADEs resulted in a visit to the family 
doctor or hospital emergency department (ED), or a readmission to hospital (2). 
The first few weeks following discharge are a particularly high-risk interval for 
ADEs because patients have often experienced a recent change in health state 
and they have frequently had several prescription changes (2).  Nearly two thirds of 
patients have three or more medicines changed during their hospital stay, and the 
likelihood that an elderly medical patient will be discharged from hospital on the 
same medication they were admitted on is less than 10% (4,5).   Almost all ADEs 
occurring post discharge are caused by new or altered medication rather than 
those unchanged from pre-admission (2).  More than half of these ADEs may be 
preventable or ameliorable (i.e., duration or severity could be decreased) (2). 
Certain patient populations are particularly at risk of ADEs following hospital 
discharge, including the elderly and those taking 5 or more medicines, with patients 
discharged on 12 or more medicines having almost three times the risk of those 
discharged on 4 or less (1,2,6).   
Reasons identified for post-discharge ADEs include poor communication during 
transitions in care, lack of monitoring and review of treatment and patients not 
taking their medicines as agreed (non-adherence) (3,6,56).  Poor communication 
may occur between healthcare professionals and patients or between 
professionals in secondary and primary care. 
This situation may be exacerbated by a condition described as ‘post hospital 
syndrome’ - a transient period of approximately one month following discharge, 
during which there is a generalised risk for a wide range of adverse health events.  
This syndrome may emerge due to the myriad of physical and cognitive stressors 
involved in a hospital admission, which can adversely affect health and contribute 
to substantial impairments during the early recovery period, an inability to fend off 
disease, and susceptibility to mental error (7).   
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3.1.1: Patient Non-Adherence 
Medication adherence can be defined as ‘the extent to which the patient’s 
medication taking behaviour matches agreed recommendations from the 
prescriber’ (12).   It is estimated that between one-third and half of all medicines for 
LTC are not taken as recommended (58).  Medication non-adherence leads to 
reduced clinical benefit, avoidable morbidity and mortality and medication wastage.  
The estimated opportunity cost of health benefits forgone because of poor 
adherence is over £500million per year in the UK, and with increases in life 
expectancies and the number of patients living with chronic illnesses, for which 
they are prescribed medication, this problem may well get worse in coming years 
(59,60).  
Unintentional non-adherence refers to practical barriers to patients taking 
medicines as prescribed. These might include problems with memory (e.g. 
forgetting instructions or forgetting to the take the medication), dexterity (e.g. 
difficulties in opening containers or using devices such as inhalers or injections), 
knowledge (e.g. being unaware of how to obtain a repeat prescription) or difficulties 
with disruptions to normal routine (12). 
Intentional non-adherence describes the way in which patients may take deliberate 
decisions to adjust their own medication use (e.g. not taking it at all or modifying 
the dose or frequency).  Intentional non-adherence is thus an action that is rational 
in terms of patients’ beliefs, circumstances, priorities, preferences and 
experiences, although these perceptions and actions may differ from medical 
expectations and rationality (12). 
There is a degree of overlap between the categories of unintentional and 
intentional non-adherence.  For example, forgetting can be unintentional but might 
be influenced by intentional or motivational factors such as a lack of perceived 
need for treatment.  In contrast, practical barriers may be overcome where 
motivational factors are high (12). 
Medication adherence therefore depends on the patient having the knowledge, 
motivation, skills and resources required to follow the agreed recommendations.  In 
addition, adherence is a dynamic process, whereby the experience of adherence 
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or non-adherence can alter pre-disposing factors such as beliefs about medication 
(60).  This complex interaction has been mapped to a model known as the COM-B 
model for human behaviour (60).  COM-B hypothesises that interaction between 
three components, Capability, Opportunity and Motivation (COM) causes the 
performance of a behaviour (B) and hence can provide explanations for why a 
recommended behaviour (such as taking a medicine in a particular way) is not 
engaged in.  Each component can influence behaviour directly and, in addition, 
opportunity and capability might influence motivation and so affect behaviour.  
Performance of the behaviour can in turn influence capability, opportunity and 
motivation (Figure 3.1).  The COM-B model therefore includes and expands upon 
the concepts of unintentional and intentional non-adherence (60).   
 
 
Figure 3.1: Application of COM-B to adherence, reproduced from (60). 
 
Factors associated with unintentional non-adherence are particularly prevalent 
among people aged 75 years and over. These include a greater prevalence of 
cognitive problems, multiple pathology leading to complex polypharmacy, living 
alone and dexterity problems (12,13).  Older people, like younger people, may also 
make intentional decisions to change or stop their medication without professional 
advice, due to side effects, symptom changes or perceived inefficacy of treatments 
prescribed (12).  
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Non-adherence and Hospital Admissions 
In a large observational study of 3784 patients screened by pharmacists on a 
hospital medical admissions unit in England, adherence problems were the cause 
of 1.3% of all admissions (61).  The drug class most frequently associated with 
admissions due to adherence problems was loop diuretics, although, antiepileptics, 
nitrates, corticosteroids and insulins were also associated with adherence related 
admissions (61). 
These results are similar to those of a study in Denmark, where 1.8% of 333 
admissions were found to be the direct result of adherence problems (62).  The 
authors of this study found that non-adherent patients were prescribed more 
medicines than patients with no reported adherence problems, supporting the 
theory that polypharmacy is a risk factor for non-adherence.  They also noted that 
as one-third of patients were admitted due to symptoms that were apparently 
already being treated, some of these cases may be the consequence of 
undetected non-adherence.  Adherence in this study was assessed during patient 
interviews, which the authors state may be unreliable if patients under-report 
adherence problems. Therefore, the contribution of adherence problems to 
admissions may have been underestimated (62).   
The role of non-adherence may be even more important in hospitalisations of the 
elderly.  American researchers interviewed 315 consecutive elderly patients 
admitted to an acute care hospital and found that 11.4% were due to non-
adherence (63).  Again, polypharmacy was associated with a higher risk of 
adherence related admission, as was the involvement of multiple different 
physicians and poor recall of medication regimen (63). 
All of the studies discussed above are now well over 10 years old.  Given the aging 
population and increase in polypharmacy in recent years as discussed in Chapter 
1, it is possible that now adherence related admissions among the elderly are even 
more prevalent. 
Adherence Following Hospital Discharge  
Patients in hospital receive nearly 100% of their prescribed medication regimen, 
and therefore have favourable odds of experiencing optimal therapeutic outcomes 
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from medicines while hospitalised.  If patients deviate from the intended regimen 
following discharge, breakthrough symptoms may occur; leading to avoidable 
morbidity and hospital readmission (6). 
In an American study, 147 patients aged 65 or older discharged from hospital on 
more than 2 medicines (mean 9.3) and receiving home health services were 
followed up in their homes 2 weeks after discharge (64).  Forty-four percent of 
participants were under- or over adherent with at least one medicine.  The 
probability of non-adherence in this study increased by 16% for each extra 
medication a person was taking. Patients with cognitive impairment were 2.5 times 
more likely to be non-adherent to at least one medication than those without. 
Researchers in an Australian prospective cohort study of 68 patients discharged 
from hospital to their own home on more than 2 medicines utilised telephone 
follow-up one month after discharge to assess adherence (65).  Participants had a 
mean age of 70 years and were prescribed a mean of 9.5 medicines. Forty percent 
reported non-adherence to one or more regular medications, equally split between 
intentional and unintentional non-adherence, with some patients displaying both 
types.  The most common reasons for intentional non-adherence were that patients 
felt the medication was unnecessary, and experiencing adverse effects.  Medicines 
intentionally discontinued by patients included respiratory drugs, gastric acid 
suppressants and anti-hypertensive drugs.  Medicines subject to unintentional non-
adherence included anti-hypertensive and lipid lowering drugs and gastric acid 
suppressants.   
A similar study in Italy enrolled 100 patients aged 65 years of age or older (mean 
age 78 years) discharged from medical wards and receiving at least four 
medications (8).  Non-adherence with at least one medication was reported for 
55% of patients at 15-30 days post discharge and 70% by 3 months after 
discharge.  Again, feeling the medication was unnecessary and fear of side effects 
were the main reasons for non-adherence.  At the first follow-up, the mean number 
of drugs prescribed to non-adherent patients was significantly higher (9.5) than in 
patients with regular medication adherence (8.2).  Diuretics, psycholeptics, 
analgesics and laxatives were the drugs most commonly associated with non-
adherence.  The authors conclude that simplifying drug regimens and reducing the 
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pill burden as well as boosting the patient’s understanding of the prescribed 
medications should be considered targets for intervention to improve adherence. 
No published studies from the UK could be located specifically investigating post-
discharge medicines adherence. However one study conducted in Southeast 
England aimed to explore patients’ problems with new medicines prescribed in 
primary care for chronic conditions (66).  On telephone follow-up at 10 days, 30% 
of 226 patients were already non-adherent.  Two-thirds of patients were 
experiencing one or more problems with their new medication, in terms of side 
effects, concerns or practical problems, and 61% had unmet information needs.  
As changes made to medication regimens in hospital may well be more complex 
than adding a single new medicine, problems with post-discharge adherence are 
likely to be even more prevalent than in this study. 
If patients do not understand why their medications are important or the potential 
for negative outcomes if non-adherent, then they may be more likely to self-cease 
medications. This is particularly true of treatment for asymptomatic disease, as 
patients cannot see a tangible benefit of their medication (67). 
Community pharmacists are well placed to help patients gain this understanding 
and support medicines adherence following discharge from hospital. 
 
3.1.2: Poor Communication during Transitions of Care 
Most errors and adverse events following discharge result from a breakdown in 
communication between the hospital team and the patient or primary care 
physician (56).  In England, the 2009 Care Quality Commission (CQC) report 
Managing patients’ medicines after discharge from hospital found that information 
shared between GPs and hospitals when a patient moved between services was 
often patchy, incomplete and not transferred quickly enough (68).  The report 
stated that acute trusts needed to improve the quality of information sent to GPs in 
discharge summaries, and that Primary Care Organisations (PCOs, formally 
Primary Care Trusts, now replaced by CCGs), needed to ensure that safe 
processes were in place for critically reviewing medication changes and updating 
patients’ records after discharge.  Both acute trusts and primary healthcare 
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professionals were urged to ensure that they communicated more effectively with 
patients about their medicines, both at the point of discharge and after return to the 
community.   
The need to improve discharge information and patient education around 
medicines was highlighted again by a Department of Health action plan to improve 
the use of medicines and the RPS guidelines on transfer of care and medicines 
optimisation (55,69,70).  All of these papers make reference to the importance of 
post discharge medication reviews, and advise hospital pharmacists to collaborate 
more with patients’ community pharmacists, in order to ease transitions in 
pharmaceutical care.   
However in the UK there have historically been, and continue to be, gaps in 
communication regarding medicines between hospitals and primary care on 
hospital discharge.  In a questionnaire survey of 163 UK hospitals published in 
2000, 42% of respondents stated that reasons for medication changes were ‘never’ 
given on discharge summaries, and 48% that this information was only ‘sometimes’ 
given (71).  Ninety-five percent of hospitals reported that they either never involved 
community pharmacists in the discharge process, or did so in <10% of discharges.  
Where this did occur the communication was usually via telephone, and restricted 
to patients taking unusual medicines or needing multi-dose compliance aids.  
Recent (2016) research involving telephone interviews with 13 chief pharmacists, 
or suitably qualified nominees, from North-West England found that it is still 
‘uncommon’ for information to be sent from hospital to community pharmacy (72).  
From the community pharmacists’ perspective, a postal questionnaire completed 
by 163 community pharmacists in northern England in 2001 found that 96% would 
not know if a patient of theirs had recently been in hospital, which supports the 
findings from the questionnaire survey above (73).  Eleven years later, in a survey 
of community pharmacists in Ireland, 91% of respondents reported no or only 
occasional contact by a hospital when patients were being discharged (74).  
Similarly, semi-structured interviews with 14 community pharmacists from one 
primary care organisation in England found that these pharmacists did not routinely 
receive information when a patient had been in hospital and often only found out 
via ‘ad-hoc’ conversations with patients or carers (75).  Information that was 
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received was not always consistent or comprehensive.  However when information 
was received, pharmacy staff would make an effort to communicate with patients 
regarding changes.  Ten of the 14 pharmacists interviewed gave examples of when 
poor communication had compromised patient safety, for example wrong doses of 
medicines being taken, patients running out of medicines and incorrect repeat 
prescriptions being dispensed due to the lack of timely updating of records, as 
identified in the Moving Patients, Moving Medicines, Moving Safely document (76).  
The situation was reportedly exacerbated by the fact that discharge information 
was not always received or processed in a timely fashion by GP surgeries (75). 
Medication Discrepancies  
Medication discrepancies on discharge from hospital are differences between the 
medicines prescribed on discharge, and the pre-admission regimen (56).  
Discrepancies may also occur between the discharge prescription and the 
medicines actually taken by the patient following their return home (77).  Reported 
rates of medication discrepancies on, or following, discharge vary widely, with 
differences between studies in the terminology and definitions used as well as 
study populations and methodology.  For example, some studies use the discharge 
prescription itself to detect discrepancies, whilst others use the first prescription 
subsequently issued in primary care.  Studies also vary in the way results are 
reported (e.g. percentage of patients experiencing at least one discrepancy or total 
number of discrepancies) (6).  Some studies differentiate between intentional 
discrepancies (where there is a difference between pre-admission and discharge 
medication but this can be clinically justified with reference to discharge 
documentation), and unintentional discrepancies, which may lead to medication 
errors and ADEs in primary care if not promptly resolved (78,79).   
There are numerous reasons why unintentional discrepancies between pre-
admission and discharge medication may occur (56).  Firstly, incomplete medicines 
reconciliation on admission to hospital may mean that discrepancies are present 
throughout the patient’s admission and carried forward onto the discharge 
prescription.  Researchers have identified unintentional error rates on hospital 
prescriptions at admission of between 30 and 70%, and while intensive medicines 
reconciliation activities by hospital pharmacists within 24 hours of admission can 
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dramatically reduce the number of unintentional discrepancies on discharge; this is 
not currently standard practice in UK hospitals (80).   
Secondly, acute illness may lead to significant modification to pre-admission 
medication.  However once the acute phase of the illness is over, many of these 
medicines will need to be re-started.  Failure to review and resume these 
medicines may lead to unintentional discrepancies on discharge.  Conversely, 
some medicines which were required during hospitalisation may be unnecessarily 
carried forward onto the discharge prescription (56).  
In the PRACtIcE study (Section 2.5), 36 out of 37 patients were found to have 
discrepancies between pre-admission and discharge medication regimens when 
their GP records were reviewed (42).  Discrepancies were found between 
discharge communications and subsequent GP prescriptions in 43.2% of 
discharged patients, including 28% of all new medicines.  In a recent study of 403 
discharge prescriptions processed by Dutch community pharmacies, 92% led to 
one or more problems with continuity of care, including 356 medication 
discrepancies (81).  There were also 33 cases where a drug had been prescribed 
with an unclear indication, and the number of problems per prescription increased 
with increased number of prescribed drugs post-discharge.   
These two studies, however, did not report on what proportion of these 
discrepancies was intentional.  A systematic review and process mapping of 
medication use in primary care in the United Kingdom, published in 2009, reported 
that unintentional discrepancies were found in 11 to 27% items prescribed on 
discharge (82).  Unintentional discrepancies in repeat medication subsequently 
received from the GP were found in around half of all items issued, affecting 57% 
patients.  The fact that the rate of unintentional discrepancies was higher in studies 
of post-discharge prescriptions issued in primary care than in those evaluating 
discharge prescriptions directly suggests that the rate of prescribing errors post 
discharge could potentially be reduced by completing thorough medicines 
reconciliation in the community setting, before the issuing of the first post-
discharge prescription by the GP. 
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Further highlighting the difference between intentional and unintentional 
discrepancies, researchers at a teaching hospital in Spain who reviewed 954 
discharge documents reported that, although discrepancies were found in 87%, 
most were intentional and could be resolved with reference to the discharge letter 
(78).  Only 5% of discharges contained unintentional discrepancies.  It is likely to 
be relevant here that the authors describe a rigorous process for medicines 
reconciliation on admission to the hospital, and excluded any discharges where 
this had not been completed.  It was also specified that clinicians at the study 
hospital made reference to the admission list of medication when preparing the 
discharge prescription.  This is likely to reduce the number of omitted medicines 
from pre-admission, which is a frequent cause of discrepancies in other studies 
(3,79,81).  This reiterates the value of thorough medicines reconciliation on 
admission to and discharge from hospital in reducing unintentional medication 
discrepancies.   
Researchers at a tertiary care teaching hospital in Canada found that 41% of 
patients had at least one unintentional medication discrepancy on their discharge 
prescription (79).  Thirty per-cent of the discrepancies were assessed as having 
the potential to cause patient discomfort or clinical deterioration.  The researchers 
separately studied ‘potential’ unintentional discrepancies; situations where clear 
patient directions regarding the management of medication, for example the post-
discharge status of a pre-admission medicine, were omitted or not explicitly 
documented on the discharge letter (these are likely to have been classified as 
discrepancies in their own right in some of the other studies discussed).   The 
medication listed on these discharge summaries may be correct, and 
discrepancies clearly intentional when interpreted by a healthcare professional with 
reference to the patient’s reason for admission and clinical status on discharge.  
However, these ambiguities, affecting 55% of discharges, could cause confusion in 
patients without this specialist knowledge, which could then lead to unintentional 
non-adherence and patient harm. 
This situation was demonstrated during a follow-up study of 50 elderly patients 
(mean age 77 years) discharged from a district general hospital in England, who 
were visited at home by a pharmacist after the initial supply of medicines given by 
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the hospital should have run out (83).  Forty-five (90%) patients were following a 
different regimen to that prescribed on discharge: 11 were taking a different 
dosage, 10 had stopped medicines that were prescribed and 20 were taking 
medicines which had not been prescribed.  This latter group included patients who 
were taking medicines which had been prescribed for them pre-admission but had 
not been noted during their hospital admission, as well as medicines that had 
intentionally been stopped by the hospital.  Some of the differences between the 
discharge prescription and medications subsequently being taken were clinically 
unimportant (e.g. a change in brand name) or intentional (e.g. following advice 
from a healthcare professional subsequent to their discharge).  However many of 
the patients had not been reviewed by their GP, and some of the discrepancies 
could have had serious consequences.  For example, 11 patients had not obtained 
further supplies of medication before the supply from the hospital had run out, 
leading to a break in treatment.   
A similar study in the United States of America (USA) focussed on the factors 
contributing to post-discharge medication discrepancies, which were found in 14% 
of 375 patients aged over 65 who were visited within 72 hours of discharge by a 
geriatric nurse practitioner (77).  As well as being older, the participants in this 
study were predominantly Caucasian and all had prescription drug coverage (i.e. 
they did not need to pay for prescription medication), which makes them more 
similar to the population studied in this thesis compared to other studies reviewed.  
Causes of discrepancies were found to be equally split between patient and 
system associated factors.  The most common system-associated causes of 
discrepancies were incomplete or ineligible instructions on how to take medication 
and conflicting information from different sources.  The most prevalent patient-
associated cause of discrepancy was non-intentional non-adherence due, for 
example, to patients resuming pre-discharge medication on their return home.   
Five medication classes accounted for half of all identified medication 
discrepancies: anticoagulants, diuretics, angiotensin-converting enzyme inhibitors, 
lipid-lowering agents and proton pump inhibitors.  Two variables were significantly 
associated with patients having experienced medication discrepancies: the number 
of medications taken (patients with discrepancies were taking an average of 9 
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medicines whereas those with no discrepancies were taking an average of 7) and 
the presence of congestive heart failure.  The emergency readmission rate among 
patients with medication discrepancies (14.3%) was significantly higher than that 
among patients with no medication discrepancies (6.1%).   
It is notable that the rate of discrepancies was much lower in the American study 
than the smaller English study.  Other than differences between the two countries 
in terms of transfer of care procedures, which may have affected results, one 
possible reason for the higher rate of discrepancies in the English study is that the 
time to follow-up was longer.  Non-intentional deviation from the discharge regimen 
may become more prevalent once the hospital supply of medicines has run out, as 
patients may become confused about what to do next and this may be 
compounded by delays in continuity of supply or errors on subsequent 
prescriptions issued in primary care (83).  This theory is supported by the process 
mapping research referred to above which found that discrepancies were more 
prevalent in studies of post-discharge prescriptions issued in primary care than in 
studies of the discharge prescriptions themselves (82).  The English study also 
used a broader definition of discrepancy; for example changes in dose timings 
even if the overall dose remained the same, and changes in brand names even if 
these did not lead to a deviation in the actual medication usage.   
However a further American study evaluating post-discharge medication 
discrepancies found similar high discrepancy rates as the English study. In this 
study, 94% of 101 patients had at least one discrepancy (84).  Forty percent of 
patients had at least one discrepancy attributable to adherence barriers; similar to 
the figures reported in studies specifically investigating post-discharge adherence 
(8,64,65).  Sixty-nine percent had one or more system related discrepancies, most 
commonly due to incomplete or inaccurate instructions on prescriptions, conflicting 
information from different sources, therapeutic duplication or incorrect dosage.  
The authors note that the higher number of discrepancies in their study compared 
to earlier American studies could be due to the complex health problems and 
polypharmacy among patients in their study (average number of medicines per 
participant was 10.4).  They also note that medication history taking on admission 
to hospital may have been sub-optimal in their study, and that increasingly strict 
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formularies in the acute setting lead to extensive substitution of medications which 
may have increased the potential for discrepancies in the hospital to home 
transition.  Additionally, the definition of discrepancy used in this study was broad 
and included situations such as non-use or dose reduction of analgesics 
prescribed on discharge because these were no longer needed.  As already 
discussed, there are inconsistencies in published research as to whether such 
situations should qualify as discrepancies or non-adherence at all (8,65).  
Patient Involvement and Education    
The fact that many patient-associated medication discrepancies, knowledge gaps 
and adherence problems were found in the studies described above highlights the 
need to place the patient at the centre of their care.  NICE guidance on medicines 
optimisation states that good communication between healthcare professionals 
and patients is needed for involvement of patients in decisions about medicines 
and for supporting adherence (85). 
However, while receiving care in hospitals, patients often assume a passive or 
dependent role as clinical staff members address their needs, including the 
administration of medication (79).  It has also been suggested that the brief period 
prior to discharge is not an ideal time to convey new and complex information to 
older patients, as pain, anxiety, sleep deprivation, or delirium may limit receptivity 
to new learning (77).   Furthermore, at hospital discharge patients may be 
overwhelmed with information, at a time when their primary concern is to get home 
as quickly as possible (81).    In spite of this, once at home, patients (and their 
family members) are abruptly expected to assume a significant self-management 
role in the recovery of their condition and in the management of their medications, 
for which they may feel unprepared (77).   
In the Dutch study of transfer of care issues identified by community pharmacists, 
patients’ lack of medication knowledge was illustrated by the high need for patient 
education (406 instances among 403 patients, with some patients having more 
than one knowledge deficit) (81).   In the two American studies of nurse domiciliary 
visits post discharge, nearly a third of the patient-level discrepancies were 
attributed to participants not knowing that they were supposed to take a medication 
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or a lack of knowledge about taking the medication as prescribed (77,84).  In the 
Italian telephone follow-up study, 72% of patients did not understand the purpose 
of all their medications at the first follow-up and 75% at the second (8). 
UK studies have also found that patients do not always feel adequately prepared to 
participate in their post-hospital care.  Elderly patients in the pharmacist home-visit 
study recalled little information being given about medicines whilst in hospital, 
particularly with regards to the purpose of their medicines, how to take them and 
potential side effects (83).  This may reflect a true lack of communication between 
hospital staff and patients, or patients forgetting information that had been given.   
Qualitative interviews in the UK with patients aged >75 and their caregivers found 
that inadequate explanations about medicines at discharge were commonly 
reported and lead to medicines being omitted, incorrect doses being taken, 
confusion and anxiety (86).  Better communication between staff, patients and 
carers could, it was felt, significantly improve the hospital discharge procedure and 
the value of clear, concise lists of prescribed medicines was emphasised by many 
participants.  Participants also highlighted the need for prompt and effective 
communication between the hospital and their GP and community pharmacist as 
they felt that being given the responsibility for this was a particular burden. 
In the study in North West England interviewing chief pharmacists, interviewees 
admitted that patients had limited involvement in their own discharge from hospital 
(72).  Furthermore, all agreed that patients are not always counselled on 
medication changes and that it is unclear who is responsible for doing this.  In a 
questionnaire survey of 104 patients on their day of discharge from one of these 
hospitals, only 22% of participants felt that they had been fully involved in their 
discharge (87).  Over a third were unclear about what medicines they should be 
taking after discharge, calling into question the quality of information given to 
patients and whether it is provided at an appropriate time, thus highlighting a need 
for improved communication with patients regarding post-discharge medication 
regimens.  In that study, pharmacists were the least likely healthcare professional 
to provide patient counselling (only 13% reported being counselled by a 
pharmacist). This supports previous evidence that hospital pharmacists are unlikely 
to be providing adequate patient counselling (72,88). 
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In a 2013 survey of 1218 medical inpatients at six hospitals in North-West England, 
only 44% of patients felt fully informed about medicines (88).   The survey also 
enquired as to whether participants had been asked if they had any concerns 
about medicines; 63% answered no, or could not recall whether they had been 
asked or not.    In a recent inpatient survey involving many of the same hospitals, 
76% of participants reported receiving enough information about medicines (89).  
However, 16% could not recall discussing medicines with any healthcare 
professional and only 38.5% felt involved in the decision to make changes, 
indicating that there may still be gaps in the support given to hospitalised patients 
regarding changes to medicines.  In a telephone follow-up to this survey, 31% of 
patients reported needing support with their medicines after discharge.  Issues 
included not knowing which medicines to continue taking, how long to take newly 
prescribed medicines, dose queries, side effect queries and wanting more 
information in general, particularly with respect to newly prescribed medicines or 
significantly changed regimens.  
In the most recent NHS Adult Inpatient Survey, 71% of patients reported being 
given clear written information regarding medicines by the hospital, and 75% stated 
that the purpose of their medicines and how to take then were explained in a way 
they could understand (90).  However the extent of the information provided to 
patients in the NHS inpatient survey and their retention of it are not reported.  
When asked about the specific scenario of information pertaining to possible 
medication side effects, only 38% of patients in the NHS survey reported being told 
‘completely’ about side effects to look out for.   
Taken together, this research indicates that the majority of patients discharged 
from hospital have unmet information needs regarding medication. 
 
3.2: EXTENT AND IMPORTANCE OF READMISSIONS IN OLDER PEOPLE 
Emergency readmissions to hospital (unplanned admissions which occur within 
one month of the original discharge) are rising year on year, with an increase of 
27% between 2002 and 2012 (91).  In 2012, around 15% of patients aged over 75 
were readmitted within a month of discharge (92).  In 2012-13, 19% of the 5.3 
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million emergency admissions to NHS hospitals were readmissions, and it has 
been estimated that each readmission costs the NHS £2114 on average (48,93).  
Therefore, emergency readmissions to hospital cost the NHS over £2.1billion each 
year. 
According to an analysis published by the DoH in 2008, there is no single 
explanation for the increase in readmissions, but a number of possible contributing 
factors are cited (94).  These include increasing number of patients admitted from 
A&E departments (increasing the overall number of admissions, some of which will 
be readmissions), changes in patient expectations (so they will re-present if they 
feel the original problem was not adequately dealt with or experience side effects 
from treatment), the quality of community health and social care services and 
transitional care between providers.   Increased prevalence of LTC, particularly 
those associated with high healthcare usage such as heart disease and COPD, 
may also be contributing to the rise in readmission rates.  In the context of the 
elderly, multiple co-morbidities and an increased likelihood of suffering the adverse 
effects of treatments increases both the likelihood and length of stay on 
readmission.  The average length of stay following emergency readmission for 
patients aged 75 or over in 2006-7 was more than twice that of those aged 16-74; 
13.9 days compared to 6.4 days (the overall average length of stay for all patients 
following emergency admission at that time was 7.6 days (48)).  The DoH’s report 
also suggests that a move towards treating less severe or complex cases in the 
community, when in the past they would have been admitted, may also mean that 
the patients treated in (and discharged from) hospital are more severely unwell 
than they were in the past.  In such a scenario, an increase in the proportion of 
patients requiring readmission would not be surprising (94).  
Emergency readmissions are included in the NHS Outcomes Framework as an 
indicator of quality care in the NHS (95).  To provide the most suitable care for 
patients when they leave hospital (and therefore reduce the likelihood of 
readmission), hospitals need to have robust discharge planning arrangements in 
place.  The NHS tariff of payment to secondary care providers specifically 
recommends more collaborative working and better coordination of clinical 
intervention with community and social care providers (96).  It also states that 
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hospitals should co-ordinate with the patient’s family and GP regarding medication 
as part of the discharge plan, to reduce the risk of readmission.   In addition to this, 
financial penalties have now been introduced for hospital trusts when emergency 
readmissions occur.  These are determined locally following a clinical review of a 
sample of 30-day readmissions to determine the proportion that could have been 
prevented through actions that might have been taken by the hospital, primary care 
team, community health services or social services (96).  The aim of the review is 
not to identify poor quality care in hospitals, but to identify actions that could have 
been taken to prevent readmission.  The review leads to the setting of a ‘threshold’ 
level of readmissions, above which the hospital will not receive any payment.  
Where money is retained from not paying for emergency readmissions, this should 
be reinvested by the commissioner in post-discharge services that support 
rehabilitation and reablement and, in turn, may help to prevent avoidable 
readmissions (97).  
However, determining the preventability of a readmission is challenging.  Reports 
in the literature vary widely but overall, approximately one-third of readmissions 
may be preventable (98,99).  Importantly, the preventability of medication related 
readmissions has consistently been judged to be higher than this, as will be 
discussed below, and therefore investment in improving medicines related transfer 
of care may represent a rational ‘first step’ in reducing the risk of readmission. 
 
3.3: THE IMPACT OF MEDICATION ON READMISSIONS AMONG OLDER 
PEOPLE 
In 2012, Age UK, the country’s largest charity for older people, commissioned a 
piece of research in order to understand the causes and effects of emergency 
readmissions from the perspective of older people who had experienced them 
(100).  Eighteen older people were asked to share their experience, beginning from 
their first admission to hospital through to the discharge and return home, and then 
their experience of the readmission to hospital.  Several interviewees had a poor 
experience of being discharged from hospital, including a lack of information about 
how to take medication, and a lack of co-ordination between secondary and 
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primary care settings impeding access to supplies of medication post-discharge.  
Some interviewees also expressed a desire for a more person centred experience 
and to be more involved regarding decisions about their care.  Where connections 
were made between their first admission and the readmission, these tended to be 
related either to the first admission not addressing the underlying health problem, 
or a lack of clarity at the point of discharge leaving them confused about the care 
they should be receiving once they left hospital, including how to take their 
medication.   
Four senior stakeholders, whose role or organisation was connected to the issue of 
emergency hospital readmission amongst older people, were also interviewed for 
Age UK’s study.  Stakeholders agreed that an important component of discharge is 
the provision of information, the development of a care plan for the patient’s care in 
the community, or simply the provision of advice for self-care. Variable care in the 
community, including communication failure between the acute and community 
settings, was also raised as a potential contributing factor to emergency 
readmissions.   
As well as communication deficits between hospital staff and the patient and 
primary care team, taking more than 5-6 medicines on discharge has been 
identified as an independent risk factor for emergency readmission (101,102).  
Medicines most frequently implicated in preventable drug related readmissions 
include diuretics, antihypertensives and non-steroidal anti-inflammatories (including 
low-dose aspirin) (102-105). 
A meta-analysis of 15 studies of preventable drug related hospital admissions 
found that studies reporting only readmissions assessed 14% as related to 
medication, approximately four times higher than those including first admissions 
as well (46).  An audit of readmissions occurring during a 1-week period in 2012 at 
a teaching hospital in North-East England identified medicines as a causative or 
contributing factor in 20% of 81 cases (102).  Three-quarters of these were judged 
to be medicines related and avoidable, meaning that 15% of all readmissions were 
related to preventable DRPs.  A much larger, prospective study of patients 
discharged from a hospital in North-West England found similar results; 
approximately one-fifth of 403 patients re-admitted within one year had an ADR as 
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a contributing factor to re-admission, and of those approximately half (ie 10% of the 
total) were definitely or possibly avoidable (103).  Increasing age was a significant 
risk factor for ADR related readmission; the median age of patients readmitted due 
to ADR was 74 years, as opposed to 68 years for all readmitted patients and 56 
years for those who were not readmitted. 
An American study of 100 patients discharged from an acute medical unit and 
readmitted within 60 days assessed that 64% of readmissions were related to a 
DRP (106).  Increasing age and missing a follow-up appointment were associated 
with an increased risk of readmission, whilst the presence of a clinical pharmacy 
consultation during the original admission was associated with a reduced risk.  The 
high number of medication related readmissions in this study compared to those 
above may be due in part to the broad definition used, which encompassed lack of 
treatment effect, adverse effects and factors related to treatment costs.   The study 
authors also note that the hospital used in the study did not routinely reconcile 
medication on admission or discharge, which may increase the number of ADEs 
following discharge and hence the number of readmissions. 
Medication related readmission rates have consistently been found to be higher in 
the elderly.  In a UK observational study of 108 consecutive emergency 
readmissions of patients aged 75 or over, 38% were assessed to be related to 
medication and 61% of these were considered to be preventable (ie 23% of all 
readmissions were judged to be due to preventable ADEs) (104).  Reasons 
identified for the preventable medication-related readmissions included poor 
documentation of changes to medication and associated lack of follow-up 
(accounting for 10% of all readmissions) and unrecognised poor adherence 
(accounting for 6.5% of all readmissions).  A similar study in Australia found that 
18% of all readmissions among a patient population of average age 79 were due to 
preventable ADEs (105).  Nearly half of these were attributed to inadequate 
communication and/or monitoring of medication (accounting for 8.2% of all 
readmissions).  Adherence problems were found in 53% of readmitted patients, 
including both under-adherence (usually due to side effects) and over-adherence 
(due to a belief the dose or frequency were not effective).  This prevalence is within 
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the range reported previously in studies of post-discharge adherence problems 
(8,64,65). 
 
3.4: POSSIBLE MECHANISMS TO IMPROVE MEDICINES RELATED 
TRANSFER OF CARE 
Moving Patients, Moving Medicines, Moving Safely suggests a variety of 
interventions that can be put in place by hospitals to improve medicines related 
transfer of care (76).  Among these are thorough medicines reconciliation on 
admission and discharge, improved pharmaceutical counselling accompanied by 
written information or reminder charts, pharmacist written discharge summaries, 
providing community pharmacists with information regarding discharge medication 
and the use of a pharmaceutical care plan or ‘pharmacy discharge sheet’ as a 
means of communication between hospital and community sectors regarding 
medication needs in the post-discharge period.  The guideline recommends that 
these interventions are integrated with initiatives to improve electronic information 
transfer between sectors (76).   
Many of these suggestions were used as the basis for projects initiated by the RPS 
transfer of care guidelines’ ‘early adopter sites’, although the success of these 
projects has been varied (10,107).  Other hospital initiated mechanisms that have 
been studied as a means of improving medicines related transfer of care include 
involving a pharmacist in a multi-disciplinary discharge planning team, telephone 
helplines manned by hospital pharmacy staff, and pro-active telephone, clinic or 
home follow-up from hospital based staff (108).  
The CQC report Managing patients’ medicines after discharge from hospital stated 
that PCOs should evaluate the level of pharmacist support available to them, 
focussing on medicines management after discharge, to improve safety and 
efficacy (68).  This evaluation was to include a review of the number and 
deployment of pharmacy staff providing direct support to GP practices to provide a 
greater focus on post-discharge medication reviews and adherence support, 
particularly for complex or older patients.  PCOs were also asked to evaluate the 
level of MURs carried out by community pharmacies, how these were targeted, 
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and improving feedback on outcomes when reviews were carried out.  MURs are 
patient-pharmacist consultations, designed to assess any problems patients have 
with their medicines and to help develop the patient’s knowledge of their 
medicines.  In 2011, NHS Employers and the Pharmaceutical Services Negotiating 
Committee (PSNC) stipulated that 50% of MURs provided by community 
pharmacies should target patients in pre-defined groups identified as being at risk 
of medication related problems or poor adherence.  In 2015 this proportion was 
increased to 70%.  Patients recently discharged from hospital were identified as 
one of these groups, along with patients with respiratory conditions, those taking 
particular ‘high risk’ medications, and as of 2015, patients with cardiovascular 
disease or risk factors (9). 
3.5: SUMMARY 
Older patients are particularly at risk of DRPs following discharge from hospital.  
Reasons identified for this include poor communication regarding medicines on 
transfer of care, lack of monitoring and review of treatment, and patient non-
adherence to medication.  If not promptly addressed, some DRPs may ultimately 
lead to preventable readmissions to hospital. 
The most effective intervention strategies to improve medication adherence involve 
regular monitoring, follow up and feedback for patients, and there is no reason why 
post-discharge adherence should be any different (56).  Encouraging older patients 
to visit their community pharmacist for review soon after leaving hospital could be a 
simple way of developing a regular monitoring and support system for discharge 
medication regimens, improving adherence and reducing readmissions.  A more 
comprehensive literature review of the role of the pharmacist in improving the 
transition from hospital to home, with a particular focus on community pharmacy, is 
covered in the next chapter. 
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 CHAPTER 4: LITERATURE REVIEW 
 
4.1: SEARCH STRATEGY 
In order to define previous and ongoing research into interventions that support 
medicines related transfer of care for older people discharged from hospital, either 
led by or involving pharmacists, a comprehensive literature search was 
undertaken.  Databases searched included the Cochrane Library, Embase, 
Medline, CINAHL, Web of Science, PubMed, Database of Abstracts of Reviews of 
Effects (DARE), NHS Economic Evaluation Database (NHS EED), National 
Institute for Health Research Dissemination Centre, Health Management 
Information Consortium (HMIC), Electronic Theses Online System (EThOS), NHS 
Evidence and the ClinicalTrials.gov Registry.  In addition the website of the 
Pharmaceutical Journal (www.pharmaceutical-journal.com) was searched as its 
material, whilst being highly relevant to the practice of pharmacy in Britain, is not 
referenced in many mainstream databases.  A full reproduction of the search 
strategies employed is found in Appendix 1. 
Reference lists of the articles identified via the above resources were reviewed to 
identify further papers not identified in the main search.  In addition, related papers 
‘suggested’ by websites such as PubMed and Science Direct were also 
considered; this presented a further means of locating relevant research.  Finally, 
other research known to the author, for example from networking at conferences or 
knowledge developed through experience of working as a specialist care of the 
elderly pharmacist in a district general hospital was reviewed for inclusion. 
In order to gather the fullest base of literature to evaluate, all apparently relevant 
titles were reviewed, whether they related to controlled or uncontrolled trials, 
service evaluations, conference abstracts or review articles.  Following initial title 
screening, the abstracts of papers which appeared relevant were reviewed and 
where these met inclusion criteria, every effort made to access the full, English 
version of the paper.   
Inclusion criteria for review: 
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 Evaluation of intervention(s) to improve transfer of medication related care 
on discharge from hospital 
 Intervention(s) delivered in full or part by pharmacists 
 Focus on patients aged >65 
Practice guidelines and government policy papers including recommendations for 
improving the quality of medicines related transitional care on discharge from 
hospital were also collated and will be discussed in the context of the research 
papers reviewed in Sections 4.2 - 4.4 of this chapter. 
During this literature review a more narrative approach is taken than might be 
expected in a full systematic review, and meta-analysis was not appropriate due to 
the heterogeneity of papers reviewed.  However where applicable Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria 
were followed; for example reproduction of search strategy, inclusion and exclusion 
criteria, reporting of study characteristics and results, consideration of limitations of 
studies reviewed, summary of evidence and interpretation of the results in the 
context of this thesis (109).  Figure 4.1 represents a flow diagram describing the 
literature search based on the PRISMA template.   
Reasons for excluding papers from review: 
 Unable to access full version of paper in English 
 Average age of participants <65 (unless study evaluated older participants 
during subgroup comparison) 
 Study recruited only those who were: 
o Surgical patients 
o Cognitively impaired 
o Discharged to residential care 
 Study focused on specific clinical condition only (e.g. heart failure, diabetes, 
COPD) 
 Pharmacist not involved in transfer of care intervention 
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 Intervention limited to inpatient services without a transfer of care element 
 Published after 2013.  Later publications could not have informed the design 
of the study, which forms the basis of this thesis, as all study planning was 
complete and approvals gained by the early part of 2014.  Instead, these 
papers will be reviewed in Chapter 8 (Discussion) of this thesis, placing the 
author’s work in the context of current developments. 
 
 
Figure 4.1: PRISMA flow diagram of literature search 
 
40 records identified 
through other sources 
4144 records 
screened 
101 full text papers   
assessed 
332 abstracts 
screened 
3812 records excluded 
(duplicates or not 
relevant following title 
screening) 
4104 records 
identified through 
database searching 
129 records excluded 
from literature review as 
published after 2013 (but 
will be reviewed for 
inclusion in discussion) 
102 records excluded  
30 papers excluded  
73 papers remaining 
47 papers reviewed in 
Chapter 3 
26 papers not included 
as duplicated findings 
already discussed 
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Database searches were performed from the earliest date available for each 
database at various stages throughout the progression of this PhD to inform study 
design and evaluation.   A final search was run in April/May 2017, to present an 
overview of how this field of research has expanded over recent years.  The 
growing importance of the transfer of care agenda is also reflected in the 
increasing number of national policy and practice guidelines published in this area 
(68,69,110-112).  As shown in Figure 4.2, there has been a sharp increase in 
activity in this field since 2011, when the project described in this thesis was first 
conceived.   
 
Figure 4.2: Number of papers relevant to medicines related hospital 
discharge care of older people, by year of publication 
 
4.2: PAPERS PUBLISHED BEFORE 2000 
The first papers reporting on pharmacist involvement in the transfer of care of 
elderly patients from hospital to the community were published in the mid-late 
1990s.  The inception of this research area in the UK was influenced by a number 
of factors, including the publication of the DoH’s Community Care Act 1990, which 
aimed to improve the provision of services and support for people affected by 
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problems associated with aging, mental illness or physical/sensory disability, to 
allow them to live as independently as possible (113).  Integration of primary and 
secondary care was identified as an important aspect of this type of care provision, 
and in a RPS policy statement on the pharmaceutical aspects of community care, 
the development of patient held documentation relevant to inpatient treatment and 
discharge and the improvement of links between hospital and community 
pharmacists were key recommendations (114).   
Around the same time there was a recognition of the growing problem of 
medication non-adherence and ADEs amongst the elderly post-discharge 
population and rising numbers of potentially preventable readmissions. This 
coincided with the development of the concept of pharmaceutical care and the role 
of the clinical pharmacist, with subsequent identification of the potential of the 
pharmacy profession to provide support in addressing these problems (115-119). 
4.2.1: Pharmaceutical Discharge Counselling and Follow-up 
One early paper, published in 1994, reports on a small pilot study conducted over 
five months on three care of the elderly wards at Ryhope General Hospital, North-
East England (115).  This before and after study aimed to evaluate provision of an 
inpatient pharmaceutical care service and a pharmacy discharge care plan as a 
means of communication between the hospital and community sectors.  Not all 
patients recruited received all elements of the service, which included medicines 
reconciliation on admission (n=38), performing a pharmaceutical assessment 
(n=38), counselling the patient before discharge (n=42) and providing the patient's 
GP and nominated community pharmacist with their medication details (including 
details of therapy changes and recommendations for ongoing pharmaceutical care, 
n=43).  The study found that drug knowledge increased from baseline scores 
performed at the time of recruitment, and 73% of patients demonstrated 100% 
medication compliance assessed by tablet count.  Whilst only half the 
recommendations for action by the GP or community pharmacist were followed, 
the authors acknowledged that the service was new, and in their opinion the more 
important recommendations had been actioned.  The service was noted to be time 
consuming for hospital pharmacists to deliver, with the authors recommending 
targeting those most likely to benefit, for example the elderly on multiple drug 
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therapy. 
The first RCT of a pharmacy-led transitional care service for older patients was 
conducted in the USA, and also published in 1994 (Table 4.1, page 84) (116).   
Clinical pharmacists provided intervention group patients with counselling on 
discharge medication prior to leaving hospital, followed by four follow-up 
consultations over three months. Medication adherence, assessed using a 
questionnaire administered via telephone, was found to be significantly higher in 
the intervention group post discharge.  In addition, polypharmacy was reduced in 
the intervention group. 
This study, however, failed to show a difference in hospital readmissions between 
groups after 6-month follow-up, with approximately one-third of both groups being 
readmitted at least once.  The authors suggested that their study population 
(n=706) was too small to detect a significant difference in overall readmissions and 
that several thousand patients might be needed to do so.  They also suggested 
replication of their study among ‘high-risk’ patients, such as those taking particular 
medicines that are known to be associated with serious ADEs, prescribing errors or 
poor adherence.   
The concept of tailoring transfer of care interventions to patients anticipated to be 
at high risk of readmission was explored during a 1998 Australian RCT involving 
762 discharged patients (Table 4.1) (117).  All intervention group participants 
(n=381) received discharge counselling from either a pharmacist or nurse 
regarding compliance with medication and detection/reporting of worsening in their 
clinical condition.  In addition, intervention patients deemed at high risk of 
readmission (defined as 2 or more of the following criteria: age >60, prescribed 2 or 
more medicines, admission within the previous 6 months, living alone or 
possessing limited English language skills) received a home visit one-week post 
discharge from a hospital pharmacist and nurse (n=314).  At this home visit, the 
pharmacist assessed compliance and medication knowledge and made 
interventions where problems were identified, ranging from education, provision of 
compliance aid or medicines chart, organisation of daily medication monitoring by 
carers or referral to the patient’s regular community pharmacist for ongoing 
support.  The nurse then assessed participants’ physical and psychosocial status 
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and referred for community based support as needed. 
At six-month follow-up, there was a significantly lower number of readmissions and 
out-of-hospital deaths in the intervention group.  However, the number of patients 
in whom these endpoints occurred was not significantly different between groups.  
Post-hoc analysis suggested that patients particularly likely to benefit from home-
based intervention included those with chronic heart failure or respiratory disease, 
and those who were at risk of poor medication adherence or ADEs (e.g. those 
prescribed more than 5 medicines). 
It should be noted that the above study involved a pharmacist and nurse working 
together to provide an intervention, and it is not possible to clarify the relative 
contributions of the actions of each to the reported positive results.  Similarly, as 
the ‘high-risk’ subset accounted for 82% of the intervention group patients (who 
therefore went on to receive the home visit) it was not possible to clarify the relative 
contribution of the discharge counselling component of the intervention. 
The effects of discharge counselling and post-discharge domiciliary follow-up were 
assessed in two 1997 UK RCTs of hospital generated pharmaceutical care for 
older patients (Table 4.1) (118,119).  One study, by Smith et al, involved 53 
patients aged >65, identified by ward pharmacists as being at risk of DRPs 
following discharge (118).  Intervention group participants received pharmacist 
discharge counselling and a written care plan, which they were instructed to show 
to their GP and community pharmacist.  They were also provided with a telephone 
helpline number for any medicines related queries.  Control group patients 
received standard pharmaceutical care, including a medicine record card 
containing a summary of when to take their medicines together with a copy of their 
discharge prescription.  All participants were visited 7-10 days post discharge for 
follow-up assessment and resolution of any identified DRPs.  At this visit, 
compliance (as assessed by interview and tablet count) was significantly higher in 
the intervention group.  However unintentional medication discrepancies between 
discharge and home medication regimens were common in both groups (almost 
half of the intervention group and two-thirds of the control group) and some form of 
DRP was identified for three-quarters of intervention group patients and 96% of 
controls.  No participants contacted the helpline with a medicines related query. 
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This study suggested that, although pharmacist discharge medication counselling 
and provision of a written care plan may lead to improved adherence among older 
patients, the potential for DRPs after discharge is still high and patients cannot be 
relied upon to identify and tackle these problems on their own.  It should be 
acknowledged that limitations of this study, such as its small size and short follow-
up period, prohibited any assessment of the effects of the intervention on 
subsequent health service usage.  It is also not reported what percentage of 
intervention group patients actually showed their medication care plan to their 
community pharmacist, and what, if any, subsequent actions were taken by the 
pharmacists to support these patients. 
The second study, by Begley et al, was an RCT of a post-discharge domiciliary 
pharmacy visit involving 190 patients discharged from 3 hospitals in one UK health 
authority (119).  Eligible participants were aged >75 years and prescribed at least 3 
medicines, with one or more having a twice daily or higher dosage frequency.  
Intervention participants received 5 visits between 1-2 days and 12 months 
following discharge, during which the pharmacist reviewed their medicines use and 
storage and offered solutions where problems were identified.  In order to 
determine any placebo effect of receiving a visit on participants’ medicating 
behaviour, this study utilised 2 control groups, one which received 5 visits to collect 
follow-up measures but no intervention, and one which received one baseline visit 
1-2 days post discharge and one final visit at 12 months to collect follow-up 
measures only. 
Adherence, measured by tablet count, was higher in the intervention group at all 
follow-ups, and inappropriate drug storage and hoarding decreased over the 12-
month study period, whereas there was no change in these behaviours in the 
control groups.  The number of GP visits was also lower in the intervention group, 
although this only reached statistical significance between the 3 and 12 month 
visits.  As with the previous study, readmissions were not studied. 
Summary 
Collectively these early studies indicated that transfer of medicines related care for 
older patients could be improved by pharmacist interventions involving discharge 
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counselling in association with post-discharge follow-up, or repeated follow-up.  
This is evidenced by improvements in medication knowledge and/or compliance in 
patients who received these interventions. Targeting ‘high-risk’ patients such as 
those with complex polypharmacy, particular clinical conditions such as heart 
failure or respiratory disease, or those at risk of DRP after discharge, may increase 
the potential for success of these interventions.  Collaborative working with other 
healthcare professionals (HCPs), such as nurses, to provide a holistic package of 
care, may also increase their value.  
Data regarding healthcare usage following pharmacist interventions in transfer of 
care were however lacking in these early studies.  Although improved compliance 
and drug knowledge are worthy objectives they are only really proxy outcomes in 
improving patient health and quality of life.  Demonstrating a reduction in 
readmissions and A&E visits would be valuable both in terms of reducing 
healthcare costs and improving patient outcomes.  In order to detect differences in 
these outcomes though, larger sample sizes are likely to be needed than were 
achieved in most of these early studies. 
4.2.2: Information Transfer and the Role of the Community Pharmacist Pre- 
2000 
Whilst the above studies, in the main, focused on hospital generated care and 
follow-up, other early research focused on improving information transfer between 
secondary and primary care regarding medication changes made in hospital and 
associated patient needs.   Some researchers hypothesised that community 
pharmacy could be the ‘missing link’ in reducing DRPs after discharge.  A quasi-
experimental study conducted by Duggan et al in East London, UK, and published 
in 1998, aimed to reduce prescribing discrepancies post hospital discharge by 
providing 264 intervention group patients with a list of their discharge medication to 
pass to their community pharmacist (Table 4.1) (120).  Eighty-nine percent of these 
patients handed the information to their community pharmacist, and the study 
reported a reduced rate of medication discrepancies in the intervention group after 
2 weeks (32.1% of drugs had an unintentional discrepancy vs 52.7% in the control 
group, P<0.001).  Almost all (96%) of the community pharmacists involved were 
enthusiastic about the service; the only criticism was the clarity of some of the 
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information received from the hospital, with electronic transfer of information 
suggested as a possible solution.  Although the vast majority of patients in this 
study did deliver the information to their pharmacist, it should be noted that the 
study only recruited patients up to the age of 79, and nearly half were aged under 
65.  Older patients, who are the focus of this thesis, may have reduced mobility 
and find it more difficult to deliver the information to the pharmacy, and indeed 
other studies have found much lower rates of patient self-referral to community 
pharmacy post discharge (10,107,121,122). 
A different approach to transferring discharge information was taken by a hospital-
community pharmacy liaison service for patients from medical and elderly wards at 
Airedale general hospital in West Yorkshire, UK.  During a 6-month pilot, the 
hospital pharmacy faxed details of medication changes, reason for admission, 
special needs, discharge medication and any other relevant information for 82 
patients to their community pharmacy upon discharge (123).  Fifty-four potential 
DRPs were identified by community pharmacists, the largest proportion (one-third) 
of which were related to patient compliance, and a quarter of which related to GPs 
medication records not being updated before the first post-discharge prescription 
was generated, leading to prescribing errors or missing items.   
The authors of this service evaluation concluded that faxed discharge sheets can 
offer a better level of communication and co-operation between hospital and 
community pharmacists, and provide an opportunity to resolve medication 
problems before a patient arrives at the community pharmacy.   However, they also 
note that the successful transfer of information between hospital and community 
pharmacy relies on patient ‘loyalty’ to one particular community pharmacy; as 
evidenced by the fact that in over a third of cases the patient did not visit their 
nominated pharmacy, and the pharmacists were unable to make contact to resolve 
potential problems.  This is in contrast to other studies where high (86-90%) levels 
of patient loyalty were observed (120,124).   
Around the same time, researchers in the USA evaluating a hospital-community 
pharmacy referral form conducted 120 interviews with 91 participating community 
pharmacists (121).  Initially the forms had been given to patients to hand in to their 
community pharmacist, but after finding that the majority of patients did not do this, 
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forms were also posted to the community pharmacy.  Like Duggan, these authors 
suggested electronic transfer of information from the hospital pharmacy to address 
this problem.   
Eighty-five percent of interviewed pharmacists indicated that the referral form 
provided information that resulted in a benefit to the patient through enabling 
tailored counselling regarding their medicines.  Eighty-seven percent of 
interviewees felt the information provided had a positive impact on patient-
pharmacist interactions, and 62% were able to incorporate the information into a 
database to direct future patient care.  The most useful aspect of the form was felt 
to be the discharge medication list, although some pharmacists called for greater 
emphasis being placed on discontinued medicines.   Suggestions for 
improvements included intended duration of use of the medicines, the follow-up 
plan, extent of discharge counselling provided, name and telephone number of the 
attending physician (equivalent to consultant in the UK), and the patient’s 
prognosis.  Despite this enthusiasm for information, many pharmacists indicated 
that drug-dispensing functions occupied too much of their time to allow them to use 
the forms to improve patient care.   
A further early trial of enhanced transfer of information regarding medicines on 
discharge in Aberdeen, UK involved 90 patients sequentially assigned to 
intervention or control groups (125).  Intervention patients were given a pharmacy 
information letter providing details on their discharge medication, along with verbal 
counselling.  A copy of the letter was sent to the patient's GP, community 
pharmacist and community nurse by post or fax.   
This study found that, compared to control group patients (who had received 
discharge counselling as part of ‘standard care’), fewer intervention group patients 
had problems managing their medicines within the first 2 weeks post discharge 
(22% vs 46%, p<0.05).  The commonest problems identified were related to 
adherence (usually unintentional due to a lack of understanding of the discharge 
medication regimen) and the complexity of medication regimens.  This indicates 
that verbal discharge counselling alone in this study was not enough to prevent 
DRPs, possibly due to poor patient recall and the low level of counselling of care 
givers, who were involved in home medication management of many of the 
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participants.  These findings support the need for multiple component 
interventions, with reinforcement post discharge as identified in the studies by 
Smith and Begley above, and the involvement of care-givers where appropriate 
(118,119). 
The contribution of community pharmacists in this study was limited by the fact 
that, similar to the Airedale study, only 54% of patients presented their first post-
discharge prescription to their nominated pharmacy.   
Summary 
Most early studies involving patients’ regular community pharmacist in their transfer 
of care had small sample sizes and were non- or quasi-experimental in design.  
This, together with a limited range of outcome measures (for example no data on 
healthcare resource usage or participants’ quality of life are reported in any of the 
studies reviewed in this section) limits the conclusions that can be drawn from their 
results. 
Where these early studies are valuable is in providing a background on which 
future transfer of care services could be built; for example the unreliability of 
requesting patients to transfer their own discharge information to their pharmacist, 
and the type of information required by community pharmacists on referral.  These 
studies also provide ‘proof of concept’ that, when discharge information is received 
by community pharmacists, it can be used to identify medication discrepancies and 
detect other DRPs. 
 
4.3: TRANSFER OF MEDICINES RELATED CARE AFTER 2000 
4.3.1: Studies Involving Patients’ Regular Community Pharmacists 
Around the turn of the millennium, there was a reduction in the number of new 
papers reporting on transfer of care interventions involving pharmacists.  However, 
in 2001 the first UK RCT of co-ordinated discharge planning by hospital and 
community pharmacists was published by Nazareth et al (Table 4.1) (126).  
Patients aged >75 were assessed and their medicines rationalised by a hospital 
pharmacist, given discharge counselling and a medication discharge plan, which 
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was also provided to their carers, GP and community pharmacist.  The community 
pharmacist then conducted a home visit 7-14 days post discharge to reconcile 
medicines, check patient understanding and adherence and intervene where 
necessary.  Second or third visits could be provided at the community pharmacist’s 
discretion. 
Despite the comprehensive and time-consuming nature of this care package, there 
were no significant differences between intervention and control groups in 
readmissions, death, outpatient attendances, GP visits, medication adherence, 
general wellbeing or satisfaction with care at 3 or 6-month follow-up.  Looking to 
explain the lack of effect, the authors note that the average age of their participants 
was 84, most had at least 3 LTC and all were prescribed complex medication 
regimens.  Moreover, the baseline level of adherence was high, offering little room 
for improvement.  It is worth noting that community pharmacists were unable to 
visit 22% of the patients referred to them, and it is possible that this cohort were 
different in some way to the patients who were visited, making them more likely to 
benefit. 
Further research was published the following year by Stowasser et al, who 
conducted an RCT to evaluate the benefits of a medication liaison service (MLS) in 
Australia (Table 4.1) (127).  The MLS pharmacist liaised with intervention group 
patients’ GPs and community pharmacists at the point of admission to reconcile 
medicines and prepared a comprehensive discharge summary including details of 
all medication changes and recommendations for follow-up.  This information was 
provided to the GP and community pharmacist within 24 hours of discharge.  
Participants were randomly selected from the daily admission list and no inclusion 
criteria in terms of age, number of medicines or likelihood of DRPs were set.  
Although younger than the participants in most of the other studies reviewed here 
(mean age 66.5 years), participants did experience a high degree of polypharmacy 
(mean 7.6 medicines per patient), which as addressed in earlier chapters does 
increase the risk of DRPs following discharge. 
At 30-day follow-up, there were numerically fewer patients readmitted in the 
intervention group (12 (11%) vs 17 (13%)), although this did not reach statistical 
significance (p=0.076).  Intervention group patients also required significantly fewer 
67 
 
HCP visits during this time period (7.54 vs 9.94 per patient, P<0.05).  Functional 
health and wellbeing, measured using the Short-Form 36 health survey (SF-36), 
tended to improve more from baseline in the intervention group, for all components 
other than vitality.  The authors argue that as their sample size was relatively small 
(n=240) and the overall rate of readmission fairly low, the observed reduction in 
readmissions probably did represent a true effect of the intervention, but that a 
larger study would be required to confirm this.  This limitation has been identified in 
other studies reviewed here (116,118,122,125,128-133). 
It is disappointing that this study did not report on the actions taken by community 
pharmacists following receipt of discharge information from the hospital.  As such it 
is difficult to characterise the impact that this transfer of information had as distinct 
from the other elements of the MLS (e.g. improved medicines reconciliation in the 
hospital and provision of the enhanced discharge information to the GP). 
A further Australian RCT, this time focusing more on the post-discharge element of 
transitional care, was published in 2003 by Naunton and Peterson (Table 4.1) 
(128).  This study evaluated home-based follow-up of high-risk elderly patients 
within 5 days of discharge.  Eligible patients were randomised to a home visit or 
standard care.  Patients had to be aged >60 with >2 LTCs and at least 4 regular 
medicines.  A full clinical medication review was provided to intervention group 
patients, including review of the need for all medicines and monitoring 
requirements, and where issues were identified the patient’s GP and community 
pharmacist were contacted.   
At the initial visit, 179 DRPs were identified for the 57 intervention group patients.   
By 90-day follow-up, there were significantly fewer readmissions in the intervention 
group (p=0.05), better self-reported compliance and significantly fewer DRPs.  This 
suggests that older patients (median age 75.5) with complex medical conditions 
(median=5) and polypharmacy (median = 8 medications) could benefit from a 
home visit by a suitably qualified pharmacist who has the ability to liaise with the 
patients’ GP, community pharmacist and hospital following discharge.  The findings 
from Naunton’s study need to be interpreted with caution however as it was 
relatively small (n=121).   
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A similar Australian RCT was published in 2008 by Vuong (129).  To be eligible, 
patients had to have one or more risk factors for DRPs (Table 4.1).  Dedicated 
community liaison pharmacists (CLPs) received a blinded handover from ward 
pharmacists and provided a home visit to intervention group patients within 5 days 
of discharge.  During the home visit, the CLP provided education and information 
to the patients and/or their carers, monitored techniques with administration 
devices, assessed medication supplies and storage, removed obsolete medicines 
and evaluated discrepancies with the regimen prescribed at discharge.  Any 
difficulties, problems or potential problems experienced by the patients were 
rectified or highlighted for primary care provider intervention.  A report from each 
visit was produced and faxed to the GP, community pharmacist and other relevant 
primary HCPs.   
Unfortunately, recruitment to this study (n=316) did not reach the sample size 
required for comparison of readmission rates, which are not reported.  In fact 73% 
of patients referred to the service were either excluded or chose not to participate, 
which appeared to stem primarily from the burdensome recruitment process.  
Despite the sample size being smaller than planned, this study did demonstrate a 
greater improvement in medication adherence in the intervention group compared 
to the controls (p=0.028), as measured using a modified Morisky scale (a tool that 
quantifies self-reported medication adherence).  The impact of liaison with 
participants’ regular community pharmacist, and any subsequent actions taken by 
the community pharmacists was not evaluated. 
Another RCT, by Holland et al in 2005, of a home-based medication review 
following discharge, focussed on patients aged >80 (the HOMER study, Table 4.1) 
(134).  They recruited 872 patients, across 10 UK hospitals, who were randomised 
to standard care or to be visited at home by a pharmacist approximately 1 week 
after discharge.  Pharmacists assessed patients’ ability to self-medicate and 
medicine adherence, educated the patient and carer, removed out of date 
medicines, reported possible drug reactions or interactions to the GP, and reported 
the need for a compliance aid to the community pharmacist.  One follow-up visit 
occurred at 6-8 weeks after recruitment to reinforce the original advice.  
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This study found that at 6-month follow-up there was a higher readmission rate and 
number of GP visits in the intervention group; however there was a trend towards 
fewer deaths in this group.  One possible explanation for these findings proposed 
by Holland et al is that pharmacists did help patients to understand their conditions 
better, leading them to recognise warning signs and seek help earlier. This positive 
view is weakly supported by the non-significant decrease in deaths observed in the 
intervention group.  Another explanation is that by improving adherence to 
prescribed medication, this study actually increased the rate of iatrogenic illness to 
which this elderly group of patients (mean age 85.5) may have been particularly 
vulnerable; however the actual aetiology of the readmissions and GP visits was not 
explored.  Finally, by visiting patients at home and spending relatively long periods 
of time there the researchers acknowledge that they may simply have added to the 
complexity of care, creating confusion or causing patients to focus more on their 
problems.   
These latter two factors hint at the importance of focussing on the patient’s agenda 
during medication review.  By ascertaining what the patient actually wants and 
needs to know about their medicines (as opposed to what we think they ought to 
know) we can avoid the situation of ‘information overload’ and patient confusion.  
By encouraging open discussion regarding baseline adherence to medication and 
being aware of the potential consequences of increased adherence (for example 
hypotension and falls if previously unused blood pressure medicines are suddenly 
re-started), we can minimise (or at least be alert to) iatrogenic adverse effects as a 
result of improved adherence.  This view is supported by other commentary on this 
study, which suggests that the medication reviews carried out were not holistic, 
were limited by lack of access to clinical records and means to verify the 
correctness of the discharge medication list, and that the additional training 
received by the pharmacists involved may not have been adequate in relation to 
their previous clinical level of practice (135,136).   
Recruiting patients from 10 different hospitals and using 22 different pharmacists to 
deliver the intervention could be viewed as a positive factor as it may make the 
results more generalisable to the ‘real world’ situation.  However the heterogeneity 
of the pharmacists and the patient population (for example the intervention group 
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included more patients with dementia) should perhaps be taken as an indication 
that the results of HOMER do not necessarily mean that home medication review 
by pharmacists is ineffective or detrimental, but that more work is needed to 
ascertain target patients and the most appropriate form of the review and level of 
training required by the pharmacists involved. 
Holland et al themselves called for research into more effective forms of 
medication review, possibly based in general practice with full access to clinical 
notes and a close working relationship with the patient’s GP.  In Naunton’s study 
above, the importance of liaising with other practitioners was also emphasised.  It 
may be worth noting that Naunton’s patients were, on average, 10 years younger, 
so may have had more potential to benefit from the intervention and been less 
vulnerable to iatrogenic adverse effects (128).   
It would be interesting to recreate Holland’s study using the patients’ regular 
community pharmacist, who they were perhaps more used to interacting and 
discussing medication related problems with.  This may have made the intervention 
seem less confusing and more part of routine practice by avoiding the introduction 
of yet another HCP to their care.  The same could be said for the domiciliary visits 
in the studies by Naunton and Vuong above.  Empowering the regular community 
pharmacist would also give them a platform from which to provide ongoing 
pharmaceutical care in the long term, which research or hospital based 
pharmacists are unable to do. 
Another study which involved, but did not focus on, patients’ regular community 
pharmacists, was a quasi-experimental study by Al-Rashed et al who reported on 
the value of pharmaceutical counselling of elderly patients prior to discharge (Table 
4.1) (122).  Eligible patients were aged >65, taking 4 or more medicines, and at 
risk of DRPs post discharge in the professional opinion of the ward pharmacists 
who referred them.  Intervention group patients received comprehensive 
medication discharge counselling.  All patients then received a visit from a research 
pharmacist at 2-3 weeks and 3-months post discharge, who collected follow-up 
measures and provided advice on the correct use of medication. 
The intervention group in this study displayed better medication knowledge and 
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compliance than the control group at both follow-ups, with a significant increase in 
compliance between first and second follow-up in the intervention group only. GP 
visits and readmissions were also significantly lower in the intervention group.  This 
study involved fewer patients than the others evaluated here (n=83) and caution is 
required in interpreting the results as the participants were not randomised but 
instead two different hospital wards were used for intervention and control groups.  
Although older than those in Stowasser and Vuong’s studies, participants were 
slightly younger than in Nazareth’s and Holland’s (mean age 80 vs 84 vs 85.5 
years) but were prescribed more medicines on average (7 vs 6 vs 6) and all had 
been identified as at risk of DRPs.  It could be that this study population had more 
to gain from the pharmacy intervention than Nazareth’s (who were already highly 
compliant with their medication), or Holland’s.  This indicates the importance of 
targeting patients who have the potential to benefit from interventions as well as (or 
in preference to) those who are ‘high risk’ due to demographic factors. 
A further observation from this paper is that despite being explicitly instructed to do 
so, only 4.4% of patients showed their discharge summary and medication 
reminder card to their community pharmacist, casting further doubts on the 
feasibility of relying on patients to transfer discharge information to those 
expressed above.  This low rate of information transfer also meant that any 
opportunity for the community pharmacist to contribute to improved patient 
outcomes in this study was minimal. 
The Australian home medicines review (HMR) programme was introduced in 2001 
and involves an accredited pharmacist visiting patients in their homes to identify 
drug-related problems and make recommendations to optimise medication 
management.  HMRs organised for patients post-discharge have been shown to 
improve the transfer of medicines information between hospital and community 
practitioners and improve communication between patients and their health 
professionals (137-139).   However, conducting timely post-discharge HMRs has 
proved problematic.  A pilot study investigating whether hospital-initiated 
medication reviews (HIMRs) could be implemented in a more timely manner than 
HMRs demonstrated that when at-risk patients with a mean age of 75 were 
referred directly to accredited pharmacists on discharge from hospital, HIMRs were 
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conducted in a mean of 11.6 days post-discharge (140).  Issues raised by 
pharmacists during HIMRs were awarded a rank of clinical significance by an 
expert panel, with 43% judged to have a significant impact on patient care.  
However, the impact on actual patient outcomes was not studied, which limits 
determination of the true benefits of the service.  After the HIMR, the patient’s GP 
and community pharmacist were given copies of the report, but in common with 
many of the studies above, actions subsequently taken by the community 
pharmacists are not reported. 
More opportunity was provided for community pharmacists to contribute to post 
discharge care in a 2004 RCT of a hospital-community liaison pharmacy service by 
Bolas et al (130).  This study was based in Northern Ireland, UK, and involved 162 
participants aged >55 (mean = 74) prescribed at least 4 medicines (mean = 6.8) 
who were randomised to receive the liaison pharmacist care package or standard 
discharge care.  The care package included an inpatient review of medicines use, 
discharge counselling, medicines record sheet informing patients how to take their 
drugs and a discharge letter detailing the changes made to drug therapy which was 
faxed to the GP and community pharmacist on discharge.   A medicines helpline 
was available to all patients following discharge.  Results showed that at 10-14 day 
follow-up, there were fewer discrepancies in the intervention group between 
medicines prescribed on discharge and those taken at home, and medication 
knowledge had increased.  At 3 months’ post discharge there was no difference in 
readmissions between groups, although the small sample size in this study is likely 
to have limited its power to detect such a difference.  As with Smith’s 1997 study 
there was a low uptake on the use of the helpline with only 11 calls within a 10-
month period.   
Bolas also surveyed GPs and community pharmacists and found that 57% of GPs 
and 95% of community pharmacists considered the discharge letter had improved 
the standard of information exchange at discharge.  However, in common with 
Stowasser’s study, no data was collected with regards to what interventions, if any, 
were made by community pharmacists following receipt of this information.   
Further studies by this research group published in 2007 and 2012 demonstrated 
how integrated medicines management (IMM) from admission through discharge 
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was associated with a reduction in readmissions, increased time to readmission 
and reduced length of stay on readmission (Table 4.1) (141,142).  Their service 
included a comprehensive medication record sheet given to the patient and faxed 
to the GP and community pharmacist on discharge.  Both these studies involved 
larger numbers of participants (n=762 and n=833 in the 2007 and 2012 studies 
respectively) than most of the studies discussed thus far.  However, it is important 
to note that neither of the studies were RCTs.  Both were limited by their quasi-
experimental design and by capacity issues in delivering the service – not all 
intervention group patients received all components of the IMM service, and there 
was likely under-recording of the interventions that were conducted.  This makes it 
difficult to discern if there were key interventions which contributed to its success, 
results may have been different if delivery and recording of the intervention were 
more complete.  Additionally, in the 2012 study the small size of the comparison 
group may reduce the validity of the results.  Again no data was collected 
regarding interventions made by community pharmacists in these two studies, 
although all 27 community pharmacists who completed a satisfaction questionnaire 
in the 2007 study felt that the faxing of the discharge details improved the 
information exchange between the health care sectors, and 92% believed the 
process to be beneficial to the care delivery to their patients. 
In the Netherlands, discharge prescriptions are supplied by a community 
pharmacy; usually the discharge prescription is sent directly from the hospital to 
the pharmacy where the patient is registered (143).  The regular community 
pharmacist therefore plays an important role in transfer of care.  In 2001, the 
Association of Amsterdam Community Pharmacists adopted a programme (the 
IBOM-1 intervention) to improve the pharmaceutical care of patients who were 
discharged on 5 or more medicines.   
Evaluation of this programme involved thirty-seven community pharmacies (self-
selected as control or intervention) (Table 4.1).  Each was asked to recruit 20 
consecutive patients discharged from hospital.  Intervention pharmacies provided 
counselling to 92% of patients, a daily medication intake scheme to 82.7%, a 
‘medication passport’ to 38.7%, removed redundant home supplies of medication 
for 25.6% and synchronised medication for 11%.  Twenty-one percent of 
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intervention patients also received some form of follow-up counselling.  In contrast, 
only 19% of patients received counselling as part of usual care, and additional 
interventions were provided to only 4.2%.   
Despite this intervention, there were no significant differences between study 
groups in persistence (i.e. time to discontinuation) with long-term medicines or 
mortality at 9 months.  The authors note that despite the importance of a home visit 
as part of the IBOM protocol, less than two-thirds of intervention group patients 
received a home visit, thus reducing the potential effect of the intervention.  The 
authors also suggest that one of the factors accounting for the lack of effectiveness 
of the IBOM protocol could be the unstructured nature of the medication review by 
the pharmacists, who were not trained for this specific task.  Additionally, they 
argue, in most cases, only one visit was provided whereas repeated follow-up may 
be necessary to impact on outcomes such as readmissions.  The authors 
recommended a further trial involving more intensive medication review and 
repeated follow-up over a period of 1 year from discharge. 
Such a trial was published in 2012 by Ahmad et al, involving 340 patients aged 
>60, discharged from hospital in the Netherlands taking 5 or more medicines 
(Table 4.1) (144).  Community pharmacies were randomised as control or 
intervention pharmacies.  Pharmacists working at intervention pharmacies were 
given training in medication review and pharmacy technicians were trained in 
counselling using cognitive behavioural technique (145).  Intervention pharmacists 
and technicians worked together to provide a post-discharge medication review 
and 5 follow-up consultations over a period of 12 months.  At 12-month follow-up, 
the number of DRPs per patient had decreased in the intervention group, but 
increased in the control group (p=0.05), with the effect being more pronounced 
among patients with hypertension or heart failure.  Effects on other outcomes, such 
as ADEs, readmissions, A&E visits and quality of life are not reported, making the 
overall impact of this intervention difficult to assess.  This is disappointing as this 
study could potentially answer many of the questions previously raised by other 
authors.  For example, repeated counselling over a prolonged period, although 
advocated by several researchers, has not been studied elsewhere according to 
the findings of this literature search.  Specific training for community pharmacists 
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has also been called for but not widely adopted or evaluated.  Additionally, utilising 
pharmacy technicians to provide ongoing follow-up, if effective, could be valuable 
in freeing pharmacist time and reducing costs.  
In Canada discharge prescriptions are also dispensed by community pharmacies.  
A 2008 Canadian study investigated the effect on post-discharge discrepancies of 
supplying a medication discharge plan (MDP) to community pharmacists (Table 
4.1) (146).  The MDP was given to all patients and also to the community 
pharmacists of intervention group patients only.  It included many of the elements 
called for by community pharmacists in previous studies, including contact details 
of the hospital pharmacist and physician, admission medication with status at 
discharge of each of these, intended duration of new medication, and any 
recommendations made by the hospital pharmacist (121,130).  To be eligible for 
this study, patients had to have at least 2 changes to drug therapy during 
admission.  All patients (intervention and control) received comprehensive 
pharmaceutical care during admission, including medicines reconciliation, case 
discussion with physicians and discharge counselling. 
Discrepancies between the MDP and community pharmacy dispensing records 
were found for just over two-thirds of patients in both groups one week after 
discharge, whilst discrepancies between the MDP and patient reports of 
medications taken were found in over half.  Just over one-third of discrepancies in 
the community pharmacy records were judged independently by a clinical 
pharmacist and family medicine doctor to be significant but not life-threatening, 
whilst 48% of patient discrepancies were in this category.  Interestingly, the rate of 
serious patient discrepancies was higher in the MDP group (13.5% vs 0.7%, 
p=0.02). 
The researchers therefore concluded that provision of the MDP to community 
pharmacies was not effective in reducing post-discharge medication discrepancies.  
Suggested reasons for these results included incomplete medicines reconciliation 
in the hospital setting and failure of community pharmacists to incorporate all the 
information in the MDP into their dispensing records.  Further training of hospital 
and community pharmacists and incorporating the MDP into the discharge 
prescription itself were suggestions for improvement. 
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Summary  
The studies discussed above suggest that the role of the community pharmacist in 
the transfer of care of older patients has been hampered by a lack of information 
transfer from hospitals and a deficit of time or skill to act on this information 
effectively when received (121,143,146).  Most studies providing post-discharge 
follow-up used domiciliary visits, which are reported as being time consuming to 
deliver (122,126,128,129,134).  Domiciliary visits by community pharmacists in the 
UK, whilst not prohibited by the current contractual arrangements, are restricted by 
the need to apply separately for each visit conducted and restrictions on the time 
they may be away from the pharmacy premises.  Additionally, not all studies which 
involve community pharmacists actually report on the role they play following 
enhanced communication from secondary care, instead utilising hospital, research 
or other specially trained pharmacists to provide the majority of post-discharge 
follow-up.  Indeed, only 5 of the (quasi) experimental studies discussed in Sections 
4.2.2 and 4.3.1 involved the community pharmacist as a ‘main player’ 
(120,126,143,144,146).  None of these studies demonstrated a reduction in 
readmission, ED visits or medicines adherence versus a comparison or control 
group, although medication discrepancies were reduced in one study and DRPs in 
another (120,144).  Therefore, there remains a gap in the evidence base around 
the effectiveness of enhanced information transfer and subsequent medication 
review by community pharmacists for older patients discharged from hospital. 
Support for community pharmacists to become more effectively involved in the 
transfer of care of older patients is needed, such as detailed referrals from 
secondary care for identified, appropriate patients, the facility to provide continued 
follow-up (ideally via home visit and possibly with the assistance of pharmacy 
support staff), training on the more clinical aspects of medication review and the 
provision to work in conjunction with other members of the multidisciplinary team 
(MDT) in secondary and primary care.   
4.3.2: Studies Not Involving Patients’ Regular Community Pharmacists 
As discussed in Chapter 3, not all readmissions are drug related and not all ADEs 
and drug related admissions are preventable, so a more realistic outcome measure 
77 
 
of the success of pharmaceutical transfer of care interventions might be to reduce 
the number of preventable ADEs occurring post discharge.  An improvement in this 
outcome was demonstrated by Schnipper et al, who conducted an RCT of 152 
patients who were randomised to receive pharmacist medication review and 
counselling at discharge and a telephone consultation 3 to 5 days later, or standard 
care (Table 4.1) (131).  The telephone call focussed on adherence to medication 
and follow-up appointments, detection of medication discrepancies, signs of early 
side effects and providing patient counselling and/or primary care physician 
feedback when appropriate. 
At discharge, changes to medication regimens were recommended in 60% of 
intervention group patients.  Despite this, by the 3-5 day telephone call, 29% of 
intervention group patients had unintentional discrepancies between their 
discharge regimen and medicines they were currently taking. These findings back 
up earlier research that medication review and counselling on discharge are not 
enough on their own to prevent DRPs post discharge (118,119,125).  By 30-day 
follow-up, unexplained discrepancies were similar in both control and intervention 
groups (65% and 61%, respectively), again indicating that repeated follow-up may 
be necessary. 
Despite the high number of discrepancies at 30-day follow-up, preventable ADEs 
had occurred in only 1% of the intervention group and 11% in the control (p=0.01), 
whilst the rate of preventable, medication-related ED visits or hospital readmissions 
was 1% in the intervention group and 8% in the control (p=0.03).  Total ADEs and 
healthcare utilisation did not differ between groups.  These results highlight the 
importance of selection of outcome measures when evaluating the contribution of 
pharmacists to medicines related transfer of care.  As the role of the pharmacist is 
to optimise the management of medicines, it may be unrealistic to expect a 
reduction in overall healthcare utilisation from a pharmacist intervention without 
using a very large sample in order to obtain sufficient power; therefore focussing 
on medication related events may be more suitable.  It would also be unrealistic to 
expect such an intervention to prevent unpreventable ADEs; therefore evaluation 
of preventable events as a primary outcome might avoid a true effect of the 
pharmacist intervention being missed. 
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A similar RCT published in 2009 by Gillespie et al involved 368 patients aged >80 
(Table 4.1) (132).  Intervention group patients received medicines reconciliation on 
admission, education and monitoring throughout admission as well as discharge 
counselling.  Recommendations on therapy were made to physicians throughout 
admission by the pharmacist.  Pharmacists also prepared detailed medicines 
related discharge information for the primary care physician of all intervention 
group patients, and contacted the patients 2 months after discharge to ensure 
adequate home management of medicines and answer any questions.  Control 
group patients received no pharmacist input.  As in Schnipper’s study, there was 
no significant difference in overall readmissions between control and intervention 
groups after 12 months, however ED visits were reduced by 47% in the 
intervention group relative to the control (49 vs 93 visits respectively).  When drug 
related readmissions (12.3% of the total readmissions) were studied, 9 were in the 
intervention group and 45 were in the control group, equating to an 80% relative 
risk reduction. These results may indicate that focussing on outcomes which 
pharmacists can be expected to impact (i.e. drug related readmissions rather than 
overall admissions) are more likely to reveal positive results.   
The authors of this study note that mortality rates were high at 32% over the 12-
month follow-up (no difference between intervention and control).  This is perhaps 
not surprising given the mean age of participants was 86.6 years.  However, it is a 
point to consider when designing research studies with very elderly patients – 
sample sizes may need to be increased accordingly when a prolonged period of 
follow-up is planned.  Polypharmacy was more prevalent in the intervention group 
(mean 8.7 vs 7.3 medicines, p=0.004).  This might mean the intervention group 
were more at risk of adverse outcomes and therefore the effect of the intervention 
may have appeared less.  Alternatively, the increased burden of polypharmacy in 
the intervention group may reflect a greater opportunity for pharmacists to 
contribute positively to the management of these patients, providing evidence for 
targeting of patients for pharmacist intervention based on the number of medicines 
prescribed.    
Support for this theory was provided by a 2013 USA study evaluating a discharge 
medicines reconciliation and counselling service (Table 4.1) (147).   Subgroup 
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analysis found that among patients prescribed >5 medicines, 30-day readmission 
rates for the intervention group were reduced more significantly compared to 
control (17.7% vs 29.5%, p=0.002) than when the whole study population was 
evaluated (16.8% vs 26%, p=0.006).  These findings were even more pronounced 
when patients prescribed >10 medicines were considered (19.5% intervention vs 
42.5% control group patients readmitted within 30 days, p<0.001).  Participants 
aged >65 were also more likely to benefit from the intervention, with readmission 
rates of 10.9% for older intervention group patients vs 31.4% for older controls 
(p=0.001).  These findings provide some background in targeting patients who 
have the most to gain from pharmacist interventions.   
A key limitation of this study was that it was not randomised; the pharmacist was 
asked to target patients who were prescribed problem medicines or major 
polypharmacy (>10 medicines).  Not surprisingly, therefore, the intervention group 
contained significantly more such patients than the control group, although age and 
gender mix was similar.  However, as with Gillespie’s study, if anything this makes 
the reduction in readmission rate in the intervention group more impressive, as it 
comprised a higher risk population. 
Another study involving elderly patients with polypharmacy was a pilot RCT 
conducted in 2009 in the USA.  Koehler et al investigated the effects of a care 
bundle provided by a nurse and clinical pharmacist on 30 and 60-day readmissions 
and ED visits combined (Table 4.1) (133).  To be eligible, patients needed to be 
aged >70, take >5 medicines, have >3 LTCs and require assistance with activities 
of daily living.  The pharmacist reconciled medicines for intervention group patients 
on admission and discharge, provided clinical medication review and medication 
counselling throughout admission and on discharge, and made a follow-up 
telephone call at 5-7 days post-discharge.  At 30 day post-discharge fewer 
intervention group patients had been readmitted or visited the ED (10% vs 38.1%, 
p=0.04).  However, by 60 days the difference was not significant (30% vs 43%, 
p=0.52).  The authors suggest that an optimal intervention would capitalise on the 
hospital based staff’s ability to improve short term readmission/ED visit rates while 
linking patients to longer term care to extend these outcomes.  Pertinently, a 
retrospective comparison study from the USA published by Kilcup et al in 2011 
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reported how a telephone call 3-7 days post discharge to reconcile and review the 
use of medicines discharge reduced readmissions at 7 and 14 days, but the effect 
had dissipated by 30 day follow-up (Table 4.1) (148).  This provides more evidence 
that repeated follow-up may be necessary to produce a sustained effect on 
outcomes post-discharge.   
Koehler’s study was limited by its small sample size (n=41), which, like in Vuong’s 
study above, was attributed by the authors to recruitment difficulties related to the 
onerous informed consent process (129).  However, the results do support the role 
of a targeted, interdisciplinary care bundle provided on both sides of the 
secondary-primary care interface in improving patient outcomes. 
Another recent American study evaluated the effect of a pharmacist discharge 
counselling service on 30-day readmissions (Table 4.1) (149).  Patients were 
stratified according to their risk of readmission; high risk patients had to have 5 or 
more risk factors, medium risk patients had 4 risk factors and low risk patients had 
3 or less.  Patients who received the pharmacist service were compared to a 
retrospectively selected comparison group of patients admitted during the study 
period who had not received the service.  The evaluation found a lower 30-day 
readmission rate among medium risk intervention patients only (3.8% vs 18.9% in 
the comparison group, p=0.033). 
The criteria for defining risk in this study were more stringent than in the others 
discussed in this chapter, where only one or two risk factors were required.  
Although the results of this non-experimental study must be interpreted with 
caution, it might be that in today’s population there are some patients whose needs 
are so complex that pharmaceutical interventions alone will not significantly affect 
the risk of readmission, reinforcing the need to target patients appropriately to a 
particular intervention. 
This concept is supported by a recent service evaluation of the introduction of a 
Medicines Care Plan (MCP) for patients discharged from elderly care wards at a 
large English teaching hospital (150).  Initially, hospital pharmacists used the 
PREVENT screening tool to identify high-risk patients but it was felt that the 
majority of patients screened were high-risk using this tool (151).   Therefore 
81 
 
clinical judgement was used instead, whereby the identification of a specific 
medicines-related post-discharge need acted as the trigger for recruitment of the 
patient to the project and creation of a MCP.  Patients and carers were also 
educated and signposted to HCPs in Primary Care for follow-up where appropriate. 
These included community pharmacists, practice pharmacists, GPs, district nurses, 
community matrons and practice nurses.  Evaluation found that 16% of the 204 
MCP patients were re-admitted within 30 days compared to 22% of 1161 
comparison patients. However as this was not designed or powered to be a 
research project, and the difference in size between the intervention and 
comparison groups was so large, the significance of these results is not clear. 
Summary 
Many of the interventions in the studies discussed above have aspects in common, 
but there is significant variation in the results reported.   Commonly, interventions 
involve some degree of input from a hospital pharmacist whilst participants are 
inpatients, comprising one or more of: medicines reconciliation, medication review, 
discharge counselling and provision of medication related discharge information to 
the patient, carers and community care providers.   Follow-up interventions may 
then be provided by hospital or research pharmacists or the patient’s own 
community pharmacist.  The nature and intensity of these follow-up interventions is 
also variable, with some being by telephone and others by home visit, some 
providing a clinical medication review whilst others are more adherence focussed.  
Some studies involve repeated follow-up whilst others investigate one follow-up 
contact only.  Studies also involve varying degrees of multidisciplinary working and 
levels of training for the pharmacists providing the interventions.   
It may be that nuances in how the various components of transfer of care 
interventions are combined and delivered can explain some of the differences in 
results reported.  Most of the studies reporting significant benefits in terms of 
reduced readmissions, ED visits, DRPs, or improved medication adherence 
involved either a combination of pre- and post-discharge components (so-called 
‘bridging’ interventions), repeated review post discharge with the benefit of hospital 
discharge information to support these follow-ups, or full clinical review post-
discharge with liaison with primary HCPs to solve identified problems 
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(128,129,131,133,144,149).  Both telephone and domiciliary reviews have been 
associated with positive outcomes, although telephone reviews may be more 
suitable for younger patients or to reinforce education already provided in a face-
to-face setting (132).  This was the view taken by the patient and public 
involvement (PPI) group for this study, who voiced concerns regarding discussing 
a subject as complex and personal as their medication regimen over the phone 
(see Appendix 2).   
The populations in the research reviewed above also varied between studies.  
Even studies limiting recruitment to ‘older’ patients reported a range of mean 
participant ages, and whilst it was shown by at least one study that patients aged 
>65 benefitted more from the intervention than younger patients, other researchers 
who failed to demonstrate a positive effect on outcomes have suggested that the 
advanced age of their participants (>84), may be one of the factors explaining the 
lack of benefit of their intervention (126,134,147).  Participant groups also varied in 
terms of the number of medicines taken, with a higher degree of polypharmacy 
being associated with a greater effect of the intervention by some researchers 
(132,147).  A number of studies only recruited patients who were ‘at risk’ of 
readmission or DRPs, and even these definitions varied widely, from the clinical 
judgement of ward pharmacists to meeting a pre-specified number of criteria from 
a specific list (122,126,128-130,133,141,142,144,149).  Most studies targeting ‘at 
risk’ patients showed positive results in terms of readmissions, ED visits, DRPs 
and/or adherence (122,128-130,133,141,144).  Studies that did not show positive 
results tended to have less stringent criteria for defining risk, for example studies 
that used age and number of medicines only were less likely to produce significant 
results unless the average number of medicines taken was >6 (126,130,134,144).  
However in Still’s study, where very stringent criteria were used, the finding that 
only ‘medium risk’ patients appeared to benefit suggests that a balance may be 
needed to target interventions to patients who can benefit from pharmacist transfer 
of care interventions without having such complex needs that specialist care 
packages are required (149). 
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Table 4.1: Studies of interventions involving pharmacists in transfer of care 
of older people at discharge 
First 
Author 
Year / 
Location 
Design Intervention Study 
population  
Follow-up 
period 
Outcomes 
Ahmad 2012 
Nether-
lands 
Quasi-
experiment 
Post discharge 
medication 
review by 
specially trained 
community 
pharmacist 
Counselling 
using cognitive 
behavioural 
therapy by 
pharmacy 
technicians at 1, 
3, 6, 9 and 12 
months post 
discharge 
340 (180 
intervention, 
160 control) 
Age >60. 
No. meds >5 
12 months DRPs: mean 
number per 
patient 
decreased from 
baseline to 
follow-up in the 
intervention 
group compared 
to control 
(p<0.05) 
 
Al-Rashid 2002 
UK 
Quasi-
experiment 
Discharge 
medication 
counselling. 
Medication 
reminder card 
and medication 
and information 
discharge 
summary 
sheets (MIDS) 
given to all 
participants for 
themselves and 
their GP and 
community 
pharmacist 
83 (43 
intervention, 
40 control), 
identified by 
ward 
pharmacists 
as being at 
risk of DRPs. 
Age >65 
(mean 80). 
No. meds >4 
(mean = 7.1) 
2-3 weeks 
3 months 
Medication 
knowledge: 
better in 
intervention 
group at both 
follow-ups 
(p<0.01) 
Adherence: 
higher in 
intervention 
group at both 
follow-ups 
(p<0.01) 
GP visits: fewer 
in intervention 
group at both 
follow-ups 
(p<0.05) 
Readmissions: 
fewer in 
intervention 
group at both 
follow-ups 
(P<0.05) 
Other: 34.6% of 
patients showed 
a copy of their 
MIDS to their 
GP; 4.4% 
showed it to 
their pharmacist 
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Begley 1997 
UK 
RCT 5 home visits 
over 12 months 
post discharge 
for review of 
medicines use. 
2 control 
groups, 1 of 
which received 
5 visits to 
collect follow-up 
measures only 
(Control(V)), 
and 1 of which 
received 1 
baseline visit 1-
2 days post 
discharge and 1 
visit at 12 
months to 
collect follow-up 
measures only 
(Control(NV))  
190 (61 
intervention, 
63 in 
control(V) 
and 66 in 
control(NV)) 
Age >75 
>3 meds with 
at least one 
having twice 
daily dosage 
2 weeks 
1 month 
3 months 
12 months 
GP visits: fewer 
in intervention 
group (p<0.01 
for 3-12 month 
time period) 
Adherence: 
better in 
intervention 
group at all 
follow-ups 
(P<0.0001) 
Medication 
knowledge: NS 
diff 
Inappropriate 
storage of 
drugs: 
decreased in 
intervention 
group (p<0.01)  
Drug hoarding: 
decreased in 
intervention 
group  
Bolas 2004 
UK 
RCT Inpatient review 
of medication 
use. 
Discharge 
medication 
counselling. 
Medicines 
record sheet 
informing 
patient how to 
take their drugs. 
Discharge letter 
detailing 
changes made 
to drug therapy 
(faxed to GP 
and community 
pharmacist on 
discharge). 
Medicines 
Helpline. 
162 (81 
intervention, 
81 control) 
Age >55 
(mean 74) 
No. meds >4 
(mean 6.8) 
 
10-14 days 
3 months for 
readmission 
only 
Medication 
discrepancies 
after 
discharge: 
fewer in 
intervention 
group with 
respect to drug 
name (p<0.005) 
and dosing 
frequency 
(p<0.004).  
Dose 
discrepancies 
approached 
significance 
(p<0.07). 
Medication 
knowledge: 
greater in 
intervention 
group (p<0.001) 
Readmissions: 
NS diff 
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Duggan 1998 
UK 
Quasi-
experiment 
Copy of drugs 
prescribed at 
discharge given 
to patient to 
pass on to 
community 
pharmacist 
501 (264 
intervention, 
237 control) 
Only 
recruited 
patients up to 
age 79 (54% 
were aged 
>65) 
2+ weeks Medication 
discrepancies 
after 
discharge: 
fewer in 
intervention 
group (P<0.001) 
Other: 89.2% 
took information 
to community 
pharmacist 
Gillespie 2009 
Sweden 
RCT Inpatient 
medicines 
reconciliation/ 
review 
Medication 
counselling 
throughout 
admission and 
on discharge.   
Telephone 
review of 
medicines use 
2/12 after 
discharge.  
368 (182 
intervention, 
286 control). 
Age >80  
(mean 86.6) 
Mean no. 
meds=8.7 in 
intervention 
group, 7.3 in 
control 
12 months A&E visits/ 
readmissions: 
Fewer in 
intervention 
group (RR=0.84, 
95% CI: 0.72–
0.99) 
A&E visits 
only: Fewer in 
intervention 
group (RR=0.53, 
95% CI: 0.37–
0.75) 
Readmissions 
only: NS diff 
Drug related 
readmissions: 
Fewer in 
intervention 
group (RR=0.2, 
95% CI: 0.1–
0.41) 
Holland 2005 
UK 
RCT 2 home visits 
over 6 months 
for review of 
medicines use  
872 (437 
intervention, 
435 control). 
Age >80 
(mean 85.5) 
No. meds >2 
(mean = 5.9) 
 
6 months Readmissions: 
More in 
intervention 
group (RR 
1.3,(CI 1.07-
1.58), p=0.009) 
Deaths: Trend 
towards fewer in 
intervention 
group (hazard 
ratio = 0.75, 
0.52 to 1.10; P = 
0.14) 
Quality of life: 
NS diff 
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Hugtenburg 2009 
Nether-
lands 
Quasi-
experiment 
Review of 
discharge 
prescriptions by 
community 
pharmacist. 
Post discharge 
medication 
counselling via 
telephone, 
home visit or in 
the pharmacy. 
Daily 
medication 
intake scheme. 
Removal of 
redundant 
home supplies  
Follow-up 
counselling.  
Medication 
synchronisation 
715 (336 
intervention, 
379 control) 
Mean age 
intervention 
group = 69.7, 
control= 72.7 
Mean no. 
medicines 
=7.8 in 
intervention 
group, 7.1 in 
control 
9 months Adjustments 
made to the 
quantity 
of drugs 
dispensed: 
higher in 
intervention 
group (average 
cost saving 
€19.5 per 
patient) 
Deaths: NS diff 
Medication 
persistence: 
NS diff 
Kilcup 2011 
USA 
Retrospective 
comparison 
Telephone 
reconciliation 
and review of 
medicines use 
3-7 days post 
discharge 
494 (243 
intervention, 
251 
comparison) 
Mean age = 
67 
Mean no. 
meds = 7 
7 days 
14 days 
30 days 
Readmissions: 
fewer in 
intervention 
group at 7 days 
(p=0.01) and 14 
days (p=0.04). 
NS diff at 30 
days. 
Koehler 2009 
USA 
RCT (pilot) Care bundle 
provided by 
nurse and 
pharmacist. 
Pharmacist 
provided 
medicines 
reconciliation on 
admission and 
discharge, daily 
medication 
review, 
discharge 
medication 
counselling and 
telephone call 
5-7 days post 
discharge 
41 (20 
intervention, 
21 control). 
Age >70, 
(mean = 
78.5) 
No. 
medicines >5 
LTC >3 
Required 
assistance 
with ADLs 
30 days 
60 days 
A&E visits/ 
readmissions: 
fewer in 
intervention 
group at 1st 
follow-up 
(p=0.04) but 
difference not 
significant by 2nd 
follow-up 
(p=0.52) 
Lalonde  2008 
Canada 
RCT Medication 
discharge plan 
(MDP) sent to 
community 
pharmacies 
(who dispense 
discharge 
medication) and 
treating 
physicians 
83 (42 
intervention, 
41 control) 
>2 changes 
to meds 
Mean age = 
71.5 
Mean 
meds=10 
1 week Medication 
discrepancies 
between MDP 
and pharmacy 
dispensing 
records/patient 
self report: NS 
diff 
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Lipton 1994 
USA 
RCT Discharge 
medication 
counselling.   
Four 
consultations 
over 3/12 post 
discharge 
(mainly 
telephone).   
Simplification of 
medication 
regimen.  
Pharmacists 
consulted with 
physicians at all 
stages. 
706 (350 
intervention, 
356 control).   
Age >65  
Meds >3 
6-8 weeks 
12-14 weeks 
6 months 
Readmissions: 
NS diff. 
Adherence: 
Higher in 
intervention 
group at 1st 
(p<0.035) and at 
2nd (p<0.001) 
follow-up. 
Polypharmacy: 
NS diff at 1st 
follow-up, 
intervention 
group taking 
fewer medicines 
at 2nd follow-up 
(p<0.001) 
Naunton 2003 
Australia 
RCT Home visit 5 
days after 
discharge for 
full clinical 
medication 
review. 
All participants 
received home 
visit 90 days 
after discharge. 
121 (57 
intervention, 
64 control) 
Age >60 
(median 
75.5) 
LTC >2 
Meds >4 
(median=8) 
 
 
3 months Readmissions: 
fewer in 
intervention 
group (p=0.05) 
Deaths: NS diff 
DRPs: fewer in 
intervention 
group (P<0.01) 
Adherence: 
higher in 
intervention 
group (p<0.001) 
with significant 
increase 
between initial 
visit and 90 day 
visit in 
intervention 
group. 
Polypharmacy: 
NS diff 
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Nazareth 2001 
UK 
RCT Assessment 
and 
rationalisation 
of medication. 
Discharge 
medication 
counselling.   
Medication 
discharge plan 
given to patient 
and sent to GP, 
community 
pharmacist, 
carers and any 
other relevant 
party. 
Home visit by 
community 
pharmacist 7-14 
days post 
discharge for 
review of 
medicines use. 
362 (181 
intervention, 
181 control) 
Age >75 
(mean = 84) 
Meds > 4 
(mean=6) 
3 months 
6 months 
NS diff in: 
Readmissions, 
Death, 
Outpatient 
attendance, GP 
visits, Hospital 
bed days, 
Medication 
adherence or 
knowledge, 
General 
wellbeing or 
Satisfaction 
 
Pal 2013 
USA 
Prospective 
cohort study 
Discharge 
medicine 
reconciliation 
and counselling. 
769 (537 
intervention, 
192 control) 
Mean age = 
55.5 years 
30 days In patients 
aged >65,  
readmission 
rate was 10.9% 
intervention vs 
31.4% control, 
p=0.001 
Schnipper 2006 
USA 
RCT Discharge 
medication 
counselling. 
Telephone call 
3-5 days post 
discharge for 
review of 
medicines use. 
 
152 (79 
intervention,7
3 control) 
Mean age = 
66 
Mean no. 
meds = 8 
30 days ADEs: NS diff 
overall but fewer 
preventable in 
intervention 
group (p=0.01). 
A&E visits/ 
readmissions: 
NS diff overall 
but fewer 
preventable 
medicines 
related in 
intervention 
group (p=0.03) 
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Scullin 2007 
UK 
Service 
evaluation 
with random-
isation 
Inpatient 
medicines 
reconciliation/ 
review 
Medication 
counselling 
throughout 
admission and 
on discharge.   
Comprehensive 
meds record 
sheet given to 
patient, GP and 
community 
pharmacist. 
 
762 (371 
intervention, 
391 control). 
Mean age 70. 
>1 of: meds 
>4, high risk 
drug, 
admission in 
last 6/12, 
age>65 and 
on anti-
depressant 
12 months Readmissions: 
fewer in 
intervention 
group (p=0.027). 
Length of stay 
on 
readmission: 
trend towards 
shorter in 
intervention 
group (p=0.068). 
Time to first 
readmission: 
longer in 
intervention 
group 
(P=0.0356) 
Scullin 2012 
UK 
Naturalistic 
experiment 
Inpatient 
medicines 
reconciliation/ 
review 
Medication 
counselling 
throughout 
admission and 
on discharge.   
Comprehensive 
meds record 
sheet given to 
patient, GP and 
community 
pharmacist. 
833 (749 
intervention, 
84 control). 
Mean age 
70.5. 
>1 of: meds 
>4, high risk 
drug, 
admission in 
last 6/12 
12 months Readmissions: 
NS diff in 
number. 
Length of stay 
on first 
readmission: 
shorter in 
intervention 
group (p=0.013). 
Time to first 
readmission: 
trend towards 
being longer in 
intervention 
group  
Smith 1997 
UK 
RCT Discharge 
medication 
counselling and 
care plan.  
Telephone help 
line.  
Home visit for 
all participants 
7-10 days post 
d/c for follow-up 
assessment 
and resolution 
of DRPs 
53 (28 
intervention, 
25 control), 
identified by 
ward 
pharmacists 
as being at 
risk of DRPs.  
Age >65. 
Average no. 
meds = 5.3 
7-10 days Adherence: 
better in 
intervention 
group (p<0.01).  
Unintentional 
discrepancies: 
NS diff. 
Other: 
Pharmaceutical 
counselling 
required during 
home visit in 
fewer 
intervention 
group patients 
(p<0.01). 
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Stewart 1998 
Australia 
RCT Discharge 
counselling 
(medicines and 
clinical 
condition) by 
nurse / 
pharmacist. 
Home visit one 
week post 
discharge by 
nurse and 
pharmacist for 
high risk 
patients) 
762 (381 
intervention, 
381 control) 
Mean age = 
66 
6 months Readmission/ 
death: lower in 
intervention 
group (p<0.001).   
Readmission 
days: less in 
intervention 
group (P < 
0.001). 
A&E visits: 
Lower in 
intervention 
group (< 0.001).   
Still 2013 
USA 
Retrospective 
comparison 
Discharge 
medication 
counselling and 
provision of 
medication list. 
Patients 
targeted for 
intervention 
were high risk 
for readmission 
or were 
identified by 
hospital staff as 
in need of 
medication 
counselling 
Comparison 
patients were 
predominantly 
medium and 
low risk  
748 (228 
intervention, 
520 
comparison). 
Mean age of 
intervention 
group (62) 
was younger 
than high 
(70) or 
medium risk 
(68) 
comparison 
patients 
30 days Readmissions: 
Medium risk 
intervention 
patients had 
lower 
readmission rate 
then medium 
risk controls 
(p=0.033) 
Stowasser 2002 
Australia 
RCT Medicines 
reconciliation on 
admission. 
Preparation of 
‘Medication 
Liason Service 
communication’ 
(enhanced 
medication care 
plan) and faxing 
of this to GP 
and community 
pharmacist on 
discharge. 
240 (113 
intervention, 
127 control) 
Mean age = 
66.5 
Mean no. 
meds = 7.6 
 
30 days Readmissions: 
Trend towards 
fewer in 
intervention 
group 
Healthcare 
professional 
visits: fewer in 
intervention 
group (p<0.05) 
Functional 
health and 
wellbeing (SF-
36): Intervention 
group tended to 
improve more 
on all 
components 
apart from 
vitality  
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Vuong 2008 
Australia 
RCT Home visit 
within 5 days of 
discharge to 
review 
medicines use 
316 (152 
intervention, 
164 control) 
Mean age = 
72 
Mean no. 
meds = 10.5 
8-12 weeks Adherence: 
improved more 
in intervention 
group (p=0.028) 
 
NS diff – no significant difference between groups 
RR = risk ratio 
CI = confidence interval 
ADLs = activities of daily living 
HF = heart failure 
Meds = medicines 
 
4.4: TRANSFER OF CARE INTERVENTIONS INVOLVING PHARMACISTS: 
SYSTEMATIC REVIEWS 
A number of systematic reviews reporting on the effectiveness of transfer of care 
interventions involving pharmacists have been published, both prior to and since 
the commencement of the study which is the focus of this thesis (11,108,152-162).  
As with the studies reviewed above, each review has a slightly different focus, but 
the vast majority of the studies discussed are included in at least one of these 
reviews.  Below, the findings of the most relevant of the reviews published before 
2014 will be discussed in the context of this thesis and in light of the studies 
reviewed above. 
A 2012 systematic review of 36 RCTs aiming to improve handovers between 
hospital and primary care considered the effect of interventions on a range of 
outcomes, including readmissions and ED visits as well as patient satisfaction and 
quality of life, and outcomes related to the improvement of continuity of care after 
discharge (for example, timeliness and accuracy of discharge information) (152).  
Not all interventions involved pharmacists but of those that did, 6 of the studies 
reviewed in Section 4.3 were included (126,129-131,133,146).  The reviewers 
found that effective interventions comprised components that focussed on 
structuring and reconciling discharge information, coordinating follow-up care, and 
direct and timely communication between providers.  In particular interventions 
involving medicines reconciliation were frequently associated with significant 
effects.  The following year, a review of 47 studies  investigating the effects of 
hospital initiated transitional care interventions on clinical adverse events, ED 
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visits, and readmissions was published (108).  Nine of the studies discussed in this 
chapter were included, 4 of which were also included in the earlier review 
(116,117,122,126,130-133,141).  The second review drew the conclusion that 
nearly all interventions which had a positive effect on outcomes used a ‘bridging’ 
strategy, involving both pre- and post- discharge components.  This finding 
supports the conclusions drawn from the primary research studies in this chapter. 
In the same year, a systematic review focussing specifically on improving 
continuity of care in medicines management included 14 studies, 10 of which are 
reviewed in this chapter (11,118,120,122,126,127,129-131,143,146).  The 
conclusions drawn were similar to those presented here; that patient education and 
counselling provided upon discharge and reinforced after discharge, sometimes 
together with improved communication between HCPs, was shown to reduce the 
risk of ADEs and hospital re-admissions in some studies, but that the effect was 
not consistent.    
One explanation for this inconsistency in results from published studies could be 
the methodological limitations and inconsistencies identified by reviewers, the 
majority of which have been discussed earlier in this chapter.  These include 
heterogeneity in intervention types (including number and intensity of patient 
contacts), patient populations enrolled (including level and definition of risk for 
post-discharge adverse events) and outcomes measured, which precluded the 
reviewers from arriving at clear conclusions (11,108,152).  The reviewers also note 
that some of the outcome measures selected may not be sensitive enough to 
demonstrate the effectiveness of the interventions, or that the primary studies were 
underpowered to show significant benefits.  This is also consistent with the 
analysis presented in Section 4.3.2, which discussed that sometimes the selection 
of arguably more relevant outcome measures by researchers (such as drug related 
readmissions as opposed to all readmissions) lead to a greater apparent benefit of 
the intervention (131,132).   
In Rennke et al’s 2013 review in particular, it is suggested that in the race to 
reduce hospital readmissions, there has been a lack of attention to the potential 
additional benefit of strategies to reduce specific post discharge adverse events, 
including ADEs (108).  The reviewers argue that these events should be targeted 
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because they still represent significant failures to ensure patient safety, even if they 
do not ultimately lead to ED visits or readmissions.  The reviewers considered that 
medication safety interventions led by clinical pharmacists seem to be a promising 
approach, indicating a need for larger trials with an explicit plan to measure 
clinically significant adverse events.  
Importantly from the community pharmacy perspective, even among the most 
comprehensive intervention strategies reviewed by Rennke et al there was little 
evidence of active engagement of primary care providers in the transitional care 
planning process.  This again is in line with the findings discussed in this thesis 
chapter, where community pharmacists were either not involved in interventions at 
all, or only involved ‘after the fact’ when the vast majority of the intervention had 
already been provided elsewhere (117,118,122,125,127,128,130-
134,141,142,147-149).  The reviewers point out that primary care providers may be 
best positioned to detect and prevent adverse events before an ED visit or 
readmission, and thus their active engagement in discharge safety efforts may 
prove fruitful.   
Also published in 2013 (and since updated in 2016) was a Cochrane review of 24 
RCTs investigating individualised discharge planning (153,161).  The reviewers 
concluded that a discharge plan tailored to the individual patient probably brings 
about reductions in hospital length of stay and readmission rates for older people 
admitted to hospital with a medical condition. These reviewers excluded trials 
evaluating interventions where discharge planning was not the main focus of a 
multifaceted package of care (for example those focussing on pharmacist 
interventions only), and therefore only included 2 of the trials reviewed in this 
chapter (126,130).  However, the findings of the Cochrane review are still relevant, 
as medicines management is an important part of discharge planning, and from the 
research presented above, the integration of pharmacists into the MDT appears 
key to their contribution to the success of transfer of care interventions.   
Summary 
Overall, these systematic reviews indicate that there is a lack of high-quality 
research, disproportionate to the magnitude of the problem of discontinuity during 
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care transitions.  The heterogeneity in design of many studies limits interpretation 
and may explain why there is no consistent evidence that pharmacist interventions 
can improve patient outcomes following transfer of care.   
 
4.5: CURRENT TRANSFER OF CARE RESEARCH AND HEALTH POLICY 
PRIORITIES IN BRITAIN 
Spinewine’s 2013 systematic review of interventions to improve continuity of care 
in medicines management suggested that future studies should fit within initiatives 
that are promoted at the national level (11).  It is important to consider how the 
research conducted in this programme of study will fit in with DoH and NHS 
agendas to promote high quality transfer of medicines related care.  This will 
ensure that the intervention developed, if successful, will be more smoothly 
incorporated into routine practice.    
Following the publication in 2009 of the CQC Report Managing patients’ medicines 
after discharge from hospital, the RPS campaign “Keeping patients safe when they 
transfer between care providers — getting the medicines right” was launched in 
2011 (68,110).  This led to the publication of good practice guidance, and the 
inception of an “early adopter” programme to help organisations put the guidance 
into practice at a local level (10,55).  The guidance included a suggested core 
content of records for medicines when patients transfer care providers, and 
indicated that it would be good practice for patients’ community pharmacists to 
receive a copy of this information.   
As discussed in Section 3.4, 2011 also saw the introduction of ‘target groups’ for 
the nationally contracted community pharmacy MURs, including patients recently 
discharged from hospital.  The RPS guidance suggested that secondary care 
providers should ensure that patients discharged from hospital who have had 
changes made to their medicines are aware that they can request a post-discharge 
MUR (dMUR) from their community pharmacist (55).  Furthermore, hospitals 
should work with community pharmacists to evaluate the impact of these reviews. 
Around the same time, guidelines to support closer collaboration between hospital 
and community pharmacists, including a template hospital to community 
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pharmacist referral form, were published by the NHS (163).  An action plan 
released by the DoH steering group on improving the use of medicines in October 
2012 identified routine referral from hospitals for dMURs in appropriate patients as 
one way in which patients can be better supported to make appropriate use of their 
medicines (69).   However, no extra resources have been made available to 
hospitals to identify patients who may benefit from such a service nor have any 
formal mechanisms for liaison between hospital and community pharmacists been 
established.  This lack of formal communication channels between hospital and 
community pharmacies was identified as a challenge by the DoH, which 
recommended that dedicated programmes of support should be established, so 
that dMURs become an integral part of the medicines pathway where appropriate. 
Until this happens, the onus is on the patient to self-refer to their community 
pharmacy.  However, early feedback from sites piloting the promotion of dMURs is 
that self-referral of patients is low, with less than 3% of patients ‘signposted’ to the 
service actually taking it up (10,107).  This reinforces earlier concerns that 
signposting to community pharmacies for post discharge support is not effective 
(121,122).  A focus group of patients in Croydon CCG, one of the RPS early 
adopter sites, found that patients expected community pharmacists to be able to 
access their discharge information electronically, rather than “relying on the patient 
to supply it on a piece of paper” (107).  Another of the early adopter sites felt that 
part of the problem is that “many patients come out of hospital and need time at 
home to recuperate, [which] is at odds with the requirement for patients to be 
present in the pharmacy for an MUR” (164).  An online survey exploring the 
provision of dMURs in March 2013 in West Yorkshire, England, found that although 
76% of MURs conducted in the last month were targeted, less than 1% were 
dMURs (165).  Key barriers to provision were not receiving discharge medication 
summaries and restrictions on provisions to housebound patients.  Both of these 
barriers where tackled by a project in South Staffordshire where, as part of a multi-
faceted approach to improve discharge planning, elderly patients discharged from 
an intermediate care unit were referred by fax to their regular community 
pharmacist for a domiciliary dMUR.  Community pharmacists involved in this 
project received £25 per visit in addition to the £28 MUR fee (166).  The project as 
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a whole resulted in fewer admissions to A&E and fewer emergency re-admissions, 
as well as an 81% improvement in measures of functional independence following 
discharge, with a net health saving of £413,819 in the first year.  However the 
contribution of the dMUR element to this was not investigated. 
Another opportunity for community pharmacists in England to support continuity of 
care after discharge is the New Medicines Service (NMS), which was introduced 
around the same time as targeted MURs (167). The NMS aims to provide support 
to people who are newly prescribed a medicine to manage a LTC (currently 
asthma, COPD, hypertension, type 2 diabetes and those prescribed antiplatelet/ 
anticoagulant medicines).  The initial NMS intervention takes place 7-14 days after 
the prescription of the new medicine, and aims to identify any problems either with 
the treatment or otherwise in relation to the patient’s self-management of their long 
term condition, and the need for further information or support.  In a further 14-21 
days a follow-up consultation takes place to identify and resolve any further or 
persisting medication related issues.  The NMS contract allows for referral of 
patients who have been recently started on these medicines during a hospital 
admission, as well as specifying that, although face-to-face consultations are 
preferable, telephone consultations may be undertaken if the patient prefers (168).  
Along with the repeated follow-up the provision for telephone contact represents a 
possible advantage over the dMUR, which may only be provided on the pharmacy 
premises unless special permission is applied for (9).  An obvious disadvantage of 
the NMS in the post discharge context is that often patients will have had multiple 
changes made to their medicines whilst in hospital, in which case a full dMUR 
would likely be preferable. 
Very little research on post-discharge NMS could be located at the time of this 
literature review; however what evidence there is suggests that uptake is low.  A 
questionnaire study of 56 eligible patients discharged from a teaching hospital in 
South West London revealed that only 9 (16.1%) were aware of the service and 3 
(5.3%) had been referred to it (169).  A pilot NMS referral service of patients from 
the stroke unit at one North West London hospital initially found that, in common 
with the research above, ‘signposting’ of patients (verbal and written) to their 
community pharmacist was not successful: at 4 week follow-up only one pharmacy 
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of the 65 contacted had conducted a hospital-referred NMS, and of all the patients 
contacted, none had remembered the NMS referral (170).  ‘Many’ community 
pharmacists said they would value direct contact from the hospital and patients 
revealed that long-term medication management is one of a number of challenges 
that they face when they go home and it may not be an immediate priority for them.  
Therefore, the hospital pharmacy started to contact the patient’s community 
pharmacy by telephone before discharge an asked them to telephone the patient at 
home one week after discharge to offer the NMS.  Community pharmacists were 
contacted 4 weeks after discharge and of the patients referred, 33% (9/28) had 
received an NMS intervention.  Although this represents an improvement, the 
authors stated that further work was needed to identify reasons for the lack of NMS 
uptake.  However, they concluded that telephone referral for dMUR/NMS adds 
minimal time to the discharge process and, supported by inpatient written and 
verbal information to patients, could be an effective way to increase the number of 
patients accessing these services after hospital discharge. 
It is known that other projects are in development around the country to improve 
the transfer of medicines related discharge information to community pharmacies 
and increase the uptake of dMURs/NMS.  One notable example is the ‘Refer-to-
pharmacy’ tool at East Lancashire Hospitals NHS Trust, which transfers discharge 
information and referrals electronically to a patient’s regular community pharmacy 
at their time of discharge (107).  However the widespread development and 
implementation of such a tool is likely to be resource and time intensive.  In the 
interim, exploration of other methods for increasing referral and uptake of these 
services is needed in order to fulfil the national guidance.   
In addition, despite the promotion of dMURs as a way to improve medicines related 
transfer of care, their impact on adherence and subsequent hospital readmission is 
currently unknown.  In 2011-12, the MUR service as a whole cost the NHS 
£72million (171).  The service has also attracted criticism, with larger organisations 
pressurising employee pharmacists to meet stringent targets for MUR provision, 
prioritising service quantity over quality and compromising the professional 
judgement of pharmacists over which patients to target for MUR (171-174).  Before 
electronic referral systems are introduced on a national basis there is a need for 
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evidence of the benefit to patients of dMURs, to justify the investment of time and 
money to implement both the referral process and the dMUR itself.   
Another notable initiative to support transfer of medicines related care by 
enhancing the role of the community pharmacist is the Welsh DMR service, 
implemented in November 2011 (175).  The DMR service builds on the MUR and 
comprises a two-part intervention by the patient’s community pharmacist.  The first 
part involves medicines reconciliation by the community pharmacist between the 
hospital and GP lists, and the raising of any discrepancies with the GP.  The 
second part involves an MUR style discussion with the patient and provides an 
opportunity to ensure any discrepancies have been rectified.  An evaluation of the 
DMR service was being undertaken at the same time as the planning phase of this 
PhD study, but was not published in time to inform it. 
 
4.6: IMPLICATIONS OF LITERATURE REVIEW FOR THIS DOCTORAL STUDY 
This thesis will aim to build on the strengths of, and gaps in, previous research 
regarding medicines related transfer of care, replicating successful components of 
previous studies as interpreted from the literature. These include involving 
pharmacists on both sides of the hospital-primary care interface, with special 
emphasis on reconciling medicines and reinforcing discharge information post-
discharge.  
The study will focus on a patient population who are known to be at risk for ADEs 
following discharge (i.e. those >65 who have had medicines changed during 
admission).  Patients will not be excluded on the basis of mild cognitive impairment 
or relying on carer assistance with medication (unless these factors preclude them 
from physically accessing the intervention under study).   Both process measures 
and clinical and humanistic outcomes will be studied. 
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4.7: FINALISED AIM AND OBJECTIVES 
Overall Aim of PhD: To investigate the feasibility and potential outcomes of a 
transitional care service for older patients which utilises community pharmacists via 
the dMUR service. 
 
Objectives of PhD:  
 Identify barriers and facilitators to transfer of information between hospital and 
community pharmacy on discharge 
 Provide a basis for the collection of evidence regarding a service which is 
currently nationally commissioned but the benefits of which have not yet been 
reported (dMUR) 
 Identify appropriate outcome measures to investigate the impact of the service 
 Identify ways in which the dMUR service could be improved 
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CHAPTER 5: METHODOLOGICAL CONSIDERATIONS 
This chapter will describe the rationale behind the various methodological elements 
that are used within this study.  An overview of the different research methods 
used is presented in Figure 5.1 below.  A brief introduction and discussion of the 
importance of patient and public involvement (PPI) to this research is followed by a 
description of why a mixed methods approach, combining both quantitative and 
qualitative techniques, was chosen.  Potential study designs, and the reasons for 
the chosen design, will then be covered.  This is followed by a description of how 
key elements, such as sample size, follow-up periods and outcome measures were 
selected.  Operational aspects, such as the rationale behind participant inclusion 
and exclusion criteria will be explained, before potential methods of data collection 
and analysis are discussed.  The chapter finishes with a description of the ethical 
aspects requiring consideration during the design of this study. 
 
Figure 5.1: Research Methods Used to Evaluate the dMUR Referral Service 
 
 
 
dMUR Referral 
Service Evaluation -
Research Methods 
Used
Hospital Pharmacy
•Focus group
•Questionnaire
Participant follow-up
•Postal questionnaire 
(measuring medication 
adherence, health related 
quality of life, enablement 
and other medication 
reviews undergone)
•Semi-structured interview
Community Pharmacy
•Questionnaire
dMUR Data
•dMUR provision by community 
pharmacies
•Delphi review of interventions 
made
Hospital Attendance Data
•Tracking of readmissions and 
A&E visits via Patient 
Adminsitration System
•Case note-analysis of 
readmissions
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5.1: INTRODUCTION 
As discussed in Section 4.5, the DoH action plan on improving the use of 
medicines recommended that a programme that promotes and supports joint 
working between secondary and primary care should be developed (69).  Such a 
programme would ensure that patients recently discharged from hospitals are 
routinely referred to community pharmacies where appropriate, to get the support 
they need to take their medicines more effectively.  Furthermore, the DoH plan 
stated that, where appropriate, dMURs should become an integral part of the 
medicine pathway.  This is despite the lack of direct evidence of the benefit of 
MURs on patient outcomes.  
As described in previous chapters, problems with medication on transfer of care 
may be particularly prevalent and have more severe consequences in older 
patients.  Older patients taking multiple medicines may have significant potential to 
benefit from pharmacist intervention on transfer of care.   
It is also known that older people are often excluded from clinical trials, and 
building a study with this population in mind may require consideration of more and 
different factors compared to a trial involving younger people (176,177).   Older 
people, particularly those who have recently been acutely ill or in hospital, may be 
reluctant to participate in research (176).  In a review of all RCTs published in the 
journal of the BGS over an 18 month period, none had recruited patients from an 
acute hospital setting (176). 
Exploring the logistics of setting up the referral service, including participant 
recruitment, randomisation to dMUR or standard care, and data collection, as well 
as determining the acceptability of the new service to patients, are therefore vital 
initial steps in this programme of work.  As no published work has assessed the 
impact of dMURs on patients’ quality of life, medication adherence or hospital re-
admissions, suitable measures and ways of capturing this data need to be 
investigated. 
In light of this, a feasibility study is planned to investigate these factors and identify 
areas for improvement of the service or study design, and evaluate the potential to 
progress to a full RCT. 
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5.2: PATIENT AND PUBLIC INVOLVEMENT 
A growing body of evidence suggests that patients and the wider public can be 
involved at most stages of healthcare, including research into new services, and 
that this can have a number of benefits (178), such as  increasing research quality 
and relevance (179).  The National Institute for Health Research (NIHR)’s 
INVOLVE programme defines public involvement in research as research being 
carried out ‘with’ or ‘by’ members of the public rather than ‘to’, ‘about’ or ‘for’ them. 
This includes, for example, offering advice as members of a project steering group, 
or commenting on and developing research materials.   
As this doctoral research focuses on a direct-to-patient service (the dMUR), which 
requires active participation of patients when they are perhaps at their most 
vulnerable (i.e. shortly after a hospital discharge), it is felt that their involvement in 
this feasibility study is important. 
Priority objectives for PPI in this research include: 
 Obtaining the views of potential ‘end users’ as to the value of the service 
 Refining eligibility criteria, particularly with regards to targeting patients who 
may benefit the most 
 Ensuring that the methods proposed for the study are acceptable and sensitive 
to the situations of potential participants, for example: 
o Access to medical notes by members of the pharmacy team to complete 
an eligibility screen  
o Being approached to take part in the study whilst unwell in hospital 
o Being randomised to be referred for a dMUR, or to be discharged ‘as 
usual’ 
o Details of medication changes during hospitalisation being sent to their 
community pharmacy 
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o The intervention itself, i.e. attending their community pharmacy for a 
dMUR within 4 weeks of discharge (or having a dMUR at home or via the 
telephone if their community pharmacist is able/willing to offer this) 
o The dMUR ‘action plans’ being sent back to the research team for 
scrutiny 
o Being sent questionnaires and/or interviewed about their experiences 
after discharge 
 Making the language and content of participant information more appropriate 
and accessible (for example participant information leaflets and follow-up 
questionnaires)  
 Helping to ensure that the research uses outcomes that are important to the 
public 
With this agenda in mind, the aim is to recruit a PPI group consisting of patients or 
members of the public in the target demographic (aged >65 who have had 
changes to medicines whilst in hospital), as well as friends, family and carers of 
these people. The views of this group on the topics above will then feed into the 
overall final study design. 
 
5.3: ELEMENTS OF STUDY DESIGN 
This study is experimental in nature as it involves assessment of the effect of an 
intervention - a community pharmacy based dMUR within four weeks of hospital 
discharge (180).  A number of possible designs for experimental studies exist 
which needed to be considered; these are discussed in Section 5.3.2.  Other 
important elements of study design include decisions regarding sample size, 
follow-up periods and the selection of outcome measures; these are discussed in 
Sections 5.3.4 - 5.3.6. 
Underpinning all these decisions is the ontological and epistemological position of 
the researcher.  This position drives the decision as to whether the research 
conducted is of a quantitative or qualitative nature, or whether a combination of the 
two (the ‘mixed methods’ approach) is appropriate.  All further decisions regarding 
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study design follow on from this.  Section 5.3.1 therefore discusses the ontological 
and epistemological perspective of this research and why a mixed methods 
approach was chosen. 
 
5.3.1: Mixed Methods Approach 
The quantitative and qualitative research paradigms are each based on a particular 
patterned set of assumptions concerning reality (ontology) and knowledge of that 
reality (epistemology).  The quantitative paradigm is based on positivism, or 
realism – the ontological position that there is only one truth, an objective reality 
that exists independent of human perception, separate from the observer and 
waiting to be discovered.  Science is characterised by empirical research; all 
phenomena can be reduced to empirical indicators which represent the truth.  
Epistemologically, the investigator and investigated are independent entities. 
Therefore, the investigator is capable of studying a phenomenon without 
influencing it or being influenced by it (181).  The goal is to measure and analyse 
causal relationships between variables within a value-free framework.  Techniques 
to ensure this include randomisation, blinding, highly structured protocols, and 
written or orally administered questionnaires with a limited range of predetermined 
responses (181). 
In contrast, the qualitative paradigm is based on interpretivism and constructivism.  
Ontologically speaking, there are multiple realities or multiple truths based on one’s 
construction of reality.  On an epistemological level, there is no access to reality 
independent of our minds. The investigator and the object of study are interactively 
linked so that findings are mutually created within the context of the situation which 
shapes the inquiry. The emphasis of qualitative research is on process and 
meanings. Techniques used in qualitative studies include one-to-one and focus 
group interviews and participant observation (181). 
Sale et al argue that qualitative and quantitative research methods have grown out 
of, and still represent, different paradigms (181). However, they state that the fact 
that the approaches are incommensurate does not mean that multiple methods 
cannot be combined in a single study if it is done for complementary purposes.  In 
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this way the strengths of one method can enhance the other, although they remain 
independent (additive).  It has been argued that mixed methods research, 
combining quantitative and qualitative approaches, can be particularly useful in 
healthcare research as only a broader range of perspectives can do justice to the 
complexity of the phenomena studied (182-184).  By combining qualitative and 
quantitative findings, an overall or negotiated account of the findings can be forged, 
which is not possible by using a singular approach (185).   
This study therefore combines quantitative and qualitative methodologies.  
Sequential data analysis is used, where results from each methodology are 
analysed in sequence with the purpose of informing, rather than being integrated 
with, findings from the other methodology (186).  Findings are then integrated at 
the stage of interpretation and conclusion.  Positivism is the primary ontological 
position of this research, coloured by a certain degree of interpretivism, as 
advocated by Howe (187). 
Mixed Methodology within This Thesis 
Analysis of a qualitative focus group is used to inform development of a 
quantitative survey for all pharmacists working on wards during participant 
recruitment. 
Qualitative consensus methodology is used to provide an illustration of the 
potential significance of community pharmacist interventions, to complement 
quantitative data on hospital visits, quality of life scores, adherence and 
enablement scores. 
Quantitative analysis of participant recruitment rates, dMUR uptake rates and 
dMUR ‘action plans’ are further explored using qualitative participant interviews.   
Other parts of this study are analysed using purely quantitative techniques, for 
example hospital readmission rates, health related quality of life, adherence and 
enablement scores. 
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5.3.2: Possible Study Designs  
Randomised Controlled Trial (RCT) 
These are trials where participants are randomly allocated to receive either an 
intervention or nothing (control).  If well implemented, randomisation should ensure 
that intervention and control groups only differ in their exposure to treatment (188).  
This reduces the chance of confounding variables affecting the results and gives a 
greater degree of confidence that any difference in outcomes between participant 
groups is caused by the intervention rather than inherent differences between 
participant groups.  This increases the internal validity of the study.  In view of 
these advantages a randomised controlled design was eventually chosen for this 
PhD study.  Further discussion of why other designs were discounted in favour of a 
randomised controlled design is presented below. 
Clustering in RCTs 
In a cluster RCT, the unit of randomisation is a cluster of participants.  For example 
in this study, hospital wards could be randomly assigned as control or intervention 
wards, with all participants from those wards allocated to the assigned study group 
(188).   This approach will not be used as all the wards had different specialities.  
Therefore using hospital ward as the unit of randomisation would have been likely 
to result in non-comparable groups. 
Blinding In RCTs 
Blinding participants to the administration of the intervention in a trial can eliminate 
the possibility that observed effects are due to differential use of other treatments 
in the intervention and control groups (for example control group patients actively 
seeking out a medication review by other means because they know they are not 
going to be offered one through the study) (189).  However, it is not considered 
feasible to blind participants in this study to their allocation to intervention or control 
group.  Offering control group participants a ‘sham’ intervention of no proven worth 
may be seen as unethical as well as time-consuming and resource intensive to 
deliver in the context of a PhD project.   
Blinding study personnel can prevent biased assessment or interpretation of the 
outcome (for example the investigator looking more carefully for outcomes in the 
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intervention group) (189).  However it is not possible to blind the researcher who 
will be recruiting participants and collecting data for this study or the community 
pharmacists who will be delivering the intervention.  This is due to lack of resource 
as the research student is required to receive the results of participants’ study 
allocation, complete the referral process to the community pharmacist, follow-up 
dMURs which are not reported back with the community pharmacists, administer 
different follow-up questionnaires to intervention and control groups, and conduct 
qualitative follow-up interviews.  It would not be possible to perform all these roles 
and remain blinded to participants’ group allocations.   
Note -the consultant who will be involved with the assessment of causality 
readmissions (Section 6.6.2) will be blinded to participants’ allocation, which will 
reduce the chance of bias in this part of analysis. 
Non-randomised between-groups design 
These studies compare outcomes for a group of patients who received an 
intervention with a ‘comparison’ group who have been assigned by means other 
than randomisation.  Analytic methods can adjust for baseline factors that are 
unequal between the two study groups, but it may not be possible to adjust for all 
differences and this may lead to under or over-estimation of the effects of the 
intervention (190,191). 
Non-randomised comparison studies use a variety of methods to assign 
participants to study groups.  Psuedo- or quasi-randomisation involves techniques 
such as allocating every other participant, for example, to the treatment group, or 
assigning one hospital ward as ‘intervention’ and one as ‘control’.  Whilst being 
logistically easier than employing a full randomisation process, the predictability of 
these methods permit the investigator to tamper with the recruitment process by 
manipulating the sequence or eligibility of participants, which will introduce bias 
(190). 
Some studies assign participants to groups according to certain criteria; for 
example, in this study, less mobile patients could be assigned to the control group 
to remove the problem of attending the pharmacy for a medication review.  This 
would likely increase participant numbers by allowing broader inclusion criteria or 
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reducing perceived burden of partaking in the study for patients with poor mobility.  
However this type of technique may lead to unevenly matched groups – for 
example sicker or less motivated patients are likely to end up in the control group, 
which may artificially inflate the apparent effectiveness of the intervention (189). 
A number of studies reviewed in Chapter 4 used a comparison group of patients 
who would have been eligible for the intervention but did not receive it due to finite 
capacity to deliver the service (141,142,147,149).  This has the potential to 
increase sample sizes and simplify the recruitment process, however again it 
increases the chance the two groups will be different at baseline and reduces 
confidence in the results produced. 
Time-series/before and after design 
This design involves evaluating the effects of an intervention by comparing the 
outcomes of study participants before the intervention with those measured 
afterwards. The participants investigated before and after the intervention would be 
from the same sites or centres, and may be the same people or different samples 
(192).  For example in this study, a group of patients discharged before the 
introduction of the dMUR referral service could be compared to a group discharged 
from the same hospital after the introduction of the service.  However in this 
scenario, the study groups may not be comparable in their characteristics, 
introducing bias (192).   
In a ‘within group’ before and after design, measurements are made before and 
after each participant receives the intervention; with each participant serving as 
their own control to evaluate the effect of the intervention (189).  This design has 
the advantage that innate differences between groups are eliminated as 
confounding variables.  However, this design will not be used for this research 
because it is already anticipated that recruitment might be challenging, and 
administering questionnaires to elderly patients in hospital in addition to the 
informed consent process may be unduly burdensome and reduce willingness to 
participate in the study (129,133,176).   
The major disadvantages of before and after studies are the lack of a concurrent 
control group, and, in this study in particular, the chance that factors other than the 
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intervention may affect outcomes (189).  For example, quality of life measurements 
taken at baseline (whilst patients are in hospital) may expected to be lower than 
those taken later when they are back at home.  Measurements such as medication 
adherence may be difficult to assess in a hospitalised patient as responsibility for 
medication administration in hospital is generally taken over by nursing staff, and 
even if patients are asked regarding adherence behaviour prior to admission the 
reliability and validity of such measurements is likely to be affected by recall bias. 
Subsequent measurements may be affected by the complexity of changes to the 
medication regimen made in hospital, rather than the effects of the intervention.  
Comparing readmissions in the follow-up period to those in the same time period 
leading up to the baseline admission may also be possible but again the 
subsequent readmission may be affected by various factors other than the 
intervention.  For these reasons, this design is not viewed as suitable for this study. 
Cross-over design 
This design involves half the participants receiving the intervention initially and the 
other half serving as control, then after a designated time period the initial control 
group receive the intervention and the original intervention group switch to control 
(189).  This design would obviously not be feasible for a study such as this, where 
the intervention is time-limited (i.e. referral for dMUR within 4 weeks of discharge).  
 
5.3.3: Chosen Design: Randomised Controlled Feasibility Study 
The design chosen for this feasibility study is a randomised controlled design.  This 
was selected due to the already stated advantages of RCTs in relation to the other 
designs considered.  To explore the feasibility of a future full RCT, the willingness 
of potential participants to consent to randomisation is viewed as an important part 
of this research.  A non-blinded design was chosen due to the methodological 
difficulties with blinding in this study as explained above. 
It was decided to use a post-test only design, whereby outcome measures are only 
collected at follow-up and not at baseline.  As discussed, administering a battery of 
questionnaires to an elderly patient in hospital, in addition to the informed consent 
process, may be viewed as unduly burdensome by potential participants and 
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thereby reduce recruitment.  This view was supported by the PPI group who felt 
that even the participant information leaflet for the study was off-putting in its length 
(see Section 5.6.2).  It was also felt that randomisation of participants would reduce 
the need for baseline measurement of outcome variables as these would be 
expected to be the same in each group.  Therefore any effect of the intervention 
should be demonstrated by differences in outcome measures between the groups 
at follow-up. 
 
5.3.4: Sample Size 
It is proposed that between 60 and 100 patients will be recruited (randomised 
between intervention and control groups).  This number is deemed appropriate as: 
 The sample size selected needs to provide adequate representation of 
parameters of interest for this feasibility study, such as participant recruitment 
and attrition rates. 
o Recruitment rate: The lowest recruitment rate among the studies in the 
literature review was Vuong’s 2008 RCT of a community liaison 
pharmacist service, which recruited 27% of patients referred (129).  
From exploratory work carried out as part of this study on the emergency 
admissions unit (EAU) at SONT between 3rd and 14th June 2013 it was 
estimated that 23% of newly admitted medical patients would be eligible 
for referral to the researcher (Appendix 3).   Analysing the number of 
discharge prescriptions processed by pharmacy on the first weekday of 
each month between July 2012 and June 2013 showed a mean of 23 
discharges from medical wards per day (Appendix 3).   This indicates 
that a minimum of 5 patients should be referred by ward pharmacists per 
working day for full eligibility screen and consent.  Over 12 weeks this 
should result in 300 patients referred to the researcher.  A sample of 300 
patients would allow a recruitment rate of 30% (ie effect size of 0.3) to be 
detected with 85% power (see Figure A4.1 in Appendix 4) 
o Attrition rate: Experimental/quasi-experimental studies of transfer of care 
interventions involving older patients have reported attrition rates of up to 
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64% (143).  In a service evaluation of telephone referral from hospital to 
community pharmacy for stroke patients to receive the NMS, 67% of 
patients did not receive the service within 4 weeks.  A sample size of 60 
participants in this study would allow us to detect an attrition rate of 70% 
with 85% power (see Figure A4.2 in Appendix 4). 
• One of the objectives of the study is to investigate if emergency 
readmissions in this patient group can be characterised in terms of their causality 
and the contribution and preventability of medication related problems.  A baseline 
six-month readmission rate of approximately 20% (based on readmission data for 
patients aged >65 to SONT Nov 2011-Oct 2012) is expected.  Therefore a sample 
size of 60-100 patients should generate between 12 and 20 readmissions to study.  
This should be adequate to pilot the application of the criteria chosen. 
• A published audit of sample sizes for pilot and feasibility trials registered in 
the UK Clinical Research Network database found that the median sample size for 
ongoing feasibility studies was 36 participants per arm (range 10-300) (193).  The 
sample size of 60-100 proposed for this study therefore sits comfortably within the 
range used by other researchers. 
 
5.3.5: Follow-up Periods 
Patients will be followed up at two time points; 4 weeks and 6months post 
discharge.  Four weeks was chosen for two reasons. Firstly, the service 
specification for dMURs states that they should normally take place within that time 
period. Secondly, data on emergency readmissions (those that occur within one 
month of discharge) are included in the NHS Outcomes Framework as an indicator 
of quality care in the NHS (95).   
A six-month follow-up will be included to determine any lasting effect from the 
intervention.  Six months was chosen as Cochrane reviews of interventions to 
improve adherence to long term medications include only studies that are six 
months or longer in duration.  Between November 2011 and October 2012, data 
from SONT showed a one-month readmission rate of 9%, rising to 19% at six 
months and 24% at 12 months.  It can therefore be seen that almost 80% of one-
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year readmissions to SONT occur within the first six months.  This suggests that a 
period of six months from discharge to final follow-up is appropriate for this study. 
 
5.3.6: Outcome Measures 
One of the objectives of this feasibility study is to determine appropriate outcome 
measures to be used to assess the effect of the dMUR referral service.  As 
discussed in the previous chapter, research into transitional care involving 
pharmacists has been hampered by the use of outcomes that were too broad or 
only proxy measures of improved health or quality of life.  For example, measuring 
the difference in all-cause emergency readmissions between groups may 
underestimate the positive effect of a pharmaceutical intervention on preventable, 
medication related readmissions, or adverse events that do not ultimately lead to 
readmission (108,131,132).  Drug knowledge and adherence are only really 
meaningful if they can be transferred into improved quality of life, feeling of 
empowerment, or a reduction in ADEs or health service usage. 
Therefore this study will measure patient orientated outcomes including: 
 Hospital readmission rates with particular focus on medication related 
readmissions and their preventability 
 A&E attendance rates 
 GP consultation rates 
 Health related quality of life (HR-QoL) 
 Patient satisfaction with service (or related measure) 
Readmissions 
Reports in the literature estimate that between 20 and 64% of hospital 
readmissions may be related to problems with medication, the majority of them 
preventable, with the associated burden for patients and the healthcare system 
(104-106,194,195).  It would therefore be desirable to determine whether referral 
for a dMUR is associated with a reduced risk of non-elective readmission to 
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hospital.  Additionally, reduced likelihood of readmission was viewed to be the 
most desirable outcome of dMUR referral by the study’s PPI group (Appendix 2).  
Some studies of hospital initiated pharmacy interventions have used length of stay 
on readmission as an additional outcome (116,117,126,128,141,142).  It is 
conceivable that by managing their medication and medical conditions more 
appropriately as a result of their dMUR, intervention group participants will 
recognise signs of clinical deterioration or adverse effects of medication before 
they become too severe, and therefore require fewer days in hospital on 
readmission, even if the readmission itself is not prevented.  Improved knowledge 
of their medication regimen and sources of support after discharge may reduce 
time spent on medicines reconciliation and initiation of appropriate medicines 
management on admission and the complexity of the discharge process, providing 
another potential means of shortening a readmission.  Therefore length of stay on 
readmission will be used as an outcome measure for this study. 
A&E Attendances 
Sometimes patients may attend the hospital’s A&E department, and, following 
assessment and any necessary tests and treatments, be discharged from there 
rather than being admitted to a ward.  As many as 1 in 3 A&E visits may be 
medication related, with over two-thirds of these being preventable (196-198).  
Therefore not measuring A&E attendance as a separate outcome could result in 
effects of the intervention going unidentified (196,197).  As well as adverse drug 
reactions, other medication related causes of A&E attendance include non-
adherence, and even having run out of medicines (196-199).   Such problems 
could potentially be reduced by dMUR interventions.  Therefore a comparison of 
the number of A&E visits between intervention and control groups was identified as 
a potentially important outcome to measure.  This is in keeping with several 
previous studies of hospital pharmacy initiated interventions that have reported the 
effect on A&E visits as well as actual readmissions (133,200-203).   
GP Consultation Rates 
GP visits were a recurring theme during PPI group sessions for this study 
(Appendix 2).  Participants described examples of GP consultations regarding 
114 
 
medicines they had made following discharge and also expressed frustration at the 
difficulty of arranging such appointments.  This raised the question of whether, with 
proper promotion and targeting, there is a role for dMURs in freeing up GP 
appointments by answering questions patients have re medicines post discharge.  
A number of the studies reviewed in chapter 3 used the number GP visits made by 
participants as an outcome, with fewer visits indicating a positive effect of the 
intervention (119,122,126,127,134).  With the current pressures on GP services, 
any intervention that reduced the demand for appointments would indeed be hailed 
as a success.  It is therefore planned to compare number of GP visits in each 
group as an outcome measure in this study.   
Medication Review other than dMUR 
It would be desirable for dMUR with the community pharmacist to reduce the need 
for medication reviews by other HCP.  It must be remembered that the dMUR is 
primarily focussed on increasing patient understanding and appropriate use of their 
medication, rather than being a clinical review, and so will not remove the need for 
additional review (for example with the GP or practice pharmacist) altogether.  
However, as discussed in the preceding section, GP appointments are currently 
being taken up with medication related queries post-discharge.  It could be that the 
number of additional medication reviews would be a more sensitive measure to 
detect the benefit of dMURs on healthcare usage than GP visits overall (which may 
be for a variety of reasons other than medication).  
HR-QoL 
Pharmaceutical care encompasses pharmacist involvement in designing, 
implementing and monitoring therapeutic plans in collaboration with other 
healthcare professionals, which can be integrated with other aspects of healthcare, 
e.g. medical and nursing care (204).  As such, the dMUR referral service embraces 
the central tenets of pharmaceutical care and one way to demonstrate the added 
value of the service would be through detecting improvements in outcomes such 
as quality of life, or more specifically, HR-QoL.  HR-QoL has been defined as “The 
value assigned to the duration of life as modified by the impairments, functional 
states, perceptions and social opportunities that are influenced by disease, injury, 
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treatment or policy” (205).  It is a multidimensional construct that generally includes 
assessments of physical, mental, and social functioning (206).  As such it seems 
important to attempt to capture any effect of dMUR on HR-QoL.   
Many factors contribute to and affect a person’s HR-QoL, of which the use of 
medication is only one.  Generic HR-QoL instruments assess a range of issues, 
and some of their content may be of little relevance to individuals in a particular 
context (207).  For this reason, measures may lack sensitivity to small but 
significant changes in a particular area of an individual’s life (such as the better 
understanding and use of medication).  Pharmaceutical care–based activities may 
influence patient knowledge, medication adherence, and drug therapy effects via 
an avoidance of drug-related problems, but it is unclear how each intermediate 
outcome influences HR-QoL (206).   
Previous research has shown inconsistent effects of pharmaceutical care 
interventions on HR-QoL in the elderly (204,206).  It has been suggested that this 
could be due to the greater disease burden in this patient population, meaning that 
the appropriate use of medication may only have a small effect on overall QoL, 
which may not be detectable unless sample sizes are large (204,206).  
Furthermore, the potential impact of medicines optimisation on HR-QoL in patients 
with chronic disease may take longer to develop than the follow-up period of this 
study (206).  Therefore, although potentially important in demonstrating the value 
of pharmaceutical care activities, it has been recommended that HR-QoL 
measurement should be complemented with other indicators to measure the 
influence of pharmacist interventions (206).  HR-QoL will be used as an outcome in 
this study but will be supplemented by another measure that may be more 
sensitive to patients’ perception of health gain following a dMUR, as discussed in 
the next section. 
Patient Enablement 
Whilst patient satisfaction questionnaires generally attempt to measure patients’ 
perceptions of outcome, their structure often appears to measure the extent to 
which expectations relating to the process of the delivery of care has been met, 
rather than whether there has been achievement of a specific health gain (208).  
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Howie et al therefore developed a series of questions about patients’ experience of 
consultations, which identified a concept complementary to, but different from, 
satisfaction, which related to the themes of patient centeredness and 
empowerment.  They termed this concept ‘enablement’ and defined it as the 
patient’s ‘perception of their ability to understand and cope with their health 
problem’ immediately following the consultation (208,209).  The Patient 
Enablement Index (PEI) will therefore be used to supplement HR-QoL as an 
outcome measure in this study.    
Furthermore, ‘feeling more able to live a normal life’ as a result of better medication 
management was identified as the most worthwhile outcome of this study by one of 
the PPI group members (Appendix 2).  Self-efficacy (belief in one’s own ability to 
successfully perform an action) is a concept closely related to enablement.  
Measuring enablement is therefore viewed as a valuable addition to the outcome 
measures to be studied in this piece of research.   
Medication Adherence 
Medication adherence will be measured as, despite only being a proxy measure for 
clinical outcomes, health benefits from more appropriate medication adherence 
may only manifest months or years later and therefore a six-month follow-up may 
underestimate these (210).  In addition, improving adherence is a key aim of the 
MUR service (168).  Therefore difference in adherence between intervention and 
control groups is an important outcome measure for this study. 
Process Measures 
As discussed in the literature review, even among the most comprehensive 
transfer of care intervention strategies reported, there was little evidence of active 
engagement of primary care providers in the transitional care planning process, or 
of measurement of the effectiveness of communication between hospital and 
community (108,153).  One of the key objectives of this study is to identify barriers 
and facilitators to transfer of information between hospital and community 
pharmacy on discharge.  A mix of qualitative and quantitative techniques will be 
used to evaluate the effectiveness and efficiency of the dMUR referral process, 
including questionnaire surveys of both hospital and community pharmacists and 
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maintenance of a record of time taken to make referrals and any communication 
problems that occur. 
Other process measures to be evaluated as part of this study include: 
 Rate of referral by ward pharmacists of potentially eligible patients.  If 
referrals are lower than expected (see Section 5.3.4 above) reasons will be 
explored.  Ways of doing this are discussed in Section 5.4 below.  An 
understanding of these issues will mean that they can be addressed where 
possible and the implications for the feasibility of the service and any future 
RCT assessed. 
 Recruitment rate and reasons for non-eligibility and refusal to participate.  
Older people are often excluded from clinical trials, and building a trial with 
this population in mind may require consideration of more and different 
factors compared to a trial involving younger people (176,177).   Older 
people, particularly those who have recently been acutely ill or in hospital, 
may be reluctant to participate in research (176).  Therefore there is 
potential for recruitment to be lower or take longer than expected.   
 Drop-outs with reasons if possible.  This will help to refine sample size 
calculation for any future RCT and develop participant retention strategies 
(e.g. adjusting the way follow up data is collected or recommending changes 
to the way the service is delivered). 
 Percentage delivery of dMURs by community pharmacists, timescale to 
complete dMURs and manner of delivery (e.g. in-pharmacy, telephone, 
home visit). 
 Return rate of dMUR action plans to researcher.  This will help to predict the 
volume of data generated at this stage for a given number of dMURs 
performed, and the likely increased workload for the researcher in following 
up those dMURs where action plans were not returned. 
 Return rate of postal questionnaires/participant diaries. Previous studies 
have shown a wide range of response rates so clarification of likely rate in 
this patient group would help finalise sample size for a future RCT. 
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In addition, the number and type of interventions made by community pharmacists 
will be collated and their potential clinical significance evaluated.  As with 
adherence, the actual significance of these interventions may be difficult to 
translate directly into patient or economic benefit; therefore a form of objective 
prospective estimate is required (Section 5.6.6). 
 
5.4: HOSPITAL PHARMACIST FOCUS GROUP 
Very few potential study participants were referred to the researcher by ward 
pharmacists during the early weeks of recruitment.  Focus group methodology was 
chosen to explore the reasons behind this because it allows interaction between 
participants to develop themes and issues raised. (211).   Participants can question 
each other and comment on each other’s experiences and views in a social 
context.  Another advantage of focus group methodology is that participants can 
provide checks and balances on each other, and extreme opinions tend to be 
challenged by other participants, thereby providing a natural quality control on the 
data gathered.   They may also feel able to voice opinions and criticisms that would 
not be captured by a 1:1 interview or questionnaire, thereby allowing the facilitator 
to discover what people really think about the topic and why.  The facilitator plays 
an important role in clarifying ambiguity as part of the discussion.  The most 
important issues tend to be focussed on and group consensus, if present, is easy 
to gauge.  Less inhibited participants may encourage contribution from quieter 
ones, who may have been reluctant to be interviewed on their own or felt they had 
nothing to say. 
In addition, a focus group provides a way of gaining the opinions and ideas of 
several individuals at once, and therefore can be an economical way of gathering a 
relatively large amount of qualitative data when time is short.  This was important 
as solutions to the poor recruitment rate needed to be identified and put into 
practice as soon as possible, without taking too much time out of the recruitment 
process itself, which was ongoing at this time.   
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5.5: COMMUNITY PHARMACIST QUESTIONNAIRE 
A questionnaire will be used in preference to a focus group or 1:1 interviews, as 
opinion from as many community pharmacists as possible are wanted and it would 
not be practical, with the resources available, to interview all those involved.  
Questions are adapted from the questionnaire previously used with hospital 
pharmacists at SONT and from the recent evaluation of the Wales DMR service 
(20).   
 
5.6: STUDY OPERATION 
5.6.1: Participant Eligibility Criteria 
As discussed in Section 4.3.2, one difficulty in the interpretation of previous 
transfer of care research is the heterogeneous participant selection criteria used, 
which may affect participants’ likelihood of benefitting from the interventions 
studied (11,108,152).  Given the increasing elderly population and the scant 
resources with which to fund interventions, it makes sense to offer these 
interventions to those most likely to benefit.  In turn, therefore, there is a need to 
target eligibility criteria for studies of these interventions toward those patients who, 
based on the literature (as presented in Chapters 3 and 4), we think will benefit the 
most.  This should help to provide a realistic picture of the actual effect of an 
intervention on its target population.   
Risk of Post-discharge DRPs  
A reduction in DRPs following pharmacist intervention has been associated with 
patients aged 65 or over, taking six or more medicines, certain clinical conditions 
(e.g. heart failure or respiratory disease) and being prescribed a ‘problem 
medication’ (such as anticoagulants, insulin, combination antiplatelets, digoxin or 
narcotics) (117,147,148).  Based on these previous works, in an attempt to target 
patients who could benefit from dMUR referral, it was decided to recruit patients 
aged >65 who were either: 
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 Prescribed >5 regular medicines, as taking >5 medicines has been identified 
as an independent risk factor for readmission in several studies 
(40,103,212) or 
 Had changes to their medicines whilst in hospital, since changes to 
medication regimens are often poorly communicated and lead to 
readmission (104).     
It was decided not to include factors relating to co-morbidities or specific ‘high-risk’ 
medicines because this will make the screening process more involved, and the 
view was taken that there was likely to be significant overlap between these factors 
and the ones already included.  For example patients having three or more clinical 
conditions are likely to also be taking five or more regular medications. 
Medical Index Admission 
It was decided to recruit only patients admitted under the care of the medical 
directorate, as although surgical patients often do have medical problems, they 
would be less likely to experience changes in long-term medicines during their 
admission and would be less likely to obtain benefit from the dMUR process.  This 
is supported by the fact that surgical readmission rates tend to be lower than those 
for medical patients (94).  
Independent with Medications at Home 
MURs with carers are not allowed under the current arrangements for the provision 
of MURs as an NHS service by community pharmacists.   MURs are currently only 
available to the patient themselves and require significant engagement from the 
patient.  It is felt, therefore, that patients whose carers took overall responsibility for 
their medication would not be suitable participants in this particular study, and will 
be excluded.   
Independence with medication is also considered not to apply to patients who 
receive all their medication in a multidose compliance aid (MCA) made up in a 
community pharmacy.  Therefore this is set as an exclusion criterion.  Patients with 
MCAs who also have to take medications that cannot be included in their MCA 
(e.g. inhalers, warfarin, weekly bisphosphonates, ‘when required’ drugs) must be 
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independent in taking this medication, and therefore they can be included in the 
study. 
Nomination of Regular Community Pharmacy 
The national service specification for MURs states that a patient must have been 
using a particular community pharmacy for at least three months to be eligible to 
obtain an MUR from them (168). However, ‘prescription intervention’ MURs (where 
the need for an MUR is highlighted by a significant problem on the patient’s 
prescription that reveals the need for a more detailed examination of the patient’s 
medication regimen) are not subject to this criterion.  It is felt that dMURs could be 
seen to fit this category; therefore for the purposes of this study patients can 
participate as long as they are able to nominate a pharmacy they will start to visit 
regularly to obtain their prescriptions post-discharge.  
Ability to Access Community Pharmacy for MUR 
It is recognised that a significant number of elderly, recently discharged patients 
may have poor mobility and be unable to attend their community pharmacy without 
extreme difficulty.  Unless they are able to have (and will accept) a domiciliary or 
telephone MUR, these patients will be excluded.  The numbers of potential 
participants excluded on this criterion will be recorded and any impact considered 
during interpretation of the study results. 
Patients who are deemed unable to give informed consent  
Due to the age demographic involved with this study and associated prevalence of 
cognitive impairment it is anticipated that this will be an issue. Potential participants 
will be given written and verbal information about the study and given time to 
discuss participation with the chief researcher, relatives and carers as needed.  No 
effort will be made to coerce individuals to take part and any concern over the 
advice will be sought from a patient’s medical or nursing team if there is any doubt 
over their ability to give consent.   
Patients already enrolled on to the study  
It is possible that a patient may have been recruited to the study but then re-
admitted. These patients will be excluded. 
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5.6.2 First Approach to Potential Participants 
Ideally, the first approach to a potential participant regarding the study would be 
made by a member of the medical or nursing team responsible for their care, as 
these professionals are more likely to be familiar to patients and this is likely to 
help with recruitment.  All PPI group members agreed that they would be most 
likely to participate if they were approached by their hospital doctor or nurse, rather 
than a pharmacist or researcher.  However, the time needed to engage and train 
all physician and nursing teams at SONT makes this unfeasible.  Instead, ward 
based pharmacists and technicians (who should also be familiar to their patients) 
will be utilised in the role of making the first approach to potentially eligible patients, 
as described in Figure 6.1 and Section 6.5.3.  This compromise also avoids the 
ethical issues associated with access to the patient’s notes by the researcher 
before the patient is aware of the study. 
Participant Information 
Some PPI group members felt that the initial participant information leaflet (PIL) for 
the study was too long and that this might be off-putting.  Following discussion, it 
was decided to split the PIL into two leaflets.  The first will give a general overview 
of the study and the dMUR service and is designed to be left with potentially 
interested participants.  The researcher will then approach these people with the 
second leaflet to discuss participation in more depth.   
5.6.3 Design of dMUR Referral Form 
The RPS has produced a recommended core content of records for when patients 
transfer between care providers (110).  This information is similar to that which has 
been reported as desirable to receive on transfer of care by community 
pharmacists (121,130,213).  The referral form for this study was developed with 
reference to the RPS core content alongside the hospital to community pharmacist 
referral form published by NHS Employers and the PSNC (214). 
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5.6.4 Measurement of Outcomes 
Readmissions 
Readmissions to SONT will be measured using the hospital patient administration 
system (PAS).  Obviously, the PAS will not identify readmissions to other hospitals.  
Initially an application was made to the HSCIC for an extract of hospital episode 
statistics (HES) data.  This would have provided dates of hospital admission and 
discharge for each participant, the provider responsible for their care during these 
admissions, and their destination on discharge.  However, this type of patient 
tracking was not feasible to organise within the time and financial constraints of this 
study. 
Additionally, the likelihood of the patient group under study being admitted to 
another Trust is predicted to be low, as the population under study is not a mobile 
one and the geographical locality from which they are to be recruited is largely 
served by SONT.  Participants will also be asked to keep a diary of readmissions, 
to be returned with their follow-up questionnaire.  The topic of readmissions will 
also be addressed during face-to-face interviews with a sample of participants (see 
later in this section and Section 6.5.4).  These methods will provide a means of 
capturing information regarding admission to other Trusts.   
If a readmission has occurred, the patient’s notes will be reviewed by a consultant 
geriatrician and the researcher, using published criteria to identify medication 
related adverse events and assess to what extent these could have contributed to 
re-admission and whether they could have been prevented (61,62,215).   
A&E Visits 
As with readmissions, it is easy to collect data on A&E visits to SONT via the PAS; 
data on A&E visits to other Trusts will not be captured. 
GP Visits 
Initially it was planned that participants’ GPs would be contacted by telephone to 
obtain information.  However this idea was discarded, partly because of the time it 
would take to obtain the information, and also because of potential difficulties in 
surgeries allowing this information to be released.  Instead, participants will be 
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asked to record the number of times they saw their GP in the same diary they will 
be given to record hospital attendances. 
Medication Review other than dMUR 
This will be assessed by a mixture of closed and brief free text questions on the 
participant questionnaire.  This will allow more specific information to be collected 
(i.e. identity of the reviewer, whether the review was HCP or patient initiated) than 
attempting to gather this data via the participant diary. 
Adherence 
Methods of measuring adherence can be classified as direct or indirect.  Direct 
methods include directly observed therapy and measurement of concentrations of 
a drug or its metabolite in blood or urine.  Direct methods are obviously impractical 
for this study due to the time required and lack of access to the necessary 
equipment and/or personnel.  Also their intrusive nature is unlikely to be accepted 
by potential participants.  Questioning the patient (either via interview, 
questionnaire or medication diary), assessing clinical response or physiologic 
markers, performing pill counts, ascertaining rates of refilling prescriptions and 
using electronic medication monitors are all indirect methods of assessing 
adherence; with a combination of methods being the most accurate way of 
assessing adherence (67).   
However given the time and resource limitations of this study, a questionnaire is 
the sole method chosen.  A number of validated adherence scales have been 
described in the literature, with the first published and most commonly used being 
Morisky’s Medication Adherence Questionnaire (MAQ) (216,217).  The original four 
item MAQ has since been supplemented with additional items to better capture 
barriers surrounding adherence behaviour, to form the 8-item Morisky Medication 
Adherence Scale (MMAS) (218,219).  The MMAS score can range from 0 to 8, with 
high adherence being defined as score 8, medium adherence as 6-7, and low 
adherence as <6 (218).   
Additionally, the MMAS has been successfully triangulated with medication 
possession ratios (days of supply issued divided by number of days patient is 
expected to have consumed the medicine) and clinical values from GP computer 
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records (220).  It has also been shown to have high concordance with 
antihypertensive medication pharmacy fill rates in older patients in two separate 
studies (221,222).  A significant association between low adherence as identified 
by the MMAS and uncontrolled blood pressure in an older population has also 
been demonstrated (221).  The MMAS has also been used to measure adherence 
in the context of post-discharge pharmacist medication review in a previous study 
(129). 
A disadvantage of the MAQ/MMAS is that they do not assess patient self-efficacy 
(belief in ability to successfully perform an action required to give a desired 
outcome), which has been found to be an important predictor of medication 
adherence (223).  Other scales exist that do address this concept, for example the 
Self-efficacy for Appropriate Medication Use Scale (SEAMS) and the Brief 
Medication Questionnaire (BMQ) (223,224).  However these scales are not as 
quick or as easy to complete or score as the MAQ/MMAS (216).  As the 
measurement of adherence is only one of the aspects to be covered in the follow-
up questionnaire administered to participants in this study, minimising length and 
therefore participant burden was viewed as key to maximising return rates. 
Reducing participant burden was particularly relevant for the current study 
involving elderly participants, who may be suffering from multiple medical 
conditions, frailty and/or mild cognitive impairment and therefore be more likely to 
suffer measurement fatigue with more lengthy assessments. 
Taking all the above factors into account, the decision was made to use the 8-item 
MMAS for the measurement of adherence in this study.  Modifications were made 
to the original MMAS to remove specific references to high blood pressure 
medication (for which the original tool was developed).  Slight changes were also 
made to some of the wording following input from the PPI group.   
There is however no guarantee that even if adherence can be measured 
accurately, that it will translate into improved health.  Health related quality of life 
was therefore identified as an additional outcome that is meaningful to the patient 
and might be obtained following more appropriate use of medicines. 
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Health Related Quality of Life (HR-QoL) 
The measurement of HR-QoL can be approached using general or disease-
specific instruments. General (or ‘generic’) instruments provide an overall summary 
of HR-QoL and can be used to compare patients across different conditions, while 
specific instruments focus on a particular disease, patient group, or area of function 
(206,207).  HR-QoL instruments have the potential to provide clinicians and 
researchers with measures of the effectiveness of interventions by capturing HR-
QoL changes in a patient population over time and comparing information on 
patients assigned to different treatment groups (206). 
As the participants in this study are anticipated to have a range of medical 
conditions, it appears most appropriate to use a general instrument to assess 
differences in HR-QoL between intervention and control groups.  Ideally, a tool 
designed specifically for use with older people would be utilised, as many HR-QoL 
questionnaire items tend to be phrased predominantly in relation to the person’s 
physical functioning and may thus inadvertently discriminate against older persons, 
whose physical function is likely to be not as good as that of younger people (207).  
However no valid measure specifically designed to assess HR-QoL in the elderly 
could be found in the literature.  Although generic QoL measures, such as the 
Older People’s Quality of Life Questionnaire (OPQOL), Control, Autonomy, 
Satisfaction, Pleasure - 19 items (CASP-19) and World Health Organisation Quality 
of Life questionnaire - version for older people (WHOQOL-OLD) have been 
developed for use with the elderly, these do not measure HR-QoL as such and 
therefore are unlikely to be sensitive to changes in QoL as a result of a dMUR 
(207,225). 
The most widely used generic health status questionnaires in healthcare 
evaluation, both in studies of pharmacist interventions and in the elderly population 
as a whole are the Medical Outcomes Study 36-Item Short-Form Health Survey 
(SF-36) and its variations, including the shorter SF-12 (206,207).  As with the 
adherence scale, the HR-QoL assessment is only a part of the follow-up survey 
participants will be asked to fill in, and therefore brevity is viewed as important to 
increase response rate.   
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However, the importance of not sacrificing too much in terms of the quality of the 
measure by reducing its length is also recognised.  The SF-12, currently in version 
2 (SF-12v2), takes two minutes to complete and consists of 12 questions which 
yield an eight-scale profile of functional health and wellbeing, as well as two 
physical and mental health based summary measures (226).  The SF-12 
reproduces the physical component summary (PCS) and mental component 
summary (MCS) measures from the SF-36 with at least 90% accuracy (226).  
Scores from the SF-12v2 can also be adjusted for age, by comparing with age-
group ‘norms’ (226).  In this study, relevant age groups are 65-74 and 75 and over.  
This will allow comparison of the HR-QoL of the study population with the age-
group population norms, which may assist in interpretation of other outcomes.  The 
SF-12v2 was therefore chosen as the HR-QoL measure for this study. 
Patient Enablement 
The PEI was developed in the UK in the 1990s as a measure of quality in general 
practice doctor-patient consultations (208,209).  The tool was developed in 
response to a lack of suitable outcome measures to assess quality of care in 
situations where consultations are for multidimensional problems with physical, 
psychological and social elements as well as the need for health promotion 
intermingled in a complex way (208,209).  Enablement has been linked to health 
outcomes such as self-management and quality of life in patients with asthma and 
inflammatory bowel disease (227,228).  Since its development, the PEI has been 
translated into Polish, Croatian, Chinese, French, Portuguese and Swedish, 
generally exhibiting high internal reliability (229-235).  As well as GP consultations, 
it has been used following nurse practitioner, acupuncture and homeopathy 
consultations, and has generally shown consistent results across the different 
professions (236-238), although to date it has not been used by community 
pharmacists.  
The PEI consists of 6 questions with multiple choice responses of “much better,” 
“better,” and “same or less” or “not applicable”, which are scored 2, 1, and 0 
respectively, giving a score range of 0-12.   It has since been suggested that a PEI 
score of ≥6 is required for clinically meaningful enablement (227,239).   
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Three of the 6 PEI items are now included in the General Practice Assessment 
Questionnaire (GPAQ), which is used for annual GP practice patient surveys and 
GP revalidation in the UK (240).  This indicates that the concept of enablement and 
the PEI itself have gained recognition as routine measures of consultation quality in 
the NHS, demonstrating formal recognition of the value of the PEI and supporting its 
use in this study. 
The PEI will be used at 4-week follow-up with the intervention group only, as it is 
designed to measure enablement in the immediate period following a consultation.  
Therefore it will not be relevant to the control group at all, and is unlikely to be 
relevant to the intervention group by 6 months.  The wording of the original tool was 
changed slightly in order to make it more relevant to the evaluation of an MUR rather 
than a GP consultation.   
Use Of Postal Questionnaire Follow-up 
The MMAS, SF-12v2 and PEI use closed questioning techniques, lending 
themselves to inclusion in to a questionnaire to allow for efficient, uniform and 
inexpensive data collection (189).   Initially, telephone administration was 
considered as a way of maximising response rate, but following PPI discussion, a 
postal questionnaire was decided upon as this was their preferred method.  Postal 
questionnaires also reduce the chance of interviewer bias and may allow 
participants to answer sensitive questions more honestly (241).  Postal follow-up 
has been used successfully in previous trials involving older patients (242). 
The biggest problem with postal questionnaires is non-response, which reduces 
sample size and can introduce bias if non-responders differ from responders.  A 
number of ways of increasing response rate have been trialled and reviewed 
(241,243,244).  The methods felt to be most suitable for this study by the PPI 
group were: 
 A follow-up contact by post with a second copy of the questionnaire.  Two 
weeks after the first questionnaire had been sent was felt to be a suitable time 
period for this, and only one follow-up was felt to be appropriate.  The group 
suggested encouraging participants by way of a covering letter to contact the 
researcher if they were having difficulty completing the questionnaire. 
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 Having the hospital’s logo or frank on the envelope and wording the covering 
letter as coming from the hospital (as opposed to the University as suggested 
by the Cochrane review) 
 Personalised covering letter using mail merge. 
 Including a stamped (not franked) addressed envelope in which to return the 
questionnaire. 
Semi-structured Interviews 
Questionnaires, however, are less suited to the exploration of the views, 
perceptions and experiences of participants (for example how they felt about the 
support they were given to manage their medicines on transfer of care), or to 
gaining a knowledge of why individuals behave in a certain way (for example why 
an intervention group participant may decline to attend their dMUR) (245).  
Qualitative interviews can help to gain insight into participants’ situational 
experience not detectable by the use of a questionnaire (246).  They can also 
collect the answers to open questions that require explanation or guidance, and 
interviewers can prompt participants to answer questions more fully to provide 
more in-depth information (189).   
As dMUR referral is new, and the dMUR itself is relatively new and little used, it is 
important to understand how patients feel about such an initiative and their own 
perceptions of the benefits or lack thereof.  It is also valuable to compare these 
perceptions and experiences with those of participants who did not have a dMUR, 
in terms of problems experienced with medication and other sources of support 
used or required by patients. 
Qualitative interviews can also be used to contextualise the quantitative data 
gained from the postal questionnaire (246).  For example the PEI could be 
supplemented with examples of how participants felt more able to understand and 
cope with their medication following the dMUR, or why they did not. 
There are three main types of qualitative interview: structured, semi-structured and 
in depth (247).  Structured interviews usually consist of the interviewer 
administering a questionnaire in a standardised manner, whilst semi-structured 
interviews consist of open ended questions defining the area to be explored, from 
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which the interviewer or interviewee may diverge in order to pursue an idea in 
more detail.  In-depth interviews cover one or two issues in great detail.  After 
introducing these issues, further questions from the interviewer are based on what 
the interviewee says and consist mostly of clarification and probing for details 
(247).  For this study, it was decided that a semi-structured technique with a fixed 
topic guide which could be adapted to the views and experiences of each 
participant would be the most suitable. 
It will not be feasible to interview all participants; therefore a purposive sampling 
technique will be used to identify a maximum variation sample of participants 
based on baseline characteristics.  
Recall has been identified as a limiting factor in collecting data directly from 
participants in this type of study.  However, a copy of the dMUR ‘action plan’ 
provided by the community pharmacist for intervention group patients should be 
held by the researcher at the time of interview, and participants asked to have their 
own copy to hand as a reference during the interview.  Although participants may 
not be able to recall all aspects of their dMUR, this in itself will be important to 
explore, as advice which has been forgotten is unlikely to be followed, limiting the 
usefulness of the dMUR.  All intervention and control group participants can refer 
to their participant diary, discharge summary and other sources of medication 
support they use during the interview to prompt and clarify answers if necessary. 
During PPI group sessions, it was queried whether interviewed participants would 
also be expected to complete the questionnaire at the same time as this would add 
to participant burden.  The PPI group suggested leaving the questionnaires with 
interviewed participants along with a pre-paid envelope in which to return them.  
However, it was finally decided that the researcher will request interviewees to fill 
out their questionnaire before the interview to avoid the interview content biasing 
their questionnaire answers.  Having the questionnaire affect interview content is 
more acceptable as this would be more easily accounted for during analysis and 
might indeed provide a basis for interesting narrative from participants during 
interview.  Additionally, leaving questionnaires with participants might result in 
some not being returned, whereas this would not be a factor if the questionnaire 
was completed and taken away with the researcher.  
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5.6.5 Analysis of Quantitative Data 
It is acknowledged that during this study the small number of participants to be 
recruited means that the study will be under-powered to detect statistically 
significant differences in quantitative outcomes between groups.  For example, 
previous research has demonstrated that around 20% of all one-month 
readmissions in the elderly may be caused by preventable DRPs (104,105).  Local 
one-month readmission rates for patients aged >65 years are in keeping with 
national figures at around 10%.  If 20% of these (i.e. all the preventable drug 
related readmissions) could be prevented by a dMUR, this rate would be reduced 
to 8%.  To detect this 2% absolute reduction with 80% certainty (power) at a 
significance level of p=0.05, a sample size of 3,231 participants in each group 
would be needed.  This was calculated using the formula: 
n=P1(1-P1)+P2(1-P2) / (P1-P2)2 x f(α,β) 
where n= number of participants per group 
 P1 = proportion of control group readmitted 
 P2 = proportion of intervention group readmitted 
 α = significance level (2 tailed) 
 1 - β = power of test 
 f = value calculated from α and β (248) 
 
n = 0.1(1 – 0.1) + 0.08(1 - 0.08) / (0.1 – 0.08)2 x 7.9 
n = (0.1636 / 0.0004) x 7.9 
n = 409 x 7.9 
n = 3231  
 
This is far beyond the capacity of this PhD project. 
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However for methodological rigour, and in preparation for any future RCT, the most 
appropriate test for each outcome (readmissions, A&E visits, adherence, HR-QoL) 
will be applied (Section 6.6.1).   Any differences between groups that do appear 
significant could be used to identify outcomes worthy of further investigation. 
Obviously results from the PEI will only be available for intervention group patients 
so there will be no way of applying a statistical test.  Previous studies have 
reported the mean PEI with a 95% confidence interval. 
Statistical tests will also be used to compare baseline characteristics for control 
and intervention groups, to check for homogeneity. 
Independent samples t-tests 
T-tests are used to compare the mean value of a continuous outcome between two 
groups.  The t-test assumes normal distribution and similar variance between 
groups (249). 
Mann-Whitney U-test 
The Mann-Whitney U test compares the distribution of a given variable between 
groups.  Mann-Whitney is a non-parametric alternative to the independent samples 
t-test, used when data are ordinal or requirement for normality is not met (249).  
There is no standard way for Mann-Whitney to handle tied ranks; therefore if a 
number of values in each group are identical, accuracy will be reduced. 
Chi-squared test 
Chi squared compares two or more proportions from independent groups.  Chi-
squared can also be used to test for an association between two nominal variables 
or between a nominal and an ordinal variable.  It assumes 80% of expected 
frequencies are greater than 5 and all expected frequencies are greater than 1 
(249).   
If these assumptions are not met, Fisher’s exact test can be used (249). 
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5.6.6 Analysis of Qualitative Data 
Qualitative analysis aims to capture, portray and explain the social worlds of the 
people under study (250).  It has, in the past, attracted criticism for a lack of 
transparency surrounding how findings are derived; with limited detail of data 
analysis procedures in many reports of qualitative research from which to interpret 
its context and meaning (251).  In this respect, it is helpful to adhere to the 
‘analytical hierarchy’, the process through which qualitative 'findings' are built from 
the original raw data (250). 
The hierarchy is a form of conceptual scaffolding within which the structure of the 
analysis is formed (250).  It involves three forms of activity: data management, in 
which the raw data are reviewed, labelled, sorted and synthesised; descriptive 
accounts, in which the analyst makes use of the ordered data to identify key 
dimensions, map the range and diversity of each phenomenon and develop 
classifications; and explanatory accounts, in which the analyst builds explanations 
about why the data take the forms that are found and presented (250). 
Participant Interviews 
For this study, the technique of framework analysis (FA) will be used to identify 
emergent themes and allocate codes to different issues raised relating to these 
themes during interviews.  Unlike entirely inductive and iterative qualitative 
approaches such as grounded theory, FA may be shaped by existing ideas and is 
less focused on producing a new theory.  It was developed for addressing specific 
questions and in that sense can be seen as an applied research approach that is 
useful for informing both policy and practice (251).  These attributes make FA an 
attractive choice for the current study, where semi-structured interviews will be 
conducted using a pre-defined topic guide based on questions relating to NHS 
patients’ experiences of post-discharge support with medication.  
FA is a matrix based method which facilitates rigorous and transparent data 
management such that all the stages involved in the analytical hierarchy can be 
systematically conducted. It also allows the analyst to move back and forth 
between different levels of abstraction without losing sight of the 'raw' data 
(250,251).  The ‘thematic framework’, which is the core of FA, is used to classify 
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and organise data according to key themes, concepts and emergent categories.  
The thematic framework for a particular study comprises a series of main themes, 
subdivided by a succession of related subtopics.  Each main theme is then 
displayed or 'charted' in its own matrix, where every participant (or ‘case’) is 
allocated a row and each column denotes a separate subtopic. Data from each 
case is then synthesised within the appropriate part(s) of the thematic framework 
(250). 
Most spreadsheet 'worksheets' can be easily adapted to accommodate a thematic 
chart. Extra worksheets can be created within a spreadsheet file to store additional 
thematic charts, so that one file can host synthesised data for an entire study 
(250).  The use of charting in FA assists transparency and enables investigators 
with competing responsibilities, e.g. a part time PhD student, to stop the analysis 
and return later to continue where they left off.  FA can also be useful for those 
new to qualitative research because it provides a clear track of how data moved 
from interview transcripts to themes, with summaries in charts enabling 
researchers to discuss ideas (251).  These advantages all support FA as the 
approach of choice for the analysis of the qualitative data from this study. 
Analysis of Community Pharmacy Interventions 
Feedback from community pharmacists on the content of dMURs will be analysed 
to describe, and if possible assign a monetary value to, the potential significance of 
the interventions made.  This was not an original objective of this research but was 
viewed as a valuable extension following observation of the level of detail provided 
in the dMUR action plans returned by community pharmacists.  
Significance may be considered in terms of improving the efficacy of the patient’s 
medication regimen or improving the standard of care in some other way, avoiding 
harm or preventing a hospital admission.  This will go some way towards 
characterising the quality of the MURs carried out, a concern raised in previous 
research (252-256).   
Any action taken or piece of advice given to the patient during the dMUR, as 
reported by the community pharmacists who undertook the dMURs, will be 
classified as an intervention for the purposes of this analysis. 
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In order to select the most appropriate tool for assessing the community 
pharmacists’ interventions, the literature was reviewed for previously applied 
methodologies for evaluating the significance of pharmacists’ interventions.  Each 
was considered in terms of what the researcher considered to be the 
characteristics of the ‘ideal’ model for the proposed analysis: 
 Sensitive to the type of interventions typical of a community pharmacy MUR.  
Although dMURs may have the potential to reduce hospital admissions, their 
primary focus is to increase patients’ knowledge of and adherence to their 
medicines.  Therefore an impact on admissions may not be apparent 
immediately or easily definable, whereas other benefits to patient care may be 
(for example reduction in medicines related anxiety or side effects, or 
improvement in medicines efficacy without impact on the risk of admission 
within the time scope of the study).   
 Considers interventions in terms of both harm avoided and efficacy/benefit 
gained. 
 Allows for grading of outcomes in terms of importance and probability of 
occurrence. 
 Allows allocation of a monetary value to the interventions considered. 
 Considers the timescale over which the outcome of the intervention will be 
apparent. 
 Differentiates between interventions that were actioned and those that were not 
(ie recommendations not accepted by the prescriber), where this information is 
available. 
 Simple and quick for assessors to apply during peer review. 
 Includes examples of interventions in each category, to guide reviewers. 
Possible methodologies are described below and summarised in terms of the 
above characteristics in Table 5.4, page 143. 
RiO Score 
This tool is adapted from The Hospital Avoidance Scale within the RiO healthcare 
management system (257).  Each intervention is assigned to one of three 
categories, whereby each level 3 intervention and every 10 level 2 interventions 
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equates to one avoided admission.  A cost avoidance figure is attributed to each 
potentially saved hospital admission (based on the average length of stay for an 
older person).   
This method has been used previously to assess the value of a number of 
pharmacist services, including clinical medication reviews for care home residents 
or otherwise ‘high risk’ elderly patients, as well as for domiciliary MURs (258-260).  
This method is, however unlikely to be sensitive to interventions which may 
improve patient care without impacting on hospital admissions.  Therefore this tool 
is unlikely to be the most effective for analysing dMUR interventions and will not be 
used in this study. 
Eadon Criteria / School of Health and Related (ScHARR ) model 
The Eadon criteria were first reported in 1992, when the quality of interventions 
made by ward pharmacists over a 12-month period were measured using a six 
point scoring system, shown in Table 5.1 (261). 
Table 5.1: Eadon Scoring System for Pharmacist Interventions 
Intervention type Score 
Intervention which is detrimental to the patients well-being 1 
Intervention is of no significance to patient care 2 
Intervention is significant but does not lead to an improvement in 
patient care 
3 
Intervention is significant and results in an improvement in the 
standard of care 
4 
Intervention is very significant and prevents a major organ 
failure or adverse reaction of similar importance 
5 
Intervention is potentially life-saving 6 
 
More recently, the ScHARR model (developed by the School of Health and Related 
Research at the University of Sheffield) has been used to apply a monetary cost to 
the patient’s outcome had the intervention not taken place, as illustrated in Table 
5.2 (262). 
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Table 5.2: ScHARR Model for Assigning Economic Value to Pharmacist 
Interventions 
Significance of Error Eadon Score ScHARR Cost 
Avoidance(£) 
Potentially lethal 6 1085-2120 
Potentially serious 5 713-1484 
Potentially significant 4 65-150 
Minor 1-3 0-6 
 
The detailed economic modelling used by ScHARR considers the incidence of an 
outcome and the likely impact of the intervention, as well as the costs associated 
with the interventions, the treatment of preventable ADEs and the value of the 
health lost as a result of an ADE.   
The Eadon score has the advantage of considering interventions which contribute 
proactively to patient care, rather than focussing on reactive interventions to 
prevent harm.  This is demonstrated by the results in the original report of the 
Eadon score and a recent consultant pharmacist case management study, where 
53% and 84% of interventions respectively were judged to have improved patient 
care (261,263).  This compares to 31% in a previous study which considered only 
interventions which were made to prevent harm in response to prescribing errors 
(261).   
The tool has previously been applied to interventions made by pharmacy staff 
working in a variety of settings (secondary, intermediate and primary care) 
(260,261,263).  No previous reports of its application to community pharmacy 
interventions could be found, which would be a caution in interpreting the results of 
an analysis using this method.  However, its strengths (sensitivity to ‘lower impact’ 
and ‘proactive’ interventions, ability to assign a monetary value to the interventions 
made, previous use in a variety of care settings) make this model seem an 
appropriate choice for use in this study. 
NPSA Matrix 
The NPSA matrix is a risk-scoring methodology from the National Patient Safety 
Agency, which asks assessors to think about the worst possible consequence of 
the identified issue(s) going unresolved and assign scores from 1 to 5 for the 
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likelihood and consequence of patient harm.  These two scores are then used to 
assign an overall risk score using Table 5.3 (264).  
Table 5.3: NPSA Risk Scoring Matrix 
  Likelihood score 
Consequence 
score  
1 - Rare 2 - 
Unlikely 
3 - 
Possible 
4 - Likely 5 – 
Almost 
certain 
5 Catastrophic 5 10 15 20 25 
4 Major 4 8 12 16 20 
3 Moderate 3 6 9 12 15 
2 Minor 2 4 6 8 10 
1 Negligible 1 2 3 4 5 
  
The risk is then reassessed after the intervention is made to establish if the 
intervention helped.  Finally, a saving of £2000 (based on the cost of an unplanned 
hospital admission) is assigned if the first risk score was red (15 or more) AND the 
second risk score (after the intervention) downgraded the risk to another colour 
(<15). 
The NPSA risk matrix has the advantage of being a recognised tool used to assess 
risks of harm in a variety of contexts (265,266).  However only those interventions 
judged to have prevented a hospital admission can be assigned a monetary value 
according to this system.  In addition, it leads the scorer to consider an intervention 
only in terms of harm avoided, rather than benefit gained.  No examples of its 
application to the community pharmacy sector could be found.  In view of these 
disadvantages, this tool will not be used in this study. 
Hawksworth’s Method (Reported 1999) (267) 
In this methodology, interventions are awarded a score between 0 (definitely not) 
to 10 (100% confident), to the nearest whole number, for each of the following 
criteria: 
 Detrimental to the management of the patient 
 Improved the efficacy of the patient’s therapeutic management 
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 Prevented harm to the patient 
 Prevented a hospital admission 
This method has the benefit of allowing the same intervention to be graded on 
more than one dimension (for example, the same intervention may be awarded a 
score for both improved efficacy of treatment and prevention of harm, and then a 
further score for the likelihood of a hospital admission having been prevented).  
The range of scores available increase its flexibility, however this may also make 
application and interpretation more complicated.  In addition, no monetary value 
can be assigned to interventions scored using this method.  No recent work 
applying this tool could be located to inform its use in this study.  Considering these 
drawbacks, this method will not be used in this study.   
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Buurma’s Method (Reported 2004) (268) 
In this method, the following algorithm is applied to each intervention: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Buurma’s Algorithm for Analysing Community Pharmacist 
Prescription Interventions 
This tool was developed for the analysis of community pharmacy prescription 
interventions, made in response to ‘errors’ detected; so although it has been 
previously used in the community sector, it is not certain how easily MUR activities 
would map onto the algorithm.   
The structured process involved in this model may improve the validity of scores, 
but may be more cumbersome for reviewers to apply than some of the other 
methods described above.  Additionally, no monetary value has been assigned to 
interventions using this tool.  No recent work, or work conducted in England, that 
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applied this methodology could be found.  In view of these factors this tool will not 
be used in this study. 
Westerlund’s Method (Reported 2009) (269) 
This method splits community pharmacist interventions into those which could 
prevent an adverse drug effect and those which could lead to improved therapeutic 
effect.  Interventions are categorised as preventing or initiating a primary care 
contact, or preventing a hospital admission; with the costs of these outcomes then 
applied to the interventions to produce an economic assessment.   
This method recognises that some pharmacist interventions may initially increase 
societal cost (e.g. by initiating a GP visit).  However, these costs may be recouped 
in terms of improved health in the future, a factor which, although acknowledged in 
the report, was not factored into the economic assessment.  Those interventions 
which did not initiate or prevent a primary care contact or hospital admission were 
not included in the economic analysis.  This reinforces the benefit of resources 
such as ScHARR, which include a detailed modelling of the expected net benefit of 
interventions.  No reports of the application of this method in England could be 
found. These disadvantages led to the discounting of this method for use in this 
study. 
SMART methodology (Reported 2008) (210) 
This methodology was employed to evaluate recommendations made by 
pharmacists conducting medication review clinics in primary care in Canada.  Each 
recommendation was assessed in terms of expected strength of impact on 
patient’s health, and expected time to this impact.     
The researchers found that a moderate or marked impact on patient health within 
the 5-month follow-up period would have been expected for only 15.5% of all 
recommendations.  The authors argue that this may help to explain why there was 
no significant difference in patient outcomes between control and intervention 
groups at the end of their study.  Timescale of expected benefit is an important 
factor to remember in the analysis of pharmacist interventions, particularly those 
associated with adherence, as the clinical effect may not be apparent for some 
time.  The fact that this model takes this into account is a strength.  However the 
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fact that there is no way of assigning a monetary value to the interventions and the 
fact that this model has only been applied to clinical medication reviews in primary 
care in Canada, (so it’s applicability to the community pharmacy setting in England 
is unknown) are disadvantages and this method will not be used in this study. 
Ibanez-Garcia’s Method (reported 2015) (270) 
This method was employed to analyse prescribing errors intercepted by 
pharmacists working at a tertiary care hospital in Spain.  Interventions involving 
errors in the most serious 4 subcategories (associated with one or more of 
hospitalisation, permanent harm or risk of death), were then assigned a value 
according to the probability of this outcome.  These scores were then multiplied by 
the estimated cost of treating an adverse drug event (€6857), and the return on 
investment based on a pharmacist’s salary was calculated.   
Considering both the likelihood and severity of the outcome in question is a 
strength of this model, however a weakness is that, in common with some of the 
other methods discussed, it considers interventions only in terms of harm avoided, 
rather than benefit gained.  It has additionally never been used in a community 
pharmacy setting.  Furthermore, it only assigns a monetary value to the most 
severe cases, and therefore would be unlikely to be useful in the economic 
assessment of MUR interventions.  These pitfalls lead to it being ruled out as the 
method of choice for this study. 
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Table 5.4: Summary of Advantages and Drawbacks of Scoring Tools for 
Pharmacist Interventions 
 
Conclusion: Choice of Scoring Tool 
Considering the advantages and drawback of each tool as above, the Eadon-
ScHARR model was selected as the most suitable for application in this study. 
Application of Scoring Methodology 
Various ways of applying the scoring tools exist, including self-application by the 
pharmacists performing the interventions, and peer review by other pharmacists or 
different classes of healthcare professionals (210,258-261,263,265-270).  Peer 
review using a consensus methodology will provide more objectivity and allow 
each intervention to be graded by more than one assessor.  In addition, the added 
burden of scoring their own interventions may discourage community pharmacists 
 RiO Score Eadon-
ScHARR 
NPSA 
matrix 
Hawksworth 
method 
Buurma 
method 
Westerlund 
method 
SMART 
method 
Ibanez-
Garcia 
method 
Sensitive to 
MUR type 
interventions 
No Yes No Not when 
considering 
monetary 
value 
Yes Unclear Yes  Yes 
Considers 
both harms 
avoided and 
benefits 
gained 
No Yes No Yes Yes Yes Yes No 
Grades 
outcomes in 
terms of 
probability 
and 
importance of 
outcome 
No Yes Yes Yes 
 
Yes No Yes Yes 
Assigns 
monetary 
value to 
interventions 
Yes for 
admission 
avoided 
Yes Yes for 
admission 
avoided 
No No Yes (primary 
care 
contacts and 
hospital 
admission) 
No Yes for 
admission 
avoided 
Considers if 
intervention 
was actioned 
No Yes No No No No Yes No 
Simple/ quick 
for assessors 
to apply 
Yes Yes Yes Uncertain No Uncertain Uncertain No 
Includes 
examples of 
interventions 
Yes No No No No No Yes No 
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from taking part in the study.  For these reasons, a qualitative consensus 
methodology using the Eadon scoring system will be employed for this research. 
Two consensus methods commonly adopted in medical, nursing, and health 
services research are the Delphi process and the nominal group technique, also 
known as the expert panel (271).   The Delphi technique involves expert 
contributors individually responding to survey questions and submitting the results 
to a central coordinator. The coordinator processes the contributions, looking for 
central and extreme tendencies, and their rationales. The results are then fed back 
to the respondents. The respondents are then asked to resubmit their views, 
assisted by the input provided by the coordinator. This process continues until the 
coordinator sees that a consensus has formed.  In the Delphi technique, the 
experts do not know who the others experts are during the process (272).  The 
nominal group technique uses a highly structured meeting to gather information 
from relevant experts about a given issue. It consists of two rounds in which 
panellists rate, discuss, and then rerate a series of items or questions (271). 
The Delphi process has the advantage of not being limited by physical distance 
between participants, where time and cost make group meetings unfeasible.  It can 
bring together the views of experts who do not traditionally communicate and who 
represent diverse backgrounds with respect to experience or expertise.  The 
separation of participants reduces interaction bias, for example domination by 
quantity or strength of personality of participants with a particular opinion (273).  
However, this has the drawback that participants are not able to discuss issues, as 
would be possible with the nominal group technique. This may lead to 
misinterpretation, and ‘discouraged dissenters’ dropping out, forcing an artificial 
consensus (274).  Although this drawback will be kept in mind, it was decided that 
organising a physical meeting between members of the peer review panel would 
be too logistically difficult, and therefore the Delphi process was selected for use in 
this research. 
In previous peer reviews of scoring tools for pharmacist interventions (not 
necessarily via a Delphi process), many studies showed that reliability of scores 
was not affected by the profession of the rater (275).  However others found 
differences in scores assigned between pharmacists and physicians.  Wright et al. 
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demonstrated that community pharmacists, hospital pharmacists, GPs and 
specialist physicians attribute significantly different values when undertaking these 
assessments (276).  Selecting reviewers familiar with the types of events being 
reviewed should improve consistency of scores (275).   For this reason reviewers 
invited to participate in the Delphi process for this study will be from different 
sectors and professional backgrounds (hospital, community and general practice 
pharmacists, hospital physicians and GPs) but familiar with the types of medication 
related issued faced by older patients on transfer of care and their consequences.   
Delphi studies usually use panels of at least 15 members (272).  However this may 
not be feasible for this small study.  From a pragmatic point of view a panel of eight 
members seems reasonable (four pharmacists and four doctors, with 
representation from both primary and secondary care to reflect the range of 
professionals who may award different values to the same intervention).  The use 
of a smaller panel than might be expected must be acknowledged in the 
interpretation of results. 
 
5.7 ETHICAL CONSIDERATIONS 
 
5.7.1 Risks, Burdens and Benefits to Participants 
Participants will be expected to visit their community pharmacy, which may be 
difficult for frailer/elderly patients. Any patient who envisages significant difficulty 
accessing their community pharmacy, and whose pharmacy does not offer 
domiciliary or telephone MURs, will be excluded from the study, as the distress 
involved in trying to attend may outweigh the benefits arising from the dMUR. 
However, these frailer patients may be those that would benefit the most from 
support with their medication. For this reason, a record of the number of patients 
who would otherwise be eligible for the study, but are excluded because of a high 
probability of difficulty in leaving home during the first few weeks post discharge, 
will be kept. Participants who are recruited but then unable to attend for an MUR 
will be asked about this experience at follow-up.  This group of patients may then 
form a target for the basis of future research. 
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Participants may not wish to be interviewed in depth, or may be concerned about 
their identity being known. They will be reassured of the confidential nature of data 
handling during the study and reminded that they are free to withdraw at any time 
without giving reason. Training (formal and informal) will be accessed to ensure the 
researcher has the necessary skills for conducting semi structured interviews. It is 
hoped this will make the interviewing process as positive as possible for the 
participants. 
Any medication related problem that becomes apparent during the normal clinical 
care of the patient during admission will be dealt with in the usual way. No aspect 
of routine clinical care will be withheld from study participants. 
MURs are available to all patients who fit the criteria laid down by the PSNC 
service specifications (168). Whilst the control group will not be actively referred for 
a MUR during the study, they will not be denied an MUR should they self-refer to 
their community pharmacy.  This will mimic 'usual care'. 
When considering the burdens and benefits to participants in this study, it must be 
noted that there is little evidence that the MUR service is cost effective and that no 
research currently exists that shows a measurable benefit of MURs on clinical 
outcomes (277).  Results from this research should add to the knowledge pool to 
help ensure only evidence based services are funded by the NHS. 
 
5.7.2 Older People as a Vulnerable Group 
Although older people may be viewed as a vulnerable group, this vulnerability may 
make them particularly likely to benefit from medication adherence support. 
However, an individual who is unable to understand what participation in this study 
means and therefore unable to give informed consent is unlikely to be able to 
engage in the MUR process. 
Potential participants will be given written and verbal information about the study 
and given time to discuss participation with the chief researcher, relatives, carers 
etc as needed. No effort will be made to coerce individuals to take part and any 
concern over the capacity of the patient to consent will be discussed with the 
patient’s medical or nursing team. 
147 
 
 
5.7.3 Confidentiality 
In order to initially screen patients for eligibility, access to a patient’s hospital 
prescription chart will be required, and patients themselves will be required to 
answer questions about how they currently manage their medication. Screening 
will be done by the patient's own ward pharmacist or technician as part of their 
normal clinical service. 
Each participant will be allocated a 3-digit participant identification number (PIN) 
according to their order of entry into the study. Only this number will be used in any 
table or report generated as part of the study. A list of study PINs and 
corresponding hospital identification (ID) numbers will be kept in order to identify 
participants during follow-up. This and all data containing person identifiable 
information will be held on an electronic NHS ‘sharepoint’ to which only the 
investigator and those approved by the investigator will have access. 
Once a participant has been consented, baseline demographic data will be 
collected from their medical notes.  This will be entered into a database on the 
sharepoint, which will identify the participant only by their PIN. Only NHS encrypted 
portable devices will be used if necessary to transfer data. 
In order to send referrals for dMURs to community pharmacists, secure faxes (i.e. 
in areas inaccessible to persons outside the clinical care team) will be used.  
Telephone calls will be made to these pharmacies by hospital pharmacy support 
staff to alert them a fax is being sent and acknowledgement of receipt by return fax 
or telephone call will be requested. 
The community pharmacist will send a copy of each dMUR action plan / outcome 
back to the hospital pharmacy using NHS or encrypted email or the secure fax 
procedure outlined above. 
Copies of referrals and faxed MUR action plans will be scanned onto the 
sharepoint and the originals destroyed. 
Interview transcripts will be anonymised and transferred into electronic format as 
soon as possible after the interview has taken place. 
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If it is necessary to recall patient notes as part of the follow-up process these will 
be kept locked away in the pharmacy department and used only for the purpose of 
the study and only by the investigator and the consultant geriatrician involved in 
their analysis. 
Communication with GP surgeries will be done via a secure fax or NHS.net email 
with the patient’s consent. A copy of the original consent form will also be faxed to 
the GP surgery as proof that the patient has agreed to take part.  A covering letter 
and GP information sheet will also be sent (Appendix 5). 
Once the study is complete, any remaining paperwork and electronic files 
containing patient identifiable information will be destroyed, apart from an 
electronic list of patient hospital ID numbers and corresponding PIN to allow 
contact to be maintained, for example to allow feedback of results to participants. 
Feedback regarding issues identified during a dMUR or other part of the study will 
not be given to any person other than the researcher and the patients GP, unless 
there is a serious risk of harm to the participant or others. In such cases, it may be 
necessary to provide a participant’s relative / carer or other relevant person with 
details of issues identified during the course of the study. If this is required, the 
participant will be informed of the line of action being taken. This would be 
according to normal ethical practice within the NHS. 
 
5.7.4 Conflicts Of Interest 
As the investigator works in SONT as a clinical pharmacist, it is likely they will be 
involved in the routine care of some of the potential participants.  As there are no 
other members of the research team it will not be possible for anyone else to 
inform and consent potential participants.  However care will be taken by the 
researcher not to exert any influence over a patient’s decision to participate. 
There may also be a conflict of interests in the motivation of community 
pharmacists to agree to accept referrals as part of the study.  Community 
pharmacists are remunerated for providing MURs, so it is feasible that some may 
be motivated to take part for financial gain (or pressure from their managers in the 
case of pharmacists who work for chains of pharmacies) rather than the desire to 
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provide a clinical service (173).  This may affect the quality of the MURs received 
by some participants, and therefore the outcomes experienced by these 
participants.  However as long as there is a wide geographical spread throughout 
the catchment area in the community pharmacies who sign up for the study, it can 
be assumed that this effect, if present, will be neutralised overall. 
If medication related issues become apparent during follow-up, the participant will 
be referred back to their community pharmacist or GP as appropriate, whether or 
not this will affect the results of the study.  Such incidences will be anonymised and 
addressed during data analysis. 
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CHAPTER 6: MEDICINES SUPPORT REFERRAL SERVICE: 
MATERIALS AND METHODS 
This chapter describes the methods used during the randomised controlled 
feasibility study of a referral service from hospital to a community pharmacy for a 
dMUR.  An overview of the study is followed by a description of the engagement of 
hospital and community pharmacy staff.  Then participant eligibility, recruitment 
and randomisation procedures are covered, before data collection and analysis 
methods used are described. 
 
6.1 PATIENT AND PUBLIC INVOLVEMENT 
In order to support PPI in this research, a successful application was made to the 
NIHR’s PPI bursary scheme for £270, to cover refreshments and travel expenses 
for meetings, which were to be held at SONT. 
Patient group and public representatives were recruited by placing flyers (Appendix 
6) in outpatient departments and the outpatient pharmacy at SONT, via an 
advertisement in the Foundation Trust Members Newsletter (Appendix 7), and 
directly by the researcher from the Trust's cardiac rehab programme, warfarin clinic 
and care of the elderly ward. 
Recruitment of the PPI group took place during February and March 2013.  
Following an initial contact by telephone, fourteen members were invited via post to 
the first group meeting.  Of these, seven attended and came to form the core PPI 
group.   
A total of 6 PPI group meetings took place between April 2013 and January 2014.  
Sessions were audio-recorded with the group members’ permission so the 
researcher could concentrate on facilitating the session.  Specific questions 
addressed and detailed notes from the sessions can be found in Appendix 2. 
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6.2: STUDY OVERVIEW 
During standard care at SONT, patients are discharged with at least seven days’ 
supply of medicines and a summary of care record sent to the patient’s GP.  The 
patient also receives a printed copy of the discharge summary.  In this study, 
patients who intend to self-medicate once back at home are screened for suitability 
for a dMUR.  Suitable patients are offered a dMUR with their nominated community 
pharmacist.  On discharge, a referral form (Appendix 8, (214)) is completed and 
faxed or emailed to the community pharmacy along with copy of their discharge 
medication and participant consent form (Appendix 9).  The patient then has a 
dMUR at their chosen community pharmacy within 4 weeks of discharge. 
The new service and how it compares with standard hospital discharge care, along 
with an indication of the research elements of this study up to the point of dMUR, is 
shown diagrammatically in Figure 6.1.   Participant follow-up for both groups is 
illustrated in Figure 6.2. 
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Green = Standard Care            Yellow = New service           Purple = Research procedure 
Figure 6.1: Flowchart Showing Participant Recruitment and Randomisation 
Randomised 
to control 
Randomised to 
intervention 
Researcher informs patient fully 
about study. Patient consent to take 
part? 
Tell patient to expect telephone call 
from community pharmacy following 
discharge to arrange dMUR 
Community pharmacist contacts 
patient to arrange MUR 
 
Fill in MUR referral form. Fax referral, discharge 
medication list and consent form to community 
pharmacist within 24 hours of discharge.  Telephone 
community pharmacist to check referral received  
Discharge with 
standard information 
Follow-up at four weeks and 
six months post discharge 
(see other flowchart) 
Enter into randomisation 
Patient receives 
MUR within 4 weeks 
of discharge 
 
Inform GP of 
patient’s 
participation 
Yes 
No 
No 
Exclude and discharge with 
standard information 
Provide brief verbal overview of study/dMUR service.  
Patient interested?  
No 
Leave Participant information part 1 with 
patient and notify researcher 
Check remaining eligibility criteria.  Is patient eligible? (NB 
if patient housebound community pharmacy and patient 
must both agree to domiciliary or telephone dMUR) 
Yes 
Potentially eligible for dMUR  
Yes 
Attempt to clarify on next 
pharmacist ward round 
Unable to ascertain 
Pharmacy medicines reconciliation 
No 
Not eligible for dMUR 
Patient aged 65 or older admitted to Southport & Ormskirk NHS Trust 
under medical directorate 
Patient intends to self-medicate at home and able to nominate 
community pharmacy? 
Yes 
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Figure 6.2: Chart Showing Flow of Participants through Remainder of Study 
 
A briefing session for medical consultants was held to inform them of the study and 
ensure they were happy for their patients to be approached regarding participation.  
Nursing staff looking after patients identified as potentially eligible for recruitment 
were consulted on an individual basis by the researcher to inform them their patient 
was being approached. 
 
Randomisation 
Standard care Intervention 
Receive dMUR  
4-week follow-up 
o Check for readmission via Patient 
Administration System. 
o Case note analysis to identify medicines 
related readmissions 
6-month follow-up – procedure as for 4-week follow-up 
minus in-depth interview 
 
6-month follow-up – procedure as for 4-week follow-up 
minus in-depth interview 
Postal follow-up: 
Adherence questionnaire  
SF-12 v2  
Diary 
Home visit (purposive sample): 
In-depth interview 
Diary 
Adherence questionnaire 
SF-12 v2 
o Check for readmission via Patient 
Administration System. 
o Case note analysis to identify medicines 
related readmissions 
 
4-week follow-up 
Postal followup: 
Adherence questionnaire  
SF-12 v2  
Enablement index 
Diary 
Home visit (purposive 
sample): 
In-depth interview 
Adherence questionnaire 
SF-12 v2 
Enablement index 
dMUR feedback received from pharmacy.  
(Contact pharmacy if no feedback received by 
4-week follow-up) 
Postal prompts after 2 
weeks if questionnaire not 
returned  
Postal prompts after 2 
weeks if questionnaire not 
returned  
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6.3: HOSPITAL PHARMACY STAFF TRAINING 
A training session was conducted for hospital pharmacy staff (ward based 
pharmacists and technicians) on the study procedures, including: 
 Identification of potentially eligible patients (see Figure 6.1) 
 Making the ‘first approach’ to potential participants to introduce the study and 
leave part 1 of the participant information leaflet with any patients that show 
an interest 
 Notification of potentially eligible patients to the researcher (verbally, by 
written communication or by email) 
 Annotations required on medication charts by ward pharmacists when 
medicines change (to allow accurate completion of the MUR referral form by 
the researcher) 
 
6.4: COMMUNITY PHARMACIST RECRUITMENT 
A covering letter and information sheet about the study were distributed via email 
to all community pharmacists (n=77) by the Local Pharmaceutical Committee in the 
two NHS England Areas served by the hospital (Appendix 10).  Those wishing to 
take part were asked to complete and return a consent form (Appendix 11) to the 
researcher by post, fax or email.  The consent form also requested that the 
community pharmacist provide their contact details, including a safe-haven fax 
number through which to receive referrals, and indicate whether they felt able to 
provide domiciliary or telephone MURs.   Forms were circulated twice, after which 
pharmacies who had not returned sign-up forms were contacted by telephone to 
check they had received them and to answer any questions.  Those who requested 
it were sent the details of the study again.   
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6.5: PARTICIPANT RECRUITMENT 
6.5.1: Inclusion Criteria 
 Patient under care of medical directorate  
 Patient aged 65 years or older 
 Patient either prescribed five or more regular long term medications or has 
had one or more changes to medications during hospital stay.  
 Intention by the patient to be independently self-medicating once back at 
home 
 Patient either using the same community pharmacy regularly for at least 
three months prior to admission (as per national eligibility criteria for MURs) 
or able to nominate a community pharmacy they will use regularly on 
discharge 
 Patient’s community pharmacy signed up to receive referrals from the 
hospital 
6.5.2: Exclusion Criteria 
 Patient will have a relative or carer managing their medication once they are 
back at home 
 Patient unable to name a regular community pharmacy 
 Patient unable to visit the community pharmacy for a dMUR (unless the 
community pharmacy offers telephone/domiciliary MURs) 
 Patient’s community pharmacy is not signed up to receive referrals as part 
of study 
 Patient lacks capacity to give consent to participate in study 
 Patient has already been enrolled in the study during a previous admission 
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6.5.3: Consent and Randomisation 
The first approach to a potential participant was to be made by a ward pharmacist 
or technician.  The procedure used to gain informed consent was: 
1) Ward pharmacists identified potentially eligible patients and gave a brief 
verbal overview of the study. 
2) If the patient agreed, an 'Initial contact slip' (Appendix 12) and 'participant 
information part 1' (Appendix 13) were left with the patient.   
3) The researcher was notified. 
4) A sticker (Appendix 14) was inserted in the patient’s case notes to inform 
the ward team that the patient had been identified as potentially eligible for 
the study. 
5) The researcher visited the patient to check eligibility. 
6) If the patient was eligible, the researcher discussed the study in more detail, 
including 'participant information part 2' (Appendix 15) and consent form 
(Appendix 9), answering any questions as necessary. 
7) If required, a period of 24 hours was allowed for the patient to decide 
whether or not to participate. 
8) The researcher re-visited the patient to confirm if the patient was willing to 
participate and, if so, obtain informed consent.   
9) Sticker (Appendix 16) and copy of consent form was inserted in patient’s 
case notes to inform the ward team that the patient had been recruited to 
the study.  Copies of the consent form were also left with the patient and 
faxed to their GP on discharge.  The original consent form was kept in the 
study file. 
Following consent, participants were randomised to either receive a dMUR with 
their nominated community pharmacy or standard hospital discharge care as 
outlined above.  Intervention group participants were informed prior to discharge to 
expect their community pharmacist to contact them to arrange a dMUR.  Control 
group patients were not approached again.    
Data regarding baseline characteristics of participants were collected in terms of 
general demographics and factors that could affect their risk of DRP or 
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readmission.  A copy of the data capture form is included in Appendix 17.  These 
characteristics were compared between groups using Chi-squared (for categorical 
data) or the independent samples T-test (for continuous data). 
Randomisation Technique 
Before recruitment commenced, a randomisation tool 
(http://www.webcalculator.co.uk/statistics/rpermute3.htm) was used by research 
technicians at the University of Wolverhampton (independent of the study) to 
generate a random permutation of 100 digits, assigning them to one of two groups 
(control and intervention).  Sealed envelopes containing the assignments were 
created and numbered according to the random sequence.  These were delivered 
to SONT, where they were stored in the research department and opened by 
SONT research staff in sequence as participants were consented. 
For those participants recruited in to the intervention arm, a dMUR would then take 
place within 4 weeks of hospital discharge (as per national criteria) (168).  Matters 
identified by the community pharmacist and actions taken were, together with the 
participant’s consent, returned to the investigator for use in data analysis. 
A period of 3-6 months was initially allowed in order to recruit the required number 
of participants.  This was later extended to 9 months due to slow recruitment.    
 
6.6: DATA COLLECTION POINTS 
Participants were followed up at four weeks and six months.  The data collected at 
each point is described below. 
 
6.6.1: Identification of Readmission  
At each follow-up point, the participant’s hospital ID number was entered into the 
hospital’s electronic PAS.  This allowed identification of any hospital attendances 
since discharge, and also allowed for the possibility that a participant was actually 
an inpatient at the time of follow-up.   If a re-admission had occurred, the patient’s 
notes were reviewed to evaluate contributing medication problems (Section 6.6.2).   
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6.6.2: Participant Diaries 
On enrolment into the study, participants were initially given a diary to keep of 
readmissions and GP visits, to be returned with their four-week follow-up 
questionnaire (Appendix 18).  A second diary was to be posted to each participant 
with the four-week follow-up questionnaire, which was to be returned with their six 
month follow-up questionnaire.  
  
6.6.3: Postal Questionnaire 
All participants were posted a questionnaire at each follow-up point, unless they 
had been selected to receive a face-to-face interview, in which case the researcher 
took this with them at the time of the interview.  Different versions of the 
questionnaire were created for control and intervention participants at 4-week 
follow-up as only intervention participants were being asked questions related to 
dMURs (including the PEI).  A further version for all participants was created for 6-
month follow-up with slightly different wording to reflect the time frame being 
covered by the questionnaire (since the last contact by the researcher rather than 
since discharge).  No participants were asked to complete the PEI at 6-month 
follow-up.  Copies of all three questionnaires are included in Appendices 19-21.   
A personalised covering letter was created and sent with all questionnaires 
(Appendices 22 and 23).  The covering letter briefly reminded participants about 
the study and encouraged them to complete and return the questionnaires.  A 
stamped addressed envelope was included in which to return the questionnaires. 
If a participant did not return their questionnaire after two weeks, a reminder note 
(Appendices 24 and 25) was sent with a further questionnaire.  If a response was 
not received after another four weeks, the participant was not contacted again.  
Patients who did not return questionnaires at 4-week follow-up were still contacted 
at the 6 months follow-up point using the same procedure.  
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6.6.4: Semi-structured Interviews 
A sample of participants from both control and intervention groups were visited at 
home and interviewed in depth at the four-week follow-up point, regarding their 
experiences of medication support during and following their hospital stay (see 
appendices 26 and 27 for copies of interview schedules).  Interviewees were 
selected purposively in an attempt to represent the maximum variation of 
participant characteristics. 
Interviews were audio recorded to ensure accurate data capture. The interviews 
aimed to explore: 
 The participant’s perception of the medicines information they were given during 
their original admission. 
 For participants who received a dMUR, the information provided by the 
community pharmacists and what the outcome of the dMUR was from the 
patient’s perspective.   
 Any form of medication review the patient had that was not part of the study, the 
reasons for and outcomes of this. 
 If an intervention group participant had not had their dMUR, the reasons for this. 
 If a participant had had a hospital or GP visit since discharge, whether this was 
linked to problems with medication adherence. 
 
6.6.5: Hospital Pharmacist Focus Group 
Due to slow participant recruitment during the early weeks of the study all ward 
based pharmacists and technicians working at SONT were invited to take part in a 
focus group, aiming to identify possible reasons for the slow recruitment rate and 
discuss solutions.  The researcher acted as the facilitator for the focus group, 
which was audio-recorded with the participants’ permission.  An information leaflet 
(Appendix 28) and consent form (Appendix 29) were circulated before the session, 
which took place in the pharmacy department at SONT.   
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A complete topic guide for the focus group is included in Appendix 30.  Due to the 
low referral rate of potential participants for the study, it was desirable to start the 
session on more general ground to stimulate discussion and ensure the focus 
group participants did not feel threatened or as if the session had been designed to 
interrogate them about why they had not been referring more patients into the 
study. 
 
6.6.6: Hospital Pharmacist Questionnaire 
In order to see if the issues identified during the focus group affected the pharmacy 
department more widely, and the extent to which the solutions posed were felt to 
be useful, the qualitative data from the focus group was used to develop a 
quantitative questionnaire to be circulated to all pharmacists at SONT. 
The final questionnaire consisted of a mix of open, closed and Likert (5-point 
agreement scale) questions.  It was piloted on one pre-registration pharmacist, one 
band 6, one band 7 and two band 8a pharmacists working for the Trust, who were 
aware of the project but had not been actively involved in the recruitment phase of 
the study.  These members of staff were asked to record how long the 
questionnaire took to complete, and to assess all questions for comprehension.  All 
staff reported the questionnaire took 10-15 minutes to complete.   Following their 
feedback, minor amendments were made to two questions. 
After piloting, the questionnaire was circulated (via email and on paper) to all 22 
pharmacists who had been working at SONT during the feasibility study.  Email 
reminders were sent 2 and 4 weeks later.  A copy of the questionnaire is included 
in Appendix 31. 
 
6.6.7: Community Pharmacist Feedback 
dMUR ‘Action Plans’ 
A copy of the actions taken and/or advice given during each dMUR conducted as 
part of the study was to be returned to the researcher by the participant’s 
community pharmacist by fax, post or email.  If dMUR feedback had not been 
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received by four-week follow-up, the community pharmacist was contacted by 
telephone to ascertain if the dMUR had taken place.  If it had not taken place, 
reasons for this were explored and the participant re-referred for a dMUR if 
necessary.  If the dMUR had taken place a copy of the MUR feedback was re-
requested. 
Community Pharmacist Questionnaire 
Following referral of the last participant for dMUR, community pharmacists who 
had participants referred to them during the study were sent a self-completed 
questionnaire.  The questions specifically addressed the quality of referrals sent by 
the hospital and the community pharmacists’ opinion of the service.  A copy of this 
questionnaire is included in Appendix 32. 
Prior to survey distribution, all pharmacies who had a dMUR referral from the hospital 
were contacted by phone to confirm that the pharmacist who had received the 
referral was still working from those premises. If the original pharmacist was no 
longer working at that pharmacy, a forwarding telephone number was requested and 
an attempt made to contact the pharmacist at their new working premises.  Following 
verbal consent, surveys were sent by fax or email.  Surveys could be returned by 
fax, email or post.  Follow-up phone calls to non-responders were made at 2 and 4 
weeks to prompt return of the survey.   
 
6.7: METHODS OF DATA ANALYSIS 
 
6.7.1: Statistical Analysis of Quantitative Data  
This study aims to find out as much as possible about which outcomes may be 
worth investigating further with regards to the effectiveness of dMUR referrals.  
Therefore, it would be desirable to ensure any effects of the intervention are not 
missed because of the relatively large proportion of participants in the intervention 
group (nearly one-third) who did not go on to receive their dMUR.  For this reason, 
results were analysed according to both an intention to treat (ITT) and a per-
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protocol (PP) approach (described below); however the PP analysis will be 
interpreted with due caution due to the potential for bias. 
All statistical tests performed on the data collected during the study were 
conducted using the electronic Graphpad software (available via 
https://www.graphpad.com/)  
Intention to treat  
In this approach, all participants are included in the analysis according to their 
randomised group, irrespective of whether they received the intervention (ie had a 
dMUR) or not (189).  This was the primary analysis approach as it avoids the 
problem of bias that may be introduced if participants who do not adhere or drop 
out of the study are different in some way to those who adhere to the study 
protocol.  However, ITT analyses may underestimate the full effect of the 
treatment, as participants who did not receive a dMUR will be included in the 
analysis of the effects of dMURs. 
Per protocol  
In this approach, only participants who adhere to the study protocol are included in 
the analysis (189).  In this study, a PP analysis would exclude intervention group 
patients who did not have a dMUR within 4 weeks of discharge.  Per protocol 
analysis also excludes participants who did not return a completed follow-up 
questionnaire and therefore did not provide a full set of data on the outcome 
measures.  
Recruitment Rate 
The total number of participants recruited was analysed in relation to: 
 The total number of medical patients discharged from SONT during the 
recruitment period 
 The number of potentially eligible patients identified by ward pharmacists 
but not recruited, along with the reasons for failure to recruit   
 The variation in recruitment rate during different periods in the recruitment 
phase was also analysed in relation to factors which could affect this 
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Baseline Characteristics 
Demographic characteristics of both the control and intervention groups were 
compared using Chi-squared (for dichotomous data) and the independent samples 
t-test (for continuous data) to check for homogeneity between groups.  This 
included calculation of the Medication Regimen Complexity Index (MCI) of each 
participant, to rule out existing differences in the complexity of their medication 
regimen as a cause of any differences in outcomes (particularly adherence) 
between groups (278).   
Dropout Rate and Loss to Follow-Up  
Overall loss to follow-up was calculated using the percentage of the total number of 
original participants for whom follow-up data was available.   
Delivery of dMURs 
The delivery of dMURs as per study protocol (within 4 weeks of discharge) and 
overall were calculated as a percentage of all patients referred.  Reasons for non-
delivery were collated in order to make recommendations for increasing uptake, if 
appropriate.  
Readmission 
The proportion of participants in each group having one or more readmission 
during the follow-up period (dichotomous data) was compared using Chi-squared 
at both 4-week and 6-month follow-up.  When the conditions for Chi-squared were 
not met, Fisher’s exact test was used instead. 
The relative risk of readmission in the intervention group at each time-point was 
also calculated, along with 95% confidence intervals (CI).   
In addition, the total number of readmissions in each group (ordered discrete data) 
was compared at 4-week and 6-month follow-up using the Mann-Whitney U-test.   
The mean length of readmission episodes in each group was also compared using 
the Mann-Whitney U Test.  
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A&E Attendances 
The proportion of participants in each group having one or more A&E visit (but 
being discharged from here rather than admitted to a hospital ward) was compared 
using Chi-squared at both follow-up points.  The relative risk of an A&E visit in the 
intervention group at each time-point was also calculated, along with 95% CI. 
In addition, the total number of A&E visits in each group was compared at 4-week 
and 6-month follow-up using the Mann-Whitney U-test.   
HR-QoL and Adherence Scores 
SF12-v2 and MMAS scores were treated as continuous numerical data and 
compared between groups using an unpaired t-test at both follow-up points. 
Enablement 
Previous studies have reported the mean PEI with a 95% CI.  Therefore the same 
practice was employed here for intervention group participants who received a 
dMUR and returned a scorable questionnaire.   
 
6.7.2: Qualitative Data Analysis 
Readmission Data 
The hospital notes of each readmitted participant were examined by a consultant 
geriatrician and specialist care of the elderly pharmacist (the researcher).  Any 
ADEs identified on readmission were assessed for causality and contribution to 
admission and consideration was given to whether these could have been 
prevented by the dMUR.  Previous work on identifying medication related hospital 
admissions was used as a guide during these sessions (see Appendix 33) 
(61,62,215).  The consultant was blinded to the study group of the participants. 
dMUR ‘Action Plans’ / Feedback 
Each piece of advice given to a participant or recommendation made to their GP as 
a result of the dMUR was classed as an intervention for the purposes of this study.  
Interventions were grouped by type to identify any recurrent issues.  Contents of 
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individual action plans were also used to inform discussion during semi-structured 
interviews with participants at 4 week follow-up.  
To assess the potential clinical impact of interventions made, an expert panel was 
convened and Delphi methodology used to arrive at consensus. The term “expert” 
in this context has been described as “clinicians practicing in the field under 
consideration” (271). Therefore the expert panel for this study comprised 5 
pharmacists, 2 medical practitioners based in academia and 2 family doctors.  
Consensus was defined as 75% agreement between reviewers’ scores as 
advocated by Diamond et al (279).  In addition, consensus can also be achieved 
when stability of the distribution of scores occurs (272,273).  If variation between 
rounds is less than 15%, a state of stability is said to exist (273,279).  It was decided 
to use 75% agreement as the primary target, but also to consider the variance in 
scores if the 75% threshold was not reached.   
All recorded interventions were collated and reviewers were instructed to award 
each intervention a value according to the Eadon scoring criteria (Table 5.1, page 
137).  Space for free text comments was provided after each statement, allowing 
reviewers to provide a rationale for their positions.  The resulting questionnaire was 
piloted by a hospital pharmacist who had not been involved with the study to 
ensure clarity and that enough detail was provided to allow reviewers to answer.   
The pilot identified that clear instructions needed to be available to reviewers on 
when the different scores should be applied (particularly the score of 3). 
The questionnaire was then sent to Delphi panel members via email to score 
independently.  A copy of the ‘Round One’ questionnaire, including instructions to 
reviewers, is reproduced in Appendix 34. 
Reviewers were asked to return their scores within two weeks.  Reminder emails 
were sent at 2 and 4 weeks if no reply had been received.   If no response was 
obtained by week 6, that participant was viewed as having left the process.   
Following the return of ‘Round One’ Delphi questionnaires, all scores and free-text 
comments were collated.  Each reviewer then received a personalised ‘Round Two’ 
survey, with box plots showing their score along with median and upper and lower 
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quartiles for group scores.  These personalised surveys were then circulated to 
reviewers, returned and analysed using the same process as for ‘Round One’.   
Once consensus was achieved, the ScHARR model, used to apply an ‘opportunity 
cost’ saving to medication errors and adverse drug events avoided, was mapped 
onto the Eadon score to determine the economic impact of pharmacist interventions 
(262,263).  These values were totalled to give an overall cost avoidance (expressed 
as a minimum-maximum range in line with the ScHARR reference figures) for the 
interventions reviewed.  These figures were then divided by the number of 
interventions reviewed to estimate a mean cost avoidance per intervention.  Finally, 
this was multiplied by the mean number of interventions made per dMUR to estimate 
a cost avoidance per dMUR carried out during the study (again expressed as a 
range). 
Semi-structured interview data  
Interviews with participants were audio-recorded with the participants’ verbal 
consent and transcribed verbatim.  Transcripts were then analysed using FA.   
During the process of FA, transcripts were reviewed and recurring or important 
themes identified.  These were of both a substantive nature, such as attitudes, 
behaviours, motivations or views, or more methodological, such as the general 
atmosphere of an interview or the ease or difficulty of exploring particular subjects.  
A conceptual framework was then devised by grouping themes and subthemes 
hierarchically.  A copy of this conceptual framework can be found in Appendix 35.  
The framework was then applied to the raw data, so that each interview transcript 
was indexed in according to which parts of the conceptual framework applied.  The 
data were then sorted using Microsoft Excel to construct a set of thematic charts.  
Brief notes summarising the key points were then made in each chart’s cell where 
a particular subtheme had appeared in a particular participant’s interview, along 
with a quote from the transcript to illustrate this.  Where one passage was relevant 
to more than one theme or sub-theme, this was cross referenced in each cell to 
which the passage applied.  Interpretative comments were added to the charts 
where applicable.  
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Each theme was then examined across all interviews and the range of perceptions, 
views, experiences or behaviours demonstrated by the participants studied.  Key 
dimensions within each phenomenon were noted in order to compare and contrast 
different manifestations of the data.  Links or connections between two or more 
phenomena were also looked for. 
Explanations of phenomena within the data were then considered, based on 
explicit reasons given by participants themselves, or implicit reasons inferred by 
the researcher.  Both the behaviour and intentions of the participants and 
contextual factors were considered in this analysis of the data.  When developing 
implicit accounts of phenomena, the researcher searched for underlying ‘logic’ in 
what participants had (or had not) said during the interviews, drew on patterns 
identified within the data and looked for the interweaving of apparently 
unconnected themes which nevertheless occurred in close proximity within the 
interviews.  Findings were also compared with existing knowledge or theory when 
developing these implicit accounts. 
Hospital Pharmacist Feedback 
Following the hospital pharmacist focus group, the recording of the session was 
transcribed and emailed to all participants for comment.  A printout was then made 
and read through in its entirety, with notes being made of themes that were either 
recurrent or important enough to stimulate discussion within the group.  A coding 
index was created identifying different issues occurring within these themes, which 
allowed the data to be labelled according to the code applicable to particular 
sections of the transcript. 
Quantitative data from the hospital pharmacist questionnaire survey was analysed 
descriptively using Excel and responses to open-ended questions themed. 
Community Pharmacist Questionnaire 
Data from the community pharmacist questionnaire survey were analysed as for 
the hospital pharmacist questionnaire. 
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6.8: ETHICAL APPROVAL 
Ethics approval for this study was obtained from the Northwest Research Ethics 
Committee (Ref 13/NW/0779). 
 
6.9: LOGISTICAL PROBLEMS WITH OPERATIONALISING STUDY DESIGN 
6.9.1: Initial Approach to Potential Participants 
As described in Section 6.5.3, this was to be made by ward pharmacy teams, who 
were to give initial study information to the patient and notify the medical team via 
the patients’ case notes.  However it appeared that this was only done in a minority 
of cases and most of the time the researcher ended up making the initial approach 
to the patient following identification by the ward pharmacist. 
6.9.2: Involvement of Pharmacy Technicians in Recruitment 
Initially it was envisaged that pharmacy technicians would assist ward based 
pharmacists with identifying and making the initial approach to potential 
participants, and notifying the researcher when a potential participant was 
identified.  However due to a shortage of ward based technicians and other 
demands on their time, this was not possible. 
6.9.3: Participant Diary 
Following confusion from early participants about how to complete the diary, and a 
number of diaries being returned incomplete or not at all, it was decided to discard 
the diary as a means of data collection (and therefore GP visits as an outcome) 
during this study.   
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CHAPTER 7: RESULTS 
This chapter presents the data collected during this PhD research project.  Firstly, 
results pertaining to the barriers and facilitators to transitional care of older patients 
utilising community pharmacy via the dMUR referral service will be considered.  
These include data relating to the engagement of both community and hospital 
pharmacists with the service and the impact on of this on participant recruitment. 
Participant recruitment data are then presented along with reasons encountered for 
exclusion and refusal.  Next is a description of participant attrition during the course 
of the study and how this affected the calculation of participant outcome data.  This 
is followed by presentation of quantitative participant outcome data according to 
both intention to treat and per protocol analyses.  Following this are the results of 
the analysis of the case-notes of participants who were readmitted to hospital 
during the study’s follow-up period. The results of the framework analysis of semi-
structured participant interviews are then laid out.  Data relating the dMURs 
themselves are then presented, in terms of completion rate, the type of 
interventions made by the community pharmacists conducting these reviews and 
the clinical significance of these interventions as assessed by peer review.  The 
chapter closes with data relating to community pharmacists’ perceptions of 
delivering the dMURs referred to them by the hospital. 
 
 
7.1: MEDICINES SUPPORT REFERRAL SERVICE: BARRIERS AND 
FACILITATORS 
 
7.1.1: Community Pharmacist Recruitment 
Seventy-three out of the 77 pharmacies (95%) in SONT’s catchment area agreed to 
participate in the study.  Thirty-two (44%) stated they could provide telephone 
dMURs with a further ten (14%) who might be able to do this.  Regarding domiciliary 
visits, ten (14%) could offer dMURs in this format, with a further 5 (7%) responding 
that they ‘possibly’ could.  Where a potential participant required a telephone or 
domiciliary dMUR and their nominated pharmacy only expressed this as possible, 
the pharmacist was contacted and asked specifically whether they would provide the 
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service to that patient.  If the response was negative, that patient was excluded from 
the study. 
 
7.1.2: Impact of Community Pharmacy Accessibility on Participant 
Recruitment 
Inability to access a dMUR from their regular community pharmacy was the second 
most common reason for excluding patients from the study (n=22, 10% of patients 
screened, 24.2% of exclusions, see Table 7.2).  These patients, who all used 
pharmacies that did not provide domiciliary visits, felt they would be unable to 
attend the pharmacy for a dMUR.  Additionally, they were unable to have a 
telephone dMUR, either because of cognitive or hearing difficulty, or because their 
community pharmacy did not offer telephone MURs.    Three patients who could 
not attend their community pharmacy but would have been able to have a 
telephone MUR refused to take part because they did not like the idea of 
discussing their medication over the telephone.   Two patients used community 
pharmacies within the study catchment area, but which were not signed up to 
receive referrals during the study.  One patient was excluded because she did not 
use any one particular community pharmacy.   
 
7.1.3: Hospital Pharmacist Focus Group 
This focus group aimed to identify possible reasons for the slow participant 
recruitment rate during the early weeks of the study and discuss possible solutions.   
Five hospital pharmacists attended the entire focus group, with two more entering 
part way through.    Each pharmacist was assigned a number according to the 
order in which they first spoke during the session.  The pharmacists are therefore 
referred to as P1 to P7 throughout the transcript.  Two participants were NHS 
Agenda for Change (AfC) Band 6 (basic grade, rotational, ward based 
pharmacists), four were Band 7 (specialist, ward based pharmacists), and one was 
Band 8a (specialist pharmacist, with ward/clinic based roles as well as managerial 
and service development roles). 
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Five major themes were identified.  These were:  
1. Problems with current procedure for transfer of medicines related care 
2. Attitudes (largely positive) to the referral service and post discharge 
medicines use review (dMUR)s as a whole 
3. Barriers to dMUR referral service 
4. Solutions for dMUR referral service 
5. Priority/target groups for referral for DMUR 
A full reproduction of the coding index developed from the focus group transcript, 
including themes and subthemes can be found in Appendix 36.   
Problems with current procedure for transfer of medicines related care 
At the start of the focus group, participants were asked to give examples of 
problems they had experienced with transfer of medicines related care from the 
hospital back into the community.  This was aimed at providing background to the 
study and context for the rest of the discussion.  Two main issues were identified 
by participants: the quality of communication of medication changes on discharge 
and the timeliness of information transfer from secondary to primary care. 
Poor communication of medication changes that occur in hospital can lead to 
uncertainty on the part of patients, carers and primary care health professionals 
over what these changes are.  The process used in SONT around discharge and 
medicines was highlighted as an issue, specifically the communication of 
discontinued medicines: 
P2: I get [queries from primary care] like: ‘has this stopped?’  
P1: Yeah [agreeing with P1] 
P2: And it’s not documented on the [electronic discharge summary] 
This issue is discussed further in Section 8.3.1. 
The timeliness of information transfer from secondary to primary care, and the 
subsequent integration of this information into primary care records were also 
raised as concerns.  Examples were cited of cases where patients had been re-
admitted on medication regimes that had been altered during a previous 
admission, which may or may not have contributed to the re-admission: 
P3: …the GP hadn’t had the information.  And it was about two or three weeks.  So 
they’d come back in on drugs that were stopped.  Quite a few. 
172 
 
P5: You definitely get prescribing errors where the patient’s come in with a GP 
letter, and maybe they’ve been really recently admitted…and the doctors clerk 
them off the information they’ve got there at the time, and it’s not until the 
pharmacist checks the second source … or until the old notes appear, or whatever, 
that we realise that there have been changes 
 
Attitudes to the referral service and dMURs in general 
The role of dMURs in preventing prescribing errors following discharge was alluded 
to when P3, who had spent time working in community pharmacy, described an 
example of an opportunistic dMUR she had done, where a patient had erroneously 
been taking both an antiplatelet and anticoagulant, both of which are classed as 
high risk medicines for hospital admission (45):  
P3: we automatically try and pick up MURs on anything new, particularly high risk 
medicines, and she was on apixaban and aspirin, and the GP hadn’t had the 
information to stop the aspirin, so they were both there.  So I did an MUR with her, 
and we got to the bottom of it, and contacted the GP and managed to get it 
stopped.  And she was a good one…. 
Although not a planned dMUR, the positive attitude engendered by this examples 
such as this could act as a facilitator to the referral service.   
Indeed, the concept of the dMUR referral service was met with broadly positive 
comments from the group: 
P4: It’s probably a very necessary thing really 
P2 / P5: Mmm[agreeing] 
The most widely expressed potential benefit of dMURs was the reinforcement of 
advice regarding changes to a medication regimen that had been provided for the 
first time in hospital.  Pharmacist number 5 explained the reasoning behind this 
view:  
P5: I think also, as well, at the point of discharge, and during hospital admission, 
for these patients, there’s quite a lot going on, and maybe, you know, they’re just 
coming to terms with the fact that they’ve suddenly got to take this many medicines 
and maybe at that point they’re not going to take it in, and maybe they need to be 
followed up when things are slightly calmer, and they’ve got used to the idea 
P2: Yeah 
P6: Even the warfarin, sometimes, with the warfarin counselling on the ward, its 
probably better a couple of days later isn’t it, back in community? 
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P2 / P5: Mmm 
P3: Which is ideally placed, because they’ve got the new medicines service, and 
MUR… 
 
This acknowledges that, although patients may be ‘counselled’ on medicine 
changes during hospital admission, this is not necessarily enough for adherence to 
the new regimen.  The dMUR therefore could be viewed as a resource to back up 
or build on discussions started in hospital: 
P3: [Hospital pharmacists] can counsel [patients], and then refer them 
P3 was able to identify a number of benefits for patients receiving dMURs that she 
had identified during her own personal experience, including identifying side 
effects, particularly with cardiac patients, and promoting adherence in medicine 
taking: 
They [dMURS] help people understand the importance of taking their medicines. 
[One patient] had a reaction to statins, and [her husband] was started on statins 
and he stopped him taking them, and he’s had a few heart attacks!  And it’s that 
kind of thing. You just need to talk to [patients], don’t you?   
I’ve picked up on people with side effects, particularly post cardiac issues 
 
Barriers to the dMUR Referral Service 
Lack of familiarity with community pharmacy processes was considered a barrier to 
the dMUR referral service, since at least one pharmacist attending the focus group 
was not familiar with community pharmacy services: 
P4 (in response to question from facilitator to group about their opinions on 
dMURs):  I haven’t worked in retail for years. 
Despite being in support of the referral service and dMURs in general, P3 had 
doubts over the motivation of community pharmacists to conduct post-discharge 
medicines reconciliation and solve problems identified as a result: 
P3: …So I think pro-active chemists… but it probably won’t work with all.   Because 
some of them are lax about it.  
The focus group highlighted a number of barriers to the effective running of the 
dMUR referral service.  The most frequently recurring theme was that of the limited 
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time available on the wards, which made them less able to spend time identifying 
and referring patients into the service: 
P4: It’s just a time problem isn’t it; you just haven’t got the time 
P1: [Talking about increasing involvement of ward pharmacists beyond marking 
potential patients on the ward bedplan] It’s not going to happen… 
P4: It’s too much time isn’t it? 
P1: It’s just too much 
P3: …it’s really difficult to think about at the moment, because we’re all inundated, 
with no time 
P3: …from a time constraint issue, here, it’s difficult, isn’t it? 
The issue of funding was also raised, with one participant alluding to the fact that 
community pharmacies get paid to provide dMURs, whilst hospitals get nothing for 
referring patients to the service: 
P3: We’re lacking the funding, aren’t we, to be sitting down with every patient that’s 
started on new drugs…..we would almost need a payment….if you get paid for that 
referral, cos in the community pharmacy contract there’s room for those kind of 
things...  It’s actually worthwhile the community pharmacists doing it.   
 
Identifying suitable patients and engaging them with the idea of post-discharge 
follow-up with their community pharmacy was also a recurrent theme within the 
focus group:  
P6: there’s lots of elderly people, isn’t there, who might not be suitable 
P3: Mmm 
P1: Yeah, and the nursing homes and dementia and all that business 
P5: I think also, as well, at the point of discharge, and during hospital admission, 
for these patients, there’s quite a lot going on, and maybe, you know, they’re just 
coming to terms with the fact that they’ve suddenly got to take this many medicines 
and maybe at that point they’re not going to take it in, and maybe they need to be 
followed up when things are slightly calmer, and they’ve got used to the idea 
P2: Not all of them will have a regular chemist anyway 
Related to this was the perceived difficulty in establishing who a patient’s 
community pharmacist was, which would make the referral more time consuming: 
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P2: Sometimes it is hard though, because they’re just like, I don’t know “Oh it’s on 
[name of street]” 
P3: Or “it’s near the shops” 
P2: And then you’re having to ask them, “what is it? A Rowlands or a Lloyds or 
what?” 
 
Although in the initial feasibility study recruitment process, it was intended that 
ward pharmacists would establish whether a patient had a regular community 
pharmacy, and if so, who that was, before referring them to the researcher, 
comments made during the focus group indicated that this was not in fact being 
done: 
F: So, do you find it easy to identify who the chemist is? 
Pause 
P1: I don’t [identify the chemist]!  You do that!  I just put [researcher’s name on the 
bed plan] and you do it! 
This lack of integration of the activities needed for referral to community pharmacy 
with the routine work of the hospital pharmacy team recurred in other parts of the 
focus group, as a barrier to selecting patients who might benefit from post 
discharge follow-up: 
P1: …It just won’t enter their [ward pharmacists’] heads.  Either because of time 
constraints, or because it’s not normal practice 
This situation may be exacerbated by the high patient turnover on particular wards, 
which was raised as a contributing factor to difficulties in pharmacists retaining the 
information required about the patient in order to refer them on: 
P1: …when you’ve got 10 [new admissions], you do one and forget, you do one 
and forget… and  it’s hard then, you know, and it’s like that every day on the short 
stay unit 
When discussing potential ways of continuing the service once the researcher was 
no longer managing all referrals, the extra effort that would be required to make 
referrals using the current discharge system was viewed as a barrier: 
P1: …If you ask us to free-type the chemist [on to the discharge summary] it won’t 
happen  
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The suggestion by participants that this could be mitigated by introducing ‘drop-
down’ lists on the electronic discharge system was then tempered by concern that 
increasing the number of steps in the process might lead to errors, if referrals were 
to be made this way: 
P1: You know, the more steps you have though, the more chance there is of 
something going wrong, you know, ticking the wrong box 
P4: Yeah, sometimes [the e-discharge system] does make it easier to make an 
error.  Especially when you’re rushing 
 
A further barrier raised was the issue of information governance and patient 
confidentiality when transferring information about altered medication to community 
pharmacies: 
P2: There’s probably information on [the discharge summary] that the community 
pharmacist doesn’t need… 
Noises of agreement from group 
P2: And that might be where the consent issue comes in because, I don’t think 
information governance would allow it would they, because they’re getting 
information they don’t need 
However it was acknowledged that the community pharmacist would need some 
background information in order to support the patient with an altered medication 
regimen: 
P3: Maybe just the medicines, we could find a way of just transferring… 
P6: But then the community pharmacist still wouldn’t know what had changed and 
why 
 
Solutions for the dMUR referral service 
Solutions to the low referral rate were identified, with the commonest theme being 
improvements to the e-discharge system to make good quality referrals easier to 
make: 
P1: …what if we could have something on the [e-discharge system], where you 
could click a button and they would get it? 
P1: It needs to be computerised, and then once you’ve done it you can forget 
about it. 
P1: It wouldn’t be too onerous on the [e-discharge system] 
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P2: Mmm 
P1: You know, drop-down list of chemists, find all the suitable patients, tick yes and 
that would be it 
 
P4: May be we need a box… on [the e-discharge] that says new, increased, 
decreased, or something like that, just to highlight changes to the drugs 
Integrating promotion of dMURs and the dMUR referral process into established 
activities of hospital pharmacy, having been identified as a barrier currently, was 
identified as an area that could be improved with relatively little effort: 
P1: …you could [get patient consent] when you were talking to them about their 
medicines 
P2: Yeah 
P1: It’s not too… if it’s already part of the process you do 
P2: Yeah 
P1: It’s built in, isn’t it, at the end of each conversation, “oh, by the way, when you 
go home I’m just going to set up for you to have a chat with your chemist” – you 
can just put it like that, can’t you?  And they’ll probably say “yeah, ok”. 
 
Target groups for dMUR referral 
Priority or ‘target’ patient groups for post discharge referral was a recurring theme 
throughout the focus group.  This theme arose early in the session from discussion 
of past experiences between participants.  From this, it could be deduced that 
groups of patients who might be priorities for referral included cardiac patients, 
patients prescribed new medication during admission and patients using high risk 
medications such as anticoagulants: 
P3: [Talking about experience of working in community pharmacy] …we 
automatically try and pick up MURs on anything new, particularly high risk 
medicines, and she was on apixaban and aspirin 
P1: What if they’re on new meds?  What if they didn’t come in on anything and they 
go home on six? 
P2: Yeah 
P3: Yeah, that’s even more important 
P3: I’ve picked up on people with side effects, particularly post cardiac issues 
In response to these comments, and coupled with the low referral rate of potential 
participants, it was desirable to find out if the pharmacists were prioritising 
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particular patients to refer, and if so whether this was helping or hindering the 
process.  Therefore the facilitator asked directly: 
F: …do you think we should be referring all patients, or do you think we should try 
and identify patients that would be able to engage and benefit from it? 
Arguments both for and against targeting were made:  
P1: If you’re being selective, you’re relying on individual pharmacists to do that.  
And not all will do that. 
 
In fact, a role for community pharmacists in targeting patients who would benefit 
from dMUR so that hospital pharmacists did not have to be selective over which 
patients they referred was identified: 
P4: Maybe, if [we referred] all [patients], then the chemists… 
P1: Could decide [which to contact to arrange an MUR] 
P4: ...would know the patients better than we would and they would know which 
patients might need counselling more than others 
 
However, this was quickly countered: 
P2: I think they might get a bit inundated though 
(Laughter) 
P2: I mean if it was, like, every hospital 
A final consensus was that an effort did need to be made to be selective when 
referring patients: 
P3: I think it probably does need to be targeted, thinking about it 
P1:  Targetted? 
P2: Mmm [agreeing] 
P6: Yeah, because as well, in this hospital, there’s lots of elderly people, isn’t 
there, who might not be suitable 
P3: Mmm [agreeing] 
P6: So then the community chemist is going to get too overwhelmed with going 
through loads 
P1: Yeah and the nursing homes and dementia and all that business 
Noises of agreement 
P3: So I think you probably need to think, if it’s someone going home, managing 
their own medicines without any help from anyone… 
 
Actions Following Focus Group 
179 
 
Analysis of hospital pharmacy focus group data led to modification of the 
participant recruitment process for the study.  Firstly, criteria for referral to the 
researcher were simplified, to reduce the burden on the ward pharmacists.  
Pharmacists were asked to refer any medical patient over the age of 65 who in 
their professional judgement would benefit from a dMUR.  Secondly, referral to the 
researcher could be made simply by noting the patient’s hospital number on a 
special communications board by the back exit to the dispensary. 
Additionally, an effort was made to encourage ward pharmacists to integrate the 
possibility of dMUR referral into their routine ward visits, by sending regular email 
reminders about the study and the types of patients that were appropriate.   
Outcomes Following Changes to Recruitment Procedure Based on Focus Group 
Findings 
The number of potential participants identified by ward pharmacists did increase 
after the focus group.  One hundred and ten potential participants were identified 
over the 12 weeks following the focus group, a mean of 9 per week, compared to 
67, or 6 per week, during the 12 weeks prior to it, a 50% increase.   The 
recruitment rate also increased by a similar amount; 11 participants were recruited 
in the 12 weeks before the focus group (mean 1 per week) and 18 in the 12 weeks 
after (1.5 per week, 50% increase).  However, the number of patients referred to 
the researcher was still small compared to the number of patients discharged from 
the Trust each week (mean 219 discharges per week for medical patients aged 65 
or older during the study period according to internal data).    
 
7.1.4: Hospital Pharmacist Questionnaire 
It was acknowledged that the opinions expressed during the focus group were not 
necessarily representative of the majority of pharmacists working at the hospital.  
In particular, only one senior clinical pharmacist and no senior managers had 
attended the focus group.  In order to see if the issues identified during the focus 
group affected the pharmacy department more widely, and the extent to which the 
solutions posted were felt to be useful, qualitative data from the focus group was 
used to develop a quantitative questionnaire (Appendix 31).   
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Nineteen of the 22 questionnaires (86%) were returned.  The profile of respondents 
by NHS AfC banding and patient facing role was representative of the profile of the 
department as a whole (apart from those in a managerial role who were 
proportionately over-represented in the questionnaire responses) and is presented 
in Table 7.1. 
Table 7.1: Profile of Hospital Pharmacists Returning Questionnaire 
AfC Band (Patient facing role) Number of Respondents (% of all respondents) 
6 (Non-specialist) 6 (31.6) 
7 (Specialist) 5 (26.3) 
8a (Specialist) 5 (26.3) 
8b or above (Managerial) 3 (15.8) 
 
General views toward the service were broadly positive. The majority of 
respondents (n=16, 84.2%) agreed with the statement that the service would foster 
better working relationships with community pharmacists. All but one (n=18, 
94.7%) agreed that dMURs would allow adherence problems and medication 
errors, following hospital discharge, to be identified and resolved sooner than they 
otherwise would be.  Further, 16 (84.2%) felt dMUR referrals would help patients 
manage their medicines better after being in hospital. 
However, as identified in the focus group, 18 (94.7%) respondents agreed that 
referring patients for dMUR is not yet ingrained in the daily work of a ward 
pharmacist.  
From the choices provided on the questionnaire, the most common reason for 
pharmacists referring patients to the service was that new medication had been 
started in hospital.  This was cited by 13 (68.4%) of the respondents.  This was 
followed by the concern that a patient was at risk of poor adherence (n=6, 36.8%) 
and that changes to doses of medicines had been made during admission (n=5, 
26.3%). Other reasons selected included that patients were taking ‘high-risk’ drugs 
(n=4, 21.1%), had asked for more information regarding medicines, had medicines 
stopped in hospital (n=3, 15.8% each), lacked understanding of their medication or 
were experiencing polypharmacy (n=1, 5.3% each). 
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Barriers to Referral  
Ten (52.6%) respondents agreed with the statement that time spent on dMUR 
referrals takes hospital pharmacists away from other patients, whilst 11 (57.9%) 
agreed that the patient's priority is to get home from hospital, so it is hard to 
engage them with the concept of the dMUR service. 
Fourteen (73.7%) respondents reported identifying fewer than five patients per 
month for referral during the recruitment period.  Reasons given from the options 
provided by the questionnaire are shown in Figure 7.1.  Time pressure was the 
most commonly cited barrier (n=13, 68.4% identified this as a ‘major’ or ‘always’ a 
barrier).  This was followed by forgetting to look for patients, and patient length of 
stay being too short to engage them with the service (n=7, 36.8% each).  Six 
(31.6%) respondents had difficulty in identifying suitable patients.  Having to 
complete a referral form was only viewed as a major/always barrier by two 
respondents; however this was likely due to the fact that during the feasibility study 
the referral form was filled in by the researcher.  Nursing home residents, dementia 
sufferers and patients in poor clinical condition were identified via free text as 
commonly encountered patients who respondents felt were unsuitable.  Two 
respondents (AfC grade 8b or above) cited via free-text their managerial role as the 
reason for identifying few/no patients, whilst pharmacists covering surgical, 
admissions, palliative care and frail elderly specialities identified the type of ward 
they worked on as yielding few suitable patients.   
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Figure 7.1: Barriers to dMUR Referral Identified by Hospital Pharmacists 
 
Identifying a patient’s regular community pharmacy was not viewed as a major 
barrier by any of the respondents, in contrast to concerns raised during the focus 
group.  Again, this could have been due to the fact that to maximise recruitment 
during the feasibility study, the researcher had ascertained which pharmacy 
participants wished to use.  
Potential Solutions to Improve the Service 
Of the potential solutions offered in the questionnaire (Figure 7.2), investing in 
hospital pharmacy staff time and sending referrals electronically to community 
pharmacy were identified as the most likely to make a ‘substantial’ or ‘major’ 
improvement to the service (n=17, 89.5% respondents each).  Additionally, 16 
(84.2%) respondents identified that better documentation of medication changes 
on discharge summaries would result in improvement.  Greater promotion of 
dMURs to patients, both in hospital and in the community, was identified by 12 
(63.2%) of respondents as a potential solution for the service, as was targeting 
specific patient groups. 
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Figure 7.2: Potential Improvements to dMUR Referral Service Identified by 
Hospital Pharmacists 
 
7.2 PARTICIPANT RECRUITMENT 
 
Recruitment took place between 7th April 2014 and 6th January 2015.  Over the 9-
month period 337 potential participants were identified by ward pharmacists, which 
ultimately resulted in 60 patients recruited (Figure 7.3). 
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Figure 7.3: Summary of Participant Recruitment 
 
This represents a recruitment rate of 17.8% of patients referred by ward 
pharmacists, or 45.5% of eligible patients.  Reasons for exclusion and refusal are 
shown in Table 7.2.   
 
 
 
 
337 Patients referred to 
researcher 
89 discharged before researcher screen 
14 < 65 years old 
223 approached and fully 
screened by researcher 
 
132 eligible 
 
60 recruited 
 
  
72 refused  
  
 
91 ineligible  
 
237 patients approached 
 
 11 transferred to another hospital 
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Table 7.2: Reasons for Ineligibility (n=91) and Refusal (n=72) 
Ineligibility Number (%) 
Protocol exclusions  
Patient not self-medicating at home  28 (30.8%) 
Unable to access dMUR from chosen 
pharmacy  
22 (24.2%) 
Being discharged out of study area 11 (12.1%) 
Participants community pharmacy not 
taking part in the study 
2 (2.2%) 
Patient does not use a regular pharmacy  1 (1.1%) 
Patient exclusions  
Lack of capacity to consent   11 (12.1%) 
Too unwell to approach  9 (9.9%) 
MUR not needed  7 (7.7%) 
  
Reason for Refusal* Number (%) 
Patient sees no benefit to MUR 20 (27.7%) 
Patient already has good links with 
community pharmacy 
15 (20.8%) 
Unwilling to engage with research 14 (19.4%) 
Health reasons 11 (15.3%) 
Time constraints 11 (15.3%) 
Would rather see GP 6 (4.5%) 
Hospital counselling adequate 4 (3%) 
Patient does not want telephone MUR 
(home visit not available and patient 
cannot attend pharmacy) 
3 (2.3%) 
Patient does not agree with changes to 
medicines 
2 (1.5%) 
“Too old” 2 (1.5%) 
Belief that medicines information will 
automatically be transferred to community 
pharmacy 
1 (0.8%) 
*The number of reasons for refusal is greater than the number of patients refusing, as some 
patients gave more than one reason. 
 
No significant differences existed in age or gender between patients who refused 
to participate and the study participants.  However, refusing patients tended 
towards being older (p=0.0831, two tailed independent samples t-test).  There was 
also a trend towards more females being among the refusers, although this was 
not statistically significant (p=0.0657, chi-squared test).   
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There were no significant differences detected in baseline characteristics between 
participants in control and intervention groups (Table 7.3).  However, the 
intervention group tended towards being more likely to live alone (43% vs 21%, 
p=0.0628).   
 
Table 7.3: Participant Baseline Characteristics 
Baseline characteristics Overall 
(n=59) 
Intervention 
(n=30) 
Control 
(n=29) 
P value (2-
tailed) 
Test used 
Female (%) 33 (56) 16 (53) 17 (59) 0.6826 Chi-
squared 
Mean Age in years (Range) 78 (65-92) 79 (68-92) 77 (6-89) 0.1142 T-test 
Living alone (%) 19 (32) 13 (43) 6 (21) 0.0628 Chi-
squared 
Mean number meds 
(Range) 
9 (2-19) 9 (3-16) 9 (2-19) NA NA 
Mean MCI (Range) 20 (5 - 41.5) 21 (7.5–41.5) 19 (5-40.5) 0.3476 T-Test 
Cognitive impairment (%) 11 (19) 7 (23) 4 (14) 0.3469 Chi-
squared 
Mean number co-
morbidities (Range) 
4 (2-8) 4 (2-8) 4 (2-8) NA NA 
Admission in last 30 days 
(%) 
11 (19) 8 (27) 3 (10) 0.108 Chi-
squared 
Admission in last 12 
months (%) 
29 (47) 15 (53) 13 (45) 0.6908 Chi-
squared 
Mean length baseline 
admission in days (Range) 
7 (1-27) 6 (2-19) 7 (1-27) 0.7730 T-test 
 
There were a total of 7 participants (3 intervention and 4 control) who used a 
community pharmacy dispensed MCA for some of their medication but had extra 
medications (e.g. inhalers, warfarin) with which they had to independently self-
medicate.  The MCI for these participants was adjusted so that all solid medicines 
in one compartment of the MCA (i.e. morning, lunch, tea or night) were classed as 
one medicine for the purposes of the calculation. 
 
7.3 PARTICIPANT DROPOUT AND LOSS TO FOLLOW-UP 
Of the 60 patients originally recruited, 10 were lost to the study because they either 
died (n=2), were admitted to a care home (n=4) or were no longer self-medicating 
at follow-up (n=4).  The overall return rate of usable questionnaires was 74.6% at 
four-week follow-up and 59.3% at six-month follow-up.  Eleven participants who 
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were inpatients or did not return a usable questionnaire at four weeks were 
included in the six-month follow-up as per the study protocol.  Overall, 24 
participants were lost to the study by six-month follow-up.  These losses and the 
points at which they occurred are shown in Figure 7.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C=control group participants 
I = intervention group participants 
Figure 7.4: Summary of Participant Dropout and Loss to Follow-up 
 
In addition to these losses, a further 14 participants were excluded from the PP 
analysis as they either did not take part in their dMUR (intervention group, n=7), 
had their dMUR after the 4-week window specified in the study protocol 
60 participants randomised 
15 did not complete 
four-week follow-up 
 
2 admitted to care home (C) (excluded from 
further follow-up) 
2 readmitted at time of follow-up (1xI, 1xC) 
(included in 6 month ITT follow-up) 
1 RIP (I) (excluded from further follow-up) 
1 no longer self-medicating (C) (excluded from 
further follow-up) 
1 x incomplete questionnaire returned (I) 
(included in 6 month ITT follow-up) 
8 unknown (3xI, 5xC) (included in 6 month ITT 
follow-up) 
 
1 admitted to care home (I, unknown at 4/52) 
2 readmitted (I) 
1 RIP (C, readmitted at 4/52) 
3 no longer self-medicating (1 x I, readmitted at 
4/52, 2 x C) 
2 x incomplete questionnaire returned (I, 1 also 
returned incomplete questionnaire at 4/52) 
10 unknown (3xI, 7xC) 
 
19 did not complete 
six-month follow-up 
59 four week follow-up 
questionnaires distributed 
 
1 discharged to care home (excluded 
from follow-up) 
 
55 six-month follow-up 
questionnaires distributed 
 
36 completed six month 
follow-up questionnaires 
received 
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(intervention group, n=6) or requested a dMUR when one was not planned (control 
group, n=1). 
The 4-week PP analysis therefore included 30 participants (19 control and 11 
intervention group).  This represents attrition of 49% of randomised participants 
between discharge and 4-week follow-up (34% of control and 63% of intervention 
group participants had deviated from the study protocol by this stage). 
The 6-month PP analysis included 24 participants (15 control and 9 intervention). 
This represents attrition of 59% of randomised participants between discharge and 
6-month follow-up (48% of control and 70% of intervention group participants had 
deviated from the study protocol by this stage). 
 
7.4: PARTICIPANT OUTCOME DATA 
Results showed no significant differences in any of the outcomes studied between 
the intervention and control groups, in either the ITT or PP analysis at 4 week or 6-
month follow-up (Tables 7.4-7.7).   
Table 7.4: Intention to treat analysis: 4-week follow-up 
Outcome Intervention 
(n=30) 
Control 
(n=29) 
p-value 
(2 tailed) 
Test 
Used 
Patients having > 1 non-elective 
readmission 
6 (20%) 5 (17.2%) 0.7377 Chi-
squared 
Relative Risk of Readmission in intervention group = 1.2 (95% confidence interval = 
0.41 - 3.50) 
Total number of non-elective 
readmissions 
8 6 0.8026 Mann-
Whitney  
Mean Length of Readmissions (days) 4.38 7.00 0.1713 Mann-
Whitney 
Patients having > 1 A&E attendance 7 (23.3%) 8(27.6%) 0.7643 Chi-
squared 
Relative Risk A&E attendance in intervention group = 0.86 (95% confidence interval = 
0.33 - 2.24) 
Total number of A&E attendances 9 9 1 NA 
Morisky Medication Adherence Score 
(MMAS) 
7.20 7.54 0.3475 T-test 
Health related Quality of Life (SF-12v2) 
Physical 
34.77 34.50 0.9174 T-test 
Health related Quality of Life (SF-12v2) 
Mental 
44.41 42.68 0.6164 T-test 
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Table 7.5: Intention to treat analysis: 6-month follow-up 
Outcome Intervention 
(n=30) 
Control 
(n=29) 
p-value 
(2 tailed) 
Test 
Used 
Patients having > 1 non-elective 
readmission 
15 (50%) 16 (55.2%) 0.7924 Chi-
squared 
Relative Risk of Readmission in intervention group = 0.94 (95% confidence interval = 0.58 – 
4.50 ) 
Total number of non-elective 
readmissions 
26 23 0.9690 Mann-
Whitney  
Mean Length of Readmissions (days) 5.67 7.04 0.4487 T-test 
Time to First Readmission (days) 72.87 57.81 0.4315 T-test 
Patients having > 1 A&E attendance 16 (53.3%) 17 (58.6%) 0.7909 Chi-
squared 
Relative Risk of A&E attendance in intervention group = 0.94 (95% confidence interval = 
0.6–1.47) 
Total number of A&E attendances 36 32 0.9690 Mann-
Whitney 
Morisky Medication Adherence Score 
(MMAS) 
7.40 7.22 0.5916 T-test 
Health related Quality of Life (SF-12v2) 
Physical 
40.80 35.41 0.0983 T-test 
Health related Quality of Life (SF-12v2) 
Mental 
43.42 45.34 0.5384 T-test 
Table 7.6: Per-protocol Analysis: 4-week follow-up 
Outcome Intervention 
(n=11) 
Control 
(n=19) 
p-value 
(2 tailed) 
Test 
Used 
Patients having > 1 non-elective 
readmission 
2 (18.1%) 3 (15.8 %) 1.0 Fisher’s 
exact 
test 
Relative Risk of Readmission in intervention group = 1.15 (95% confidence interval = 
0.2261 to 5.8646) 
Total number of non-elective 
readmissions 
2 3 0.9143 Mann-
Whitney 
Mean Length of Readmissions (days) 3.5 10 NA Not 
tested* 
Patients having > 1 A&E attendance 2 (18.1%) 5 (26.3%) 1.0 Fisher’s 
exact 
test 
Relative Risk of A&E attendance in intervention group = 0.69 (95% confidence interval = 
0.1601 to 2.9812) 
Total number of A&E attendances 2 5 0.7145 Mann-
Whitney 
Morisky Medication Adherence Score 
(MMAS) 
7.39 7.66 0.4276 T-test 
Health related Quality of Life (SF-12v2) 
Physical 
35.72 34.58 0.6875 
 
T-test 
Health related Quality of Life (SF-12v2) 
Mental 
44.24 42.99 0.7451 T-test 
*Unable to run Mann-Whitney U Test as fewer than 5 values per group 
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Table 7.7: Per-protocol Analysis: 6-month follow-up 
Outcome Intervention 
(n=9) 
Control 
(n=15) 
p-value 
(2 tailed) 
Test Used 
Patients having > 1 non-elective 
readmission 
3 (33.3%) 6 (40%) 0.6828 Fisher’s 
exact test 
Relative Risk of Readmission in intervention group =0.83 (95% confidence interval = 
0.2739 to 2.5352) 
Total number of non-elective 
readmissions 
3 6 0.7884 Mann-
Whitney 
Mean Length of Readmissions 
(days) 
3 11.5 NA Not 
tested* 
Mean Time to First Readmission 
(days) 
25 58 0.3664 T-test 
Patients having > 1 A&E attendance 2 (22.2%) 7 
(46.7%) 
0.3891 Fisher’s 
exact test 
Relative Risk of A&E attendance in intervention group = 0.4762 (95% confidence interval 
= 0.1251 to 1.8125) 
Total number of A&E attendances 3 
 
10  0.3554 Mann-
Whitney 
Morisky Medication Adherence 
Score (MMAS) 
7.47 7.25 0.5842 T-test 
Health related Quality of Life (SF-
12v2) Physical 
40.92 35.93 0.1769 T-test 
Health related Quality of Life (SF-
12v2) Mental 
44.74 44.69 0.9905 T-test 
*Unable to run Mann-Whitney U Test as fewer than 5 values per group 
Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license 
agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, 
Los Angeles, CA 90095-1772. 
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7.4.1: Participant Questionnaire Results 
Completed questionnaires were returned for 74.6% and 59.3% of participants at 4-
week and 6-month follow-up respectively.   
The mean enablement score (PEI) for participants who received a dMUR and 
returned a scorable questionnaire (n=16) was 3.69 (95% CI 1.68 – 5.70).  When 
those who received their dMUR as per protocol (within 4 weeks of discharge, n=10) 
were analysed separately, their mean PEI was 2.9, whilst for those who received 
their dMUR after 4 weeks (n=6) the mean PEI was 5.  The difference in 
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enablement between participants who received their dMUR within 4 weeks and 
those who received it later was not significant (P=0.2965 using an unpaired t-test). 
The mean MMAS adherence score across all participants at 4-week follow-up was 
7.37, which had dropped to 7.31 by 6 month follow-up (p=0.9408, change not 
significant using a paired t-test).   
The overall mean SF-12v2 for physical aspects of HR-QoL was 34.64 at 4 weeks 
and 38.11 at 6 months (p=0.1267, change not significant using a paired t-test).  
The overall mean SF-12v2 for mental aspects of HR-QoL was 43.55 at 4 weeks 
and 44.38 at 6 months (p=0.5287, change not significant using a paired t-test). 
 
Adjusted SF-12v2 norms are available for the 65-74 and the 75+ age groups, as 
presented in Table 7.8 (226).  It is apparent from these figures that older people 
generally perceive their physical health as being worse than their mental health.  
This was reflected in the results from this study, where physical health scores were 
consistently lower than mental health scores.   
Table 7.8: Age Adjusted SF-12v2 Norms for Older People 
Age Group Health 
dimension 
Population Norm Age-adjusted 
norm 
65-74 Physical 50 45.17 
75+ Physical 50 42.77 
65-74 Mental 50 53.83 
75+ Mental 50 54.39 
 
Medication Reviews other than dMUR 
On the 4-week follow-up questionnaire, 35% (n=7/20) of control group respondents 
and 44% (n=11/25) intervention group respondents indicated that they had some 
form of medication review other than the study dMUR, which rose to 71% 
(n=12/16) of control group respondents and 63% (n=13/22) intervention group at 6 
months.  Four participants (all control group) reported having a review with more 
than one HCP.  The HCP undertaking the review was usually the GP (51%, 
n=25/49 reviews), followed by the community pharmacist or the hospital outpatient 
department (both 16%, n=8/49 reviews).  Specialist nurses undertook 6% of the 
reviews (n=3/49) and practice nurses 4% (n=2/49).  In three cases the participants 
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were unsure of the role of the HCP undertaking the review.  The vast majority of 
reviews were initiated by the HCP; only 20% (n=5/25) of all medication reviews for 
intervention group participants and 8% (n=2/24) for control group participants were 
requested by the patient themselves (p=0.2433 using Chi-squared).  
Of intervention group participants who completed their dMUR and returned a 
questionnaire, 44% (n=8/18) had an additional medication review within the month 
following their discharge, similar to the 37% (n=10/27) of those (intervention and 
control) who did not receive a dMUR. 
Between 4-week and 6 month follow-up, 59% (n=10/17) of respondents having had 
a dMUR had a further medication review, compared to 71% (n=15/21) of those 
who had not had a dMUR.   
 
7.4.2: Case-Note Analysis of Readmitted Participants 
Overall, 19% of the total study population were readmitted within 4 weeks of their 
original discharge.  This is higher than the baseline 4-week readmission rate (9%) 
for patients aged >65 discharged from SONT and also slightly higher than the 
latest available national emergency readmission figures (11.5% for all 
readmissions and 15% for those aged over 75 in the financial year 2011-12) 
(91,92).  At 6-month follow-up, 31 (52.5%) study participants had been readmitted 
to SONT at least once, giving a total of 49 readmissions.  This is also higher than 
the SONT baseline 6-month readmission rate of 20%.   The mean length of 
readmission episodes for intervention group participants (ITT analysis) was 2.62 
days shorter at 4-week follow-up than for control group patients (p=0.1713: not 
significant when assessed by t-test).  At 6 months the difference in mean 
readmission length had lessened to 1.37 days (p=0.4487).   
Case notes for 48 of the readmissions were located and analysed (Table 7.9).  
According to the criteria applied (Appendix 33), 12 (25%) of these were at least 
possibly medication related (Figure 7.5, Causality).  In 6 cases (50% of all 
medication related readmissions), the medication was classed as the dominant 
cause of the readmission (Figure 7.5, Contribution).  Seven (58.3%) of the 
medication related readmissions were classed as at least possibly preventable, 
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with 4 (33.3%) assessed as definitely preventable (Figure 7.5, Preventibility). The 
most common type of medication related readmissions were those associated with 
patient non-adherence and idiosyncratic events such as ADRs (Figure 7.5, 
Classification).  The medication classes most commonly associated with 
readmission were loop diuretics (associated with 4/12 medication related 
readmissions) and antithrombotics (associated with 3/12 medication related 
readmissions). 
 
Table 7.9: Analysis of medication related readmissions  
Pt ID Reason for 
Admission 
Causality  
Drug 
Related? 
Classification 
of Drug 
Related 
Admission 
Contribution 
of Drug 
Related 
Problem to 
Admission 
Preventable
? 
Drug 
involved 
3 Abdominal pain 
– biliary colic 
No     
7 Cellulitis No     
11 Collapse – PAF No     
12 Dizziness - 
labyrinthitis 
No     
13 Chest pain - 
angina 
No     
13 Chest pain – 
ACS 
No     
13 Chest pain – 
NSTEMI 
No     
16 Exacerbation 
bronchiectasis 
No     
19 Seizure related 
to alcohol 
No     
22 ACS No     
22 Chest pain - 
ACS 
No     
22 NSTEMI No     
23 SOB/Chest pain 
– CCF 
No     
23 SOB Probable Non-
compliance 
Dominant Yes Furosemide  
26 Palpitation – AF No     
29 SOB/LRTI – 
Type 1 
respiratory 
failure 
No     
30 Hip/thigh/back 
pain – 
Osteoarthritis 
Possible Inappropriate 
prescribing / 
monitoring 
Partly 
contributing 
Possibly Lack of 
analgesic 
titration 
34 SOB – Infective 
exacerbation 
COPD 
No     
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36 Nausea and 
vomiting 
Possible Patient 
idiosyncrasy 
Partly 
contributing 
No Chemo-
therapy 
36 Dizziness 
?postural 
hypotension 
Possible Patient 
idiosyncrasy 
Partly 
contributing 
No Furosemide 
ISMN 
36 CCF No     
6 Chest pain – 
angina 
No     
10 Rash – drug 
eruption 
Probable Patient 
idiosyncrasy 
Dominant No Perindopril 
15 Sepsis No     
17 Chest pain – 
uncontrolled AF 
and acute kidney 
injury 
No     
24 Fall: Twisted R 
ankle / 
heamatoma 
No     
28 SOB: CCF 
?secondary to 
PAF (not known 
AF).  Started on 
furosemide 
No     
28 SOB: CCF.  
Discharged from 
EAU with note 
‘commenced on 
furosemide’ on 
discharge 
summary and 
furosemide was 
not on list of 
discharge meds 
Probable Non-
compliance 
Dominant Yes Furosemide 
28 Chest pain: ACS 
ruled out 
Probable Non-
compliance 
Dominant Yes Furosemide 
33 Delirium – 
steroid induced 
Definite Patient 
idiosyncrasy 
Dominant No Prednisolone 
38 TIA sec to atrial 
flutter 
No     
38 TIA No – 
aspirin 
added to 
anticoagul
ant to 
reduce 
risk 
    
38 Heamatoma L 
leg  
Probable Patient 
idiosyncrasy 
Dominant Possibly Rivaroxaban 
Aspirin 
38 Confusion: ?TIA 
secondary to 
rivaroxaban 
being withheld: 
however seen by 
stroke consultant 
and no further 
mention of new 
vascular event 
so ?failed 
Possible Unable to 
classify 
Less important No Rivaroxaban 
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discharge from 
above.  NB seen 
by psychiatry 
later in 
admission and 
??vascular 
dementia 
41 Unable to pass 
urine (clots) 
No     
41 Haematuria No     
41 Haematuria No     
41 Haematuria No     
42 Idiopathic 
pulmonary 
fibrosis 
No     
52 SOB: COPD / 
Poor diabetic 
control 
Possible Non-
compliance 
Partly 
contributing 
Possibly Metformin, 
gliclazide, 
saxagliptin 
(patient 
reluctant for 
injectables) 
55 Found on floor No     
55 Found on floor No     
55 Weakness/ 
epigastric pain: 
gastritis.  
Lansoprazole 
increased from 
15mg daily to 
30mg daily. 
Probable Inappropriate 
prescribing 
Partly 
contributing 
Yes Clopidogrel 
Sertraline.  
NB/ Patient 
had 
lansoprazole 
reduced 
from 15mg 
bd to 15mg 
od on 
admission 
1/3/15 as 
this is how 
it had been 
written on 
the drug 
chart by the 
admitting 
doctor and 
the team 
saw no 
need to 
change it 
back. 
55 Fall out of bed: 
general 
decrease in 
coping 
No     
57 Dizzy / poor 
mobility following 
recent GI bleed 
(h. pylori) 
No     
59 R MCA infarct No     
62 L foot ulcer No     
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PAF – Paroxysmal atrial fibrillation   ACS – Acute coronary syndrome 
NSTEMI – Non-ST elevation myocardial infarction SOB – Shortness of breath 
CCF – Congestive cardiac failure   TIA – transient ischaemic attack 
L – left       R – right 
MCA – middle cerebral artery    ISMN – isosorbide mononitrate 
 
 
 
Figure 7.5: Charts showing: A. Certainty of medication related causality, B. 
Contribution of medication, C. Degree of preventability and D. Classification 
of Medication Related Readmissions 
 
7.4.3: Framework Analysis of Semi-Structured Participant Interview Data 
Seventeen participants were interviewed in their own homes regarding their 
experiences of medication support during and following their hospital stay (see 
Appendices 26 and 27 for copies of interview schedules for control and intervention 
group participants).  The characteristics of interviewed participants are shown in 
Table 7.10. 
8%
50%
42%
A. CAUSALITY
Definite Probable Possible
50%
42%
8%
B. CONTRIBUTION
Dominant Partial contribution
Less important
34%
33%
33%
C. PREVENTABILITY
Definitely Possibly Not preventable
42%
33%
17%
8%
D. CLASSIFICATION
ADR
Non-adherence
Inappropriate prescribing/ monitoring
Unable to classify
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Table 7.10: Characteristics of interviewed participants 
PIN 
 
Study 
Group Gender Age 
Living 
Alone 
Number 
meds MCI 
Number 
co-
morbidities 
Length 
baseline 
admission 
1 Control M 89 Y 6 14.0 3 2 
2 Intervention F 74 Y 4 11.5 2 6 
3 Intervention F 77 N 6 16.5 3 11 
7 Intervention F 92 Y 9 17.5 6 11 
10 Intervention M 84 N 16 41.5 6 15 
13 Intervention F 88 N 3 11.0 6 6 
16 Intervention F 70 N 9 22.0 5 19 
24 Control F 87 N 7 19.0 3 5 
32 Control F 68 N 5 7.0 5 9 
33 Intervention F 73 N 9 20.0 4 6 
48 Intervention M 79 Y 9 18.5 4 2 
49 Intervention F 68 N 6 15.0 3 5 
52 Intervention M 73 N 13 29.0 5 2 
54 Control F 79 N 6 10.0 4 27 
57 Control F 85 Y 10 24.5 5 7 
62 Control F 79 N 13 23.0 4 8 
63 Control M 75 N 6 15.5 3 1 
 
Interviewed participants were selected to reflect a range of the entire participant 
cohort in terms of age (range 68-92 vs 65-92 years), number of medicines taken 
(range 3 – 16 vs 2 – 19), medicines complexity (MCI range 7 - 41.5 vs 5 – 41.5), 
number of co-morbidities (range 2 – 6 vs 2 – 8) and length of baseline hospital 
admission (range 1 -27 days).   
As interviews needed to begin before all participants had been recruited, the first 
three participants to be recruited were interviewed irrespective of their 
characteristics.  This allowed the interviewer to become used to the interview 
process and make any necessary modifications to the interview schedules based 
on early themes identified.  Thereafter, selection of interviewees continued 
purposively to achieve maximum variation in the demographic features described 
above.  New themes and subthemes stopped appearing relatively early in the 
interview process (at the 10th interview conducted); however a decision was made 
to continue interviewing until the full range of participant demographics had been 
represented in both intervention and control groups. 
Interviews lasted a mean of 25 minutes (range 6 – 69 minutes).  A full reproduction 
of the coding framework including subthemes is reproduced in Appendix 35.  As 
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with the hospital pharmacist focus group, some themes were pre-determined by 
the interview schedule designed by the researcher; others emerged during 
discussion between the interviewer and interviewees.    
Nine main themes were identified and are presented below. 
1. Information / Advice regarding medication given in hospital 
The general attitude of participants to the information they had received from the 
hospital about the changes to their medicines was highly variable.  Those who 
described receiving information from several sources, particularly where 
conversations were backed up with written information, seemed to demonstrate 
greater confidence in and understanding of their medication.  For example: 
'I had plenty of information…It was [the ward pharmacist] and I spoke to the 
doctors a few times.  And the nurses giving me the medication…I’d just chat to 
them’ (P1, control).   
Although not mentioned as the primary source of information, this patient also 
placed value on the written copy of her discharge summary: 
‘It’s all on here (produces discharge summary)…[I’ll] keep it.  It was handy'  
Another participant also displayed confidence in the information about medication 
given whilst in hospital: 
‘I understood it, and why the medication had been changed when I left 
hospital…The cardiologist came to see me before I left, and he understood, he 
explained a lot' (P49, intervention).   
The benefit of receiving medication information from different sources, as well as 
having access to further support following discharge was demonstrated by a 
participant who had experienced several medication changes whilst in hospital:   
'At first it was quite confusing...but I was reassured by the sister on the ward, that if 
I had a problem to ring back, which I did, erm, because it was about the warfarin 
and when I was to take it' (P3, intervention).   
The importance of family members in obtaining information on behalf of some 
participants who were less cognitively able during admission was also highlighted: 
 'Son: the [other] members of the family would get the information off the doctor 
and the nurse in the afternoon, but we used to get it off the nurse in the night 
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time…. because I mean my brother, my nephew, my sister, my niece, everyone 
was around'.  (P7, intervention).    
Not all participants described such a positive experience.  Thirteen participants 
indicated gaps in the information given at the hospital and four of these could not 
recall any discussion regarding medicines with a member of hospital staff, or being 
given any written information to take home; for example: 
'I didn’t feel I’d had any information about the tablets I was on.  I knew I was on 
metformin for my type 2 diabetes, and… but there were lots of other extra 
medicines which I had no idea what they were for.' (P54, control).  
At least one participant had experienced a hurried discharge at the expense of 
discussion about medication:  
'...it was just a bit airy fairy, the way I came out, you know, from being told that I 
might be out that day, and then erm, that I was being out.  But I had to wait for the 
pharmacy for the medication.  So we waited for the medication and they just 
brought it, and gave it to me, and we went.  That was it. There was no discussion 
about it' (P13, intervention).   
However it was not always clear whether there was a true lack of information about 
medicines given at the hospital, or whether the information given had since been 
forgotten: 
‘Interviewer: …nobody talked to you when they prescribed you the statins in the 
hospital?  
Participant: No.  Well, at least if they did I can’t remember’ (P54, control).  
This was reiterated by a participant who had had one medicine stopped and a 
further four started during admission:  
'They didn’t change my medication while I was in hospital… I can’t remember…'   
(P57, control). 
In terms of the type of information participants felt was missing from the hospital, 
side effects were mentioned by two participants, exemplified by Participant 10:   
'I wasn’t informed of the likely side effects of the three or four new medications, one 
of which subsequently proved to be upsetting for my system…’ (P10, intervention)   
Information regarding reasons for changes and indications for new medicines were 
also perceived as lacking by six participants or their carers.  For example: 
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‘Participant: Well I would like to know whether they were for blood pressure…  
(P54, control) 
However not all participants expected detailed discussions regarding medicines.  
Sometimes this was due to the perceived simplicity of the change: 
'Well it was only clopidogrel, just take one every day.  So I didn’t find that difficult at 
all …' (P2, intervention, no dMUR).    
Even participants who had multiple changes to their medicines did not always feel 
the need to understand the reasoning behind them:  
'Interviewer: So, where you aware of why they were making the changes?  
Participant: No, they never told me.   
Interviewer: Would you like to have been?  
Participant: No, not really.  I’ve been taking this medication for years now, and the 
fact that they altered it a bit didn’t bother me…I didn’t really need a lot of 
information' (P62, control).   
Two participants felt that they did not require much information from the hospital 
because they had worked with medications in the past: 
I understand my medical conditions, because of my background as a nurse' (P48, 
intervention)  
‘...It was fairly standard stuff anyway, which I did know a bit about.'  (P32, control, 
former administrator in GP surgeries).   
Some participants presented a stoical, uncomplaining attitude towards a lack of 
medication information:  
'Well I was prepared to take it on the chin so to speak, er I took the medication in 
the full belief it was going to help me' (P10, intervention).  
Here, the apparent lack of communication from the hospital was compounded by a 
lack of information seeking on the part of the patient, which may stem from the 
belief that ‘the doctor knows best’ and shouldn’t be questioned too closely.  This 
attitude was demonstrated more clearly by another participant:  
'I used to tell them when I was in hospital, if you go and see the doctor, there’s no 
point in going and not doing what he tells you, or what he suggests.  You’ve got to 
vote with him ' (P48, intervention).    
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2. Transfer of care issues surrounding medicines 
Issues relating to poor communication between healthcare providers on transfer of 
care were described by two control group participants: 
 ‘I got the warfarin with this lot [of repeat medication], and I rang [the GP’s surgery], 
and I spoke to the receptionist.  Now, whether she knew about the prescription, I 
don’t know.  But she said, ‘you shouldn’t have had the warfarin’.  They used an old 
prescription, with the warfarin on it, and it shouldn’t have been on' (P57). 
'Participant: the warfarin isn’t on my prescription, my repeat prescription yet, 
because I’ve never actually got it from the doctor’s, I’ve only ever got it from the 
hospital.  
Interviewer: Right [pause]…so has that caused a problem?  
Participant: Yeah, when I come to get some.  Because what happened was ...They 
screwed it up anyway, getting the prescription from the pharmacy, and backwards 
and forwards.’ (P63).   
The lack of timely information transfer to this patient’s community pharmacy also 
led to a switch in the brand of his newly prescribed diltiazem: 
'And they [community pharmacy] didn’t have that drug, so they had to swap it for 
another drug'  
 
3.  Contact with healthcare professionals (HCP) since discharge 
Participants described numerous contacts with HCP (mean =3 per participant 
interviewed), many with a primary focus other than medication, in the few weeks 
following discharge.  Examples included seeing phlebotomists for blood tests (2 
patients), hospital outpatient appointments for echocardiograms (2 patients), 24 
hour electrocardiograms or endoscopies (1 patient each), district nurses changing 
dressings (1 patient), practice nurses conducting annual diabetes review               
(2 patients), GP appointments for new symptoms not related to their admission (4 
patients) as well as readmissions to hospital (3 patients).   In some of these cases 
(for example one of the diabetes reviews and two of the readmissions) medicines 
had been altered.   
Eight of the 17 interviewed participants – (five out of 10 intervention group 
participants and three out of seven controls) had had a medication review other 
than a dMUR since being discharged. This may have been with their own GP:  
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'GP told me that I didn’t need to continue with the inhalers'.  (P10, intervention) 
or practice nurse:  
‘Interviewer: So, you’ve been to see the nurse as well, you were telling me?   
Participant: Yes.  She cut some [medicines] out’ (P7, intervention).   
Others had had their medication reviewed by a specialist nurse, sometimes more 
than once: 
'Interviewer: So the nurse went through your medication with you as well, you said?  
Participant: Yes, yes…. 
Interviewer: And was it [community matron] that went through all the medicines as 
well? 
Participant: Yes’ (P16, intervention).   
Another participant described having medication reviewed by both the GP and 
specialist nurse, with an associated feeling of frustration at the number of 
appointments she had:  
‘Interviewer: So that [titration of heart failure medicines]’s been managed by the GP 
initially and then…  
Participant: No, by the cardiac nurse.  Well, they’re both doing it.  This is another 
debate. Interviewer: Right?  
Participant: There’s too many fingers in too many pies.  There really is’ (P32, 
control).   
 
Some participants described appointments with the anticoagulation monitoring 
service where they had been able to obtain advice regarding a specific medicine: 
'Participant: Well I understand it [warfarin] thins the blood.... Pause...  I also 
understand if the reading gets too high it can lead to difficulty with bleeding, if I cut 
myself while shaving or if I happen to cut myself doing odd jobs about the house I’d 
have to be careful.  I’m told that wherever I go I need to have this [anticoagulant 
record book] with me, or at least advise people that I’m on warfarin.   
Interviewer: And did that advice come from the warfarin clinic?   
Participant: Yes’ (P10, intervention). 
 
4. Medication support (other than dMUR) since discharge 
Some participants took it upon themselves to seek medication support they felt 
was lacking from the hospital, and the community pharmacy was the first port of 
call for two of these:  
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'Interviewer: did that [lack of information] make it more difficult for you going home?   
Participant: No not really, because I went to see the pharmacist' 'I took it [new 
medication] down to [community pharmacist] the next day, and she talked me 
through them' (P13, intervention).   
‘I’ve got an old BNF, and I checked it, and I picked out what I thought it 
[unidentified medication given during admission] was, and I took it to [community 
pharmacist] and asked what he thought it was’ (P48, intervention).   
Other participants used the internet or the manufacturer’s information to answer 
unresolved questions:  
'The questions are either in the leaflet or in the other leaflet you can get online' 
(P32, control). 
Family members played a key role in supporting some patients to manage the 
changes made to medication in hospital:  
‘As soon as we got out of hospital, I bought that container and said, right, we’re 
going to do it this way.  I’ll pop them out and you [participant] just get them out [of 
the dosette box]’ (P7, intervention). 
'Interviewer: So, how did you find out about the changes in medication?   
Participant: Oh, my son told me!'  (P24, control).   
However, this raises the question of who has supported the family member:  
'Interviewer: Has anybody sat down with you and gone through the tablets?  
Son: No.’   
Other participants had been the recipient of support from outside agencies 
regarding their medication.  One participant described how the reception staff at 
her GP surgery had helped resolve unanswered questions regarding her altered 
medication regimen:  
'She says anything different, erm, I’m worried about, to phone her, because she 
erm, sorts my medicines out as well, erm, she said that she rang the hospital to 
see why they’d taken some of my medicines off me.  So she was very good’ (P3, 
intervention). 
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5. Barriers to medication adherence 
In the COM-B model of adherence (Section 3.1.1) barriers to adherence may 
concern a patient’s capability (mental or physical) of taking the medicine, them 
having the opportunity to take it, and their motivation to take it (60).  Interviewed 
participants demonstrated all three types of barrier, as exemplified below. 
 
Capability 
Memory was the most frequently discussed barrier to adherence, alluded to in 
varying degrees in six of the 17 interviews.  For some participants this manifested 
as a fear (real or perceived) of forgetting doses, which had motivated them to 
instigate preventative solutions:  
'It’s as well to keep a note, because otherwise I’d forget ' (P13, intervention). 
One participant described how he was in the routine of taking all his medication in 
the morning, and was struggling to remember the second daily dose of the new 
oral anticoagulant prescribed by the hospital:  
‘But for the second [dose], you know, I’ll forget' (P52, intervention, no dMUR). 
For other participants, a greater degree of cognitive impairment was compounded 
by other issues: 
‘Participant: I’m so forgetful, and I don’t always hear.  I know I’ve got a hearing aid, 
but I don’t always hear' ... 'and I depend on [my family] listening ' (P7, intervention).   
This participant also struggled with her manual dexterity:  
‘Participant: I just can’t do things with my hands any more' 
Son: my mum was really struggling with some of the tablets, trying to pop them out 
of the packs, you know out of the actual foil packs'.   
Another physical barrier to adherence was eyesight:  
'I can’t really see them properly, so, it’s a job!' (P24, control). 
 
Opportunity 
One participant felt that the complexity of her medication regimen was ‘daunting’, 
and was in the process of having her solid medicines put into MCAs by her 
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community pharmacist, so that they would be ‘all together, and at hand’ (P33, 
intervention). 
Another participant was unaware of the technique for using his new inhaler: 
‘I put that in my mouth, press it, and go ‘it’s not doing anything  
Wife: He doesn’t take it properly you know.  I don’t think anybody’s shown him how 
to actually use it!' (P52, intervention, no dMUR).   
Motivation 
Barriers to adherence concerning the opportunity to take medicines as agreed 
(such as a complex regimen) may also be compounded by motivational barriers.  
One participant in particular made several statements which may have reflected a 
lack of engagement in adhering to his complicated medication regimen, possibly 
stemming from a pre-existing belief that regarded ‘pills’ as ‘taboo’:   
'You’ve got to understand that for 60 years, I would never take a pill.  I wouldn’t 
take a painkiller or nothing.  Pills were taboo.  I would never allow them in the 
house, until this.  You know.  And now all of a sudden I’ve got to take 20 pills a 
day.'  (P52, intervention, no dMUR). 
This participant also made comments that suggested he might be suffering from 
information overload from the multiple agencies involved in his care, which may 
have further reduced his motivation to adhere: 
'So many people are telling me, that half the time it goes in one ear and out the 
other'  
 
6. Medicines management systems at home 
This theme was not included in the original interview schedule, which only planned 
to explore the subject in the context of support systems for any participants who 
were no longer managing their medication on their own at home: 
'Son: I regulate her medicines, I put them all out in…  
Participant: In one of those things (indicates ‘dosette box’ MCA)….  
Son: so it’s easier for her to remember what she’s got to take and when' (P7, 
intervention).   
However, following several participants volunteering details of their own personal 
solutions to potential adherence barriers, it was decided to explore this in more 
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detail across the interviews.  It was hoped this could provide valuable insight into 
the barriers to adherence that exist in the older post-discharge population, and the 
development of solutions, whether through dMUR or another means. 
Solutions to adherence barriers presented by participants included handwritten 
records or ‘ticksheets’ to record when medication is taken: 
'I’ll show you my list, of what I do..... I record every day, what I take' (P1, control)  
'I’d already made a checklist’ (P49, intervention).   
An alternative system, using annotation of the packaging of medicines with 
complex dosing instructions, was being used by another participant: 
'I put the date on the box, when I started taking them, and I then I just take it every 
second day from there.  So I’m not doing too bad on them' (P52, intervention, no 
dMUR).  
In these cases, the participants were using these written records as a reassurance 
that medication has been taken and to act as a prompt for which medicines need to 
be taken when, and they formed part of the ‘habit’ of medication taking.   
At least one participant had taken this idea a step further and re-dispensed her 
own medication into a ‘dosette-box’ MCA: 
‘I’ve got mine in, er, like now, I’ll just show you…(fetches dosette box)….’ (P3, 
intervention).  
Community pharmacy dispensed MCAs had also been initiated for two participants 
since discharge.  In one of these cases (P33, intervention) this was reportedly to 
simplify a complex regimen, and in the other (P 54, control) the reason was a lack 
of manual dexterity. 
Some participants also found it valuable to keep a written record of medication 
changes: 
 It’s as well to keep a note, because otherwise I’d forget' (P13, intervention).  
 
7. Discharge Medicines Use Review (dMUR) 
Of the 17 participants interviewed, eight had had a dMUR following referral from 
the hospital.  Opinions of the dMUR consultation were generally positive, with 
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participants using words such as ‘helpful’, ‘useful’ or ‘good’ to describe the 
experience.  However others were less enthusiastic: 
'Interviewer: And did you find that it was useful, having that review with the 
pharmacist? (Pause)… Please be honest!  
Participant: Er, well shall we say reassuring, I think' 'I’d been taking them 
[medicines] for quite some time, and they weren’t new to me, the majority weren’t 
new to me'   (P10).   
‘Yeah, it was alright' (P16).   
One participant, who had reported being given good information from the hospital 
prior to discharge, indicated that the dMUR, whilst reassuring her that she was 
managing her medicines well, was more suited for a different type of patient: 
'I did ask him some things, but I’d already made a checklist... but I can imagine that 
if you were given a load of tablets and didn’t really understand them or anything, 
then yeah, or perhaps someone who was a bit confused, then yeah I think it would 
be really advantageous to see the pharmacist, yeah' (P49).   
In terms of the content of the dMURs, most participants described a process of 
discussing each of their medicines in turn, with the pharmacist checking 
understanding of what the medicines were for: 
'They went through each of the medications I was taking, asking me if I knew why I 
was taking the medications.  To which I replied that I knew fairly well, why I was 
taking them' (P10).   
'We went through all the tablets and he said, do you understand those things, well I 
already did' (P3).   
However a different approach was taken during at least one of dMURs, whereby 
the pharmacist had asked questions of the participant and her son to ascertain 
what they knew already about her medication, then helped them to ‘fill the gaps’: 
'Son: we told her about the aspirin, you know, them stopping the aspirin in the 
hospital, and putting her on the digoxin, put her on that, and she said, why was 
that?' (P7).   
This consultation had helped the son gain a better understanding of his mother’s 
medication:  
'Son: It’s better for me (laughs).  I understand it a bit more.   I knew what all the 
medicines were for initially.  But it’s just understanding why she needs them'.  
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This dMUR consultation had also helped this participant’s son gain an 
understanding of the more clinical role of the community pharmacist:  
'Now it’s becoming more involved… they have to be that buffer between the doctor 
and the patient.  Because the patients are getting medicines that, really, why are 
they getting them? ...they are the people trained on the medicines and if they think 
a medicine is in conflict with another medicine, they knock it back to the doctor'.   
Another participant had also valued the opportunity to ask questions of the 
pharmacist about their new medicines: 
'...I asked him anything I wanted to about the medication.  He explained a few 
things, things I wasn’t sure about warfarin.…So em, yeah he explained, I did ask 
him a few things about what you should and shouldn’t eat, and he answered me’ 
(P49).   
Other topics discussed during dMURs, as reported by the participants, included 
logistics of obtaining further supplies of medication started by the hospital and the 
importance of checking interactions between prescribed and over the counter 
medicines: 
'if I was buying anything over the counter, to always come and ask him if it was ok 
for me to take, that it doesn’t interfere with any of my tablets'  (P3).  
One participant who had been hospitalised with an exacerbation of COPD, 
reported a discussion re her new inhalers and a check of inhaler technique:  
'And he explained the inhalers and how they worked, and why I was changed to 
the different ones' (P33).   
Although most interviewees could describe what had happened during the dMUR, 
some aspects had been forgotten by the time of the interview, which was typically 
about 2 weeks later.  One participant was still recovering from a subsequent illness 
which had affected her recall:  
 'It’s very hard for me to remember…I’m very very tired now.  I’ll just try and think 
(long pause)...' (P33).   
Another requested further reinforcement of which medicine she was no longer to 
take: 'So that’s… just write that name down for me, because….' (P3) 
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It emerged during the interviews that one aspect of the dMUR process that varied 
between community pharmacists was the method of organisation of the dMUR.  
When describing their dMUR experience, most participants indicated that they had 
been contacted by telephone to arrange the dMUR, but some had taken place 
opportunistically when the participant had happened to be in the pharmacy:  
'[pharmacist] said, have I got time to do it now, and I said yes we’ll go through 
it' (P3) 
‘I went in on the Friday, and who was there but [pharmacist]!'  (P48).   
Difficulty in leaving home, due to ill health or poor mobility, was the most commonly 
reported barrier to dMUR discussed by interviewed participants:  
 ‘You might as well say I’m housebound.  I haven’t got the confidence to go out.  At 
the moment….I couldn’t do it.  So I couldn’t make it [to the pharmacy]’ (P57, 
control).   
'There’s no-one to take me, so it’s a taxi there and back, which is costly.’ (P33, 
intervention). 
Another barrier to dMUR identified through the participant interviews was a lack of 
perceived need by the patient:  
‘Interviewer: (Briefly describes dMUR). Is that that something you think you would 
have benefitted from? (Pause) Or…?  
Participant: No… I er, I think I’m reasonably intelligent…’ (P63, control).  
These tended to be the same participants who had felt they did not need much 
support from the hospital with regard to medication, either through background 
knowledge or preference for doing their own ‘research’:  
‘I could find out.  Easily. Erm, and in this particular instance even easier than usual 
because my brother-in-law’s a cardiologist... So erm, I haven’t really needed it' 
(P32, control)  
or because their personal desire for information was low:   
'I don’t think I really need to have a chat about my medication.  As I say, I’ve been 
taking it for a number of years, and as far as I know it’s doing the job.  And I 
wouldn’t know how to talk about it, anyhow!'  (P62, control).   
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Patients' other commitments could also be a barrier to dMUR provision.  The wife 
of one participant in the control group indicated that their community pharmacist 
had been about to offer a dMUR, but they had been unable to stay:  
'He said I’m sorry I can’t, we’re on our way to a funeral!  Otherwise, they were 
going to chat to him about it, yeah' (Participant 63, control).   
At least one participant voiced the opinion that medicines should be reviewed by 
whoever prescribed them, and therefore a dMUR would be superfluous to 
requirement:  
'...I expect that whoever’s doing the prescribing is doing the reviewing.  Or else 
what’s the point?' (P32, control).   
However some participants who had not had a dMUR indicated that they would 
have liked to have had one:  
'Interviewer: So do you think that that’s something that would have been useful for 
you to have?  
Participant: Yes, yes.  Yes it would.  I don’t know whether [in the hospital] I was 
mentally fit enough to understand….’ (P54, control).  
'It’s useful to be reminded of these things, and not just take them for granted.  I 
don’t know half the things… the doctors say to me, what pills are you taking? and I 
say, I don’t know!  I just take them.  You know.  And that’s me, and that’s how… 
they never go through them’  ‘The pharmacy... we used to go to, she’d ring up and 
say call in, I want to talk to you about your meds.  And she’d bring me in and go 
through the meds with me, which I thought was a good idea'  (P52, intervention, did 
not have dMUR).   
 
8. General attitudes towards community pharmacy 
Conflicting points of view on the value of a dMUR may be influenced by the 
relationship a particular patient has with their community pharmacist.  This was 
demonstrated by one control group participant, who had recently changed her 
pharmacy.  When asked if she would have liked to receive a dMUR, she replied: 
‘I don’t know really.  Because, I used to go to [pharmacy], and they were a 
menace, they really were.  They didn’t have it in and you had to wait for it, and they 
couldn’t get it and all this.  So I stopped there.  And I got this [new pharmacy]…  
And they’re very, very much nicer than [previous pharmacy].  And I shouldn’t say 
this but as regards pharmacists, [previous pharmacy] had different ones all the 
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time.  Every time you go it’s somebody different, and they don’t know what’s going 
on.  But here, they know you.  And it’s the same ones all the time’ (P57, control). 
The importance of the relationship between patient and community pharmacist was 
a recurring theme during the interviews.  One participant was in the habit of using 
her community pharmacy as the first port of call for medicines related information:  
'If there’s any doubt about anything, we usually go there before we go to the 
surgery' (P13, intervention).   
Previous positive experience was an important factor:  
'They’re very helpful down there, and very approachable'. 
The length of relationship was also important:  
'It’s always been a good pharmacy, you know, it’s continued, erm.  A bit different 
from when he [previous pharmacist] was there but, with the two girls there now, 
they’re, the owner of the, the owner is called [name], he’s got three pharmacies.' 
(P13, intervention).   
'The girls in there understand me, I've been going for years. I don't have to wait in a 
queue now-a-days, I go in on my bike and they go, "Hello Mrs [Name], how're you 
doing?"!’ (P16, intervention).   
This long-standing relationship provided an opportunity for the patient to build up 
trust in the pharmacist and come to see them as a reliable source of support with 
medicines: 
'I’ve got full confidence in [pharmacist] because I’ve had him for a number of years 
now and he’s always explained things, and he’s been a good deal of help to me’ 
(P33, intervention).  
'I have confidence in [pharmacist]...We’d talked about medicines long before this 
happened. I used to talk things over with him.  He explained things and that 
helped.’ (P48, intervention). 
Another aspect of their interaction with community pharmacy which was valued by 
participants was the opportunity to have a private consultation: 
'He spoke to me in confidence, there was area to speak to him in confidence, so 
that was good' (P49, intervention).    
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Most of the positive comments made about community pharmacy came from 
intervention group participants, whilst control group participants seemed more 
likely to express ambivalent or negative views of community pharmacy: 
'I have used pharmacies on occasion, but usually the questions are either in the 
leaflet or in the other leaflet you can get online' (P32, control).    
‘Son: I think, when you go in to the pharmacy, to the pharmacist, it makes you 
more stressed, doesn’t it, when you go to see him?’  (P24, control).   
 
9. Residual information needs surrounding medication 
Participants who had not had a dMUR tended to express more unresolved 
information needs during interview than those who had.  These related to duration 
of treatment, side effects, indications for new medicines, how to take medicines, 
monitoring requirements, interactions of new medicines with over the counter 
medicines, goals of therapy, obtaining further supplies of medication post-
discharge and misunderstanding of previously given advice. 
 
Methodological Themes/Limitations of Interview Data 
Difficulty in discussing particular topics 
Discussing the topic of medicines information (given or required) during hospital 
admission presented difficulties in some interviews, illustrated by pauses or 
participants avoiding giving direct answers to questions.  Although not 
representative of all the interviewed participants, this may reflect a reluctance of 
certain patients to criticise the care they received or a desire to give the answers 
they thought the researcher wanted. 
Vagueness in answers regarding who had discussed medicines with them in the 
hospital may also reflect that participants had met a lot of different healthcare 
professionals during their stay and had difficulty remembering who had given which 
information.  This is understandable as being acutely unwell in hospital can be 
disorientating, particularly for elderly patients, and remembering six weeks later 
(which is when the interviews tended to be) who had given which information may 
be considered unimportant.  In addition, 13 of the 17 interviewees displayed poor 
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or partial recall of the actual medicines information given to them in hospital.  This 
suggests that sometimes the information from the hospital was either incomplete, 
or poorly recalled by the time of interview.   
Digression of interviewer into HCP role 
Knowing that the interviewer was a pharmacist appears to have led some 
participants to opportunistically ask questions regarding their medication during 
their interview, which otherwise may have remained unanswered.  In other cases, 
a clear lack of knowledge or misapprehension regarding their medicines led the 
researcher to provide information or advice which the participant would otherwise 
not have received.   
In order to analyse the extent and potential effect of this behaviour by the 
researcher, a further thematic chart was created which collated the trigger or 
prompt for each digression, the nature of the information provided by the 
researcher and any likely effect on outcomes for that participant.  From this 
analysis, three control group participants had received advice approaching a full 
dMUR from the researcher, and therefore effectively ‘crossed over’ into the 
intervention group.  An intervention group participant who had been unable to 
attend his dMUR also received this level of information.  Potential to influence 
behaviour was also noted for the other intervention group participant who had not 
had a dMUR, and for an intervention group patient who had had a dMUR but 
required reinforcement of discontinued medication and advice on how to interpret 
her dose of warfarin.  All other digressions were viewed as unlikely to affect patient 
behaviour. 
Difficulty of participants with completing questionnaire 
Two interviewed participants experienced difficulties in completing the follow-up 
questionnaire, which was posted to all non-interviewed participants but hand 
delivered to interviewed participants, who were asked to complete it before the 
interview commenced.  In one case this was due to cognitive impairment, and in 
the other it was due to visual impairment. 
Although not a theme of the interviews as such, this constitutes valuable data in 
the interpretation of why some questionnaires may have not been returned (or 
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returned incomplete), and provides a consideration in the planning of future 
research with this patient population.  This is discussed further in Section 8.5.3. 
 
7.5: dMUR DATA 
Below are presented data related to the proportion of dMUR referrals which were 
completed by community pharmacists, reasons for non-completion, the type of 
interventions made during dMURs and the potential significance of these for patient 
care. 
During the 9-month study, 30 patients were referred to their regular community 
pharmacist, resulting in 20 dMURs conducted (67% completion rate). Twelve (60%) 
were completed as per study protocol (defined as dMUR completion within 4 weeks 
of discharge).  The others were completed after 4 weeks, following one or more 
prompts from the researcher.  Table 7.11 shows the type of pharmacies used by 
those participants who were referred for dMURs during the study, and the completion 
rate (in total and as per protocol) by each pharmacy type. 
 
Table 7.11: Type of pharmacies used by referred participants and numbers of 
dMURs completed by each pharmacy type 
Type of Pharmacy 
Patients Referred 
(% of all referrals)  
dMURs completed 
(%) 
dMURs completed per 
protocol (%) 
Chain 14 (46.7) 10 (71.4) 5 (35.7) 
Independent 12 (40)  8 (66.7) 5 (41.6) 
Supermarket 4 (13.3) 2 (50) 2 (50) 
 
dMUR completion rates and completion as per protocol between the types of 
pharmacy were not significantly different (chi-squared p= 0.4227 for the difference 
between the highest (chain) and lowest (supermarket) completers of dMURs and 
p= 0.1904 for the difference between the highest (supermarket) and lowest (chain) 
completers of dMURs as per protocol).   
Patients being unable to visit the pharmacy or being non-contactable were the main 
reasons why dMURs were not completed as per protocol, although some 
215 
 
pharmacists reported not receiving the original referral or this had been lost by the 
pharmacy (Table 7.12).  
 
Table 7.12: Reasons given by community pharmacists for not completing a 
dMUR as per the study protocol 
Reason for non-completion/ 
deviation from protocol 
Number of Referrals 
Affected (% of all 
referrals) 
dMURs remaining 
incomplete following 
prompt from 
researcher (% of all 
referrals) 
Pharmacy had not tried to contact 
patient 1 (6) 0 (0) 
Referral misplaced or not received 
from hospital 3 (17) 0 (0) 
Patient non-contactable 5  (28) 2 (11) 
Patient too unwell to attend pharmacy 
and domiciliary visit not feasible 6 (33) 5 (28) 
Patient did not attend dMUR 
appointment 1 (6) 1 (6) 
Regular pharmacist absent 2 (11) 2 (11) 
Total 18 (60) 10 (33) 
 
7.5.1: dMUR ‘Action Plans’ 
The study protocol required that community pharmacists feed back to the researcher 
the outcome of each dMUR, in terms of advice given to the patient and actions 
undertaken.  In total, feedback was received for 17 of the 20 dMURs conducted.   
Thirty-five interventions were reported by community pharmacists.  The most 
common type of intervention (n=14, 40%) was provision of information to improve 
understanding of why and how they were taking their medicines.  Six interventions 
(17%) involved medicines reconciliation to ensure discrepancies between pre-
admission and discharge medications were intentional and understood.  Four 
interventions resulted in the provision or recommendation of a medication 
compliance aid (such as a monitored dosage system or a spacer device to aid inhaler 
technique).  Others included referral for monitoring (n=4) of their 
medication/condition and provision of lifestyle advice (n=3) (see also Table 7.13, 
page 217). 
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7.5.2: Impact of Community Pharmacist Intervention 
To assess the potential clinical impact of the interventions made by community 
pharmacists during the dMURs in this study a peer review was conducted using 
Delphi methodology.  Five of the 35 reported interventions were very similar in nature 
and for the purpose of the Delphi review were considered to be the same 
intervention. Hence 30 interventions in total were reviewed. 
Eight participants (all five pharmacists, both academic clinicians and one of the two 
family doctors) returned Round One surveys, and seven participants (all five 
pharmacists, one academic clinician and one family doctor) returned Round Two 
surveys.  Following Round Two, greater than 75% agreement in scores was 
achieved for 5 of the 30 interventions, although 8 more achieved 71% agreement.  
A further 8 achieved 57% agreement.  When the percentage change in mean scores 
between Rounds One and Two were calculated, the variation was less than 10% for 
28 of the 30 interventions, and less than 15% for all but one.  This indicated that 
participants were not likely to alter their scores very much if a third round was 
undertaken and at the risk of further drop-outs a further round was not conducted.   
None of the interventions made by community pharmacists were found to be 
detrimental to the patient’s wellbeing.  Fifteen interventions (50%) were assessed 
as being significant and leading to an improvement in patient care, whilst one 
intervention, where a prescription for pre-admission medication was identified and 
referred back to the doctor by the community pharmacist, was graded as highly 
significant and preventing major organ failure or adverse reaction of similar 
importance (Table 7.13).  The value of the ‘average’ dMUR conducted as part of 
this study is therefore estimated to be between £112.53 and £254.53. 
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Table 7.13: Clinical significance of 30 interventions made by community 
pharmacists during dMURs and associated cost avoidance, as estimated 
using a Delphi process 
Intervention Eadon 
Score 
ScHARR Cost 
Avoidance (£) 
1. Patient discharged after acute coronary syndrome 
struggling to remember to take medicines as 
prescribed.  Community pharmacist organised blister 
pack multi-compartment compliance aid (MCA) 
4 65-150 
2. Patient having difficulty with co-ordination of metered 
dose inhaler device.  Patient not keen on breath 
actuated device so community pharmacist requested 
spacer from GP (Unknown if spacer was actually 
provided) 
4 65-150 
3. Patient discharged with atrial fibrillation newly 
prescribed antiarrythmics and warfarin. Struggling to 
remember if she has taken all medication so 
community pharmacist provided medicine 
administration record (MAR) sheet (patient had 
previously been trying to produce own tick-sheet) 
4 65-150 
4. Community pharmacist explained to patient the system 
for obtaining future prescriptions following discharge 
after a stroke 
3 0-6 
5. Patient had been buying antihistamine to help with 
skin itching.  Community pharmacist suggested GP 
add this to repeat prescription (Actioned by GP) 
3 0-6 
6. Clopidogrel prescribed during admission for acute 
coronary syndrome for a patient already taking 
warfarin.  Patient unsure of indication, and whether 
clopidogrel will be long term.  Community pharmacist 
liaised with hospital pharmacy to find answer 
(Clopidogrel to be discontinued after 12 months) 
4 
 
65-150 
7. Community pharmacist discussed indication for new 
medication (betahistine) and how to obtain further 
supplies. 
3 0-6 
8. Community pharmacist provided information on newly 
initiated furosemide - indication (heart failure) and how 
to take to manage side effects, for example can take at 
lunchtime instead of in morning if need to go out in 
morning, rather than skipping dose altogether to avoid 
polyuria (previous poor compliance) 
4 65-150 
9. Community pharmacist explained indication for new 
medicine (finasteride 5mg daily) 
3 0-6 
10. Patient prescribed iron supplements during admission 
and noticed dark stools following discharge.  
Community pharmacist reassured patient that 
darkened stools whilst taking iron supplements is 
normal 
3 0-6 
11. Community pharmacist reinforced counselling on 
apixaban (replacement for warfarin) as patient unsure 
of reason for switch and why blood tests no longer 
required 
4 65-150 
12. Healthy living advice given re diet and physical activity 
to patient with angina 
4 65-150 
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13. Patient is a current smoker despite diagnosis of 
COPD.  Community pharmacist provided smoking 
cessation advice (unknown if acted on) 
4 65-150 
14. Patient unsure of how to take some medicines and 
reasons for taking (patient has angina, diabetes and 
chronic kidney disease stage 3B).  Community 
pharmacist reinforced times of day to take them and 
indications 
4 65-150 
15. Patient taking simvastatin in the morning.  Community 
pharmacist explained rationale for evening dosing and 
patient changed time of dose 
3 0-6 
16. Lansoprazole removed from blisterpack MCA following 
discussion with patient to facilitate administration on 
empty stomach 
3 0-6 
17. Dispersible aspirin not being dispersed as placed in 
blisterpack MCA and patient could not identify it.  
Removed from blisterpack by community pharmacy to 
aid identification 
2 0-6 
18. Patient with osteoporosis not always taking Cacit due 
to forgetfulness. Community pharmacist discussed 
with patient and son, who will now help her remember 
to take it 
4 65-150 
19. Patient not taking senna regularly but still 'very 
constipated'.  Pharmacist advised to try taking 
regularly 
3 0-6 
20. Patient had restarted isosorbide mononitrate which 
had been stopped during admission due to low blood 
pressure.  This medicine was also still on repeat 
prescription.  Pharmacist liaised with GP and 
isosorbide was discontinued. 
4 65-150 
21. Gabapentin still on current record at pharmacy.  
Community pharmacist ascertained that this had been 
discontinued and records updated to prevent re-
ordering 
 
3 0-6 
22. Colecalciferol increased during admission.  
Community pharmacist updated their records 
accordingly 
3 0-6 
23. Bisoprolol stopped in hospital but no indication as to 
why.  Re-issued by GP.  Community pharmacist 
liaised with GP surgery to clarify situation.  (Bisoprolol 
to continue) 
3 0-6 
24. Patient presented prescription for pre-admission 
medication which was identified by community 
pharmacist due to information provided with dMUR 
referral from hospital pharmacy.  Prescription referred 
back to GP surgery.  (Diuretic had been changed from 
bendroflumethiazide to furosemide, perindopril dose 
increased and warfarin and bisoprolol started) 
5 713-1484 
25. Community pharmacist asked GP to consider whether 
patient appropriate for steroid inhaler due to recent 
discharge following exacerbation of COPD requiring 
antibiotics and steroids.  (Patient had been on no 
regular inhalers prior to admission although reported 
having been on inhaled steroids in the past.  She had 
been discharged on salbutamol and tiotropium) 
3 0-6 
26. Patient started on warfarin during recent admission.  
Community pharmacist noticed INR had risen from 1.5 
4 65-150 
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to 2.5 in 7 days with no dose change and patient had 
later seen blood (small amount) after going to toilet.   
Pharmacist arranged INR clinic appointment the next 
day. 
27. Pharmacist advised patient to consult GP if dizziness 
symptoms return, for review of blood pressure 
medicines (postural drop in blood pressure had been 
evident during admission) 
3 0-6 
28. Blood pressure medicines reduced in hospital.  
Community pharmacist re-checked blood pressure and 
it was 80/44mmHg.  Pharmacist told patient to see GP. 
4 65-150 
29. Amlodipine stopped in hospital as perindopril had been 
started and blood pressure controlled by this.  Patient 
started taking amlodipine again post-discharge as did 
not realise it had been stopped. Therefore taking both 
drugs.  Pharmacist referred patient to GP. 
4 65-150 
30. Patient taking metformin and Novomix 30 insulin for 
diabetes was altering dose of metformin depending on 
blood sugars.  Pharmacist advised this is not the 
correct way to manage their readings and advised 
patient to ring diabetes nurse for review. 
4 65-150 
Total cost avoidance  £1688 - £3818 
Mean cost avoidance per intervention  £56.27 - £127.27 
Cost Avoidance per dMUR (mean = 2 
interventions per dMUR) 
 £112.53 - £254.53 
 
 
7.6: COMMUNITY PHARMACIST QUESTIONNAIRE 
Following referral of the final participant for dMUR, a self-completed questionnaire 
was sent to community pharmacists who had patients referred to them for dMUR 
during the study.  A copy of this questionnaire is included in Appendix 32. 
In total 21 pharmacists were traced and asked to complete the questionnaire and 19 
returned it (90% response rate).  
Thirteen pharmacists (68%) thought all participants referred to them were suitable 
to partake in a dMUR.  The main reason for unsuitability (n=4, 21%) was patient 
inability to attend the pharmacy.  In one case the pharmacist had been unable to 
contact the patient using the details on the referral and one pharmacist reported that 
they had not received the referral sent by the hospital.  In terms of the time taken to 
conduct a dMUR, 60% (n=9/15 who answered this question) estimated a dMUR to 
take less than 20 minutes, with the remainder stating it took up to 40 minutes.   
There were four instances (21%) where pharmacists felt they had received 
insufficient information from the hospital to enable them to conduct a dMUR.  They 
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did not elaborate on the reasons for this.  However, when asked in general what 
further information they would have liked to receive (see question 1 in Appendix 32), 
knowing the reasons for medication changes made in hospital (n=5) and the specific 
indications for new medicines (n=4) were most commonly reported.   Despite most 
respondents stating referrals were suitable, concerns were raised regarding aspects 
of dMUR process.  Seven pharmacists (37%) felt that it was hard to engage patients 
in having the dMURs, and spoke of ‘patient non-attendance’ or the ‘need to get 
special permission to conduct an MUR at home’, whilst eight (42%) stated that 
dMURs were ‘more complex’ than other types of MUR.   
Despite these concerns, community pharmacists agreed that dMURs would help 
patients to manage their medicines better after being in hospital and that adherence 
problems (n=19, 100%) and medication errors (n=17, 90%) would be identified and 
resolved sooner than they otherwise would be.  Pharmacists saw value in the service 
with free text comments such as ‘the dMUR referral service was excellent’ or ‘useful’ 
and ‘not enough patients were referred’ or that they ‘would love to have more 
involvement’.  
Eight pharmacists (42%) had performed dMURs during the study period which 
were not direct referrals as part of the service.  Most (n=7/8, 88%) reported 
undertaking between one and five, although one pharmacist stated they had done 
more than 20.  
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CHAPTER 8: DISCUSSION 
This chapter provides an evaluation of the findings of this research in the context of 
other recent and ongoing research and policy on the role of the pharmacy 
profession in the transfer of care of older people.  Firstly, participant outcome data 
from this study are discussed, followed by the qualitative findings from participant 
interviews.  Findings from the analysis of the dMURs conducted during the study 
are then evaluated.  Then follows a section exploring the barriers and facilitators to 
the dMUR referral service, from the viewpoint of the hospital and community 
pharmacists involved in the feasibility study.   
These sections are followed by an overall discussion which highlights the 
contribution of this research to the current knowledge base in this area and how 
this may be taken forward in future research and practice.  The chapter finishes 
with a discussion of the limitations of this research and their implications. 
 
8.1: PARTICIPANT OUTCOME DATA 
All quantitative outcome data regarding readmissions, A&E visits, HR-QoL and 
medication adherence showed no significant difference between intervention and 
control groups at any time point (Tables 7.4-7.7).  Whilst this is disappointing it is 
unsurprising as this was a feasibility study and the research was not designed or 
powered to detect such differences.   Rather, the suitability of the measures 
themselves to assess these outcomes during a future, adequately powered RCT 
was the matter under investigation.  However, certain findings do generate 
hypotheses for further investigation, which are discussed in the sections below. 
8.1.1 Readmission and A&E Data   
Readmission figures in this study (Section 7.4.2) suggest that both control and 
intervention group participants in this study were at higher risk of readmission than 
the general elderly population admitted to hospital.  This could be due to the high 
degree of polypharmacy (mean 9 medicines) and multi-morbidity (mean 4 
comorbidities) among participants, which have previously been associated with 
preventable medication related admissions in older people (38,212,280,281).  
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These results might indicate that the clinical judgement of ward pharmacists in this 
study was effective in identifying patients particularly in need of post discharge 
support.   
The trend towards a shorter length of stay on readmission for the intervention 
group (p=0.1713 in the ITT analysis at 4 weeks) is a key finding from this study.  A 
reduction in the average length of readmission episodes has been observed 
previously in studies of the effect of an integrated medicines management service, 
including, but not limited to, copying community pharmacists into discharge 
medication, and, more recently, with electronic referral from hospital to community 
pharmacy (18,141,142).  The current study therefore adds to the body of evidence 
that referral from hospital to community pharmacy may have potential to reduce the 
length of readmissions and a further, adequately powered study focussing on this 
as a primary outcome is warranted. 
Furthermore, intervention group participants who adhered to the study protocol 
were 52% less likely to have at least one A&E attendance within 6 months of 
discharge than control group participants.  Again, the lack of statistical significance 
of this result (p=0.3891) could be due to the small participant numbers involved.   
There could be several possible ways in which dMUR interventions could lead to a 
reduced number of A&E visits or a shorter length of stay on readmission to 
hospital.  As suggested during the HOMER study, pharmacist review could 
potentially help patients to recognise the signs of deterioration earlier so they seek 
help before their condition becomes too severe, thereby shortening length of 
admission, or preventing the need to attend A&E (134).  However, no interventions 
of this nature were reported in the dMUR feedback from community pharmacists in 
this study.   
Alternatively, patients’ improved knowledge and management of their medication 
and sources of support after discharge could conceivably shorten a readmission by 
reducing the length of the medicines reconciliation process on admission and the 
complexity of the discharge procedure (for example the need to wait until social 
care packages can be implemented to provide support with medicines).  Similarly, 
better medication adherence and organisation of ordering repeat supplies might 
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reduce the chance of an A&E attendance due to running out of medication or 
decompensation of a clinical condition following non-adherence. 
Several of the interventions described by community pharmacists conducting 
dMURs in this study (Table 7.13, page 217) involved patient education on their 
medication regimen and ordering procedures for repeat supplies, introduction of 
compliance aids to increase independence with medication, or improved accuracy 
of GP, community pharmacist and patient held records.  All these factors could 
improve adherence and continuity of treatment, thereby reducing the need to 
attend A&E with DRPs, or assist with medicines reconciliation and discharge 
planning if a patient is readmitted (thereby shortening their hospital stay).  
Conversely, interviewed participants who had not had a dMUR tended to express 
more unresolved information needs regarding medicines (Section 7.4.3).  These 
included (among others) duration of treatment, side effects, how to take medicines, 
monitoring requirements, interactions with over the counter medicines and 
obtaining further supplies of medication post-discharge.  DRPs related to any of 
these factors could precipitate an unplanned hospital attendance. 
The National Audit Office recently reported that delayed discharges from hospital 
of elderly patients who no longer need to receive acute care are costing the NHS 
£820 million per annum (282).  As such, any possible link between improved 
medicines management prior to (re)admission due to community pharmacy 
involvement, and the ability to be discharged sooner, is worthy of further 
investigation.   
When interpreting the readmission data for this study, the timing of the readmission 
in relation to the timing of the dMUR must be considered.  Two intervention group 
participants were readmitted before going on to have their dMUR, one of whom 
had two readmissions in this time period.  Both participants were readmitted within 
two days of discharge, before the dMUR could reasonably have taken place.  One 
of these participants was then readmitted again 21 days after the original discharge 
(15 days after the second discharge).   
This situation raises the issue that if a patient is readmitted before receiving a 
dMUR they have been referred for, their medicines may change again.  This would 
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render the medicines list on the original referral incorrect and could lead to 
confusion and incorrect advice being given unless a new referral is generated.  
However with good communication between the hospital and community 
pharmacy, a dMUR conducted under these circumstances could be highly valuable 
to the patient in clarifying changes and building confidence in their altered 
medication regimen. 
The scenario presented above also highlights the importance of timing of the 
dMUR intervention.  It has been suggested that the risk of medication-related 
problems is greatest in the 7 to 10 days after discharge from hospital, and that 
follow-up with a pharmacist should occur within 7 days or sooner for high risk 
patients (283-285).  Examples from the current study included two patients who 
had had medicines stopped in hospital due to low blood pressure, but had started 
taking these again erroneously on discharge (Table 7.13).  In a patient still 
recovering from an acute illness, this could quickly lead to adverse effects such as 
falls, with possible readmission.  However early medicines reconciliation with the 
community pharmacist for patients with significant changes to their medication 
regimen could prevent this happening. 
However, a compromise must be achieved between allowing time for a patient to 
recover from admission sufficiently to engage in the dMUR process, and making 
the intervention timely enough to address any medication related problems early 
enough to prevent them developing further.  As described in Appendix 2, the PPI 
group for this study had mixed feelings about the optimum timing for the dMUR, 
with opinions ranging from as soon as possible after discharge to 4-6 weeks after.   
It could be that early initial contact to answer any urgent queries, with arrangement 
of the subsequent dMUR intervention for a later mutually convenient date, would 
be the answer.  This initial contact would not necessarily have to be by the 
pharmacist; it is possible that a suitably trained member of the pharmacy staff (e.g. 
accredited checking technician) could undertake the task of making contact with 
the patient, handing over to the pharmacist if any questions of a clinical nature 
arose. 
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This two-part intervention is analogous to both the NMS and the Welsh DMR 
service.  In the DMR service, the part one intervention (medicines reconciliation) 
must be completed within four weeks of discharge, whilst there is no time limit on 
the part two (adherence review) element (20).  As described in Section 4.5, the 
NMS consists of two consultations 7-14 and 21-35 days after the prescription of a 
new medicine (167).  This is based on the finding that approximately one-third of 
patients may be non-adherent to new medicines at 10 days, and 25% remain so at 
4 weeks.  Over this time period, some problems may be resolved, but new ones 
also emerge (66).  Indeed, participants in this PhD study demonstrated a range of 
medication support needs arising at various points following discharge, as 
evidenced by both dMUR feedback from community pharmacists (Table 7.13) and 
semi-structured interview data (Section 7.4.3).  These ranged from confusion 
regarding the discharge medication regimen and/or incorrect resumption of 
medicines which had be discontinued during admission, which needed addressing 
immediately, to additional information needs (such as duration of therapy, side 
effects and interactions), which may only present themselves weeks after 
discharge.  
 
8.1.2: Participant Questionnaire Data 
Medication Reviews other than dMUR 
Medication reviews with other HCPs in the month following discharge occurred at a 
similar rate in both intervention and control groups despite the provision of dMURs 
in the intervention group.  GPs (or their practice nurses) were responsible for the 
majority of additional medication reviews carried out, although some were also 
conducted by specialist nurses not attached to the GP surgery.  The exact purpose 
of these additional reviews, what exactly prompted them, and how they were 
communicated to the other HCP involved in the patients’ care is not clear.   The 
variety of HCP reviewing one or more aspects of a patient’s medication may reflect 
a co-ordinated response to problems.   However it seems likely that in patients 
having multiple reviews with different HCP there was at least some duplication of 
effort, reflecting poor continuity of care in a fragmented system.  In this case, better 
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communication of the plan for the dMUR, and its outcome, might reduce the 
number of unnecessary reviews conducted and free up time for GPs and nurses.   
From the pharmacist’s point of view, a lack of knowledge of which services a 
patient is already receiving is compounded by uncertainty as to which aspects of 
medicines support are being delivered by these professionals.    For a patient with 
several co-morbidities, a specialist cardiac nurse, for example, may not necessarily 
also check inhaler technique, advise on pain relief or provide a tick sheet for a 
patient who is having trouble keeping track of their regimen.  A respiratory nurse is 
likely to advise on inhaler technique, but might not check the patient knows how to 
use their GTN spray.  A community pharmacist providing a dMUR could potentially 
focus on any or all of these aspects as required by the patient.  However, not 
knowing which other support the patient has recently received makes it harder for a 
community pharmacist to know which areas to target during the dMUR.   
One interviewed participant who had been seeing a community psychiatric nurse 
described how the nurse was organising her a community pharmacy dispensed 
MCA.  Interestingly, this participant had already had her dMUR when this 
suggestion was made and the community pharmacist had not perceived a need for 
an MCA.  There could be a number of reasons for this, including that the 
community pharmacist had completed an assessment and decided that blister 
packs were not necessary or appropriate for this patient.  Alternatively (or in 
addition) the patient’s needs could have changed since the dMUR, or the nurse 
may have perceived something the pharmacist did not.  Either way, the pharmacist 
and nurse being aware of each other’s input would enable them to liaise in a timely 
manner over the best support plan for this particular patient. 
The roles of the GP and their team (both HCP such as nurses and practice 
pharmacists and support staff), community specialist nurses and other services 
need to be considered when planning post discharge medicines support, so that 
different practitioners can work together.  Any plan for medicines support organised 
by the pharmacy team should be clearly communicated to the patient’s GP, and 
the hospital pharmacy team should also be aware of other follow-up organised for 
the patient, and communicate this to the community pharmacy team.  Better 
documentation on discharge summaries of the planned clinical and social care 
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package for the patient, with contact details where possible, copied to all those 
involved, would be helpful in achieving this.  Ideally, all healthcare professionals in 
primary and secondary care would have access to the same shared care record to 
which they could input their contributions to patient care and highlight concerns 
identified for another more suitable professional to address.    
However, in the current study there was little evidence of pharmacists and GPs 
working collaboratively to get the best out of the dMUR service.  Indeed, 
collaboration between community pharmacists and GPs regarding MURs of any 
type has historically been lacking (256,286-289).  The GPs of all participants were 
notified that their patient was taking part in this study; however GPs were not told 
whether their patient was in the intervention or control group.  It might be that if 
GPs were informed by the hospital that their patient had been referred for a dMUR, 
this would reduce the number of additional medication reviews performed; although 
this would need further investigation.  Community pharmacists reported conducting 
few dMURs outside of this study, and where these were performed, patients were 
identified via changes to regular prescriptions or by the patient or their carer 
informing the pharmacy.  Referrals from GPs where not mentioned as a source for 
initiating dMURs, despite some patients being uncertain or unapproachable 
regarding the service in hospital, indicating a role for screening and referral post-
discharge in primary care. 
Community pharmacist feedback did indicate that in some cases, the pharmacist 
had liaised directly with the GP to address issues arising as a result of the dMUR.  
However these tended to be where a specific problem with a prescription was 
identified, such as medicines discontinued by the hospital being restarted by the 
patient or re-prescribed by the GP.  Where a more general issue was identified 
(such as low blood pressure in a patient who had had antihypertensive medication 
altered during hospital admission), pharmacists tended to recommend that the 
patient made an appointment with the GP, rather than contacting the surgery 
themselves.  This approach has been raised as a concern during previous 
research with MURs, as it may result in problems remaining unresolved if the 
patient does not follow the pharmacist’s advice (288).  Comments made by some 
of the Delphi panel reviewing the dMUR interventions in this study  also indicated 
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that they would have ranked these interventions more highly if the pharmacist had 
liaised directly with the GP rather than relying on the patient.  However the overall 
evaluation of dMUR interventions by the Delphi panel (Section 7.5.2) indicated that 
the majority did improve the quality of care.  This highlights that there is an 
opportunity for GPs and pharmacists to work together to optimise the use of 
medicines, but as suggested by others, the potential of MURs may not fully be 
realised until there is progress made to improve GP–pharmacist collaboration 
(289). 
 
Medicines Adherence Score (MMAS) 
The MMAS in both study groups indicated overall medium to high adherence at 
both follow-up points, which may reflect over-reporting of adherence by 
participants, or recruitment bias, whereby adherent patients are more likely to 
agree to participate in the study at the outset.  Both are known issues with 
adherence research (67,126,290). 
 
When the change in adherence score between 4-week and 6 month follow-up was 
considered, it appeared that the control group experienced an overall deterioration 
(0.69 points) on the MMAS relative to the intervention group.  Previous research 
has suggested that a change of 2 or more points on the MMAS over time is needed 
to represent a real change in adherence (291).  However, these exploratory 
findings suggest that dMURs may help to prevent deterioration in medication 
adherence over time. 
 
It has been suggested by other studies that effects on adherence do take time to 
develop following a community pharmacy intervention – in the NMS evaluation, 
significant differences in the MMAS were observed at 10 but not 6 weeks (292).  A 
larger study of sufficient power is required to prove this data in relation to dMURs.    
The collection of baseline adherence measures would allow investigation of 
whether the differential change in adherence between groups represents an 
ongoing trend.  However how meaningful baseline adherence measures would be 
in patients who have just been hospitalised for acute illness is questionable, and as 
discussed in Sections 5.3.2 and 5.3.3, there are concerns that introduction of 
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baseline questionnaires into the recruitment process might further limit participation 
rates. 
Health Related Quality of Life (SF-12v2) 
One interesting finding from this PhD study was that the mean physical health 
score at six months for intervention group patients was 5.39 points higher than for 
control group patients in the ITT analysis.  Although not quite statistically 
significant, (p=0.0983), this could be due to small sample size.  However it must be 
noted that the difference in the PP analysis was less at 2.81 points (p=0.3931).  
Nevertheless, along with the finding of a trend towards higher medication 
adherence over time in intervention participants relative to control, the possibility 
that dMURs could improve patients’ self-reported physical health in the months 
following discharge is worthy of further exploration.   
Mean HR-QoL scores for control and intervention groups at both follow-up time 
points, for both mental and physical health, were lower than the age adjusted 
population norms (Table 7.8, page 191).  The low levels of HR-QoL reported by the 
participants in this study might impact on their ability to benefit from the dMUR 
service in its current form and indicate that a more intensive intervention tailored to 
their needs (for example including home visits) might be needed in order to make a 
difference. 
Enablement (PEI) 
The mean enablement score following dMUR in this study (3.69) was similar to the 
mean enablement score of 3.8 among patients aged >65 in Howie et al’s original 
cross-sectional study of GPs’ consultations (293).   However it has since been 
suggested that a PEI score of >6 is required for clinically meaningful enablement 
(227,239).  The dMURs conducted during this study fell short of this mark, which 
could be due in part to the high levels of medication adherence reported by 
participants, leaving little capacity for improvement or enablement.  Widening the 
scope of the current dMUR service by facilitating provision to patients of potentially 
greater need (for example, those who are housebound or receive significant help 
from carers with their medication) is relevant in this respect.  Additionally, 
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consideration of the reasons for this, as presented below, could help improve the 
quality of future dMURs. 
Howie et al found that enablement increases with the length of the consultation and 
knowing the doctor well.   Various pressures limit the amount of time pharmacists 
feel they can spend on an MUR with an individual patient, which may in turn 
reduce their ability to enable the patient (173,289,294).  Previous research 
evaluating post-discharge medication reviews conducted by pharmacists has 
reported these to take between 30 minutes and one hour, whilst pharmacists 
completing a recent survey estimated that a ‘standard’ MUR lasts for around 10 
minutes (20,126,128,134,174,202).  In this PhD study, all community pharmacists 
involved estimated a dMUR to take less than 40 minutes, with nearly two-thirds 
estimating them to take less than 20 minutes.   Therefore, whilst taking longer than 
a ‘standard’ MUR, the majority of dMURs in this study seem to have been 
completed more quickly than other post-discharge medication reviews.    
The importance of an established relationship with the community pharmacist in 
perceiving benefit from dMUR consultations was an emergent theme from the 
qualitative interviews conducted with participants in the current study (see Section 
8.1.5 for further discussion).  The formal association of enablement score with the 
relationship between pharmacist and patient was not within the scope of this study, 
but it seems likely that a consultation with a familiar pharmacist would have 
resulted in greater enablement, as is the case with GP consultations.  This could 
have important consequences for community pharmacies who are staffed 
frequently by locums, with patients using such pharmacies potentially deriving less 
benefit from dMUR. 
Terminology used to present the MUR service to patients may also be unhelpful in 
respect of the concept of enablement, with community pharmacy staff in an 
observational study describing the MUR as a ‘quick check’ of their medicines and 
one pharmacist in a qualitative interview study reporting introducing the 
consultation by asking patients if they had ‘a few minutes’ (173,294).  While this 
was not the manner in which the service was introduced to participants during 
recruitment to this study, how they were subsequently approached by community 
pharmacists to arrange their dMUR may have differed.   
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Conducting a dMUR under this banner is unlikely to lead to a feeling of significant 
enablement.  If enablement is viewed as a primary objective of the dMUR service 
(or indeed the MUR service as a whole), then the way they are promoted to 
patients and conducted may need to change.  As the purpose of the MUR service 
is to improve a patient’s understanding and use of medicines, and the definition of 
enablement is the patient’s perception of their ability to understand and cope with 
their ‘health problem’ (substituted for ‘medication’ in this study), one could argue 
that enablement is a desirable outcome measure for the service.  Therefore the 
concept of the dMUR as a patient centred discussion and review of the way they 
take their medicines, rather than a quick check or chat may need to emerge, and 
community pharmacists may need support to facilitate this. 
The finding that participants who received their dMUR more than 4 weeks after 
discharge had a higher mean enablement score (although not significantly so) is 
worthy of further investigation, as the optimum timing of the dMUR remains open to 
question.  Indeed, as discussed in Section 8.1.1, it has been suggested by others 
that early initial intervention is needed during the first week post-hospitalisation 
when the risk of medicines misadventure is highest.  However data from this PhD 
study suggest that this may not be the optimum time to fully engage in concordant, 
‘enabling’ discussions around medicines.  This provides further support for the 
adoption of a two-part dMUR service, akin to the NMS.  
 
8.1.3: Case-Note Analysis of Readmitted Participants 
The difficulty in demonstrating significant reductions in hospital readmissions 
following an intervention was illustrated by van Walraven and Forster (295).  They 
suggested that that 23% of all emergency readmissions are actually avoidable, and 
that in order to achieve a 20% reduction in total hospital readmissions, a 91% 
reduction in potentially avoidable readmissions would be needed.  This analysis 
demonstrates that finding an intervention that can decrease overall hospital 
readmissions in a statistically significant manner is a challenge for clinicians and 
researchers, and may help to explain why no difference between intervention and 
control groups was found in this study.   
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The reduction in potentially avoidable medicines related readmissions may 
therefore be a more appropriate outcome to measure to the benefit of pharmacist 
interventions than overall readmissions.  In the current study, the number of 
readmissions which were medication related and avoidable was judged using 
previously published criteria.  Using these criteria, one in seven of the 
readmissions occurring within the 6-month follow-up period were judged as both 
medicine related and preventable, which is consistent with previous reports 
(46,102-105).   
The finding that no preventable medication related readmissions occurred in 
patients who had completed a dMUR suggests that dMURs could be effective in 
preventing such readmissions.  However this would need confirming in a larger, 
adequately powered RCT.   
 
8.1.4 Semi-Structured Interview Data 
Opinions of interviewed participants regarding medicines information given before 
discharge from hospital were influenced by their underlying expectations and 
perceived need for information.  This in turn was determined by their background 
level of knowledge and experience of taking medication, the complexity of the 
changes that had occurred and their personal desire and capacity to be involved in 
and understand the changes.  How closely the amount and nature of information 
given matched these expectations and capabilities then determined how positively 
participants felt about the advice and support given to them by the hospital about 
their medicines.  Participants who described receiving information from several 
sources, particularly where conversations were backed up with written information, 
seemed to demonstrate greater confidence in and understanding of their 
medication, a finding which supports the work of others  (296).  Unfortunately, 
participant numbers were too small to triangulate these findings with more 
quantitative outcomes such as readmissions or adherence. 
Access to further support following discharge could be reassuring, particularly if 
multiple changes had taken place.  This finding highlights a role for dMURs as 
potentially being particularly beneficial for older patients who have experienced 
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multiple medication changes in hospital, and targeting of referrals to this patient 
group is one possibility for making the most of the service.   
However, over half the interviewed participants displayed only partial recall of 
information regarding medicines given to them in hospital, and almost a quarter 
could not remember any discussion regarding medicines, or being given any 
written information to take home.  It was not clear from the interviews whether 
information given was inadequate, poorly recalled, or a combination.  Problems 
with processing and retaining information may result from underlying cognitive 
impairment, participants’ acute medical condition, or the various other physical and 
mental stressors they were exposed to in hospital.  These findings are consistent 
with other research highlighting unmet medicines information needs among 
discharged (or soon to be discharged) patients (8,83,86-89).  Patients often meet a 
variety of health care professionals in hospital, including pharmacists, but have 
little time to learn their names or understand their roles.  Schedules are often 
unpredictable, and in patients who are already under stress, information overload 
may provoke confusion (7).  This highlights a role for dMURs in reinforcing or 
supplementing advice that was (or should have been) given for the first time in 
hospital.  The experiences of participants in this study suggest that there is a large 
group of people who could benefit from the service. 
Poor recall of information by some participants also highlights the need to include 
relatives and carers in the medication support process where appropriate.  For 
participants with persisting cognitive impairment, a dependence on others to act as 
a proxy in the receiving, understanding and implementation of information about 
medicines changes was evident.  All participants who enrolled in the study were 
required to have capacity to understand the implications of being involved and 
consent to participation, as well as the capacity to partake in the dMUR 
consultation, as these cannot be conducted solely with carers.  As such, patients 
with moderate to severe cognitive impairment were screened out.  However a 
number of participants with mild cognitive impairment were enrolled with joint 
agreement from family members.  Interviews with two such participants and their 
family members were carried out and in these cases the perceived need of the 
participant for information about medicines was replaced by that of their family.   
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The importance of carers in assisting some participants in this study with their 
medication is likely to represent only the tip of the ice-burg, because most patients 
who were not independent with their medication were excluded.  The fact that 
MURs cannot currently be conducted with carers is at odds with various guidelines 
which advocate their involvement in medicines management at care transitions 
where appropriate (76,110,297,298). 
The absence of discussion regarding medicines as a result of a hurried discharge 
described by some participants emphasises the importance of, rather than 
reserving ‘medication counselling’ for the point of discharge, talking with patients 
about changes in medicines throughout admission.   Despite a general lack of 
complaint regarding any information deficits that had occurred, most interviewed 
participants did desire knowledge of medication changes and a lack of information 
could prove unsettling.  Types of information desired, which were perceived as 
lacking from the hospital, included discussion of the reasons for changes and 
indications of new medications, as well as potential side effects, which are similar 
to findings from other research (86,89,296).  These aspects could be discussed 
with patients during a dMUR, as long as the community pharmacist was in receipt 
of suitable information from the hospital.  This highlights the importance of sending 
information regarding the reasons behind changes and exact indications for new 
medicines to the community pharmacist, as without this information, the benefit of 
a dMUR may be limited.  
In this PhD study, collaboration and information sharing between pharmacists in 
hospital and community settings was key and represents a major step forward in 
improving transfer of care.  However, it could be argued that this needs to be done 
to an even greater extent, to allow tailoring of the dMUR intervention as advocated 
above.  Community pharmacists who received dMUR referrals during this study 
would have liked more information regarding reasons for medication changes and 
the indications for new medicines, to facilitate patient centred discussions during 
dMURs.  Although this information was provided on the referral form as far as 
possible by the researcher this was limited by the space available on the form and 
the researcher’s knowledge of the participants.   
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Sending community pharmacists the full discharge summary completed by the 
patient’s own ward doctor and pharmacist would be a way of providing more 
detailed information, as well as removing the requirement for hospital staff to 
complete a separate referral form.  Concerns were voiced by the hospital 
pharmacist focus group in this study, regarding patients’ confidentiality if 
community pharmacists were to receive the same discharge summary as GPs.  
However this could be incorporated into the patient consent process for the 
referral, and does not seem to have been an issue during implementation of the 
electronic Refer-to-Pharmacy system, which shares the whole discharge letter with 
the community pharmacist (17,299).  Alternatively, the digital platform 
PharmOutcomes now allows pre-specified fields from the hospital’s electronic 
systems to be pulled through into the community pharmacy referral, to allow 
targeted sharing of information (300). 
Not all participants expected detailed discussions regarding medicine changes, 
which has also been found by other researchers (296).  Even some participants 
who had experienced quite complex changes, or changes involving high risk 
medicines, such as NSAIDs or antiplatelets, expressed a low need for medicines 
information.   Some viewed the routine of the medicines round in the hospital as 
adequate preparation for taking their altered medication regimen at home and the 
labels on the medicine boxes and patient information leaflets (PILs) inside them as 
adequate direction.  Others were used to taking multiple medicines, or had worked 
with medicines in the past and did not feel the need to have everything explained in 
detail.   
These examples demonstrate the need to explore the specific information 
requirements of the individual patient during consultations about medicines (296).  
Results of this research therefore indicate that blanket referral of all patients with 
medication changes may not be necessary or desirable in the eyes of the patient.  
Targeting referrals using patient desire for support as well as the presence of 
factors such as age and multiple medication changes may be more productive.  
Professional judgement is needed in order to explore this further with the patient, 
or offer referral at a later stage (e.g. by GP practice pharmacists), as patients may 
have knowledge gaps that they themselves are unaware of, or only realise at a 
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later stage (66).  This was demonstrated by medicines information requests from 
several participants during interviews in this study, the vast majority of which came 
from participants who had not had a dMUR. 
Interviews revealed that despite all the guidelines that exist regarding transfer of 
medicines information between providers when patients are discharged from 
hospital, there are cases where the process still does not run smoothly.  Moreover, 
delays and errors were described regarding high risk medicines such as warfarin.  
Two of the three participants where such an incident occurred were in the control 
group.  In the third case, transfer of discharge information directly to the community 
pharmacy in the form of the dMUR referral had alerted the pharmacist to the 
changes in medication, enabling him to liaise with the GP surgery and ensure the 
patient’s records were updated and a new prescription generated.  This prevented 
an erroneous prescription being dispensed.   
Interviewees described numerous barriers to using their medicines as agreed, 
including cognitive, physical, accessibility and motivational barriers, and in many 
cases had introduced personal strategies to overcome these.  Solutions to 
adherence initiated by participants themselves included handwritten records or ‘tick 
sheets’ to record when medication was taken, annotation of medicine packaging 
and personally filled MCAs.  This type of system is likely to work only if the patient 
is organised and motivated enough to keep it up to date, and where the main 
problem is a lack of confidence or low-level ‘absent mindedness’.  Despite these 
measures, complex dosing instructions could still cause confusion and repeated 
follow-up and checking of understanding by community pharmacists following a 
dMUR could be valuable.   
Some participants also found it helpful to keep a written record of medication 
changes.  Again, the importance of backing up verbal discussion with written 
information seems to be paramount for this patient group.  This could be achieved 
by a dMUR either via a dMUR action plan, or other resources tailored to the 
individual patient, for example large print PIL or dosing instructions for a new 
medicine.  Other assistance from community pharmacists as a result of dMUR may 
include medicines administration record (MAR) sheets to help patients keep track 
of doses taken, suggesting simplification of regimens (e.g. switching to once daily 
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dosing where possible), assisting with inhaler technique and performing 
assessments for introduction of MCAs.    
At least one interviewee had altered their medication dosing regimen to fit in with 
their daily life.  This participant (a retired nurse) was aware from previous advice or 
experience that the splitting of his diuretic dose was appropriate.  However in a 
patient without this knowledge the side effect of polyuria may well have reduced 
adherence.  Conversely, altering dosage regimens without prior discussion with a 
HCP may compromise the benefit of some medicines, or lead to adverse effects.  
This highlights the importance of concordant discussions to support adherence, 
which is a primary aim of the dMUR.  
Opinions of the dMUR consultation from interviewees who had received one were 
generally positive.  However participants who were used to taking multiple 
medicines, had support from other HCPs (such as specialist nurses) or who had 
been motivated to investigate and manage their own changed medication regimen 
following discharge were less enthusiastic.  These responses further reinforce that 
dMUR referral is not desirable for all older patients, and again highlight the need 
for co-ordination of services, as well as better patient education as to what a dMUR 
is and what it can provide.   
The concept of an initial contact by the community pharmacist (or suitably qualified 
support staff) following referral from the hospital has already been broached in 
Section 8.1.1.  This early contact could help to gauge the patient’s need for and 
engagement with the dMUR service, which could lead to a mutual agreement that 
an MUR is not needed at the present time.  Equally, confirming a dMUR 
appointment with an understanding of what it will entail may avoid the need for 
some patients to see their GP for the sole reason of discussing discharge 
medication.  If the GP was aware of the potential for a dMUR, they might signpost 
the patient to their community pharmacist rather than dedicate a valuable surgery 
slot to the purpose of confirming that the patient is managing their discharge 
medication.  However in order to use dMURs to significantly reduce GP workload 
in this way will require increased collaboration between pharmacists and GPs, and 
greater confidence in the MUR service on the part of both patients and GPs, than 
is currently the case (287-289,301). 
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In terms of the content of the dMURs, most participants described a process of 
discussing each of their medicines in turn, with the pharmacist checking 
understanding of what the medicines were for.  Comments made by three of the 
eight interviewees who had received a dMUR suggest that these participants had 
not learned anything new regarding their medication by attending, although one of 
these had found the consultation ‘reassuring’.  These results mirror earlier 
observational research which found that MURs tended to follow a formulaic 
approach dictated by the ‘MUR form’ (294).  Interviews with participants in that 
study also indicated that MURs did little to increase patients’ knowledge and use of 
their medication, although some felt reassured about their medicines. 
It is worth noting that the requirement to fill in the MUR form was removed in 2012, 
and replaced by a dataset to be collected following the MUR and a list of 
suggested questions designed to help shape the consultation (168).  However, 
dMUR feedback received from community pharmacists in this PhD study (during 
2014-15) showed that this form was still being used by a number of them.  It may 
be that more support is needed to develop pharmacists’ consultation skills to build 
their confidence in tailoring MURs to the individual patient’s needs and addressing 
more complex issues such as underlying beliefs about medicines (289).    
Identifying and addressing underlying beliefs about the necessity of medicines and 
any concerns which may affect a patient’s motivation to adhere to their regimen is 
an important opportunity for the dMUR consultation.  A fine line needs to be walked 
between empowering the patient with the knowledge they need to motivate them to 
manage their medicines, and overloading them so that they stop paying attention.  
Exploring the patient’s needs and identifying the information that is relevant and 
important to them may be the key to this (302).  However the extent to which 
community pharmacists are currently prepared to meet this challenge has been 
thrown open to question (289).  Consultation skills training for pharmacists is 
available but as yet there is little evidence that it has been applied to MUR 
consultations to make them more patient centred (289).  
Asking the patient to explain their understanding of the changes made in the 
hospital and why they were taking each medication, rather than simply asking the 
closed question of whether or not they understood, might be more productive in 
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highlighting gaps in knowledge and targeting where extra advice may be needed.  
This approach was taken during at least one of the study dMURs; interestingly a 
joint dMUR with Participant 7 and her son, who was her main carer (Section 7.4.3).  
This consultation had helped the son gain a better understanding of his mother’s 
medication, and also the more clinical role of the community pharmacist.  
Increased awareness, among both patients and those who care for them, of what 
community pharmacists can offer could lead to more appropriate utilisation of HCP 
within the MDT.  Thus, each member of the team is consulted according to their 
particular skills, avoiding the duplication of effort and more efficient use of 
healthcare resources.  
Another benefit of a well conducted dMUR is the identification of which patients 
may need more support following their recent discharge, as a frail elderly patient 
may never reach their previous level of functioning following a hospital admission.  
This can provide reassurance to carers that the community pharmacy will work in 
partnership with them to support safe and effective management of medications for 
the vulnerable patient.  This was also demonstrated during Participant 7’s dMUR, 
with her son being reassured by the fact that now the community pharmacist knew 
they ‘had to be a buffer’ between the GP and his mother, in terms of medicines 
management. 
The opportunity to ask questions of the pharmacist about new medicines was 
generally appreciated by participants.  The resulting advice given had allowed one 
participant to relax the restricted diet she had imposed on herself following the 
initiation of warfarin by the hospital.  Other topics discussed during dMURs 
included the importance of checking interactions between prescribed and over the 
counter medicines, the logistics of obtaining further supplies of medication started 
by the hospital, notably warfarin, and providing brief intervention advice, e.g. 
smoking cessation.  These type of interactions demonstrate the potential for 
dMURs to provide a platform on which follow-up interventions or signposting to 
other services could be built. 
Although most interviewees could describe what had happened during the dMUR, 
some aspects had been forgotten by the time of the interview, which was typically 
about 2 weeks later.  It also became apparent during interview that some 
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participants had queries which had not been addressed during the dMUR, either 
because they had only arisen subsequently, or had been forgotten during the 
original dMUR.  These examples give further support to the idea that multiple 
contacts might be needed as part of the dMUR process in some cases to fully 
reinforce and monitor changes.   Follow-up appointments could also be used to 
ascertain whether any recommendations submitted to the GP have been actioned.  
The NHS Summary Care Record, to which community pharmacists now have 
access, could be used to assist with this.  Previous research has suggested that 
pharmacists get little feedback from GPs regarding recommendations forwarded to 
them following an MUR, so following up with the patient in this way could help 
‘close the loop’ (286,288,303).  These further appointments would, however, 
require appropriate remuneration for the community pharmacist. 
One aspect of the dMUR process that appeared to vary between community 
pharmacists was the method of organisation of the dMUR.  When describing their 
dMUR experience, most participants indicated that they had been contacted by 
telephone to arrange the dMUR, but some had taken place opportunistically when 
the participant had happened to be in the pharmacy.  Although this approach may 
work for non-targeted MURs, where timing of the appointment is less important, 
dMURs are designed to be carried out within the first four weeks post-discharge.  If 
the patient has been discharged from hospital with a month’s supply of medication 
(as is often the case at SONT), they may not visit the pharmacy until towards the 
end of this time period.  Indeed, in view of the difficulties with mobility experienced 
by many study participants in the early weeks post-discharge, it may well be that 
they themselves do not present at all unless specifically arranged, sending a 
representative to collect their medicines instead and thereby missing out on the 
opportunity for their dMUR. 
Difficulty in leaving home, due to ill health or poor mobility, was the most commonly 
reported barrier to dMUR discussed by interviewed participants.  As the intention 
was to screen out housebound patients at the recruitment stage of the study 
(unless their community pharmacy offered domiciliary visits), participants who 
reported during interview that they were unable to attend the pharmacy had 
241 
 
previously specified that they would be able to do so.  The real size of this problem 
is therefore likely to be much bigger than described by the interviewed participants.   
Some participants could attend the pharmacy, but only if a carer was available to 
assist.  However this type of dMUR would be more labour intensive to organise, 
both for the hospital team, as consent from both patient and carer and their contact 
details need to be obtained and recorded in the referral, and for the community 
pharmacist to organise a convenient time for all parties to attend the dMUR.  Still, 
as demonstrated during the interview with Participant 7 and her son, these dMURs 
may be worth the effort in terms of the benefit they provide. 
Patients' other commitments could also be a barrier to dMUR provision.  The few 
weeks following discharge can be hectic as patients re-adjust to home life and 
recover from their illness.  As described by the interviewed participants, and 
reflected in the participant questionnaire data, there may be numerous other 
healthcare contacts, so that the dMUR may be perceived as unlikely to add 
anything to what their GP or the hospital can provide.  It has also been found 
previously that patient willingness to have a discussion with a pharmacist because 
of recent hospital discharge is lower than other reasons for doing so, although the 
reasons for this are not clear (174).  It could be that dealing with the aftermath of a 
hospital admission is perceived as beyond the competence of the community 
pharmacist, as it has been suggested that patients prefer to consult a physician for 
all but the most minor health issues (304).  
Some participants in this study who had not had a dMUR indicated that they would 
have liked to have had one.  Unsurprisingly, these participants tended to be those 
who had poor recall of events in hospital including advice regarding medicines.  
They also tended to be those who had difficulty leaving home in the early weeks 
post discharge (and so would have struggled to attend a dMUR at the community 
pharmacy).  Paradoxically, the very patients who may be more difficult to interact 
with in the hospital to discuss and gain consent for the dMUR, and to physically 
access in the community to deliver it, may be those who stand to benefit the most 
from the consultation.  These findings regarding the barriers to dMUR reflect other 
research, where poor patient mobility, low perceived need for the service, 
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preferring to speak to their GP and having carer support with managing medicines 
have been identified, with poor mobility being the most common barrier (305-307). 
Participants who had not had a dMUR tended to express more unresolved 
information needs regarding medicines than those who had.  These related to 
indications for new medicines, duration of treatment, side effects, how to take 
medicines, monitoring requirements, interactions with over the counter medicines, 
goals of therapy and obtaining further supplies of medication post-discharge.  All of 
these points could have been addressed during a dMUR following receipt of 
medicines-related discharge information from the hospital.  However, some (such 
as precise indication and duration of therapy) may have been difficult for the 
community pharmacist to address conclusively without such information, limiting 
the potential of a dMUR conducted under these circumstances.  This may help 
explain why dMUR provision is so low in the absence of formal referral systems 
from secondary care. 
Views on the value of a dMUR may be influenced by the existing relationship a 
particular patient has with their community pharmacist.  Previous positive 
experience and the length of the relationship were important factors, with 
participants who had been using the same community pharmacy for a long time 
tending to have a more positive view.  It would be interesting to link this finding with 
quantitative measures such as enablement in a larger study.  Consistency of the 
responsible pharmacist, so that familiarity and trust was established, was voiced by 
one participant as an important factor in whether she would feel comfortable 
participating in a dMUR.  Previous research has also found that patient satisfaction 
with pharmacy services tends to be higher when patients are loyal to one 
pharmacy where they have a good relationship with the staff and appreciate the 
overall atmosphere (308). 
This raises issues for service provision from community pharmacies that are 
largely dependent on locum cover, or ‘transient’ pharmacists who quickly move on 
elsewhere.  The 2013 General Pharmaceutical Council (GPhC) Registrant Survey 
revealed that 1 in 4 pharmacists working in the community setting are locums, 
compared to just 4% in hospitals (309).  Moreover, over a quarter of community 
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pharmacists work part-time, which has further implications for consistency of 
pharmacist in the pharmacies they work in.   
Another aspect of their interaction with community pharmacy which was valued by 
participants was the opportunity to have a private consultation.  Participants’ 
comments suggested that patients wouldn’t necessarily expect a community 
pharmacy to have a private consulting room, further highlighting a need for patient 
education around community pharmacy services.  These findings match those of 
others, where a perceived lack of privacy and confidentiality has repeatedly been 
raised as a barrier to use of extended pharmacy services, and it has been found 
that patients and the public are unfamiliar with the private consultation rooms 
offered at UK pharmacies since the introduction of the 2005 community pharmacy 
contract (304). 
In such cases, experiencing a dMUR could positively impact on patients’ overall 
attitude towards community pharmacy.  This has been shown in previous research, 
where those who have experienced a formal community pharmacy service in the 
past have higher expectations and are more willing to use other services in the 
future (174,308).  One example from the current study of how experiencing a 
dMUR had improved interviewees’ perception of community pharmacy is the son of 
participant 7, discussed above, who had gained an insight into how the community 
pharmacist could provide support to ensure optimal use of medicines for his 
increasingly frail mother after attending her dMUR with her.  It therefore seems that 
whilst having a positive existing relationship with a community pharmacist is linked 
to a positive dMUR experience as discussed above, a positive dMUR experience 
can also improve relationships going forwards, which has been found during other 
research (174). 
However, for some participants in this study, the fact that they were already used 
to using the community pharmacy as a first port of call for advice on medicines 
may have reduced the impact of a separate dMUR consultation.  Two participants 
described discussing medicine changes during their recent admission with their 
community pharmacist.  Despite this, neither had been offered a dMUR at the time 
of their initial presentation to the community pharmacy.  This suggests that 
sometimes community pharmacists may undertake at least some of the actions 
244 
 
required for a dMUR on an informal basis, but not actually acknowledge or develop 
the consultation as such.   
A possible reason for this is that community pharmacists are more comfortable 
responding to ad-hoc requests for advice than in conducting formal MUR 
consultations, as suggested during previous observational research (294).   In one 
interview study of the effect of the MUR service on pharmacists’ professional 
status, pharmacists described MUR activities involving advice giving and using 
their knowledge of drug interactions as ‘just doing what we have always done’ 
(173).  Some expressed unease about financial incentives and felt uncomfortable 
asking patients to sign MUR forms which would be submitted for payment.  
Additionally, it was suggested by the authors that MURs create an artificial 
interaction, and that advice offered in these situations, rather than occurring 
spontaneously as part of the everyday exchanges which patients are used to 
experiencing, may be resisted.  However it could be that the development of these 
impromptu interactions into full MURs where appropriate, as in the case of the two 
participants described above, could be rewarding for both pharmacist and patient. 
 
8.2: dMUR DATA 
In this study, two-thirds of referred participants received a dMUR; more than twice 
that reported in a recent study of an e-referral system in North-East England (18).  
The higher completion rate in the current study may be because the researcher 
contacted all community pharmacists at 4 weeks post hospital referral to prompt 
completion of the dMUR.  Such an approach, whilst feasible in this study, is unlikely 
to be sustainable on scale-up when accounting for secondary care pharmacy staff 
workloads.  However, the ability to build a ‘prompt’ into an e-referral system may be 
a workable solution to help increase completion rates, and may allay concerns 
expressed during the hospital pharmacist focus group that some community 
pharmacists might not be ‘pro-active’ enough to follow up dMUR referrals (Section 
7.1.3).   
The most common reason for dMUR non-completion at 4 weeks was participants’ 
inability to visit the pharmacy, which tallies with data from semi-structured interviews, 
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and was also a barrier in the e-referral study referred to above (18).  This reinforces 
that poor mobility affecting the elderly post-discharge population, along with the 
complexity of providing domiciliary dMURs (see Section 8.3.2), is a major barrier to 
dMURs being conducted.   
Nearly one-third of participants also failed to receive a dMUR within 4 weeks as they 
were not contactable by the community pharmacy.  This issue was also found by the 
researchers evaluating the e-referral system.  The reasons for this are unclear, 
although within the study around one fifth of patients were re-admitted to hospital 
within four weeks of discharge, and through participant interviews it was apparent 
that patients had multiple appointments as part of their care package post discharge. 
It is therefore possible that patients may not have been at home at the times 
community pharmacists tried to contact them.  Alternative possibilities are that 
patients were not able to get to the phone in time due to mobility issues, were 
unfamiliar with the community pharmacy’s telephone number and so did not answer, 
or that the contact details on the referral form were incorrect (18). 
The same number of participants had not received their dMUR as the referral had 
never been received by the pharmacist responsible for conducting dMURs within 
that pharmacy.  This reinforces that faxed referrals used in this study were not ideal, 
and additionally they do not have the same facility for audit trail as does an e-referral 
system, which allows for tracking of referrals (310). 
Most commonly, dMUR interventions in this study involved the provision of 
information or adherence aids to improve patient understanding of their medication 
and how to use it in the most effective, convenient and safe way.  This type of 
medicine support is in line with the ethos of the MUR service as a whole.  However, 
20% of dMURs involved intervention to reconcile unintentional discrepancies 
between discharge information and medications subsequently taken by the patient 
or prescriptions issued by the GP surgery.  This is lower than in previous studies of 
medication discrepancies following discharge, although overall numbers in this study 
are too small to draw any conclusions (82,311).  Reporting discrepancies was not a 
specific requirement of community pharmacists in the current study as this was not 
a pre-defined outcome measure.  It is possible that other discrepancies were present 
but were not reported to the researcher by community pharmacists, possibly 
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because they were resolved outside of the dMUR consultation, or because of their 
minor nature (for example ‘as required’ medicines that were no longer being taken).  
Consideration needs to be given as to whether medication discrepancies would be 
a useful outcome measure for future studies of the dMUR service. 
The timely information transfer from hospital to community pharmacy in this study 
allowed community pharmacists to act on the discrepancies identified before the 
patient’s GP, thereby enhancing standards of care.  All interventions of this nature 
were given a score of at least 4 (significant and resulting in an improvement in the 
standard of care) by the Delphi panel.   
Following the Delphi review, almost 60% of interventions made during dMURs were 
deemed to improve patient care.  In addition to interventions to resolve medication 
discrepancies, other intervention types assessed as improving quality of care (Table 
7.13) could be broadly categorised into three groups.  These included interventions 
that were expected to increase adherence to treatment (such as provision of 
compliance aids or counselling on how to take medicines to reduce side effects or fit 
in with daily routines), lifestyle advice specific to clinical conditions diagnosed during 
the recent admission (for example diet and exercise advice to a patient with angina, 
or smoking cessation advice to a patient with COPD) and onward referral to another 
HCP where a significant issue with treatment was identified (such as hypotension in 
a patient whose admission had been related to this and bleeding in a patient recently 
discharged on warfarin and clopidogrel).  Interventions involving anticoagulant and 
cardiac medicines were always viewed as significant by the Delphi panel. 
Interventions made during dMURs that were assessed as not improving the quality 
of care included explanations of repeat prescription ordering systems, updating of 
community pharmacy records, explaining indications for single medicines which may 
not have been viewed as ‘essential’ by the panel (e.g. betahistine), removing items 
from MCAs to be dispensed separately (with free text comments indicating the view 
that this defeated the purpose of the MCA), and interventions which were viewed as 
constituting clinical advice that may not have been appropriate (for example 
recommending a steroid inhaler for a patient discharged from a first exacerbation of 
COPD).   Concerns have been raised in the past regarding inappropriate clinical 
recommendations made as a result of general MURs conducted in the absence of 
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sufficient clinical information (256,286).  This non-clinical remit may be harder than 
ever to adhere to during dMURs if community pharmacists are provided with more 
clinical information by hospitals, and highlights the importance of collaborative 
working between hospitals, community pharmacists and GP teams (including 
practice pharmacists), with each team member playing to their strengths.   
Although viewed as not improving the quality of care by the Delphi panel, it has 
already been discussed that improved patient knowledge of repeat ordering systems 
and accuracy of community pharmacy medication records may conceivably prevent 
DRPs in the future, by reducing the likelihood of patients running out of medicines 
or re-ordering medicines that have been stopped, and assisting with medicines 
reconciliation if a patient is readmitted to hospital (Section 8.1.1).   This highlights 
the difficulty of assessing outcomes using qualitative consensus methodology, as it 
is not possible to predict accurately what the outcome of a given intervention will 
actually be, and the outcome assigned will always be based on the subjective 
opinion of the panel.  However the methodology used in this study accounted for this 
as far as possible, by selecting a panel of experts with practice experience in the 
field in question, from both medical and pharmacy professions, and applying the 
Delphi process with due rigor.  Overall, the significance of the interventions as 
assigned by the Delphi panel in this study represents a ‘best estimate’ of their value. 
Assigning a monetary value to the interventions made by community pharmacists 
during this study appears to show a four-fold return on investment in the MUR 
service, even when using the most conservative estimate of value delivered per 
dMUR conducted (£112.53 of value set against the MUR fee of £28, Table 7.13).  
This figure does not, however, take account of hospital pharmacist time associated 
with patient recruitment, referral and follow-up.  If these costs are factored in, there 
is still a substantial net cost saving to the NHS, of £42.53-£184.53 per completed 
dMUR.   
Further savings could be realised if the dMUR uptake rate by eligible patients could 
be increased, and/or if referrals were managed by pharmacy support staff.  E-referral 
also has the potential to reduce costs due to the reduced time needed to make 
referrals, although in this case the initial outlay for the system needs to be factored 
in (18).  Preliminary work at SONT (Appendix 3) estimated that at least 5 potentially 
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eligible patients could be identified per day.  Experience during the recruitment 
phase of this study suggests that just over half of these would actually be eligible.  
This equates to at least 780 referrals per year if all eligible patients were referred.  If 
all these patients received a dMUR of the quality experienced in this study 
(producing £112.53 - £254.53 of ‘value’ as per Table 7.13, page 217), this would 
have an estimated net value of £33,173 - £143,933 in terms of improvements in the 
quality of patient care, after adjusting for hospital staff costs and MUR fees.  If these 
referrals were managed by a Band 5 pharmacy technician, the overall net cost 
saving to the NHS resulting from dMUR referrals from this one hospital Trust would 
be around £72.93 - £214.93 per patient, or £56,885 - £167,654 per annum.  This 
again represents a 4-fold return on investment for the NHS in terms of improved 
quality of patient care.   
It must be noted that these savings are not immediately recognisable and are 
estimates only, using the application of economic modelling to opinions of an expert 
panel as to the clinical significance of community pharmacists’ interventions.  
However, in comparison, the Welsh DMR has been estimated to provide a 3:1 return 
on investment as a result of avoided A&E attendances, hospital admissions and drug 
wastage (20).  Therefore, although the current study is small and the cost savings 
presented are only theoretical, it does seem to suggest that dMUR referrals could 
provide similar return on investment. 
 
 
8.3: MEDICINES SUPPORT REFERRAL SERVICE: BARRIERS AND 
FACILITATORS 
 
8.3.1: Participant Recruitment by Hospital Pharmacists  
Recruitment rates fell well short of those anticipated.  Focus group findings in 
addition to a wider survey identified a number of possible reasons, as well as 
potential solutions.  Perceptions of hospital pharmacists in this study support what 
has been published previously: that too much information at the point of discharge 
and the desire to get home quickly may limit patients’ receptivity to advice on 
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discharge (77,81).  Therefore, follow-up via a dMUR in a calmer environment could 
be beneficial.   
Hospital pharmacists also identified some general principles of hospital policy and 
procedure that could hinder transfer of medicines related care.  Key concerns 
related to poor discharge communication about medicines, the timeliness of 
information transfer and integration of medicines information with primary care 
records. These concerns reflect findings elsewhere as reported in Section 3.1.2 
(42,68,75,76,82,312). 
Poor or absent communication of medication changes on discharge summaries 
was identified by the majority of hospital pharmacists as a factor that needed to be 
improved in order for the dMUR referral service to be used effectively.  The lack of 
clarity in written discharge information was largely attributed to the electronic (e-) 
discharge system at SONT which did not allow automatic flagging of medicines 
discontinued.  It could be that if electronic transfer of discharge information to GP 
practices becomes routine, community pharmacies could also receive a copy of 
this information at the same time.  In fact, improvement to the e-discharge system 
so that good quality referrals were easier and quicker to make was the most 
frequently mentioned solution for the dMUR referral service.   
Electronic discharge information has been called for by community pharmacists for 
two decades, and e-referral to community pharmacy has subsequently been 
introduced in a number of areas of the UK, although it is far from becoming routine 
practice (120,121,299,313).    
The most clearly stated barrier to making dMUR referrals was a lack of time.  This 
has also been cited by others as a barrier to hospital pharmacists recruiting 
patients for post discharge referral (20,314).  During this study and elsewhere, it 
has been reported that it takes an average of 20 minutes to refer a patient using a 
paper/fax system (310).  This does not include the time taken to educate the 
patient and to gain consent for information to be shared between the hospital and 
the community pharmacy.  It has been suggested that referral times can be 
reduced substantially using an electronic system, which, as discussed above, is 
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something that the hospital pharmacists involved in this study would welcome 
(299). 
Lack of time to make dMUR referrals was linked with a lack of funding, meaning 
that other duties (which were funded) took priority for hospital pharmacists.  
Investing in hospital pharmacy staff was almost universally acknowledged as likely 
to make a substantial improvement to the dMUR referral service (equal to 
electronic transfer of information to community pharmacy).  It would be interesting 
to investigate whether the concept of payment for dMUR referrals would encourage 
NHS pharmacy managers to invest in more staff time to allow referrals to 
community pharmacy to become more prevalent.   
The need for increased staff was also found in a post discharge domiciliary service 
in Portsmouth (314).  Hospital staff resources are identified as both a barrier and a 
driving force to post-discharge referral by the RPS, which cites the example of a 
local commissioning for quality and innovation (CQUIN) indicator as one 
mechanism to support the creation of efficient and effective referrals from local 
hospitals (310).  However, as a CQUIN does not actually generate new money for 
a Trust, pharmacy managers would have to negotiate internally for additional 
investment to deliver on such a CQUIN. 
Hospital pharmacists also acknowledged that referring patients to community 
pharmacy was not ‘normal practice’ for them, with many admitting to forgetting to 
look out for patients to refer.   This indicates that shifts in culture and working 
practices are needed among hospital pharmacists if referral to community 
pharmacy is to become routine.  Integrating promotion of dMURs and the dMUR 
referral process into the established activities of hospital pharmacy, for example 
during routine discussions with patients regarding their medication, as well as 
greater promotion of dMURs to patients in the community, were identified as 
substantial facilitators to the referral service.  Previous research suggests that 
awareness and understanding of MURs in general (and dMURs in particular) 
among patients and the public is low (174,289,315).  It could be that increased 
awareness of the dMUR service among patients would mean greater acceptance 
towards referral. 
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A feeling of being distanced from community pharmacy services, and an 
uncertainty as to what actions community pharmacists would take as a result of 
their referral, was expressed by some hospital pharmacists.  It has been suggested 
elsewhere that a local ‘champion’ or project manager with protected time to 
facilitate the roll-out of a referral system and drive forward the necessary 
behavioural and process changes at the hospital end is an important factor for 
successful implementation (310).   Additionally, feedback on interventions made by 
community pharmacists as a result of the dMUR referral could reinforce the value 
of the service and recognise the hospital pharmacist’s contribution to ongoing care, 
which has been called for by others (17,20) .  It has also been shown that an 
opportunity for hospital pharmacy staff to shadow those involved in providing post 
discharge medication reviews can improve attitudes and increase the number of 
referrals (314). 
Cardiac patients, patients prescribed new medication during hospital admission 
and patients using high risk medications such as anticoagulants were identified by 
focus group participants as those most likely to benefit from dMUR referral.  These 
patient groups are already targeted nationally by the MUR service (9).  However 
there was some doubt as to how individual ward pharmacists would cope with the 
additional task of selecting such specific patient groups for referral.  Questionnaire 
results also revealed a difference in opinion of whether to focus on specific patient 
groups.  Therefore the decision to specify a broad target group of patients over the 
age of 65 who, in the pharmacists’ professional judgement could benefit from a 
dMUR (e.g. multiple medicine changes), appears appropriate.  It has been 
suggested during previous quasi-experimental research and service evaluation that 
the clinical judgement of ward pharmacists as to which patients are at risk of DRPs 
post-discharge could be a valid way of identifying patients who can benefit from 
pharmaceutical intervention on transfer of care (18,122,150).  This can simplify the 
recruitment process by removing the need for specific lists of criteria or risk-scoring 
mechanisms. 
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8.3.2: Community Pharmacist dMUR Provision 
There was an almost universal willingness (95% of those approached) of community 
pharmacists to be involved in this study.  They held positive opinions of the dMUR 
service and could see the benefit to patients regarding identification of medicine non-
adherence and avoidance of medicine errors. These positive attitudes mirror those 
of the hospital pharmacists involved in the study.  
However, running the current service posed challenges to community pharmacists.  
Around a third of questionnaire respondents felt that it was hard to engage patients 
in having dMURs and this was exemplified by patients not attending appointments 
or reporting themselves unable to attend when contacted to arrange the dMUR.   
In particular, the difficulties perceived in providing dMURs other than face-to-face in 
the pharmacy limited the scope of the project, with only 1 in 7 offering domiciliary 
visits.  Whether this was a logistical inability to do so or uncertainty as to whether 
permission would be granted by the primary care organisation was unclear.   
However, responses did indicate some degree of confusion around the procedure 
required to obtain permission to carry out telephone and domiciliary MURs.  This is 
possibly due to these pharmacists not having performed such MURs previously, as 
reports indicate that the majority of MURs take place in the pharmacy 
(102,286,316,317). 
Contractually, a pharmacist has to gain approval by the local NHS England Team 
each time they wish to provide the MUR service at another location, or by 
telephone (168).  Additionally, NHS England requires that any pharmacist 
undertaking an MUR off the pharmacy premises must have obtained and supplied 
to them an enhanced Disclosure and Barring Service (DBS) certificate before 
providing the service.  These administrative burdens placed on pharmacists could 
be seen as barriers to extending this service beyond the confines of the pharmacy.  
Legally, a community pharmacist can only leave the premises unsupervised for a 
maximum of two hours per day, during which time no prescription medicines may 
be handed out (even if assembled and checked) or pharmacy medicines sold 
(318).  Although this should be ample time to provide a domiciliary dMUR, previous 
research has shown community pharmacists may feel professionally uncomfortable 
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in leaving the premises unsupervised (319).   Additionally, being absent from the 
premises and therefore unable to hand out dispensed medicines or sell pharmacy 
medicines may be seen as potentially damaging to business.  Furthermore, the 
associated costs, for example initial outlay for DBS clearance (although this should 
be reimbursed by the local NHS England Team), and travel costs to a person’s 
home each time they provide off-site dMURs, may also be off-putting for 
community pharmacists.   
One pharmacist in this study did obtain the necessary permissions and conducted 
a domiciliary dMUR.  Another attempted to obtain DBS clearance, but the length of 
the process was prohibitive and in the end this participant did not receive a dMUR.  
Further exploration of the specific barriers to domiciliary MURs as perceived by 
community pharmacists would be valuable in order to understand fully the 
difficulties involved and propose solutions.  This is particularly relevant for the 
patient population under study here, as so many reported problems in accessing 
their community pharmacy for a dMUR.   
Nearly half of community pharmacists felt that dMURs were more complex than 
other types of MUR.  Given the number of medication changes which take place for 
older people during a hospital admission this is not surprising (77,104).  It might 
also be expected that reviews involving these patients would result in a longer 
length of time needed to perform a dMUR compared to a ‘standard’ MUR, which 
under the current system for remuneration and pressures faced by community 
pharmacists, may be a restriction on their provision.  As discussed in Section 8.1.2, 
whilst taking longer than a ‘standard’ MUR, the majority of dMURs in this study 
seem to have been completed more quickly than other post-discharge medication 
reviews.  It may be possible that the referrals from the hospital provided a focus for 
the dMURs and allowed the pharmacist to spend less time ‘fact finding’ with 
patients, although this is unsubstantiated.   
Community pharmacists in this study wanted more patients referred (with a fuller 
data set) but reported performing few dMURs outside the study.  Reasons for this 
given by community pharmacists during previous qualitative research include not 
knowing patients have been in hospital, no access to discharge summaries and 
patients being housebound (165,320).  The first two of these barriers are 
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addressed by referral systems such as the one presented in this thesis, and the 
need to improve provision of the service to housebound patients is one of the main 
findings of this research.   
The difficulties in providing this type of service have also been observed in studies 
based in Northumbria and Kent, where almost 30 and 65% of people respectively 
were prevented from accessing a dMUR due to mobility or poor health (306,307).  
The fact that these patients were housebound may in itself indicate that they are 
frailer and more vulnerable, and therefore more in need of the support a dMUR 
may provide.   
All patients but one approached during recruitment were able to nominate one 
particular community pharmacy to provide their dMUR. The results of this research 
also concur with other recently published questionnaire data indicating that 95.6% 
of medical inpatients with medication changes used the same pharmacy regularly 
(89).  This loyalty can be viewed positively as data suggests patient loyalty is key 
to the successful transfer of information between hospital and community 
pharmacy (120,123,124).   
 
8.4: OVERALL DISCUSSION: IDENTIFYING THE WAY FORWARD 
It has been suggested that, because of the link between DRPs on transfer or care 
and adverse clinical outcomes, pharmacists may be the preferred HCP to intervene 
and reduce the risks involved in care transitions (159).  Since work on this PhD 
project began in 2012, there has been a sharp increase in the volume of research 
and recommendations for practice published on the role of pharmacists in 
transitions of care and supporting medicines adherence in older people generally.   
Evaluating the dMUR referral service against the findings and recommendations 
from the published literature indicates that the intervention incorporates many of 
the components necessary for a positive effect on patient outcomes, and also 
identifies other aspects which may increase its effectiveness.   
For example, a systematic review published by Nazar et al in 2015 included 14 
controlled trials involving community pharmacists in the transition from secondary 
to primary care (160).  The authors concluded that medication errors following 
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discharge can be reduced by interventions involving community pharmacists; 
however impact on other outcomes such as readmission, mortality, medication 
adherence, QoL and patient satisfaction was not significant.  All the studies 
included in that review differed in important ways from this PhD study: none 
evaluated dMURs, most did not focus on older patients and two excluded them 
entirely.  This study appears to be the first to investigate the effects of this 
intervention in this patient group. 
Ten of the 14 trials involved in Nazar’s review involved either additional training or 
funding for community pharmacists providing the interventions, at least eight 
involved domiciliary visits from the community pharmacist, and six included 
repeated contacts between community pharmacists and patients.  All of these 
factors have been identified by other researchers as integral to successful 
interventions to support transfer of medicines related care and/or medication 
adherence in the elderly (135,298,321). However, none of these key factors were 
possible within the constraints of the dMUR referral service studied here, which 
may have limited its effectiveness.  Therefore, additional training, support for 
domiciliary visits and funding to provide follow-up appointments are all 
recommendations arising from this PhD research to enhance the dMUR service. 
Other components of pharmacist interventions from continuity of care programmes 
that have been shown to improve clinical outcomes include combining 
interventions in hospital and primary care, sharing of patient information between 
the two sectors, close collaboration with other HCPs  and tailoring of interventions, 
for instance by assessing individual patient knowledge of prescribed medications 
and adherence  (159,321).   A successful review should also include the 
involvement of carers (135,298).   The extent to which these factors were 
successfully applied in the intervention studied in this thesis is discussed below. 
Feedback from hospital pharmacists involved in this study indicated that for a 
referral service to work, it needs to be quick, simple and regularly promoted until it 
became part of routine practice.  It would be integrated with the hospital’s e-
discharge system and staff would be supported with adequate time to ensure that 
patients are properly engaged and all necessary information regarding medicine 
changes are included.  These findings are supported by the guidelines given in the 
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RPS toolkit on post discharge referral (310).  Giving community pharmacists 
access to the full discharge summary (or suitably targeted fields as made possible 
by PharmOutcomes) would allow them to gain an understanding of the clinical and 
social follow-up planned for the patient and allow them to tailor their input 
accordingly. 
However the provision of more detailed information from the hospital would only 
improve the quality of the intervention if it was used effectively by community 
pharmacists.  Previous research on the content of MURs in general, and on other 
post-discharge medication reviews by community pharmacists, has indicated that 
they tend to follow a set formula of closed questions and information delivery in an 
instructional manner, circumventing more complex or indeterminate issues if these 
arise (288,294,315,322,323).   This may result in consultations becoming 
‘routinised’ and leaves little opportunity to address the patient’s own specific 
agenda.  Descriptions of dMUR interactions by participants interviewed in the 
current study suggested that the formulaic approach still tends to be the norm, 
although more patient focussed experiences were also described.  It has 
previously been suggested that pharmacists can have a greater impact on patient 
satisfaction through greater interpersonal skills than through the provision of new 
services, and this is important in building concordant dMUR consultations (308).  It 
has also been suggested that community pharmacists’ consultation skills need to 
be developed if the MUR is to meet its intended aims, and this recommendation 
may be even more important for dMURs, given the complexities of medication 
changes which may occur on transfer of care (294).   
The shortfall between the current MUR service and the needs of some patients 
was highlighted in Richard Murray’s ‘Review of Community Pharmacy Clinical 
Services’, published in December 2016 (324).   Murray recommended that MURs 
should be redesigned to include on-going monitoring and regular follow-up with 
patients, ensuring that they are an integrated part of a multifaceted approach to 
helping people with LTC that includes medicines optimisation, providing advice and 
helping people stay well.  Furthermore, the report stated that MURs should evolve 
into full clinical medication reviews, utilising independent prescribing as part of the 
care pathway.  For these to be safe and effective they would require access to a 
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patient’s full medical record.  Transfer of care and referral schemes to support 
dMUR provision were specifically advocated by the Murray review. 
However by December 2017 there appeared to have been little progress towards 
realising Murray’s aspirations (325).  Many of the barriers to the development of 
clinical roles in community pharmacy identified in the Murray review are similar to 
those identified by this PhD research: lack of integration of community pharmacy 
with other parts of the NHS, low public awareness and expectation, contractual and 
financial constraints, workload issues, variation in development and use of skill mix 
and a lack of professional and clinical confidence.  Solutions proposed are also 
similar: incentives to encourage better working relationships with GPs and other 
HCPs, better access to clinical records, public awareness campaigns, financial 
incentives for provision of enhanced clinical services, support for pharmacy 
professionals to develop improved consultation skills, a training and mentoring 
framework to support development of enhanced clinical skills, and development of 
the technician workforce to free up pharmacist capacity. 
In return for making referrals and to sustain the momentum of referral systems, 
hospital pharmacists in this study and elsewhere have requested feedback from 
community pharmacists as to the outcomes of the dMUR (17,20,314). This could 
include further requests for clarification of information or suggestions for patient 
management by community pharmacists which would fulfil the two-way 
communication suggested as necessary for a beneficial medication review. 
This study achieved a lower recruitment rate than many previous studies of post 
discharge pharmacist follow-up (see Section 8.5).  However, a recent RCT 
involving faxing of discharge prescriptions from hospital to community pharmacy, 
using a similar recruitment process to this study, reported recruitment of 23% of 
patients identified by ward pharmacists (311).  This similarly low recruitment rate 
demonstrates that recruitment of older patients from English hospital wards for 
post-discharge follow-up by their community pharmacist can be problematic.  Lack 
of perceived benefit, poor health and mobility problems have been cited previously 
as common barriers to recruitment of elderly patients to research (176,177).  All of 
these barriers were present in this PhD study, where the main reasons for 
exclusion were that patients were not in charge of their own medication at home, or 
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expected to be housebound in the weeks following discharge and therefore unable 
to attend for a dMUR.  These patients represent some of the most vulnerable to 
DRPs and therefore may have the most to gain from the service.  Consideration 
needs to be given as to how the dMUR referral service might be extended to 
include such patients. 
The PPI group for this study reviewed both the participant information and consent 
forms and agreed they provided a reasonable compromise between readability and 
providing all the necessary information.  However some potential participants who 
cited an unwillingness to become involved in research as their reason for refusal 
may have been put off by the volume of information presented to them and indeed 
some patients struggled to read it at all.  Burdensome recruitment processes have 
been cited by previous researchers in this field as a reason for low recruitment 
rates and it may be that consideration needs to be given to how recruitment 
processes could be simplified for elderly patients, particularly in the hospital setting 
where potential participants have so much else to deal with (129,133).   
It must be remembered that even if all eligible patients were to receive a dMUR, a 
large proportion of patients who could potentially benefit will still be excluded, 
either because they are housebound or have carers managing their medication.  
The recommendation that post-discharge consultations between patients and 
community pharmacists should be conducted at home echoes a recurring theme 
throughout this thesis (321).  A study of home medication reviews conducted by 
community pharmacists in the Netherlands suggested that patient interviews at 
home may elicit more and other DRPs to those conducted in a community 
pharmacy, with a possible explanation being that patients feel more comfortable at 
home and therefore are more likely to share their experiences and concerns about 
their medicines (326).  Furthermore, all medicines are available at home, whereas 
patients invited to the pharmacy might forget to bring some of their medicines, 
especially those that are used intermittently.  The authors also suggest that certain 
medication-risk factors, for example, lack of medication administration routine, 
multiple storage locations, hoarding and medication storage conditions may only be 
identified by home visits.  The recent International Pharmaceutical Federation (FIP) 
Report, Use of Medicines by the Elderly: The Role of Pharmacy in Promoting 
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Adherence also highlights the advantages of medication review occurring in the 
patient’s own home, in terms of the level of detail that can be reached regarding 
problems that patients encounter with their medicines, such as polypharmacy and 
interactions, and the opportunity to assess the usage of over-the-counter 
medicines and alternative medicines (298). 
Therefore if the current study had involved domiciliary dMURs as routine, the 
number and significance of the interventions made may have been greater, 
particularly as the elderly housebound population may be frailer and at greater risk 
of DRPs compared to more mobile patients (327).  However as acknowledged by 
the FIP, home medication reviews are time consuming for pharmacists and divert 
them from their dispensing workload, and remuneration arrangements are often 
cumbersome or inadequate (298).   
Workload pressures which may impact on the provision of the dMUR service by 
community pharmacy could be addressed by taking a team approach to actioning 
the referral and completing the dMUR.  For example support staff could be 
involved in ensuring faxed referrals are not ignored or lost, booking dMUR 
appointments, ‘chasing up’ patients who are difficult to get hold of, completing 
accuracy checks of prescriptions thereby allowing more time for the pharmacist to 
complete the dMUR and explaining the project to new employee or locum 
pharmacists. 
A pilot study of a domiciliary MUR service across the Nottinghamshire and 
Derbyshire region indicated that the service was feasible, although less than a 
quarter of pharmacies invited to take part actually did so (316).  This was despite 
being paid £56 per domiciliary MUR in addition to the £28 MUR fee, which 
indicates that there are factors other than remuneration limiting the provision of 
such services.  The authors suggest that pharmacies may not yet have 
reconfigured levels of support or organisational infrastructure to comfortably 
undertake such services.  The requirement for community pharmacies to be under 
the direct supervision of a pharmacist in order to hand out prescriptions or sell 
pharmacy only medicines is likely to be a barrier in this respect.  Additionally, 
experience in this PhD study suggests that some community pharmacists may be 
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put off by the process required to obtain permission to conduct a dMUR off 
premises.   
Self-assessment by the pharmacists in the domiciliary MUR study, using the RiO 
score, suggested that over one-third of the MURs had contributed towards 
preventing a possible or likely emergency hospital admission or readmission. 
Additionally, over one quarter had resulted in the removal of unwanted or out-of-
date medicines from the patient’s home.  This contribution to patient safety is 
unlikely to have been possible during an MUR conducted in the pharmacy, and 
may be relevant to an even greater extent when the patient has recently been in 
hospital, due to the frequency of medication changes which occur in this setting.  
This was demonstrated by the Portsmouth Hospital Discharge Medicine Review 
Service, where hospital pharmacy staff identified suitable patients for a visit by a 
domiciliary pharmacist within seven days of discharge to conduct an MUR style 
consultation and medicines cabinet check, with follow-up visits at five and 13 
weeks (328).  Service evaluation indicated that around half the patients visited had 
obsolete medicines requiring removal.  
Around half the community pharmacists involved in this study were able to offer 
telephone dMURs, whereas only one in seven could offer domiciliary visits.  There 
were therefore some patients approached for participation who, although unable to 
visit their community pharmacy for a dMUR or receive a domiciliary visit, would 
have been able to access the service via telephone.  However no participants were 
recruited to the study on this basis, and in fact three patients refused to take part if 
a telephone dMUR would be their only option.  Other patients were excluded 
because they felt unable to manage a telephone MUR (either because of cognitive 
or hearing difficulty).  Unfortunately the exact number of patients this affected was 
not recorded separately from the umbrella group of those who were excluded 
because poor mobility prevented them from visiting the pharmacy in person. 
The resistance by potential participants to receiving dMUR by telephone was 
predicted by the PPI group for this study, and it has also been found that nearly 
half of respondents to a public survey would be uncertain or unwilling to receive 
telephone follow-up from their pharmacist (174).   This is in contrast to two large 
scale evaluations of community pharmacy services which have experienced 
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success with using telephone follow-up: the Wales DWR service and the NMS 
(20,292).  The NMS evaluation found that the majority of consultations were carried 
out by telephone (292).  Face-to-face appointments were described as difficult to 
organise or arrange because patients often did not attend and this was seen as 
potentially disruptive to workflow.  However it was also acknowledged that 
telephone follow-up was not appropriate for all patients, for example where 
checking of inhaler technique or demonstration of how to take a medicine was 
required.  Additionally, the NMS is different to the dMUR as it involves discussion 
regarding one medicine only.  It cannot be assumed that telephone follow-up will 
be appropriate or acceptable to patients who require more complex interactions 
relating to their entire medication regimen.   
The DMR is more similar to the dMUR as it involves follow-up of the patient’s post 
discharge medication as a whole.  The DMR evaluation also revealed that 
telephone consultation was the most common way of completing both part 1 
(medicines reconciliation) and part 2 (follow-up discussion) part of the service (20).  
However, most community pharmacists who were interviewed as part of the 
evaluation reported that they tried to do the follow-up face-to-face as this was felt 
to be the better method to discuss adherence issues.  Time, availability and 
financial constraints were seen as the barriers to this.  It could be that, if more 
support was available for pharmacists to conduct domiciliary DMRs the service 
would have been found to be even more effective. 
It should also be noted that the DMR service remunerates pharmacists for two 
contacts with the patient or their carer, whilst the dMUR is assumed to be 
completed in one consultation and may be with the patient only.  Two telephone 
consultations may allow for clarification of points which were misunderstood or 
forgotten following the first consultation, and the discussion may be handed over to 
the carer if the patient has difficulty or is unwilling to use the telephone.  
Importantly, this PhD research targets older patients, who may have specific 
difficulties (such as hearing or cognitive impairment) which may limit their ability to 
participate in an effective telephone review. 
Previous studies evaluating pharmacist telephone follow-up post-discharge have 
shown inconsistent effects on outcomes (77,131,148,200,329).  It has been 
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suggested previously that face-to-face consultations with a pharmacist post-
discharge may offer additional benefits over telephone interventions due to the use 
of nonverbal communication to assess for understanding, and the ability to review 
correct use of medical devices such as inhalers and injections (330). 
Evidence of the need for caution and careful patient selection when conducting 
telephone medication review for complex elderly patients comes from an RCT in 
the USA which evaluated the effectiveness of a community pharmacy telephone 
medication therapy management (MTM) service on reducing hospitalisations 
among home health patients (331).  The average age of participants (n=895) was 
73 and they were taking an average of 14 medicines.  The results showed no 
significant difference in 60-day hospital admissions between intervention and 
control group (20% vs 23%, p=0.19).  However, when participants were evaluated 
based on their calculated risk of hospitalisation, those in the lowest-risk 
intervention group were significantly more likely to remain out of the hospital at 60 
days (5% vs 16%, p=0.01).  The authors suggest that these lower risk patients 
were better able to receive and retain guidance from a pharmacist over the phone 
and that face-to-face medication therapy management would better help the 
higher-risk patients.  This subgroup may require more intensive assistance to take 
medication, and a telephonic MTM program may not be sufﬁcient to meet their 
needs.  The 30-day readmission rate in this PhD study was 19%, which, as 
discussed in Section 7.4.2, is higher than national figures and is comparable to the 
60 day admission rate in the MTM study.  Participants in this study were also older 
(mean age 78) than the MTM patients.  These factors suggest that participants in 
the current study were high risk for readmission, and may not have benefited from 
telephone review of their medicines in the same way as a lower risk population. 
Involvement of carers in the transfer of care intervention in this PhD study was 
limited by the prohibition on conducting dMURs directly with them.   Advice given 
during a dMUR may arguably be even more important for patients who require 
carer support with their medicines, as they may be frailer and therefore more 
vulnerable to DRPs.  The carer may also not have been present in the hospital at 
the point of the changes to the patient’s medication being made or at the time 
when the hospital pharmacist was available for counselling, so may have missed 
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out on the chance to obtain advice.  In a 1998 UK study of pharmacy discharge 
counselling, the authors raised a concern regarding the low level of counselling of 
relatives, many of whom were involved in medicines management at home (125).  
In that study, the relatives of 6% of patients were counselled, whereas follow-up 
interviews indicated that up to 30% could have benefitted from medication 
counselling of their relatives.  More recently, a qualitative study involving interviews 
with seven older people and 12 carers revealed that, despite the carers assuming 
a significant responsibility for the administration of medicines, they were often 
disappointed with the lack of clear verbal or written information given regarding 
discharge medicines (86).  This sometimes led to incorrect use of medicine at 
home and confusion and anxiety for both the older people and their carers.   
The importance of involving carers in the discharge process, including medication 
management, has been emphasised by a number of guidance documents.  Moving 
patients, Moving Medicines, Moving Safely advised that support should be given to 
‘individuals and their carers’ who require help to develop the knowledge, skills and 
confidence to care for themselves and their condition effectively (76).  Similarly, 
one of the four key principles laid out by the RPS transfer of care guidance is that 
‘patients or their carers or advocates’ should be encouraged to be active partners 
in managing their medicines when they move, and know in plain terms why, when 
and what medicines they are taking (110).   
Since the commencement of this research, NICE has recommended that carers 
and all health and social care practitioners involved in someone's move between 
hospital and home are in regular contact with each other to ensure the transition is 
coordinated and all arrangements are in place (111).  Additionally, the FIP report 
makes repeated reference to the role of carers in supporting medication adherence 
in the elderly and indicates that carers should be included as appropriate in 
decision making, education and counselling and follow-up regarding medicines use 
(298).  The dMUR referral service could be seen to fit neatly into this guidance, if it 
were not for the exclusion of carers from receiving a dMUR on behalf of the person 
they are caring for.   It is interesting to note that over half the patients in the 
domiciliary MUR study received care from family, friends or another informal carer 
(316).  The extent to which these carers provided support with medication 
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management is not reported; neither is the degree to which carers participated in 
the MUR.  The question of how to manage dMUR provision to elderly housebound 
patients who have carers managing their medication therefore remains.  Allowing 
proxy dMURs with carers, either with the patient’s consent or directly if the carer 
has power of attorney for health, could be a solution. 
An important recent study in the context of this research is the TransitionRx study, 
based in Ohio, USA (202).  The intervention consisted of a community pharmacy 
transition of care programme following faxed referral from two local hospitals.  
Community pharmacists called the patient to make an appointment at the 
pharmacy, to take place within 7 days of discharge, for a comprehensive 
medication review including self-management advice as well as written materials to 
take away.  Telephone follow-up was provided two weeks later.  Participants were 
on average younger than in this PhD study at around 66 years, but polypharmacy 
was even more prevalent (average of 10-11 medicines per participant). 
TransitionRx found that emergency readmissions were significantly lower in the 
intervention group (6.9% versus 20%, p=0.019).  However, when interpreting these 
results it is important to note that TransitionRx was not an RCT.  Participants were 
assigned to study groups based on their own preferences and abilities – patients 
who felt they would be unable to attend the pharmacy were assigned to the control 
group and those who were uncontactable following discharge or did not attend their 
appointment at the pharmacy were reassigned to the control group.  This may have 
led to important differences between groups as intervention group patients may 
have been more able and pro-active in managing their medication and health and 
therefore at lower risk of readmission than the control group, which in addition 
contained all participants who were housebound (and potentially more frail).  
However the authors do point out that their intervention group had statistically more 
chronic conditions than the control group, which in itself made this group high risk 
for readmission. 
Other key differences exist between TransitionRx and the present study which may 
explain the success of the American intervention.  Community pharmacists 
partaking in TransitionRx were already trained to provide comprehensive 
medicines management services as part of their routine work and also received 
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additional training on clinical practice guidelines for the conditions targeted by the 
intervention (congestive cardiac failure, COPD and pneumonia), and on how to 
refer patients for social support.  Appointments with the pharmacist took place 
within a week of discharge (compared to 4 weeks for a dMUR) and lasted 30-45 
minutes (compared to the majority lasting less than 20 minutes in this study).  
Pharmacists made an average of seven interventions per patient, five more than 
were made during the average dMUR in this study.  Finally, the additional two-
week follow-up telephone call may have increased the effectiveness of the 
intervention by reinforcing initial advice and addressing any new problems that had 
arisen.   
A 2017 quasi-experimental study of collaborative medicines management on 
transfer of care by hospital and community pharmacists in Hawaii also provided 
special training for participating pharmacists (332).  Community pharmacists 
worked with patients for up to a year after discharge and also engaged with the 
patients’ physicians.  The researchers estimated a 36.5% lower medication related 
admission rate of patients aged >65 at hospitals providing the intervention 
compared to those which did not, representing a 2.6:1 return on investment.  
Again, key aspects which were not present in this PhD study include additional 
training for community pharmacists, repeated follow-up and collaboration with other 
professionals, which may contribute to enhancing the dMUR service. 
Recent research has also been conducted in the UK to evaluate hospital initiated 
pharmaceutical transfer of care interventions for older patients.  A prospective 
cohort study published in 2014 implemented person centred pharmaceutical care 
bundles for patients who were socially isolated and/or prescribed high-risk 
medicines on an older people’s medical ward (102).  Patients discharged from the 
intervention ward were offered a referral to their community pharmacy for NMS or 
dMUR if they met the eligibility criteria; patients who could not receive the service 
because they were housebound were offered the same services delivered by the 
hospital pharmacy team.  An average of 18 patients per month were identified for 
community pharmacy referral, and only 17% of these stated during admission that 
they would be unable to attend due to being housebound.  Unfortunately, the 
actual uptake of post discharge services from community pharmacies was not 
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studied.  The authors state that 90% of hospital pharmacy follow-up was possible 
by telephone, which, together with the positive results of the last study discussed, 
is at odds with the hypothesis generated by this PhD project that pharmacy post-
discharge follow-up of older people by telephone may not be appropriate.  
Telephone calls were reported to last only 5 minutes so it might be that patients 
followed up by telephone had relatively simple medication related needs.  Home 
visits lasted approximately 20 minutes plus travel time, which is similar to dMUR 
consultations in this PhD study.  During the intervention period, the emergency 
readmission rate was significantly lower on the intervention ward (17% vs 22%, 
p<0.05) than on the control ward, although the authors caution that the study was 
not powered to detect this difference.  These readmission rates are similar to those 
found in an evaluation of the Leeds IMPACT project where hospital pharmacy 
liaised with community pharmacy at transition of care for patients admitted to care 
of the elderly wards who were deemed at high risk of DRP (333).   
Emergency readmission rates in the UK studies mentioned above, which involved 
similar populations to this PhD study, are similar to the readmission rates reported 
here (102,333).  The observed reduction in readmissions in these other studies, 
although neither were suitably powered RCTs, is encouraging.  The effect sizes 
observed could be used as the basis of a power calculation for a future RCT of 
dMUR referral.  Possible differences between groups in the current study in the 
length of readmissions, as well as A&E visit rates, adherence scores and self-
reported physical health at 6 months also warrant further investigation.  
Additionally, the fact that no preventable medication related readmissions were 
observed among patients who had received a dMUR is an encouraging finding of 
this research.  Although this observation cannot be said to be causative, the 
relationship between dMURs and preventable medication related readmissions 
should be researched further. 
A 2017 RCT studying the effect of faxing discharge letters from an English hospital 
pharmacy to patients’ community pharmacies found that the number of medication 
discrepancies in GP records and patient’s descriptions of their medication 
regimens were significantly decreased in the intervention group (311).  In that 
study discrepancies were detected in the control group in 42% of patient reports 
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and in 36% of GP records, whereas interventions to correct discrepancies of either 
type were reported for 20% of dMURs in this PhD study.  As community 
pharmacists in the present study were not requested to report medicines 
discrepancies specifically, it could be that other discrepancies were identified but 
were resolved separately to the dMUR and as such were not reported.  It is also 
possible that other discrepancies were present but were not resolved by the 
community pharmacists – in the previous study, discrepancies were still present in 
19% of intervention group patient reports and 27% of these patients’ GP records at 
3-week follow-up with the researcher.  Although community pharmacists in the 
previous study were told that they could use the discharge letters to facilitate 
dMURs, no participants had received a dMUR by follow-up.  Suggested reasons 
for this included patients being housebound and the fact that dMURs may still have 
been conducted after this time.  This reinforces the need for better provision of the 
service to housebound patients and the importance of early follow-up by the 
community pharmacist, even if the full dMUR consultation cannot take place until a 
later time.  It would have been interesting to see if the residual rate of 
discrepancies in the intervention group could have been reduced further by a 
dMUR consultation. 
 
8.5: LIMITATIONS 
This work is limited by the small-scale nature of the study involving one hospital and 
the associated community pharmacists.  This means that findings cannot be 
generalised to other settings.  However this was not the purpose of this study, which 
was designed to assess the feasibility of the dMUR referral service and the chosen 
outcome measures and data collection tools, as well as identify ways in which the 
service could be improved, in preparation for a future RCT, the results of which would 
be generalisable.   
Less than one in five patients identified as potentially eligible for the dMUR referral 
service were actually recruited to this study.  Previous RCTs of post discharge 
pharmacist follow-up of older patients have reported recruitment rates ranging from 
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23% to 83% (126-129,131-134,311).  The reasons for the low recruitment rate in 
this study are multifactorial and are discussed below. 
During the study, the researcher was only able to dedicate approximately one hour 
each working day to recruiting patients.  This lead to over a quarter of potential 
participants being discharged either before approach by the researcher or before the 
researcher could return following the initial approach.  A bid for funding to allow more 
time to be dedicated to the recruitment process was unsuccessful. 
Although it was originally intended that ward based pharmacy technicians would be 
involved in identifying and referring patients during this study, this was not possible 
due to shortages of ward based technicians and other demands on their time.  This 
is unfortunate as it has been shown that pharmacy technicians can be successfully 
involved in post-discharge referral services (17,328). 
8.5.1: Rate of Ineligibility of Patients Identified 
Just over 40% of the patients identified to the researcher were ineligible for the 
study for reasons other than early discharge or not fitting the age criteria. This falls 
within the upper end of the range found by a systematic review of RCTs involving 
older people published in the journal of the BGS, where exclusion ranged from 
3.4% to 49% (176).   
The most common reason for ineligibility in this study, affecting nearly one-third of 
patients excluded, was that they were not expected to manage their own 
medication on discharge from hospital, but would be assisted by a formal or 
informal carer.  This was unanticipated, as ward pharmacists were asked only to 
refer those patients who they would expect to be self-medicating at home, and is 
also higher than the 8% of patients who were excluded for this reason in the 
Northumbria project (307).  This may reflect that ward pharmacists sometimes find 
it difficult to ascertain whether or not a patient manages their own medications at 
home, or patients’ circumstances change during their admission.   
Being housebound was the second most common reason for patients being 
excluded from this study, and is discussed extensively in other parts of this thesis.  
Almost the same number were not well enough to engage in discussion with the 
researcher regarding the study, either because of the severity of their medical 
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condition or their cognitive impairment, which may have been acute or chronic.  It 
seems unlikely that these patients would have been able to attend the community 
pharmacy in the first few weeks after discharge, which begs the question what, if 
any, alternative support they may have received with their medication.  It may be 
that these patients would be more appropriately screened for post discharge 
medicines support in primary care post discharge, when their clinical status and 
home circumstances are more certain, for example by pharmacists based within 
GP surgeries, in line with the ethos of the CQC report Managing patients’ 
medicines after discharge from hospital (68). 
Just over one in 10 excluded patients were unable to enter the study because they 
were being discharged to a residence outside the study’s catchment area (either 
their own home or that of a relative with whom they were moving in following their 
hospital stay).  As the community pharmacy who would be continuing the patient’s 
supply of medication was not signed up to receive referrals in these cases, the 
patients had to be excluded.   
8.5.2: Rate of Refusal of Potential Participants  
The refusal rate of patients fully screened by the researcher was 32.3%, which falls 
within the range found by studies included in the BGS review, where refusal rates 
of up to 54% were reported, although typical rates were found to be 12-15% (176).  
The relatively high refusal rate in this study may reflect that patients were being 
recruited from the hospital environment and had recently been acutely unwell, 
whereas none of the studies in the BGS review recruited from the acute sector.   
In terms of patients who were eligible to participate in the study, 54.5% refused.  
This is higher than in an observational study evaluating the identification of post-
discharge DRP among older patients by community pharmacists in the 
Netherlands, which reported a 31.5% refusal rate of eligible patients (334).  The 
most common reason for refusal was that patients felt ‘too sick’ to participate.  In 
that study, community pharmacists were able to provide home visits where 
necessary, which might explain why the refusal rate was lower than in this PhD 
study.  Additionally, participation in an observational study may have been viewed 
as less off-putting than a randomised controlled study such as this one. 
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In order to plan future work on both the referral service itself and the study of 
medicines support on transfer of care for older patients in general, it was desirable 
to separate refusals due to a reluctance to get involved with research from those 
that were because of the dMUR service itself.  One in five eligible patients cited an 
unwillingness to be involved in research as the primary reason for their refusal to 
take part in this study.  A similar number gave their age or state of health as the 
main barrier to their participation, with one in six citing time or work constraints.  
These patients may have viewed the commitment to the research as more 
burdensome than simply agreeing to attend for an MUR; however this was not 
necessarily the case, with comments such as ‘I’ve got enough appointments’ 
commonly being given as justification for refusal.  These comments suggest that it 
was as much the dMUR itself that was being turned down as the involvement in a 
research project.   This indicates that the concept of the dMUR was either not fully 
understood by these patients, or not viewed as a useful service for them, given 
everything else they had going on at that point in time.    
Indeed, a third of patients who refused did so because they did not see the point of 
having an MUR with their community pharmacist, with several of these actually 
saying they would rather go and see their GP with any problems or queries over 
the changes to their medication.  This suggests a lack of awareness of or belief in 
the skills of the community pharmacist in undertaking this kind of role. It has 
already been discussed (Section 8.3.1) that previous research has shown a lack of 
understanding among patients and the public of MURs in general, and dMURs in 
particular (174,289,315).  In a survey of 1000 members of the public, a quarter of 
respondents indicated that they would not go to their pharmacist to discuss 
problems with medicines, primarily due to low expectations that the pharmacist 
would be able to resolve the problem, with the majority preferring to see their GP 
(174).  Indeed, among those who had participated in MUR or NMS services, less 
than a third had experienced resolution of medicines related problems.  Willingness 
to have a discussion with a pharmacist because of recent hospital discharge was 
lower than other reasons for doing so, although the reasons for this were not 
explored.    
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In the hospital inpatient survey discussed in Section 3.1.2, only one in 10 
respondents considered the community pharmacists as a source of information 
and support regarding medicines post-discharge.  This was confirmed in post-
discharge interviews, where just 2% of interviewees reported that they had 
discussed their medicines with a pharmacist in a private area, despite many 
participants reporting a problem with one or more medicines post-discharge (89).  
The role of the community pharmacist in supporting patients with their medicine 
post-discharge therefore seems to remain underdeveloped, possibly due to poor 
patient understanding, and consideration needs to be given to how to resolve this. 
In contrast to those patients who were reluctant to access their community 
pharmacist for advice regarding medicines post-discharge, one in five of the 
patients who refused to participate stated that they already had good links with 
their community pharmacist and would rather organise their own follow-up.  In 
terms of study design, it may be that the possibility of being randomised to the 
control group, and thus ‘missing out’ on a dMUR influenced these patients’ 
decision to refuse to participate.  It would have been interesting to see if any of 
these patients actually self-referred for a dMUR following discharge and if they did, 
whether the community pharmacist had enough information to adequately support 
them with the changes to their medication.  This situation seems unlikely, however 
as all evidence to date suggests that dMUR provision is low in the absence of 
formal referral systems (165,306,310,311,335).   
One patient believed that his community pharmacist would automatically receive all 
the information about the changes to his medication, so did not see the benefit of 
participating in the study, even when advised that community pharmacies are not 
routinely informed of medication changes made during admission.  Although this 
was an isolated case during this study, this further suggests poor public 
understanding of the role of community pharmacists in the healthcare system. 
Selection bias may have been introduced through the exclusion of patients who 
were too unwell to approach in hospital, housebound, or relied on carers to 
manage their medicines.  All these patient groups are likely to be frail and at high 
risk of DRP, and therefore potentially more likely to benefit from dMUR.  Their 
exclusion could also contribute to the apparent lack of effect of the intervention. 
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8.5.3 Participant Dropout, Loss to Follow-up and Protocol Deviations 
Only 41% of participants completed this study as per protocol, which is in keeping 
with research conducted by others indicating that studies involving older patients 
experience high attrition rates (177).  Death, or deterioration in health leading to 
participants being readmitted, moving address to live in locations where their care 
needs can be better met, or simply being no longer able to complete follow-up 
measures all contribute to this and were all observed during this study 
(119,126,129,132,143). 
It also became apparent during the study that the medication support needs of 
older people may change following a stay in hospital, so that some patients who 
have been responsible for managing their own medication prior to admission 
required support to do so following discharge.  As such, a number of participants 
who were recruited on the basis of independently managing with their medication 
at home may not have fitted this criteria had they been screened post-discharge.  
Some of these cases were discovered during semi-structured interviews.  Where 
these participants did retain some independence with regards to their medication 
(for example retrieving their own doses from a carer filled MCA) they were not 
excluded, rather their experiences and those of their carers were used to inform 
discussion of how the dMUR service could be modified to support their needs. 
More participants were lost from the intervention group than the control group, due 
to difficulties in dMUR delivery.  Therefore in the PP analysis the intervention group 
is likely to have been more ‘well’ than the control group, as any participants who 
became housebound or felt too unwell to attend their dMUR following discharge 
would have been excluded, whereas they may have been able to complete the 
requirements of the control group.   
8.5.4 Limitations in Measurement and Interpretation of Outcomes 
Self-reported measures, including the MMAS, can easily be distorted by the patient 
and lead to an over-estimate of medication adherence (67,290).  Completing an 
adherence scale also requires recall and cognitive capabilities, which may be less 
than optimal in some elderly patients (290).  However these drawbacks would be 
expected to affect both intervention and control groups equally.  Ideally more than 
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one measure of adherence would be been used but the resources and time 
available for this study meant that this was not possible.  The MMAS has been 
successfully triangulated with other methods of measuring adherence (see Section 
5.6.4), which increases confidence in its use as the sole measure of adherence in 
this study.   
Apart from small participant numbers, one explanation for the lack of difference in 
HR-QoL between intervention and control groups is that the SF-12v2 is not 
sensitive enough to pick up differences in health that advice given during a dMUR 
could generate.  A recent systematic review and meta-analysis concluded that 
existing HR-QoL measures lack sensitivity and specificity to pharmaceutical care 
and are insufficient to reflect the true impact of these interventions (336).  The SF-
36 measure had the most evidence, with a moderate impact of pharmaceutical 
care activities on social functioning, general health and physical functioning 
identified by meta-analysis.  The SF-12 was chosen in preference to the SF-36 for 
this PhD study as, in addition to being much shorter than the SF-36 (and therefore 
placing less burden on participants), it has been found to reproduce the physical 
and mental component summary measures with at least 90% accuracy (226). 
A recent content analysis of HR-QoL measures found that, although the SF-36 
may be suitable to evaluate the impact of pharmaceutical care on HR-QoL to some 
extent, suitability to comprehensively capture the burden of medicine on physical, 
social and psychological wellbeing is unlikely (337).  Looking at all measures 
collectively, no single tool was specifically designed for measuring the burden of 
medicine on quality of life, nor did the measures appear suitable to evaluate the 
impact of medicine-focused interventions on HR-QoL.  The authors called for 
development of an alternative measure suitable for evaluation of the burden of 
medicine and the impact of pharmaceutical care interventions on quality of life.   
Alternatively, a longer timescale might be needed to see an effect of 
pharmaceutical care interventions on HR-QoL.  In the meta-analysis, most of the 
studies using the SF-36 measure evaluated comprehensive medication review 
interventions and had a follow-up period of 12 months and more (336).   
274 
 
A further limitation in interpreting the HR-QoL results in this study is that a number 
of forms were received with missing answers.  Although the SF-12v2 scoring 
software does have the capacity to estimate some scores where one or more items 
on the survey are not completed, some of the forms returned had too many 
missing items for this to be possible.  These forms were excluded from the results.  
Possible reasons for missing answers are that the type-face was too small or the 
questions were somewhat repetitive and therefore participants may have fatigued 
or taken the view that there was no need to complete all items.  Alternatively 
respondents may have had difficulty in understanding some questions.  Although 
the patient and public involvement group had indicated the questionnaire was 
suitable, it is possible that they were in better physical and mental health than 
some of the actual participants in the study.  The SF12-v2 user’s manual does 
state that elderly respondents are more likely to have missing items than younger 
respondents, which fits in with the number of incomplete forms returned in this 
study (226).  
This is the first time the PEI has been used for pharmacy consultations and as 
such it is not validated in this setting.  However this research could form a platform 
for further use and validation of this tool in similar settings. 
Response bias is also a limitation of this research, in that participants who were 
more adherent or less sick may have been more likely to return their 
questionnaires.  However this would be expected to affect intervention and control 
groups equally.  The low HR-QoL scores returned by participants also goes against 
the suggestion that those in poor health would not have returned their 
questionnaires.  Other shortcomings of the questionnaire used in this research, 
such as participants over-stating adherence, would also be expected to affect 
intervention and control groups equally. 
It has been discussed in other parts of this thesis that some of the outcome 
measures used may not be sensitive to the effect of dMUR interventions.  The use 
of all readmissions, rather than preventable, medication related readmissions as a 
quantitative outcome is one example of this.  However the detection of 
preventable, medication related readmissions relies on the application of criteria 
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which will always be somewhat subjective.   Particularly, the involvement of the 
researcher in the case note analysis of readmitted participants in this research 
could be seen as open to bias.  However this was seen as preferable to leaving 
interpretation and application of the scoring criteria to one person alone.  
Subjectivity is still a possibility in the application of such criteria and in a future trial 
it would be preferable for the criteria to be applied using a larger panel which did 
not include any members of the research team.  Never-the-less, this study 
demonstrated that such criteria can be applied and analysing the results 
statistically would be desirable for a future RCT if an adequate sample size could 
be recruited.   
Confounding is also possible in that patients who were well enough to attend the 
pharmacy for a dMUR may have been intrinsically less likely to be readmitted to 
hospital.  It is not known whether a dMUR would actually have prevented the 
readmissions among intervention group participants who were unable to attend 
their dMUR, had they completed the intervention as planned. 
The intention to use the number of GP visits in each group as an outcome measure 
was limited in this study by difficulties of participants with completing the study 
diary.  During a future RCT this information should be collected directly from GP 
surgeries if possible.  Other measures that could not be studied during this 
research due to lack of resources include all medication discrepancies and all 
ADEs.  These may be more sensitive to community pharmacy interventions than 
readmissions or overall HR-QoL and consideration should be given to the 
practicalities of using these outcomes in future work evaluating the dMUR service.  
A further limitation of this research is the possibility that the interaction between 
participants and the researcher, a pharmacist, may in itself improve medicines use 
among patients who had not received a dMUR and skew the results of the study, a 
phenomenon known as ‘measurement effect’.  This was most likely during the 
participant interviews, due to the digression, at times, of the researcher from the 
role of interviewer to the role of HCP.  It was found that interviewees often asked 
for advice regarding medicines in response to the open question: Is there anything 
else about your medication that you’d like to talk about?’ at the end of the 
interview.  This question was not intended to result in such requests; however 
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knowing the interviewer was a pharmacist may have led some participants to 
misunderstand or opportunistically ask questions regarding new medication which 
remained unanswered.  In addition, there were other instances where a lack of 
knowledge was demonstrated by the participant, which could have resulted in harm 
(for example where changes to medicines made in hospital had not been initiated 
properly by the patient at home).  This type of situation posed a difficulty for the 
interviewer, who was a practising pharmacist as well as a researcher.  Ignoring a 
lack of knowledge regarding medication which could realistically cause a patient 
harm would have been a breach of professional ethics on the part of the 
researcher.  Therefore, despite a knowledge of the need to separate these two 
roles to avoid contaminating the study data, the presentation of a patient with clear 
information needs caused a number of digressions from the role of researcher into 
the role of healthcare professional.  This may have affected the outcomes of the 
study as some control group participants were in effect given a dMUR during their 
interview.  This could have affected their medicine taking or self-care behaviour in 
a similar way to the study intervention and therefore reduced any differences in 
outcomes (such as readmission rate, quality of life and medicines adherence) 
between the intervention and control groups.  Conversely, extra information given 
to intervention group participants could have increased the apparent effect of the 
intervention, increasing the difference between the groups.  Even re-visiting the 
points discussed during the dMUR may have reinforced them in the minds of the 
participants, thus increasing treatment effect.  As this was a feasibility study and 
the role of statistical analysis of outcomes was limited, statistics were not re-run 
with the exclusion of these patients.  However in a future RCT, it is recommended 
that interviews, if included in the study design, should be conducted by a 
researcher who is not also a pharmacist. 
In addition, interviews with some participants were made difficult because of the 
cognitive impairment of the participant.  In two cases (one intervention and one 
control), most of the interview was conducted with the participant’s offspring, and in 
several other cases, family members were present and contributed to the interview 
to some extent.  Therefore some of the views presented may have been those of 
the participant’s family rather than the participant themselves.  Rather than being a 
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limitation, this observation goes to illustrate the importance of involving family and 
other care-givers in medicines optimisation activities, particularly where the patient 
is frail and elderly, or has cognitive impairment. 
Several themes not included in the original interview schedule were identified 
during the coding of transcripts and construction of thematic charts for the 
framework analysis of the interviews.  A limitation of this analysis is that it did not 
begin early enough in relation to conducting the interviews, due to time pressures 
on the researcher.  Had it been possible to start the analysis earlier, these 
emerging themes could have been incorporated more formally into the schedule for 
later interviews and therefore explored more deeply. 
It is important to remember that the interventions made by community pharmacists 
in this study were not outcomes in themselves, and their conversion into cost savings 
is an estimation, as it is difficult to demonstrate a direct effect of the interventions 
made.  However, the use of the Eadon-ScHARR model to assign clinical significance 
and monetary value to each intervention provides an insight into the effect of these 
interventions on patient care.  It should also be noted that using a Delphi process to 
gain consensus is still based on subjective opinion and results are unlikely to be 
reproducible (272). This is particularly pertinent here as consensus regarding the 
score to award the majority of interventions was defined by stability in the opinions 
of the reviewers, not agreement as to the score awarded.   
A larger study involving more interventions would help to validate these results, and 
if potential clinical significance and cost avoidance could be linked to other outcomes 
such as reduced readmission rates, this would help to demonstrate causality of the 
intervention on improvements in these outcomes.  A further limitation of the Delphi 
process in this research was that a relatively small panel could be convened and two 
members of the panel dropped out before the end of the process.  This led to an 
over-representation of pharmacists compared to doctors on the panel (five and two 
respectively), which may have affected results as different professionals may score 
interventions differently.  If applying this methodology again in the future, attempts 
will be made to convene a larger panel with more representation from the medical 
profession.  
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CHAPTER 9: CONCLUSIONS 
 
Bottom Line: There is potential for improved patient care and a positive return 
on investment when community pharmacists provide dMURs for older 
patients following referral by hospital pharmacists.  However, operational 
barriers exist to delivering dMURs to the frail elderly and there is a need to 
improve communication channels between health care practitioners to deliver 
a holistic package of care post discharge.   
Transfer of medicines related care from hospital into primary care remains 
suboptimal, and information overload at the point of hospital discharge may 
prevent older patients from absorbing medication counselling.  Community 
pharmacy dMURs are well placed to address these issues.   
The lack of significant differences in patient outcomes between intervention and 
control groups in this study is unsurprising as feasibility studies are not designed to 
detect them.  Although patient numbers in this study were too small to draw firm 
conclusions, results of this research include a number of interesting trends for 
further investigation.  These include trends towards shorter length of stay on 
readmission for intervention group patients and a reduction in A&E visits at 6 
months for patients who completed their dMUR as planned compared to the control 
group.  Results also suggested that dMURs may prevent deterioration in 
medication adherence and physical health over time compared to patients who are 
not referred, and that preventable medication related readmissions may be 
decreased by the provision of dMURs.  This study also suggested that dMUR 
referrals may provide a 4-fold return on investment to the NHS in terms of 
improved quality of care.   
Consistency of the responsible pharmacist in a community pharmacy may increase 
uptake of and benefit derived from dMURs due to the relationships which develop 
between community pharmacists and patients.  In turn, the experience of having a 
dMUR may improve patients’ perceptions of community pharmacy.  However, the 
format of a typical dMUR consultation may not be optimal to improve patients’ 
understanding or use of medicines.  The approach of encouraging the patient or 
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carer to take the lead may be more useful in highlighting knowledge gaps and 
targeting advice.  Broadening the consultation to incorporate patients’ physical and 
social circumstances may also help them to benefit from the dMUR.  Participant 
demographics indicate that this study involved patients at relatively high risk of 
post-discharge DRPs and readmission.  These patients may be more in need of 
medicines support and it is likely that this type of dMUR will be more complex and 
require longer consultation times than standard dMURs.  Follow-up consultations 
may be required in order to review the success of interventions made during the 
first consultation and address any new problems that have arisen 
To fulfil these requirements, community pharmacists require detailed information 
from the hospital regarding why changes were made as well as specific indications 
and duration of treatment for new medicines where these may vary.  Additional 
post-discharge changes to medicines may occur before the dMUR consultation 
takes place and community pharmacists need to be prepared for this. 
Lack of time of hospital pharmacists is a major barrier to recruiting appropriate 
patients for a dMUR referral system and making good quality referrals.   
A major barrier to older patients accessing dMURs in their current format is being 
housebound due to poor mobility or health, due to difficulties experienced by 
community pharmacists with providing domiciliary MURs.   Despite being a 
possible solution for where medication support needs are relatively simple, 
telephone dMURs may not be acceptable or feasible for older patients with 
complex medication regimens. 
Carer management of medication is another major barrier to provision of dMURs 
for older people.  A lack of perceived need for dMUR by some patients and 
preferring to talk to their GP regarding medication changes made in hospital are 
also barriers.  Elderly patients may have numerous appointments in the post-
discharge period and consideration is needed as to how to integrate dMURs and 
community pharmacy in general into their overall care package.  Better 
communication to GPs of the dMUR referral by the hospital and its outcome by 
community pharmacists may increase the usefulness of the service by encouraging 
collaborative working.  
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Chapter 10: Recommendations 
 
10.1: RECOMMENDATIONS FOR FURTHER RESEARCH 
1. The feasibility study reported within this thesis should be scaled up to a full pilot 
study, followed by an adequately powered RCT, in order to justify the additional 
cost to the NHS of an enhanced dMUR referral service.  
Trends in outcomes identified in this study indicate that using the same 
outcomes to investigate these trends further would be a rational approach.  
Additional outcomes that should be investigated if sufficient resources were 
available include number of GP visits, medication discrepancies and adverse 
drug events.   
Any future RCT investigating post-discharge follow-up of older patients should 
recruit adequate sample sizes to account for potentially high attrition rates, and 
adequate time should be allowed for recruitment.  Written information should be 
as concise as possible and potential participants should be given the 
opportunity to discuss participation with others (for example family members or 
carers).  Involvement of clinical staff known to the patient in the recruitment 
process is recommended where possible. 
 
2. The concept of multiple contacts between community pharmacist and patient as 
part of the dMUR process, as recommended in section 10.2 below, should be 
investigated in practice.  This could be done as a service evaluation with 
qualitative feedback from patients and pharmacists as to the feasibility and 
utility of the re-designed service.  Other outcomes of interest would be the 
number and type of interventions made at each contact, patient enablement 
following the main dMUR consultation, medication adherence, number and 
nature of GP contacts and readmissions during the follow-up period (which 
should be at least 6 months).  
 
3. Qualitative research should be undertaken to explore further the specific 
barriers to domiciliary and telephone MURs as perceived by community 
pharmacists.  Focus group methodology would be a suitable initial way to 
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approach this, allowing for discussion and development of ideas among 
pharmacists who may have different perceptions. 
 
4. The role of telephone dMURs in older people should be further investigated.  
Preliminary qualitative findings from the PPI group for this research and 
feedback from potential participants could be expanded, initially by surveying a 
larger number of patients as to their views on such a service.   
 
5. Alternative ways of identifying patients who may benefit from post discharge 
medicines support should be explored, for example the feasibility of screening 
by GP practice pharmacists post discharge.  
 
6. Further qualitative work should be carried out to investigate the reasons why 
dMURs appear to be such a low priority for patients, and the perceptions of 
patients who have received the service as to its utility. 
 
10.2 RECOMMENDATIONS FOR PRACTICE 
1. The contractual barrier of applying to NHS England separately each time a 
domiciliary or telephone dMUR is required should be removed.  
 
2. Greater carer involvement in dMURs should be facilitated by allowing proxy 
dMURs with carers, either with patient consent or directly if the carer has power 
of attorney for health. 
 
3. The dMUR service should be re-designed to involve at least two parts.  An 
initial contact should be made within 7 days of discharge to reconcile 
medication discrepancies, address any immediate issues and confirm an 
appointment for a full dMUR consultation. This consultation should take place at 
a mutually agreed time but experience from this work suggests that 4-6 weeks 
post discharge may be appropriate.  Further follow-up may then be required in 
some cases to check understanding of and reinforce advice given and to 
evaluate the outcome of any actions recommended to the patient or GP. 
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4. Remuneration for the dMUR service should reflect the longer time needed for 
dMURs compared to ‘standard’ MURs, the organisation and provision of follow-
up consultations, and travel expenses and/or locum cover where domiciliary 
visits are made.   
 
5. Electronic referral from hospital to community pharmacy should be 
implemented more widely.  Referrals should include (with patient consent) a 
copy of the discharge summary with full details of why medicines were changed 
and the indication, duration of treatment and monitoring requirements for new 
medicines, as well as the planned social and clinical care package for the 
patient.  The dMUR referral should also be documented on the discharge 
summary to facilitate collaborative working between professionals. 
 
6. Hospital pharmacies should be remunerated for making dMUR referrals.  This 
would allow for investment in staff time in order to engage appropriate patients 
and increase the volume and quality of referrals. 
 
7. Older people with multiple medication changes should form a key target group 
for dMUR referral. 
 
8. Pharmacy support staff should be involved both in engaging patients and 
making dMUR referrals from hospital and actioning them in community 
pharmacy. 
 
9. Prompts for community pharmacists to action dMUR referrals may be helpful in 
increasing completion rate. 
 
10. Local champions for dMUR referral by hospitals should be identified to promote 
the service and encourage referral until it becomes routine practice. 
 
11. The concept and purpose of dMUR should be promoted to patients more widely 
both in hospitals and the community. 
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12. Provision of targeted, clear and concise written information to back up verbal 
discussions during dMURs may help patients to gain benefit. 
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Appendix 1: Literature Search Strategy 
For all databases, search terms included Medical Subject Heading (MeSH or MH) term 
and keyword searches as reproduced below 
Cochrane Library: 21/04/17  
ID Search         Hits 
#1 MeSH descriptor: [Patient Discharge] explode all trees  1360 
#2 MeSH descriptor: [Pharmacists] this term only   564 
#3 MeSH descriptor: [Aged] explode all trees    1071 
#4 hospital near/4 discharge:ti,ab,kw  (Word variations searched) 6096 
#5 pharmac*:ti,ab,kw  (Word variations searched)   88190 
#6 elde* or older:ti,ab,kw  (Word variations searched)   62595 
#7 #1 or #4         6852 
#8 #2 or #5         88190 
#9 #3 or #6         62974 
#10 #7 and #8 and #9        79 
 
Title screening: 21 relevant titles identified 
 
Embase: 21/4/17 
 Search Terms Results 
11 Remove duplicates from 10 1418 
10 7 and 8 and 9 1821 
9 3 or 5 1,580,314 
8 2 or 6 6,124,893 
7 1 or 4 136,309 
6 (elde* or older).ab,kw. 1,367,384 
5 "pharmac*".ab,kw. 1,541,204 
4 "hospital discharge".ab,kw. 64,145 
3 pharmacist/ 82,089 
2 aged/ 5,378,914 
1 hospital discharge/ 96,846 
 
Title screening: 131 relevant titles identified after removing duplicates from Cochrane 
Library search 
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Medline: 21/4/17 
# Query        Results 
S10  S7 AND S8 AND S9        668 
S9 S3 or S5       2,683,623 
S8 S2 or S6         514,698 
S7 S1 or S4       49,228 
S6 AB pharmac*       508,424 
S5 AB older adults or elderly or seniors or geriatrics   218,583 
S4 AB hospital discharge      31,051 
S3 (MH "Aged")       2,614,717 
S2 (MH "Pharmacists")       13,153 
S1 (MH "Patient Discharge")     23,104 
 
Title screening: 16 relevant titles identified after removing duplicates from Cochrane 
Library and Embase searches  
 
CINAHL: 30/4/17 
 Search Terms Results 
S10 S7 AND S8 AND S9  129 
S9 S4 OR S6  37,777 
S8 S3 OR S5  622,581 
S7 S1 OR S2  16,359 
S6 pharmacists or pharmacy  37,777 
S5 older people or older adults or elderly  118,064 
S4 (MH "Pharmacists")  10,384 
S3 (MH "Aged")  589,505 
S2 (MH "Transfer, Discharge")  4,418 
S1 hospital discharge  12,115 
 
Title screening: 17 relevant titles identified after removing duplicates from Cochrane 
Library, Embase and Medline searches 
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Web of Science: 30/4/17 
 
 
Results 
 
Search Terms  
# 4 632  #3 AND #2 AND #1 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 3 703,770  TS=pharmac* 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 2 1,359,186  TS=(older OR elder*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
# 1 63,594  TS=hospital discharge 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI 
Timespan=All years 
 
Title screening: 26 relevant titles identified after removing duplicates from Cochrane 
Library, Embase, Medline and CINAHL searches 
 
Pubmed: 01/05/2017 
Search Query 
Items 
found 
#14 
Search (((("Pharmacists"[Mesh]) OR pharmac*[Title/Abstract]))  
AND (("Aged"[Mesh]) OR ((older[Title/Abstract] OR 
elder*[Title/Abstract]))))  
AND (("Patient Discharge"[Mesh]) OR hospital discharge[Title/Abstract]) 294 
#13 Search ("Pharmacists"[Mesh]) OR pharmac*[Title/Abstract] 298106 
#12 
Search ("Aged"[Mesh]) OR ((older[Title/Abstract] OR 
elder*[Title/Abstract])) 2876447 
#11 Search ("Patient Discharge"[Mesh]) OR hospital discharge[Title/Abstract] 40349 
#10 Search pharmac*[Title/Abstract] 294796 
#9 Search (older[Title/Abstract] OR elder*[Title/Abstract]) 509420 
#8 Search hospital discharge[Title/Abstract] 20997 
#7 Search "Pharmacists"[Mesh] 13221 
#5 Search "Aged"[Mesh] 2656660 
#3 Search "Patient Discharge"[Mesh] 23204 
 
Title screening: 5 relevant titles identified after removing duplicates from Cochrane Library, 
Embase, Medline, CINAHL and Web of Science searches 
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Database of Abstracts of Reviews of Effects (DARE) and the NHS Economic 
Evaluation Database (NHS EED): 1/5/17 
NB// These databases ceased to index new research at the end of March 2015 
Line   Search Hits 
1 MeSH DESCRIPTOR Patient Discharge 
EXPLODE ALL TREES 
257 
2 MeSH DESCRIPTOR Aged EXPLODE ALL 
TREES 
9686 
3 MeSH DESCRIPTOR Pharmacists EXPLODE 
ALL TREES 
140 
4 (hospital discharge) 587 
5 (pharmac*) 8595 
6 (older OR elder*) 4708 
7 #2 OR #6 12390 
8 #3 OR #5 8595 
9 #1 OR #4 783 
10 #7 AND #8 AND #9 58 
 
Title screening: 6 relevant titles identified after removing duplicates from Cochrane Library, 
Embase, Medline, CINAHL, Web of Science and PubMed searches 
 
NIHR dissemination Centre: 1/5/17 
2 relevant titles identified (since March 2015) 
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ClinicalTrials.gov Registry: 5/5/17 
Found 37 studies with search of:   "hospital discharge" AND pharmacist | Senior (aged 65+) 
Recognised Terms and Synonyms: 
pharmacist:   673 studies 
hospital discharge:   1165 studies 
discharge from hospital 
discharge hospital 
 
17 relevant titles identified after removing duplicates from previous searches.  Of these, 
one study had been terminated as unable to recruit and 5 were ‘status unknown’ 
(completion date has passed and the status had not been verified in more than two years) 
 
Health Management Information Consortium: 5/5/17 
 Searches Results 
5 1 and 4 71 
4 2 or 3 11048 
3 pharmac*.mp. [mp=title, other title, abstract, heading words] 11048 
2 exp Pharmacists/ 2138 
1 hospital discharge.mp. or exp Patient discharge/ 2354 
 
13 relevant titles identified after removing duplicates from previous searches 
 
Electronic Theses Online System (EThOS): 5/5/17 
Hospital discharge [Abstract] AND Pharmacist [Abstract]: 3 results, none relevant 
 
NHS Evidence: 14/5/17 
“Hospital discharge” AND Pharmacist: 695 results, 20 relevant titles identified after 
removing duplicates from previous searches 
 
Pharmaceutical Journal: 19/5/17 
18 relevant titles identified after removing duplicates from previous searches
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Appendix 2: Patient and Public Involvement (PPI) 
 
Questions Addressed During PPI Group Meetings 
1) What do you think of the level of medicines support you were given during 
your last hospital stay? 
2) Do you use same community pharmacy regularly? 
3) Were you aware of medicines use reviews (MURs) before today? (In 
general, or in the context of discharge from hospital) 
4) What do you think of the idea of your community pharmacist going through 
your medicines with you after you have been in hospital? 
5) How likely would you be to go for a post discharge MUR (dMUR) if your 
community pharmacist contacted you to arrange one? 
6) How easy would you find it to attend the pharmacy for a dMUR? 
7) How soon after being discharged do you think the dMUR should be? 
8) What would you want to get out of an MUR? 
9) Which of the following do you think are factors which might lead a person to 
benefit from a dMUR? 
a. Medicines changed in hospital (how many changes?) 
b. Taking a lot of different medicines (how many is a lot?) 
c. Taking particular medicines which are more likely to be associated 
with an admission to hospital: 
i. Water tablets 
ii. Anti-inflammatory or morphine related painkillers 
iii. Blood thinning medicines (Aspirin/clopidogrel/warfarin) 
iv. Medicines for diabetes (tablets or Insulin) 
v. Digoxin 
vi. Some blood pressure/heart medication (ACE-Inhibitors / beta-
blockers) 
vii. Steroids 
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viii. Sleeping tablets 
ix. Antidepressants 
d. Difficulty taking medicines (e.g. due to physical difficulty or 
forgetfulness) 
e. Any other suggestions? 
10) Does anyone have any comments on the participant information leaflet for 
the study? (Is it easy to understand, large enough font, is there anything 
else you would want to know?) 
11) Some people would not be referred for a review as part of the study.  Do 
you think that is ok? 
12) Would you be happy for your community pharmacist to receive the kind on 
information on the referral form? 
13) What do you think of the participant consent form?  Is there anything else 
that should be specified on there? 
14) Would it be OK for the researcher to contact a participant’s GP to find out 
how many times they had seem them since being discharged? 
15) Would it be OK for us to consult a participant’s hospital records to see if they 
had been re-admitted?  If they had been readmitted, would it be alright for 
us to look at their case notes to find out why? 
16) How willing would you be to be telephoned and asked questions as part of 
the study follow-up?  What about filling in something that was sent in the 
post?  
17) Please look at the following examples of follow-up questions that might be 
asked.  Do you have any comments / concerns?  How would you feel about 
answering these questions? 
18) Some people might be visited at home and interviewed in more depth about 
their medicines-related experiences since discharge.  How would you feel 
about that? 
19) Is it acceptable to repeat follow-up at six months? 
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20) What would you most like to achieve as an overall outcome of a dMUR? 
(For example fewer visits to your GP, a lower risk of going back into 
hospital, improved quality of life?) 
21) Would participants want to know about results of the study?  If so, how 
should we inform them? 
22) How would you feel about each of these people approaching you to discuss 
taking part in the study? 
a. Chief researcher 
b. Research assistant 
c. Your own ward pharmacist 
d. Your hospital doctor  
23) How should we approach our potential participants? (Leave information 
leaflet first?  Talk first and only leave info leaflet if interest shown?) 
24) We have decided not to contact peoples’ GPs to see how many times they 
had been to see them after discharge.  Instead, we would like participants to 
keep a kind of diary of if and when they had been to their GP, and if they 
had been back into hospital.  Is this something that sounds reasonable?  
What do you think of this example diary? 
25) The following have been identified as ways of encouraging people to return 
postal questionnaires.  Which do you think would be the most suitable for 
our study?  Do you have any other suggestions? 
a. Money or other incentive.  
b. Recorded delivery. 
c. Contacting participants before sending questionnaire  
d. Re-sending questionnaire  
e. Mentioning obligation to respond 
f. University sponsorship  
g. Personalised questionnaires.  
h. Hand written envelopes.  
i. Stamped as opposed to franked envelope for return  
j. Assurance of confidentiality 
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k. First class outward mailing  
 
Session 1 - 16th April 2013 
Four participants attended this first session.  The objectives of the session were to 
orientate the group members with the rationale and plans for the study so far and, 
as potential end-users of the dMUR referral service, ascertain their feelings about 
its potential usefulness and usability for patients. 
Background 
In order to put the study into context for the group members some time was first 
spent discussing members’ own previous experiences of being discharged from 
hospital with changed medication regimes.  This discussion was also intended to 
enable the researcher to better understand the types of issues faced by patients in 
case modifications to the service or study design could be made which would 
increase quality.  
Only one of the four group members (Participant A) at this session described a 
positive experience in regards to medication support during his last hospital stay.  
He felt the information he had been given about medication changes was “very 
good”.  The nurses had shown him how to use his new inhalers and he “felt quite 
comfortable” with the explanations given regarding them and other changes to his 
medication.  This support had been given by nurses and doctors in the hospital, 
and participant A could not recall seeing a pharmacist during his admission.  
However he later revealed that his atenolol had been stopped whilst in hospital but 
he had not been told why.  Therefore even this overall positive experience could 
have been improved. 
Participants B and C both described having had extensive changes to medication 
whilst in hospital and being unable to recall receiving any explanation of why the 
changes had occurred or how to take new medication.  This had led participant 
both participants to visit their own GPs after discharge specifically to discuss 
medicines started or stopped in hospital.   
These experiences highlight the potential value of the dMUR referral service, 
where, armed with information from the hospital, community pharmacists could 
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discuss patients’ concerns and fill information gaps, potentially removing the need 
for a GP appointment. 
 
MURs and Community Pharmacy 
Understanding group members’ prior knowledge of the MUR service and attitudes 
towards community pharmacy in general was also an important objective. It was 
hoped this would enable the researcher to anticipate the way potential study 
participants might respond to being approached about the study and the type of 
information needs they might have in order to decide whether to participate. 
All 4 group members at this session reported using the same community pharmacy 
regularly, which was reassuring in terms of study participants being required to 
nominate a pharmacy to receive the dMUR referral from the hospital.  However 
only 2 of the 4 members had heard of the MUR service previously (although not 
under this name). 
Participant A had been offered medicines reviews in the past by his regular 
community pharmacy.  He accepted the offers to review his medicines but didn’t 
really feel he got anything out of them (“useless thing”) largely because he felt that 
“he [the pharmacist] couldn’t change anything”.  Participant A wasn’t sure what the 
pharmacist could do during/following the MUR that would benefit him. 
Participant D had also had an MUR, at the pharmacy attached to his GP practice.  
He said he was “in and out in 2 minutes” and felt it “wasn’t worth it”.  The 
pharmacist hadn’t worn a name badge or introduced themselves.  They had only 
discussed 2 out of his 4 regular medicines and “didn’t mention the other 2 at all”.  
Participant D had been taking ranitidine since he was diagnosed with a stomach 
ulcer 25 years ago and didn’t feel like it had ever been properly reviewed.  When 
he asked his GP about it he was told ‘just take it when you need it’.  He felt that still 
being prescribed this was a waste of money as he rarely got symptoms, yet still 
received a supply every month. 
Participant B felt that personally she would not need an MUR as she “questions 
anything and everything any how”, by telephoning the pharmacist herself or seeing 
her GP, who “tells me what they are all for anyway”.   
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These experiences and attitudes raise the following questions of the current MUR 
service, some of which have also been described in the literature 
(173,174,286,289,294,315,338):  
 Are MURs being targeted to patients who can benefit from them?    
 Is there need for better explanation by community pharmacists of what an MUR 
is and is not in order to direct patient expectations?  
 Is there a need to improve the quality of MURs in order to demonstrate a 
benefit of the service?   
Participant D’s experience in particular suggests a need for better communication 
by community pharmacists during MURs and the need to take time to address all a 
patients concerns regarding medicines.  For example, helping participant D to 
make appropriate use of the prescription re-ordering system could save the NHS 
money and reduce his frustration, empowering him to take control of his own 
medication. 
Views on the dMUR service 
When asked what their personal feelings would be if offered a dMUR, all group 
members said they would be happy to see their pharmacist for a dMUR and “could 
see the value of it”.  However Participant A raised the concern that, the way the 
dMUR service had been presented by the researcher, he “didn’t know how 
[community pharmacists] would find the time”.  This echoes group members’ earlier 
feelings (and reports in the literature) that community pharmacists are failing to 
fully realise the opportunity offered by MURs, being constrained by situational 
pressures (294). 
When asked how likely they would be to go for a dMUR if one was offered, 2 of the 
4 group members foresaw specific difficulties with attending the community 
pharmacy.  Participant B was not allowed to drive for 4 weeks after leaving hospital 
so an MUR in this time would have been “impossible”.  Participant A stated that if 
his COPD deteriorated he would end up needing oxygen and would then find 
leaving home difficult.  His medication would have to be delivered and he would be 
unlikely to see the pharmacist themselves at all.  He felt that lots of people might 
struggle to attend the pharmacy soon after discharge. 
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However, when asked about telephone MURs, all 4 group members said they 
would not want one, with participant B sating: “I prefer to see a face”.  Participant B 
maintained that even if she knew the pharmacist would be telephoning her for an 
MUR she “still wouldn’t like it”.  Participant A agreed:  “I don’t like discussing 
medication over the ‘phone”. Participant C explained that he was “hard of hearing” 
and therefore struggled with telephone conversations.   
Participant D could see that a phone consultation might be useful, but only if there 
was a specific issue to discuss.  This scenario is more similar to the NMS, where 
there is only one medicine involved and follow-up consultations are often carried 
out by telephone (292).  The others agreed with Participant D but said that they 
would only want a telephone consultation if they initiated it. 
When asked about domiciliary MURs, all agreed when Participant A said “that 
would be OK”, but were concerned about the cost and how the pharmacist would 
find the time. 
In response to the question ‘How soon after being discharged do you think the 
dMUR should be?’ Participants C and D both agreed that 2 weeks after discharge 
would be optimum, whilst Participant A said that he needed 4-6 weeks to “get into 
a routine” with his new medication after discharge, so would not want an MUR 
before then.  However Participant D maintained that people who were less 
confident might “need someone there straight away to explain what they are for, 
what to do with them and to make sure you are taking them”. 
Participant A said that it would be better for pharmacists to tell people about their 
medication changes whilst they were still in hospital, just prior to discharge, as they 
could access more people this way.  However Participants C and D were both of 
the opinion that people do not always remember the content of discussions that 
happen in hospital, with participant C stating: “its only when you get home that you 
get the leaflets out” and this is when questions arise and the need for information 
presents itself.  He expressed the view that medication should be explained to 
patient away from the hospital environment, as soon as possible after discharge, in 
their own home if possible.   
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When asked what they would like to get out of a dMUR, participants A and C both 
agreed they would like “knowledge of exactly what each medicine is for”.  
Participant C would also want an “explanation of side effects of medication, which 
are most relevant to particular medicines and what to do about them”, whilst 
participant A would want “to have my own questions regarding medication 
answered.”  Participant D answered: “reassurance that what you are taking is 
suitable, being taken correctly and still needed”.  Echoing his earlier comments, he 
also expressed the view that that MURs would be good for “cutting down waste” as 
stockpiling of medication at home could be discussed and medication that has built 
up or is no longer being taken could be “taken off the automatic re-ordering system 
that seems to exist.”  The other 3 members agreed that MURs could help prevent 
wastage of medication. 
Other Points  
Interestingly, all group members expressed frustration during this session at the 
difficulty they had in arranging GP appointments.  This raises the question of 
whether, with proper promotion and targeting, there is a role for dMURs in freeing 
up appointments by answering questions patients have re medicines post 
discharge. 
 
Session 2 – 21st May 2013   
The objectives of this session were to use the PPI group members’ perspective to 
gain an understanding of how potential participants might respond to being 
approached regarding participation in the study, and also their views on some of 
the ethical considerations that had arisen during early stages of study planning.  
Group members views on eligibility criteria were sought, in case they could suggest 
any further groups of patients who they felt might benefit from being targeted, or 
any of the current eligibility criteria were unsuitable from their perspective.  
Drafts of study paperwork were shared with the group and comments on 
acceptability and suggestions for improvement invited.  The relative importance of 
potential study outcomes was also discussed. 
Eligibility Criteria 
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Some time was spent explaining the planned eligibility criteria for the study and 
obtaining the group members’ feedback.  
When asked about the number of changes to a person’s medication that might be 
required in order for them to benefit from a dMUR, Participant D felt that “Two or 
more, probably” would be needed.  He stated that this was because multiple 
changes “might suggest other factors” that would make patients particularly likely 
to benefit from a dMUR.  Such factors might include co-morbidities or a 
deterioration in physical or mental condition compared to before hospital admission 
which meant that patients might need more help with managing their medicines. 
When asked their opinion on the number of medicines a person would need to be 
taking in order to benefit from a dMUR, the initial criteria of 5 or more surprised 
participants D and F:  
Participant D “That’s a lot of medicines”   
Participant F: “I need a siesta every afternoon even without taking all those 
medicines!” 
However Participant C was already taking 8 medications and found the criteria of 5 
or more reasonable.  It was agreed that some patients might be used to managing 
multiple medicines, whilst others might have difficulties despite only taking one or 
two.  Therefore some degree of flexibility in this criterion might be required during 
recruitment.  This matches reports in the literature that ward pharmacists’ own 
judgement of need can be a successful criteria for recruitment of patients to 
medication support services (150). 
There have also been mixed reports in the literature of whether participants can 
nominate one particular pharmacy they would visit for medication support post-
discharge (89,120,123,124).  However all PPI group members agreed that they 
could nominate a pharmacy they would want to receive their dMUR referral. 
During discussion about problems with medicines adherence as an eligibility 
criteria for the study, Participant F identified a difficulty in remembering to take 
medicines as an issue that could be addressed during a dMUR.  This prompted a 
conversation regarding whether patients in hospital would admit to a difficulty in 
remembering to take medicines if approached and asked by a hospital pharmacist 
or researcher: 
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Participant D Well I’d tell the truth 
Participant C It depends how you were feeling, being in hospital you’re not in a 
natural environment 
It was agreed, however, that if identified, difficulty in remembering to take 
medicines would be a valid indication for a dMUR.  Physical dexterity was also 
raised as a barrier to adherence which could be tackled during a dMUR: 
Participant E: I do have difficulty taking the lids off bottles 
Participant D: Some of the blisterpacks, they’re hard to… 
Participant C: Yes 
Participant D: Aren’t they?  
Participant E: They cut some of my tablets down to half the dose, and I had to cut 
them in half with a breadknife!  They were going all over the kitchen!  
Participant Information 
When asked for comments on the participant information leaflet, all group 
members agreed that it was easy to understand, the font size was large enough 
and that there was enough information for study participants to know what was 
going to happen during the study: 
Participant C “It’s all set out clearly” 
Participant E was however concerned that not all potential study participants would 
have the same ability to understand the written information as the PPI group 
members. It was agreed that verbal explanation and discussion with potential study 
participants prior to recruitment was vital. 
When asked if there was anything else they would want to know, none of the group 
members could think of anything. 
Ethical Considerations 
The concept of randomisation and the fact this meant that some participants would 
not be referred for a dMUR as part of the study was explained to the group 
members, and it was asked if they felt this was acceptable.  Participant D 
responded: “Yes because I wouldn’t expect to get one”.  All group members agree 
that as dMURs were not a standard service, there were no concerns about 
randomising some participants not to be offered a dMUR during the study. 
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No concerns were raised regarding the participant consent form.  When shown the 
referral form which would be sent to their community pharmacist, all group 
members agreed that they would be happy for the pharmacist to receive this 
information.  All group members also agreed that their MUR action plan being 
shared back with the researcher would be acceptable. 
All members felt that participants’ GPs should be informed that they were taking 
part in the study, and would be happy for their GP to be contacted regarding the 
number of times they had visited since discharge if this was to be used as a study 
outcome.  
When asked how they would feel about their hospital records being consulted to 
see if they had been readmitted and, if so, why, Participant D felt that this was a 
necessary part of the research: “They’ve got to be, it’s for their benefit, you’ve got 
to have unlimited access to information”.  Participant C agreed: “You’ve got their 
best interests at heart” 
Data Collection 
Remembering group members’ concerns regarding telephone MURs at the first 
session, some time was spent discussing the most acceptable method for data 
collection from participants during the study.  Telephone follow-up was the least 
preferred method: 
Participant C It all depends how old they are 
Participant D And condition’s a factor as well 
Participant C I don’t like long telephone calls 
Participant E And you don’t know who is at the other end of the phone 
Participant D Well that’s another thing 
Participant E And you’re being rung up and asked personal questions 
However all agreed they would be happy to fill in a paper questionnaire that had 
been posted to them: 
Participant E I think that would be a better option 
Participant C/D Yes 
Participant D however clarified that there should be a pre-paid envelope provided 
for participants to return the questionnaire. 
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Examples of draft follow-up questionnaires containing adherence, enablement and 
HR-QoL scales were shown to the group members and their comments requested.  
Regarding the adherence scale, Participant E pointed out that this scale might not 
produce accurate data:  “It might be difficult for older people if you were forgetting 
to take tablets to remember you’d forgot!”  This lead to a discussion about cross 
referencing the adherence scale with GP or community pharmacy prescription refill 
data.  All group members agreed they would be happy for their GP or community 
pharmacist to supply this information. 
Regarding the questionnaire in general, all group members agreed they would be 
happy to fill it in, but that seeing the questions had reinforced for them that 
telephone follow-up was not a suitable option:  
Participant D The questions aren’t intrusive.  It’s a fairly honest sort of thing. [But 
you] couldn’t do it over the ‘phone 
Participant C You need time read it from start to finish first, and time to consider 
where to put the tick 
Participant D And where it says ‘a lot or a little’ you can actually see…  
When asked how they would feel about being interviewed at home in more depth, 
all group members felt this would be acceptable, and indeed necessary to obtain 
quality data: 
Participant D: Yes, because you can then compare that with questionnaires 
Participant E: Wouldn’t there be cost implications?  A lot of time would be spent 
driving around. 
Participant D: Yes but that’s probably the only way to get data saturation 
In terms of how long the interview should take, Participant D felt this should be no 
longer than 15-20 minutes.  Participant C queried whether interviewed participants 
would be expected to fill out questionnaires as well.  When asked for his opinion on 
this, he suggested leaving the questionnaires with the participants along with a pre-
paid envelope in which to return them.  
In terms of repeating follow-up at six months, this was again agreed to be both 
acceptable and necessary to the research: 
Participant D I think it is [acceptable] 
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Participant C You usually get a follow-up appt at six months 
Participant D You’ve got to keep track of people.  I think a follow-up later on is a 
must 
Study Outcomes 
One of the objectives of PPI in this research was to ensure that study outcomes 
were those which mattered to participants.  When asked what they most would like 
to achieve as an outcome of a dMUR, group members had differing ideas.  For 
Participant C, “feeling more able to live a normal life” (ie improved HR-QoL) would 
be a priority outcome.  Participant D felt that fewer visits to the GP and not being 
readmitted to hospital were both important outcomes, whilst Participant E agreed 
that avoiding readmission would be most important.   
In terms of letting participants know about study results, all group members agreed 
they would want to know the study’s outcome. 
When asked for their ideas of how this should be done, letter was agreed to be the 
best option.  Internet based methods of communication were not felt to be the most 
appropriate: 
Participant D No I don’t think so 
Participant E I’m a complete technophobe! 
Participant D Not everyone has a computer or email.  A letter is far better.  
Group members were also enthusiastic about an event being held to feed back to 
the study participants and were also happy to attend such an event to obtain 
informal feedback themselves: 
Participant D Yes – then we can talk to participants and get feedback.  They might 
say things about service to us they wouldn’t say to you!! 
Other Points 
Various other comments were made by group members during this session which 
shed light on potential roles for and attitudes towards the MUR: 
Participant D: (Commenting on dMUR service) “This seems to be the way to go 
about it.  A service like this might stop people like me being on all these silly things 
for years and years.”  
14 
 
This positive comment also reveals a potential expectation on the part of patients 
that their medicines might be altered and rationalised as part of an MUR or dMUR.  
The need to manage patient expectations regarding the extent of community 
pharmacists’ power to make changes to medication also arose following session 1.  
The vast majority of community pharmacists are not prescribers and the extent to 
which they are able to liaise with GPs to make changes to prescriptions is variable 
(286,288,289,303,339).  It might be that a shift in this direction is needed to fully 
realise the potential of the MUR but it is likely that much closer working between 
GPs and community pharmacists would be required than is the norm at present.   
It arose during this session that something as simple as a transparent explanation 
of the concept of generic medication as part of the MUR or dMUR might be 
welcomed by patients: 
Participant D: I always use [names pharmacy] and they will keep changing the 
tablets.  Not what they are, just the makes, but they never tell you.  So you get 
home and get the boxes and think ‘those aren’t the same’ then you have to waste a 
phone call saying ‘these are different’ and they say ‘no they’re not, they’re just 
cheaper’.  So why don’t they tell you at the time?  And that’s another thing, 
probably for older people, they probably need that advice more than other people. 
Participant C: Yes.   
Participant D And they might think, ‘ohh, I better get on the bus and go back.’   It’s 
not really on I don’t think, to change all these things.  I can understand why they do 
it, it’s to save money, but it needs some explanation.  We just need to know what 
we’ve got. 
This might be particularly relevant following a hospital discharge, as even if a 
patient’s regular community pharmacy consistently uses the same generic version 
of a medicine, the hospital may well have dispensed a different version to top the 
patient up during admission or on discharge.  This may lead to confusion, wastage 
or even overdose if patients double up on some medicines.  A dMUR might 
therefore include a ‘cabinet check’ (which could be virtual if the dMUR takes place 
at the community pharmacy and patients bring along all stocks of medication from 
home). 
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Despite a generally positive attitude of all PPI group members towards the dMUR 
service, a point raised during session 1 (by participant B), that not all patients might 
be receptive to the concept, was repeated, on this occasion by participant F:  “I 
don’t think I’d be the right sort of person because everything is organised so well 
between my doctor and the pharmacist.”  Whether, with more careful explanation 
of the role of the dMUR service, such patients would realise unmet needs which 
could be fulfilled by a dMUR, is uncertain.  However the fact that both participants 
B and F had received a full explanation of the service during the PPI group 
sessions and yet still felt a dMUR was not for them makes this unlikely.  The reality 
that some potential participants might refuse to take part on these grounds, thereby 
limiting recruitment to the study, must be accepted. 
Another repeated theme from session 1 was group members’ frustration with the 
difficulty in making GP appointments, reinforcing the idea that there is a potential 
for dMURs to reduce pressure on GPs by answering questions that patients would 
otherwise have taken to the surgery. 
 
Session 3 – 20th August 2013 
This session focussed in more depth on the recruitment process for the study and 
the methods of follow-up to be employed. 
 
Maximising Recruitment 
All group members agreed that they would be most likely to participate if they were 
approached regarding the study by their hospital doctor, rather than a pharmacist 
or member of the research team.  However concerns were raised that the doctors 
might simply be too busy to take on this role, and in this case, their nurse was 
suggested as the next best option.  This suggests that patients would be more 
receptive to the idea of taking part in research if the topic was introduced by a 
healthcare professional they already knew and trusted.  Engaging all medical 
doctors and nurses at SONT to approach patients regarding participation in the 
study was, however, not considered feasible within the resources available.  This 
may place a further restraint on recruitment, if patients refuse because they are 
approached by someone unfamiliar.  It is hoped that, if ward pharmacists are able 
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to build up a relationship with their patients, they could successfully take on the 
role of first approach to potential study participants. 
Discussion also took place about how the approach to potential participants should 
be made.  Options included leaving the participant information leaflet with the 
patient to read through first, or introducing the study first and only leaving the 
leaflet if the patient showed an interest in participating.  All group members agreed 
that to have a general chat regarding the study and only leave the leaflet if interest 
shown was the best option.  Some group members felt that the leaflet was too long 
and that this might be off-putting. However the need to present full information was 
also appreciated.  Following discussion, it was decided to split the participant 
information into two leaflets.  The first would give a general overview of the study 
and the dMUR service and would be designed to be left with potentially interested 
patients by a member of ward staff (doctor, nurse or pharmacist) following a brief 
introduction to the study.  The researcher could then approach the patient to 
discuss participation in more depth and present part two of the information leaflet.   
 
Data Collection/Follow-up 
By this point in the study’s planning it had been decided not to contact participants’ 
GPs to see how many appointments they had had since discharge (Section 5.6.4).  
Copies of the ‘diary’ proposed instead in which participants could record healthcare 
professional contacts were circulated to group members.  All members agreed that 
it was reasonable to ask participants to record the visits in the diary and that the 
format of the diary was easy to use. 
Ways of maximising the return of the postal questionnaire were discussed, based 
on a Cochrane review on the subject (244).  The methods felt to be most suitable 
by the PPI group members were: 
 A follow-up contact by post with a second copy of the questionnaire.  Two 
weeks after the first questionnaire had been sent was felt to be a suitable time 
period for this, and only one follow-up was felt to be appropriate.  The group 
suggested encouraging participants by way of the covering letter to contact the 
researcher if they were having difficulty completing the questionnaire. 
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 Having the hospital’s logo or frank on the envelope and wording the covering 
letter as coming from the hospital (as opposed to the University as suggested 
by the Cochrane review) 
 Personalising the covering letter using mail merge. 
 Including a stamped (not franked) addressed envelope in which to return the 
questionnaire. 
Methods suggested by the Cochrane review that were felt to be definitely not 
appropriate included offering money as an incentive and contacting participants 
before sending the questionnaire.  Recorded delivery or first class mailing were felt 
to be an unnecessary expense. 
The latest draft of the follow-up questionnaire was reviewed by the group.  
Concerns arose that some questions might be missed as it was double sided.  
However it was also raised that using single sided production would increase costs 
and make the questionnaire more bulky and therefore off-putting to some 
participants.  Printing ‘PTO’ on relevant pages and numbering the pages was 
agreed as a compromise. 
Participant C also suggested changing some of the wording to the MMAS.  
‘Hassled’ was therefore replaced with ‘inconvenienced’, and Medication regimen 
with ‘medication routine’ as these were felt to be more suited to older English 
participants. 
Additionally, a phrase at the end of the questionnaire reminding participants to 
return it in the envelope provided was added. 
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Appendix 3: Estimating Eligibility for Medicines Support Study – Emergency 
Admission Unit (EAU) Pilot 3-14th June 2013 
 
Eligibility Criteria Being Screened in This Piece of Work 
 Under care of medical directorate 
 Aged 65 years or older 
 Using at least one medication prior to admission 
 Self-medicating at home 
 Can nominate a regular community pharmacy  
 
Pharmacist / Ward Based Technician Roles 
 
As part of medicines reconciliation, two additional questions need to be asked of medical 
patients aged >65 (unless already obvious from the clinical notes): 
 
1) Do you manage your own medications at home?  
If the patient answers yes: 
2) Which community pharmacy do you normally use? 
 
Annotate bed plan: 
SM = self medicates 
<65 = patient less than 65 years old 
NRM = no regular medicines 
S = surgical patient 
Carer = carer manages medicines 
NH = from nursing home 
 
If patient unable to tell you the answer to one / both of the above, put “?” 
 
 
An Example 
SM from 
pharmacy name 
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Note on multidose compliance aids (MCA) 
It may seem inappropriate to classify a patient as ‘self-medicating’ if they use an MCA 
prepared by some-one else (e.g. carer or community pharmacy).  It is important to note, 
however, that patients who use MCAs may also use medicines not contained within the 
MCA, e.g. inhalers, liquids, patches, injections, ‘when required’ items and medicines with 
special administration requirements, such as warfarin,  bisphosphonates, calcium /vitamin 
D supplements, soluble aspirin.   These medicines are often those that are more complex 
to take and thus may be subject to poor adherence.  Therefore if a patient who uses an 
MCA plus additional medications views themselves as self-medicating, they should be 
classed as such. 
 
Results 
Date No. new 
Patients 
Seen 
Self 
med? 
Regular 
chemist? 
Unable 
to ask 
Excluded 
<65 NRM Surgical Carers NH Other 
3/6/13 17 9 8 1 2 1 0 2 1 1 deaf 
4/6/13 17 3 3 2 8 1 3 0 0 0 
5/6/13 15 2 2 1 3 0 3 4 1 1 Polish 
6/6/13 17 5 5 3 3 0 0 3 3 0 
7/6/13 20 1 1 9 2 2 1 2 2 1 out of 
area 
11/6/13 21 4 2 7 6 0 1 1 2 0 
12/6/13 17 6 5 3 4 0 1 3 0 0 
13/6/13 21 5 5 3 5 1 0 4 3 0 
14/6/13 20 5 5 3 6 0 2 1 2 1 
Spanish 
Total 165 40 36 32 39 5 11 20 14 4 
 
Total number medical patients = 154 
Total number eligible for referral to researcher (excluding those unavailable for 
questioning) = 36 
Percentage eligible for referral = (36/154)*100 = 23% 
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Medical Discharge Prescriptions Processed by Pharmacy on the First Weekday of 
Each Month between July 2012 and June 2013 
Date Total Discharges Medical Discharges (Excluding 
patients discharged from surgical 
wards, EAU and Observation 
Ward) 
1/7/12 27 17 
1/8/12 41 19 
1/9/12 35 21 
3/10/12 41 24 
1/11/12 58 29 
1/12/12 41 32 
3/1/13 42 20 
1/2/13 35 24 
1/3/13 51 28 
2/4/13 36 27 
1/5/13 40 18 
1/6/13 47 32 
Mean 41 24.25 
 
Estimated number eligible for referral to researcher = 0.23*24.25 = 5.58 
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Appendix 4: Graphs Showing Relationship between Sample Size and Power 
to Detect a Specific Effect Size  
 
Figure A4.1 Relationship between Sample Size and Power to Detect Effect Size of 
0.3 (With thanks to Dr Sven Batke) 
 
 
Figure A4.2 Relationship between Sample Size and Power to Detect Effect Size of  
0.7 (With thanks to Dr Sven Batke) 
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Appendix 5: Covering Letter and Information Leaflet Sent to Participants’ 
GPs  
Helen Ramsbottom 
Clinical Pharmacist and Chief Researcher for Medication Support Study 
Southport and Ormskirk Hospitals NHS Trust 
Town Lane 
Kew 
Southport 
PR8 6PN 
Tel: 01704 704161 
Mobile: 07932506802 
Fax 01704 704197 
Email Helen.ramsbottom@nhs.net 
 
 
Dear GP, 
 
Re:……………………………… DOB:………………… NHS No:…………………… 
 
The patient identified above has agreed to take part in the Medicines Support Study 
 
I am a specialist care of the elderly pharmacist and am also undertaking a PhD with the 
University of Wolverhampton and Southport and Ormskirk NHS Trust.  My research will 
investigate whether a medicines adherence support service can improve medication 
adherence and reduce GP visits and hospital re-admissions.  The study will involve the 
pharmacy department at the hospital referring suitable patients for a post discharge 
Medicines Use Review with their community pharmacist, and comparing their medication-
related experiences and outcomes with a similar group of patients who have not been 
referred.  More details about the study can be found attached. 
 
If you have any questions regarding the study, please do not hesitate to contact me using 
the details above. 
 
Yours sincerely, 
 
 
 
 
Helen Ramsbottom 
Clinical Pharmacist and Chief Researcher for Medication Support Study 
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What is the study? 
We are trying to find out if having a post discharge Medicines Use Review (MUR) with a community 
pharmacist improves patient medication adherence and reduces hospital re-admissions. 
 
Between one-third and half of all medicines for long term conditions are not taken as 
recommended.  Following a medication routine after being in hospital is particularly difficult as 
nearly two thirds of people have three or more medicines changed during a hospital stay and 
almost half experience an error with their medication on discharge. 
 
We will be identifying patients who have risk factors for medicines related problems and referring 
them for a post discharge MUR with their regular community pharmacist.  We will follow up these 
patients and compare them to another group of patients who have not been referred for an MUR. 
 
In the initial feasibility study, we will be setting up a robust referral process from the hospital 
pharmacy to community pharmacists.  We also want to check that the way we plan to collect our 
results will work.  This feasibility study will involve up to 100 patients in total.  We then hope to 
expand the study to conduct a full randomised controlled trial, evaluating a range of outcomes 
including readmissions, health related quality of life, enablement, medication adherence and the 
need for post discharge GP visits. 
 
Why has my patient been recruited? 
We are recruiting patients aged 65 and older who are either taking multiple medicines or have had 
medication changes whilst in hospital.  The patient named on the accompanying letter has been 
identified using these criteria and has consented to take part in the study. 
 
What will happen to my patient during the study? 
If one of your regular patients is selected to receive an MUR as part of the study, their usual 
community pharmacist will receive a copy of the discharge medication and a referral form 
highlighting any changes in medication that have gone on during admission.  They will arrange an 
appointment with the patient within four weeks of discharge in order to carry out the MUR. 
 
During the MUR, the community pharmacist will assess any problems the patient is having with their 
medication that may limit adherence.  These may include forgetfulness, lack of understanding of the 
purpose or importance of the medication, physical difficulty with taking the medication or side 
effects.  The pharmacist will discuss ways of resolving these issues and ensure the patient 
understands the purpose of and best way to take each medicine.   
 
Following the MUR, the community pharmacist will return a copy of the action plan produced to the 
hospital by fax or email.  This will help us to improve the medicines service we give to patients 
whilst they are in hospital.  Patients will have agreed to have this information shared with the 
researcher during the initial consent process.  
 
In order to determine if post discharge MURs improve outcomes, there will also be another group of 
patients within the study who are not referred for an MUR.  These patients will receive standard 
discharge information including a leaflet explaining the services offered by community pharmacies.  
Some of these patients may seek an MUR independently and will be treated in the same way as 
any other post-discharge patient.  This will be explored with the patient at follow-up and ensures 
that no patient will be denied an MUR as part of the study. 
 
 
General Practitioner Information—Medicines Support Study 
4 
 
We will contact all patients by post at one and six months after discharge and ask some simple 
questions to evaluate their current medication taking behaviour. Some patients will be interviewed 
in more depth about their medication-related experiences since returning home.  We will ask them 
about the medicines information given to them by the hospital, any medication review they have 
had (MUR or otherwise), and any hospital or GP visits. 
 
Will I be expected to do anything extra? 
We hope that GP time will actually be saved as part of the study, as medication education following 
discharge will be provided by community pharmacists, rather than requiring an appointment with the 
GP.  However a community pharmacy MUR is not a clinical review and you should continue your 
usual practice for reviewing the clinical aspects of the patient’s post discharge medication.  
 
The community pharmacist will usually only contact you if they have a specific recommendation to 
make requiring your action.  This is in-line with the national service specification for MURs that all 
community pharmacists follow.   The researchers will not contact you with recommendations.   
 
What will happen to the results of the study? 
The results will be included in the researcher’s PhD thesis.  They will also be presented to 
representatives from the Local Pharmaceutical Committee, Local Professional Network, NHS 
England and interested community and hospital  pharmacists.  Summaries of the results will be sent 
out to all community pharmacists and GPs whose patients have been participants in the study.  The 
results may also be made available to a peer reviewed journal.   
 
No-one will be able to identify you or your patient from the results of the study and all information 
given will be completely confidential. 
 
Does my patient have to take part? 
Your patient has given voluntary, informed consent to take part in the study.  They are free to 
withdraw at any time, without giving a reason. The patient’s consent form for the study is attached 
for your records. If you have any concerns regarding your patient’s participation, please contact us 
using the details below. 
 
Authorisation From Ethics Committee 
Ethical approval has been granted by the University of Wolverhampton, by Southport and Ormskirk 
NHS Trust, and by the Northwest NHS Research Ethics Committee. 
 
Contact for Further Information: 
If you have any questions about the study please contact the lead investigator, Helen Ramsbottom, 
or the university supervisors, who will be pleased to help you: 
 
Helen Ramsbottom    Professor Ray Fitzpatrick/ Dr Paul Rutter 
(Supervisors) 
Pharmacy Department    Pharmacy Practice Division 
Southport District General Hospital  Department of Pharmacy 
Town Lane     School of Applied Sciences 
Kew, Southport     University of Wolverhampton 
PR8 6PN     Wulfrana Street, WV1 1LY 
Tel: 01704 704161 / 07932506802  Tel: 01902 322173 
Email: helen.ramsbottom@nhs.net Email:ray.fitzpatrick@wlv.ac.uk/paul.rutter@wlv.ac.uk 
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Appendix 6: PPI Group Recruitment Flyer 
 
  
Medication Support Study—We Need Your Help! 
What is the medication support study? 
We are trying to find out if having a medication use review (MUR) with a community 
pharmacist helps people aged 65 or older to manage their medicines after they have 
been in hospital. 
Why do we need you? 
To help us plan and carry out the study in the best possible way, we need the views 
of patients, their friends, families and carers.  This will help make sure we get the 
answers that really matter to our patients. 
What is needed from you 
We will be setting up group or one-to-one discussions about the support people are 
given to manage their medicines and the questions our research is trying to answer.  
You will be invited to give your opinions on what will happen to patients who 
participate in the study, as well as some of the paperwork that will be used.   
How to get involved 
If you are interested in becoming involved, or would like to find out more information, 
please contact: 
Helen Ramsbottom 
Pharmacy Department 
Southport and District General Hospital 
Telephone 01704 704161 
Email Helen.ramsbottom@nhs.net  
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Appendix 7: PPI Group Recruitment Letter Published in SONT Foundation 
Trust Members Newsletter December 2012 
Helen Ramsbottom 
Clinical Pharmacist and Chief Researcher for Medication Support Study 
Southport and Ormskirk Hospitals NHS Trust 
Town Lane 
Kew 
Southport 
PR8 6PN 
Tel: 01704 704161 
Bleep 3737 via switchboard 01704 547471 
Fax 01704 704197 
Email Helen.ramsbottom@nhs.net 
 
Dear Foundation Trust Member, 
 
Medication Support Study Patient Involvement 
 
I am one of the clinical pharmacists at Southport and Ormskirk Hospitals NHS Trust and 
am also working on a PhD with the University of Wolverhampton.  I am investigating ways 
in which pharmacists can help people to get the maximum benefit from their medication. 
 
I am trying to find out if having a Medicines Use Review (‘MUR’) with a community 
pharmacist, shortly after being discharged from hospital, helps people to manage their 
medicines more effectively. 
 
In order to make sure my research provides the best possible information I would like to 
gain the perspective of patients and members of the public who may use our hospital 
services.  This is likely to involve group or one-to-one discussions about the support 
people are given to manage their medicines and the questions I am trying to answer 
through doing my research.  You will be invited to give your opinions on what will happen 
to patients who participate in the study, as well as some of the paperwork that will be used.   
 
If you are interested in becoming involved, or would like to find out more information, 
please do not hesitate to contact me using the details at the top of this letter. 
 
Yours sincerely, 
 
 
 
 
Helen Ramsbottom 
Clinical Pharmacist and Chief Researcher for Medication Support Study 
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Appendix 8: dMUR Referral Form 
 
 
Community pharmacy referral for post discharge Medicines Use Review 
Patient name:  Date discharged:  
NHS number:  Usual community pharmacy:  
Address:  Other relevant patient information:  
Contact telephone 
number: 
 GP details: 
 
To the community pharmacist, the above patient has been recruited into the Medicines Support 
study.  Please review the following changes with the patient as part of a Medicines Use Review. 
New or changed medicines and directions 
include dose and formulation changes 
Reasons and suggested follow up 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stopped medicines 
include rationale and recommendations if needed 
 
  
Please find a current medication list for this patient attached to this referral form 
Allergies   
Causative medicine Brief description of reaction Probability of occurrence 
   
   
 
Name of person referring: Helen Ramsbottom 
Job title: 
Clinical pharmacist and chief researcher for Medication Support 
Study 
Name and address of 
organisation: 
Southport and Ormskirk Hospitals NHS Trust 
Town Lane, Kew, Southport, PR8 6PN 
Telephone number & bleep: 01704 704161 (Pharmacy Direct Line) or Mobile 07932506802 
Email address: helen.ramsbottom@nhs.net 
Fax number: 01704 704197 
Signed:  
Please return a copy of issues identified and actions suggested during the MUR(e.g. MUR 
action plan) to the researcher using the details above 
WE ASK THAT YOU ACKNOWLEDGE RECEIPT OF THIS REFERRAL BY RETURN FAX OR 
TELEPHONE CALL TO THE NUMBER ABOVE 
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Appendix 9: Participant Consent Form 
 
Study Number:2012/028 SISD 
Patient Identification Number for this trial: 
Chief Researcher: Helen Ramsbottom 
 
Informed Consent Form (Participant): Medicines Support Study 
 
The Medication Support Study will involve the pharmacy department at Southport District 
General Hospital identifying people who might benefit from a Medicines Use Review (MUR) 
with their community pharmacist.  Half of these people will be referred for an MUR whilst the 
other half will not.   Everyone who takes part will be asked to answer some questions four 
weeks and six months after being discharged from hospital.  This will usually be by post, but 
some people will be contacted to arrange a face to face discussion. 
 
If you have read the information about the study and are willing to participate please complete 
and sign this form.  It will then be collected by a member of the pharmacy team.  Alternatively, 
you can give this form to a member of nursing staff and ask them to return it to the pharmacy 
department. 
Please initial each box 
I have read and understood parts 1 and 2 of the information sheet dated December 
2013 (version 3) for the above study. 
 
I have had the opportunity to ask questions about the study and have had them 
answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving a reason, without my medical care or legal rights being affected. 
 
I understand that the information I give as part of the study may be shared with my 
regular community pharmacy and the hospital pharmacy.  I give permission for this 
sharing of information. 
 
I understand that relevant sections of my medical notes will be looked at by the 
researchers in order to collect background information relevant to my participation in 
the study, and if I am re-admitted to hospital in order to work out if my re-admission 
could have been influenced by my medication.  I give permission for the researchers to 
have this access. 
 
I understand that relevant sections of my medical notes and data collected during the 
study, may be looked at by individuals from the University of Wolverhampton and from 
the NHS, where it is relevant to my taking part in this research.  I give permission for 
these individuals to have access to my records. 
 
I understand that I may be contacted to arrange a face to face interview with a 
pharmacist.  I agree to the interview being audio recorded, and to anonymous quotes 
being used in the study report. 
 
I agree to my GP being informed of my participation in the study.  
I agree to take part in the above study  
 
Name of participant: Date: Signature: 
Name of person taking consent: Date: Signature: 
When complete copy: 1 for participant, 1 for research site file (fax to GP and community pharmacist 
on discharge), 1 (original) to be kept in medical notes 
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Appendix 10: Covering Letter and Information Leaflet Sent to Community 
Pharmacies 
Helen Ramsbottom 
Clinical Pharmacist and Chief Researcher for Medication Support Study 
Southport and Ormskirk Hospitals NHS Trust 
Town Lane 
Kew 
Southport 
PR8 6PN 
Tel: 01704 704161 
Bleep 3737 via switchboard 01704 547471 
Fax 01704 704197 
Email Helen.ramsbottom@nhs.net 
 
 
Dear Community Pharmacist, 
 
Medication Support Study 
 
Would you like to receive post discharge MUR referrals for pre-screened patients, along 
with a copy of their discharge medication and information on changes to medications 
during admission?  All you will have to do is contact the patient to arrange a convenient 
time for the MUR, and return a copy of your actions to the hospital afterwards.  
 
I am a specialist pharmacist at Southport and Ormskirk Hospitals NHS Trust.  I am also 
undertaking a PhD with the University of Wolverhampton.  If you have not signed up 
already, I would like to invite you to be part of the ‘Medication Support Study’.  
 
My research will investigate whether a medicines adherence support service can improve 
patient medication adherence and reduce GP visits and hospital re-admissions.  The initial 
study will involve the pharmacy department at the hospital referring suitable patients for a 
post discharge MUR with their community pharmacist, and comparing their medication-
related experiences and outcomes with a similar group of patients who have not been 
referred.  More details about the study, and a consent form for you to return if you are 
willing to take part, can be found attached. 
 
If you have any questions regarding the study, please do not hesitate to contact me using 
the details above. 
 
Yours sincerely, 
 
 
 
 
Helen Ramsbottom 
Clinical Pharmacist and Chief Researcher for Medication Support Study 
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What is the study? 
We are trying to find out if having a post discharge Medicines Use Review (MUR) with a 
community pharmacist improves patient medication adherence and reduces hospital re-
admissions. 
 
Between one-third and half of all medicines for long term conditions are not taken as 
recommended.  Following a medication routine after being in hospital is particularly difficult as 
nearly two thirds of people have three or more medicines changed during a hospital stay and 
almost half experience an error with their medication on discharge. 
 
We will be identifying patients who have risk factors for medicines related problems and 
referring them for a post discharge MUR with their regular community pharmacist.  We will 
follow up these patients and compare them to another group of patients who have not been 
referred for an MUR. 
 
Why should I take part? 
Following the changes to the NHS Community Pharmacy Contract in October 2011, half of all 
MURs conducted have to be targeted towards specific patient groups, one of which is those 
that have recently been discharged from hospital.  By taking part in the study, you will receive 
referrals from the hospital for patients we have identified as being at risk of medication related 
problems post discharge.  This will help you to identify patients who will benefit from an MUR 
and provide the basis for its content. 
 
Providing feedback to the hospital will help us to identify ways to improve our own medication 
support services to patients, which may reduce problems with medication post discharge in the 
future.  
 
What will happen if I decide to take part? 
If one of your regular patients is selected to receive an MUR as part of the study, we will fax 
you a referral form detailing their discharge medication and any medication related problems 
identified during admission. 
 
You can then contact the patient to arrange a mutually convenient time for the MUR.  
According to the national guidance, the MUR should normally take place within 4 weeks of 
discharge. 
 
Following the MUR, we would like you to return a copy of the action plan (or feedback on 
matters identified and actions taken if no action plan is produced) to us by fax or email.  This 
will help us to improve the medicines service we give to patients whilst they are in hospital.  
Patients will have agreed to have this information shared with the researcher during the initial 
consent process.  
 
In order to determine if post discharge MURs improve outcomes, there will also be another 
group of patients within the study who are not referred for an MUR.  These patients will receive 
standard discharge information including a leaflet explaining the services offered by community 
pharmacies.  Some of these patients may seek an MUR independently and should be treated 
in the same way as any other post-discharge patient.  This will be explored with the patient at 
follow-up and ensures that no patient will be denied an MUR as part of the study. 
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All patients referred to you for an MUR as part of the study have been fully informed regarding 
the nature of the study and their consent to take part will have been gained. 
 
We may also ask you to provide feedback on the quality of the referrals you receive from the 
hospital, to help us review the information we supply on referral and how we identify suitable 
patients to refer. 
 
What will happen to the data I provide? 
Feedback regarding MUR action plans will be used in two ways: 
 The number and type of issues addressed during MUR will help to identify recurrent adherence 
problems faced by patients after discharge.  This will inform improvement of the medicines 
support services provided to patients who are or have recently been in hospital. 
 Discussion of their MUR with patients during follow-up interviews will help to find out whether 
recommendations made by community pharmacists are acted on by patients and whether 
these improve adherence 
 
What will happen to the results of the study? 
The results will be included in the researcher’s PhD thesis.  They will also be presented to 
representatives from the Local Pharmaceutical Committee, Local Professional Network, NHS 
England and interested community and hospital pharmacists.  Summaries of the results will be 
sent out to all community pharmacists and GPs whose patients have been participants in the 
study.  The results may also be made available to a peer reviewed journal.   
 
No-one will be able to identify you from the results of the study and any information you give 
will be completely confidential. 
 
Do I have to take part? 
All community pharmacies in Sefton and West Lancs are being asked to take part in the study.  
However it is your decision whether you want to be involved.  You are free to withdraw at any 
time, without giving a reason.   
 
Authorisation From Ethics Committee 
Ethical approval has been granted by the University of Wolverhampton, the Research and 
Development Department at Southport and Ormskirk NHS Trust, and the Northwest NHS 
Research Ethics Committee (pending). 
 
What should I do now if I want to take part? 
If you would like to take part in the study, please complete the attached consent form and 
return it by email or fax to: helen.ramsbottom@nhs.net , or 01704 704197 
 
Contact for Further Information: 
If you have any questions about the study before deciding to take part, please contact the lead 
investigator, Helen Ramsbottom, or the university supervisors, who will be pleased to help you: 
 
Helen Ramsbottom   Professor Ray Fitzpatrick/ Dr Paul Rutter (Supervisors) 
Pharmacy Department   Pharmacy Practice Division 
Southport District General Hospital Department of Pharmacy 
Town Lane    School of Applied Sciences 
Kew, Southport    University of Wolverhampton 
PR8 6PN    Wulfrana Street, WV1 1LY 
Tel: 01704 704161   Tel: 01902 322173 
Email: helen.ramsbottom@nhs.net     Email: ray.fitzpatrick@wlv.ac.uk / paul.rutter@wlv.ac.uk 
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Appendix 11: Community Pharmacist Consent Form 
   
 
 
 
Informed Consent Form (Community Pharmacy): Medicines 
Support Study 
 
If you have read the information about the study and are willing to participate please 
complete and sign this form and return it by email or fax to: helen.ramsbottom@nhs.net , or 
01704 704197 
 
Please tick each box 
I have read and understood the information sheet for the study  
I have had the opportunity to ask questions about the study and have had them 
answered satisfactorily 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason 
 
I understand that any information I give as part of the study, including patient 
details, will be treated with strict confidentiality and that I will be anonymous in 
any written reports from the research 
 
I agree to take part in the study  
 
In addition, we would be grateful if you could provide the following information: 
I am able to offer telephone MURs Yes   No  
I am able to offer domiciliary MURs Yes                 No  
I would prefer to receive referrals and other 
information relating to the study by: 
Email:    
Fax:       
My email address / fax number is: 
 
Name and address of pharmacy: 
 
 
 
 
Contact number: 
 
 
Signed: 
 
Date: 
Print Name: 
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Appendix 12: Initial contact slip for potential participants 
 
Dear ……………………………………… 
One of the hospital’s pharmacists is going to see you about a project looking at how we 
can better support patients with their medication on discharge from hospital.  Your 
consultant…………………………………… knows about this project and is in support. 
Signed ………………………………………………… (Consultant, Ward ………………….) 
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Appendix 13: Participant Information Part 1 
 
 
 
 
 
 
What is the study? 
Between one-third and half of all medicines for long term conditions are not taken 
as recommended.  Following a medication routine after being in hospital is 
particularly difficult as nearly two thirds of people have three or more medicines 
changed during a hospital stay and almost half experience an error with their 
medication on discharge. 
 
We are trying to find out if having a Medicines Use Review (‘MUR’) with a 
community pharmacist helps people aged 65 or older to manage their medicines 
after being in hospital. 
An MUR provides an opportunity for people to find out more about the medicines 
they are taking and pick up and tackle any problems they are having with their 
medicines.   
 
The research we are inviting you to take part in is called a feasibility study.  The 
results will be used to help improve the medicines service people receive when 
they are discharged from hospital.  They will also be used to help us plan a larger 
study to look at the benefits of the service in more detail.   
This part of the study will involve about one hundred patients in total.   
 
Do I have to take part? 
It is your decision whether you want to be involved in the study.  If you decide to 
take part, you are free to withdraw at any time, without giving a reason.  Any 
information you have given us can be destroyed if you wish.  You can still ask your 
community pharmacist for help with your medicines even if you are not taking part 
in the study. 
 
What will happen if I decide to take part? 
People who agree to take part in the study will be divided randomly into two groups 
(meaning you have an equal chance of being in either group).  This is called a 
randomised controlled trial (RCT).  RCTs are used in research when we want to 
compare different ways of treating people, to see if one is any better than the other.  
 
People in the first group will be referred to their usual community pharmacist for an 
MUR.  People in the second group will not be referred.  They will be called the 
control group. 
 
If you are referred for an MUR, we will send the community pharmacist details of 
any medicines that have changed during your hospital stay along with a full list of 
your discharge medication and the ward you were on, to help them prepare for 
your MUR.  No details of the reason for your admission will be sent.   
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People in the MUR group will be contacted at home by their community pharmacist 
to arrange a convenient time for them to attend the pharmacy for their MUR.  The 
MUR will take place within 4 weeks of you being discharged from hospital.  You will 
be informed before your discharge if you are going to be referred for an MUR.  
Otherwise you will be discharged as normal and your community pharmacy will not 
contact you to arrange an MUR.  If this happens to you and you would like more 
information about your medicines, you can still ask for help from your community 
pharmacist. 
 
During an MUR, your community pharmacist may produce an ‘action plan’ of the 
advice they give you.  As part of the study, the hospital will also receive a copy.  
This will help us to improve the medicines service we give to patients whilst they 
are in hospital.   
 
One month after your discharge, whether you received an MUR or not, you will 
receive some questions in the post.  You will be asked around 20 questions, about 
how you are taking your medicines and your general state of wellbeing.  This will 
take about 10 minutes.  We will provide a stamped addressed envelope for you to 
post your answers back.  A similar questionnaire will be sent six months after your 
discharge.  
 
Some people from the MUR group and the control group will be telephoned just 
before their first questionnaire to arrange a home visit by a pharmacist.   If you are 
visited at home, you will be asked in more detail about the medicines information 
given to you by the hospital, your MUR if you had one, and any other help you 
have had with your medicines since being discharged.  This should not take longer 
than 30 minutes.  These discussions will be audio recorded but will be anonymous 
(no-one will know who you are afterwards).  The discussions will help us to find out 
how much benefit people get from having an MUR, so that we can decide whether 
or not to refer more patients for an MUR in the future. 
 
We will also look at the hospital’s patient tracking system to see if you have been 
back into hospital in the first six months after agreeing to take part in the study.  If 
you have been back into hospital we will look at your records to see if your 
admission could have been related to problems with your medication.  This will 
help us to find out if people who have had an MUR are more or less likely to be 
taken back into hospital than people who have not. 
 
If this information has interested you and you are considering participation, 
please let your doctor, nurse or ward pharmacist know.  The research 
pharmacist or pharmacy technician will visit you later today or tomorrow to 
provide you with some more detailed information and answer any questions 
you have about the study. 
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Appendix 14: Sticker Applied to Case notes of Eligible Patients 
This patient has been identified as 
eligible for the Medicines Support Study 
 
REC Ref: 13/NW/0779 
 
Local Ref: 2012/028 SISD 
 
Initial information has been given to the 
patient 
  
  Signed: …………………………………….  
 
   
Position…………………………………… 
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Appendix 15: Participant Information Part 2 
 
 
 
 
 
 
What happens if I don’t want to carry on with the study? 
You can withdraw from the study at any time, without giving a reason.  We will still use 
information collected from you up to your withdrawal. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study will be addressed.  
If you have a concern about any aspect of the study, you should ask to speak to the 
researchers who will do their best to answer your questions. Contact details are at the end 
of this leaflet.   If you remain unhappy and wish to complain formally, you can do this in 
writing or by email to Southport & Ormskirk NHS Trust.  Leaflets explaining our complaints 
policy are available across the hospital, and via the Trust website: 
www.southportandormskirk.nhs.uk/PALS/ 
 
Will my taking part in the study be kept confidential? 
No-one will be able to identify you from the results of the study and the information 
collected about you will be completely confidential.   
 
Interview recordings will be transferred into writing as soon after the interview as possible, 
and then the original recording will be destroyed.    Direct quotes from the discussions may 
be used in the report of the study, but again no-one will know that it is you who said those 
words.   
 
All the information you give will be stored on a computer network that only the chief 
researcher will be able to access. As soon as the researcher’s PhD is complete (Spring 
2017), all records that could identify you will be securely destroyed. 
 
Will my GP know that I am taking part in the study? 
If you decide to take part in the study, we will send your GP a letter to let them know. 
 
What will happen to the results of the study? 
We should have all the results of the study by Autumn/Winter 2015.  The results will be 
presented to the people looking after the hospital and community pharmacies in the area.  
A meeting for patient support groups, patients and carers will also be organised, which you 
will be welcome to attend.  The results may also be made available for an approved 
medical or scientific journal.  They will be published on the Southport and Ormskirk NHS 
Trust website, and maybe also in a local newspaper.  The data will also form part of a PhD 
study conducted by the chief researcher, Helen Ramsbottom.  
 
A copy of the results will be sent to you, your community pharmacist and your GP.   
 
Who is organising and funding the research? 
The research is being organised by a pharmacist from Southport & Ormskirk NHS Trust, in 
association with the University of Wolverhampton.  The consultants Dr Horsley and Dr 
McDonald are also supporting the research.  We are hoping to get some funding from the 
National Institute for Health Research but this is not certain yet.  No-one will be paid for 
including you in the study. 
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Who has reviewed the study? 
All research in the NHS is scrutinised by an independent group of people, called a 
research ethics committee, to protect your interests.  This study has been reviewed and 
given a favourable opinion by the University of Wolverhampton, Southport and Ormskirk 
NHS Trust, and by the NHS Northwest Research Ethics Committee. 
 
What should I do now if I want to take part? 
If you would like to take part in the study, please complete the consent form and return it to 
a member of the research team, your ward pharmacist or pharmacy technician.  Or you 
can give the consent form to a member of nursing staff and ask them to return it to the 
pharmacy department. 
 
Contact for Further Information: 
If you have any questions about taking part in this study, please ask your ward pharmacist 
or pharmacy technician on their next visit.  If you would like to speak to the chief 
investigator, one of the consultants or the university supervisors, please inform your ward 
pharmacist or pharmacy technician, or use the contact information below: 
 
Helen Ramsbottom 
Pharmacy Department 
Southport & Ormskirk NHS Trust 
Town Lane 
Kew, Southport 
PR8 6PN 
Tel: 01704 704161/07932506802 
Email: helen.ramsbottom@nhs.net 
 
Dr John Horsley / Dr Patrick McDonald 
Southport & Ormskirk NHS Trust 
Town Lane 
Kew, Southport 
PR8 6PN 
Tel (secretary): 01704 705181 
 
Professor Ray Fitzpatrick/ Dr Paul Rutter (Supervisors) 
Pharmacy Practice Division 
Department of Pharmacy 
School of Applied Sciences 
University of Wolverhampton 
Wulfrana Street, WV1 1LY 
Tel: 01902 322173 
Email: ray.fitzpatrick@wlv.ac.uk / paul.rutter@wlv.ac.uk 
 
Further general information about taking part in research can be found at: 
http://www.nhs.uk/Conditions/Clinical-trials/Pages/Introduction.aspx 
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Appendix 16: Sticker Applied to Case Notes of Recruited Participants 
This patient has been recruited into 
the Medicines Support Study 
 
REC Ref: 13/NW/0779 
 
Local Ref: 2012/028 SISD 
 
   Signed: ……………………………….  
 
   Position……………………………… 
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Appendix 17: Participant Baseline Demographics Data Capture Form 
 
 
Medicines Support Study Data Capture Form: Baseline Characteristics 
Participant ID:………………………………………… 
Characteristic Value 
Age  
Female  
Living alone  
No. meds  
Consultant speciality  
Medication complexity index  
Cognitive impairment  
No. co-morbidities  
Admission within last 30 days  
No. admissions in last 12 months  
Length of baseline admission (days)  
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Appendix 18: Participant Diary 
            
Medicines Support Study  
 
Participant Diary 
Name:………………………………………………. 
 
Date:………………………………………………... 
Helen Ramsbottom 
Pharmacy Department 
Southport and District General  
Hospital 
Telephone 01704 704161 
If you need any help or would like to ask a 
question about the study, please contact: 
2 
 
 
 
  
Date What type of visit was it?  
E.g. GP appointment, 
hospital admission 
What was the reason for the visit?  (You 
do not have to complete this section if you 
do not want to) 
   
   
   
   
   
   
   
   
Please use this booklet to record every time you see your GP, pharmacist or go to the hospital.  
If you do not want to include the reason for the visit, just write the date and who you saw. 
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Appendix 19: Follow-up Questionnaire 1 – Control Group 
 
 
 
 
 
 
 
 
If you would prefer not to answer a particular question, you do not need to 
 
1.  Are you still managing your medication on your own at home? 
 
Yes □  Continue to question 2 
 
No □ Who helps 
you?................................................................................................. 
 
If you answered No, you do not need to continue with this questionnaire.  Please return it 
in the stamped addressed envelope provided. 
 
 
2. Has anyone reviewed your medication since you came out of hospital? 
 
Yes □ Who was this?................................................................................................ 
  Did you request the review?   Yes □ 
        No, they offered  □ 
No □  Continue to question 3 
 
 
3. Do you sometimes forget to take your medication? 
Yes □ No □ 
 
4. Over the past two weeks, were there any days when you did not take all of your 
medication?    
Yes □ No □ 
 
5. Have you ever cut back or stopped taking your medication without telling your 
doctor, because you felt worse when you took it?  
Yes □ No □ 
 
6. When you travel or leave home, do you sometimes forget to bring along your 
medications? 
Yes □ No □ 
 
7. Did you take all of your medication yesterday? 
Yes □ No □ 
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8. When you feel like your health is good, do you sometimes stop taking your 
medicine? 
Yes □ No □ 
 
Please turn over 
9. Taking medication every day is a real inconvenience for some people. Do you 
ever feel inconvenienced about sticking to your daily medication routine? 
Yes □ No □ 
 
 
10. How often do you have difficulty remembering to take all your medication?  
Circle one answer 
Never/rarely   4 
Occasionally   3 
Sometimes   2 
Often    1 
Every day   0 
 
 
For each of the following questions, please tick the one box that best 
describes your answer. 
 
11. In general, would you say your health is: 
12. The following questions are about activities you might do during a typical day.  Does 
your health now limit you in these activities?  If so, how much? 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
    
 a Moderate activities, such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf ...................  1 ...........  
2 ....................................................................................  3 
 b Climbing several flights of stairs ...................................  1 ...........  
2 ....................................................................................  3 
 
 
 
 
 
Excellent Very good Good Fair Poor 
     
   1    2    3    4    5 
     
 3 
 
14. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of any emotional problems (such as feeling depressed or 
anxious)? 
15. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)?  
Not at all A little bit Moderately Quite a bit Extremely 
     
   1    2    3    4    5 
Please turn over 
  
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Accomplished less than you  
  would like .................................  1 ............  2 ...........  3 ...........  4 ............  5 
 b Were limited in the kind of  
  work or other activities .............  1 ............  2 ...........  3 ...........  4 ............  5 
13.  During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result 
of your physical health?  
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the 
time 
      
 a Accomplished less than you  
  would like .................................  1 ............  2 ............  3 ............  4 ...........  
5 
 b Did work or other activities 
  less carefully than usual ..........  1 ............  2 ............  3 ............  4 ...........  
5 
 4 
 
 
16. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer 
that comes closest to the way you have been feeling.  How much of the time 
during the past 4 weeks… 
17. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends, relatives, etc.)? 
 
 
 
 
 
 
 
Thankyou for completing this questionnaire!  Please return it in the stamped addressed 
envelope provided 
 
 
Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license 
agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive 
South, Los Angeles, CA 90095-1772. 
SF-12v2® is a trademark of the Medical Outcomes Trust and is used under license.   
The SF-12v2® Health Survey is copyrighted by QualityMetric Incorporated 
 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a   Have you felt calm and   
peaceful? .................................  1 ...........  2 ...........  3 ............  4 ............  5 
 b   Did you have a lot of energy? ..  1 ...........  2 ............  3 ............  4 ............  5 
 c   Have you felt downhearted   
and low? ...................................  1 ...........  2 ...........  3 ............  4 ............  5 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
     
   1    2    3    4    5 
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Appendix 20: Follow-up Questionnaire 1 – Intervention Group 
 
 
 
 
I 
If you would prefer not to answer a particular question, you do not need to 
 
1.  Are you still managing your medication on your own at home? 
 
Yes □  Continue to question 2 
 
No □ Who helps 
you?.............................................................................................. 
 
If you answered No, you do not need to continue with this questionnaire.  Please return 
it in the stamped addressed envelope provided. 
 
 
2. Have you had your medicines use review (MUR) with your community pharmacist? 
 
Yes □  Continue to question 3 
 
No □ Why 
not?......................................................................................................... 
 
 
3. Has anyone else, other than your community pharmacist, reviewed your medication 
since you came out of hospital? 
 
Yes □ Who was 
this?................................................................................................ 
  Did you request the review?   Yes □ 
       No, they offered  □ 
No □  Continue to question 4 
 
 
4. Do you sometimes forget to take your medication? 
Yes □ No □ 
 
5. Over the past two weeks, were there any days when you did not take all of your 
medication?    
Yes □ No □ 
 
6. Have you ever cut back or stopped taking your medication without telling your 
doctor, because you felt worse when you took it?  
Yes □ No □ 
 
Please turn over 
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7. When you travel or leave home, do you sometimes forget to bring along your 
medications? 
Yes □ No □ 
 
8. Did you take all of your medication yesterday? 
Yes □ No □ 
 
9. When you feel like your health is good, do you sometimes stop taking your 
medicine? 
Yes □ No □ 
 
10. Taking medication every day is a real inconvenience for some people. Do you 
ever feel inconvenienced about sticking to your daily medication routine? 
Yes □ No □ 
 
11. How often do you have difficulty remembering to take all your medication?  
Circle one answer 
Never/rarely   4 
Occasionally   3 
Sometimes   2 
Often    1 
Every day   0 
 
For each of the following questions, please tick the one box that best 
describes your answer. 
 
12. In general, would you say your health is: 
 
 
 
 
 
 
Excellent Very good Good Fair Poor 
     
   1    2    3    4    5 
     
 3 
 
13. The following questions are about activities you might do during a typical day.  
Does your health now limit you in these activities?  If so, how much? 
 
14. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result of 
your physical health?  
 
 
15. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result of 
any emotional problems (such as feeling depressed or anxious)? 
16. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?  
Not at all A little bit Moderately Quite a bit Extremely 
     
   1    2    3    4    5 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
    
 a Moderate activities, such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf ..................  1 ............  
2 ....................................................................................  3 
 b Climbing several flights of stairs ...................................  1 ............  
2 ....................................................................................  3 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Accomplished less than you  
  would like .................................  1 ............  2 ............  3 ............  4 ...........  5 
 b Were limited in the kind of  
  work or other activities .............  1 ............  2 ............  3 ............  4 ...........  5 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Accomplished less than you  
  would like .................................  1 ............  2 ............  3 ............  4 ...........  5 
 b Did work or other activities 
  less carefully than usual ..........  1 ............  2 ............  3 ............  4 ...........  5 
Please turn over 
 4 
 
17. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer that 
comes closest to the way you have been feeling.  How much of the time during 
the past 4 weeks… 
 
 
18.  During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends, relatives, etc.)? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a   Have you felt calm and   
peaceful? .................................  1 ............  2 ............  3 ............  4 ...........  
5 
 b   Did you have a lot of energy? ..  1 ............  2 ............  3 ...........  4 ...........  
5 
 c   Have you felt downhearted   
and low? ..................................  1 ............  2 ............  3 ............  4 ...........  
5 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
     
   1    2    3    4    5 
 5 
 
19. As a result of your visit to the pharmacist for your Medicines Use Review (MUR), if 
you had one, do you feel you are…  
 Much better Better Same or less Not applicable 
Able to cope with your 
medication regimen  
_ 
    
Able to understand 
your medical 
conditions 
 
    
Able to understand 
your medications 
 
    
Able to keep yourself 
healthy _  
 
    
 
_ _ _ 
 Much more More Same or less Not applicable 
Confident about 
managing your 
medication _ 
 
    
Able to help yourself      
 
Thankyou completing this questionnaire!  Please return it in the stamped addressed 
envelope provided. 
 
Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license 
agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive 
South, Los Angeles, CA 90095-1772. 
SF-12v2® is a trademark of the Medical Outcomes Trust and is used under license.   
The SF-12v2® Health Survey is copyrighted by QualityMetric Incorporated 
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Appendix 21: Follow-up Questionnaire 2 
 
 
 
 
If you would prefer not to answer a particular question, you do not need to 
 
1.  Are you still managing your medication on your own at home? 
 
Yes □  Continue to question 2 
 
No □ Who helps you?......................................................................................... 
 
If you answered No, you do not need to continue with this questionnaire.  Please return 
it in the stamped addressed envelope provided. 
 
2. Has anyone reviewed your medication since you last heard from us? 
 
Yes □ Who was this?............................................................................................ 
 
Did you request the review?   Yes □ No, they offered  □ 
 
No □  Continue to question 3 
 
Not sure □ Continue to question 3 
 
3. Do you sometimes forget to take your medication? 
Yes □ No □ 
 
4. Over the past two weeks, were there any days when you did not take all of your 
medication?    
Yes □ No □ 
 
5. Have you ever cut back or stopped taking your medication without telling your 
doctor, because you felt worse when you took it?  
Yes □ No □ 
 
6. When you travel or leave home, do you sometimes forget to bring along 
your medications? 
Yes □ No □ 
 
7. Did you take all of your medication yesterday? 
Yes □ No □ 
 
8. When you feel like your health is good, do you sometimes stop taking your 
medicine? 
Yes □ No □ 
Please turn over 
 
9. Taking medication every day is a real inconvenience for some people. Do 
you ever feel inconvenienced about sticking to your daily medication routine? 
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Yes □ No □ 
 
10. How often do you have difficulty remembering to take all your medication?  
Circle one answer 
Never/rarely   4 
Occasionally   3 
Sometimes   2 
Often    1 
Every day   0 
 
11. In general, would you say your health is: 
 
Excellent Very good Good Fair Poor 
     
 
12. The following questions are about activities you might do during a typical day. 
Does your health now limit you in these activities? If so, how much? 
 
 
Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
 
 
 
a Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf    
 
 
 
b Climbing several flights of stairs 
   
 
 
13. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result of your 
physical health? 
 
 
All 
of the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
 
 
a Accomplished less than you would 
like      
 
 
 
b Were limited in the kind of work or 
other activities      
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14.  During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
 
All 
of the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
 
 
a Accomplished less than you would 
like      
 
 
 
b Did work or activities less carefully 
than usual      
 
 
15. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
 Not at all A little bit Moderately Quite a bit Extremely 
      
 
16. These questions are about how you feel and how things have been with you 
during the past 4 weeks. For each question, please give the one answer that comes 
closest to the way you have been feeling. 
How much of the time during the past 4 weeks... 
 
All 
of the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
 
 
a Have you felt calm and peaceful? 
     
 
 
 
b Did you have a lot of energy? 
     
 
 
 
c Have you felt downhearted and 
depressed?      
 
 
17. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting friends, relatives, 
etc.)? 
 
All 
of the time 
Most 
of the time 
Some 
of the time 
A little 
of the time 
None 
of the time 
      
 
Thankyou for completing this questionnaire!  Please return it in the stamped addressed 
envelope provided. 
Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license 
agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of 
Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive 
South, Los Angeles, CA 90095-1772. 
SF-12v2® is a trademark of the Medical Outcomes Trust and is used under license.   
The SF-12v2® Health Survey is copyrighted by QualityMetric Incorporated
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Appendix 22: Covering Letter Sent Out With Follow-up Questionnaire 1 
 
Southport and Formby District General 
Hospital 
Town Lane 
Kew 
Southport 
PR8 6PN 
 
Date 
First name Last Name 
Address Line 1 
Town Post code 
Dear Mr/Mrs Last Name, 
When you were in hospital a few weeks ago you agreed to take part in our 
‘Medicines Support Study’.  You will remember that we are trying to find out if 
having a Medicines Use Review (‘MUR’) with a community pharmacist helps 
people to manage their medicines after being in hospital.  People who agreed to 
participate in the research were randomly assigned to one of two groups.  One 
group were referred to their regular community pharmacist for an MUR after 
they had been discharged.  The other group were discharged as normal. 
 
Enclosed with this letter is the first of two follow-up questionnaires you agreed 
to complete as part of the study.  We ask that you complete the questionnaire 
as honestly as possible and return it to us in the stamped addressed envelope 
provided.   
 
Please do complete the questionnaire even if you have not had a medicines 
review  since leaving hospital as it will still help us to hear from you.   
 
We will send you the second (and final) questionnaire in five months’ time.  
After this your part in the study will be over. 
 
If you have any questions relating to the questionnaire or the study in general, 
please do not hesitate to contact me on 01704 704161 or 07932506802.  Thank 
you very much for being a participant in our study! 
 
Yours Sincerely, 
Helen Ramsbottom 
Pharmacist, Southport & Ormskirk NHS Trust 
Chief Researcher, Medicines Support Study 
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Appendix 23: Covering Letter Sent Out With Follow-up Questionnaire 2 
 
 
Southport and Formby District General 
Hospital 
Town Lane 
Kew 
Southport 
PR8 6PN 
 
Date 
 
First name Last Name 
Address Line 1 
Town Post code 
Dear Mr/Mrs Last Name, 
When you were in hospital 6 months ago you agreed to take part in our ‘Medicines 
Support Study’.  You will remember that we are trying to find out if having a 
Medicines Use Review (‘MUR’) with a community pharmacist helps people to 
manage their medicines after being in hospital.  People who agreed to participate in 
the research were randomly assigned to one of two groups.  One group were 
referred to their regular community pharmacist for an MUR after they had been 
discharged.  The other group were discharged as normal. 
Enclosed with this letter is the second follow-up questionnaire you agreed to 
complete as part of the study.  We ask that you complete the questionnaire as 
honestly as possible and return it to us in the stamped addressed envelope 
provided.   
 
After this your part in the study is over.  If you have any questions relating to the 
questionnaire or the study in general, please do not hesitate to contact me on 
01704 704161 or 07932506802.  Thank you very much for being a participant in 
our study! 
 
 
Yours Sincerely, 
Helen Ramsbottom 
Pharmacist, Southport & Ormskirk NHS Trust 
Chief Researcher, Medicines Support Study 
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Appendix 24: Reminder Letter: Follow-up Questionnaire 1 
 
 Southport and Formby District General 
Hospital 
Town Lane 
Kew 
Southport 
PR8 6PN 
 
Date 
 
First name Last Name 
Address Line 1 
Town Post code 
Dear Mr/Mrs Last Name, 
When you were in hospital a few weeks ago you agreed to take part in our 
‘Medicines Support Study’.  You will remember that we are trying to find out if 
having a Medicines Use Review (‘MUR’) with a community pharmacist helps 
people to manage their medicines after being in hospital.   
 
Two weeks ago we sent you the first of two follow-up questionnaires you agreed 
to complete as part of the study.  We have not yet received your completed 
questionnaire.  If you have returned your questionnaire to us within the last five 
days, you do not need to do anything else and can ignore this letter.  If you 
have not yet completed your questionnaire, it would be very helpful to us if you 
could do this now.  Enclosed with this letter is a second copy of the 
questionnaire in case you do not have the first.  We ask that you complete the 
questionnaire as honestly as possible and return it to us in the stamped 
addressed envelope provided.   
 
Please do complete the questionnaire even if you have not had a medicines 
review  since leaving hospital as it will still help us to hear from you.   
 
We will send you the second (and final) questionnaire in four and a half months 
time.  After this your part in the study will be over. 
 
If you have any questions relating to the questionnaire or the study in general, 
please do not hesitate to contact me on 01704 704161or 07932506802.  Thank 
you very much for being a participant in our study! 
 
Yours Sincerely, 
 
 
 
Helen Ramsbottom 
Pharmacist, Southport & Ormskirk NHS Trust 
Chief Researcher, Medicines Support Study 
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Appendix 25: Reminder Letter: Follow-up Questionnaire 2 
 
Southport and Formby District General 
Hospital 
Town Lane 
Kew 
Southport 
PR8 6PN 
 
Date 
 
First name Last Name 
Address Line 1 
Town Post code 
Dear Mr/Mrs Last Name, 
When you were in hospital just over 6 months ago you agreed to take part in our 
‘Medicines Support Study’.  You will remember that we are trying to find out if 
having a Medicines Use Review (‘MUR’) with a community pharmacist helps people 
to manage their medicines after being in hospital.  People who agreed to participate 
in the research were randomly assigned to one of two groups.  One group were 
referred to their regular community pharmacist for an MUR after they had been 
discharged.  The other group were discharged as normal. 
Two weeks ago we sent you the second of the two follow-up questionnaires you 
agreed to complete as part of the study.  We have not yet received your 
completed questionnaire.  If you have returned your questionnaire to us within 
the last five days, you do not need to do anything else and can ignore this letter.  
If you have not yet completed your questionnaire, it would be very helpful to us 
if you could do this now.  Enclosed with this letter is a second copy of the 
questionnaire in case you do not have the first.  We ask that you complete the 
questionnaire as honestly as possible and return it to us in the stamped 
addressed envelope provided.   
 
After this your part in the study is over.  If you have any questions relating to the 
questionnaire or the study in general, please do not hesitate to contact me on 
01704 704161 or 07932506802.  Thank you very much for being a participant in 
our study! 
 
 
Yours Sincerely, 
Helen Ramsbottom 
Pharmacist, Southport & Ormskirk NHS Trust 
Chief Researcher, Medicines Support Study 
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Appendix 26: Follow up interview – Control Group 
 
Introduction: When you were in hospital a few weeks ago you agreed to take 
part in a research study called the Medicines Support Study.  Today I’d like to 
ask you a few questions to see how things are going with you and your 
medication.  Is that OK? 
 
1) Thinking back to when you first came out of hospital, how did you feel 
about the information you were given to help you manage your 
medicines? 
 
Prompts: Did you feel that you had enough information to take your 
medicines as the doctors intended? 
 
If yes: Why was that? 
 
Who gave you the information? 
 
What information did they give you? (e.g. that a medicine had been 
stopped or had its dose changed, name of new medicines, what they 
were for, how to take them, side effects) 
 
How did they give it to you? (Was it written, through talking to you or 
both?) 
 
When were you given the information? 
 
If no: What do you think could have been improved? 
 
 
2) Are you still managing your medication on your own at home ( Prompt: 
or does someone else help you)? 
 
Yes    No 
 
If yes continue 
 
If no:  Who is helping you?  What do they do to help you with your medicines? 
 
 
3) Has anyone been through your medication with you since you came 
out of hospital? 
 
Yes    No 
 
If yes: Tell me about that 
 
Prompts:  Who was this? 
 
Did you ask them to look at your medication or did they offer? 
 
When did you have this review? 
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What advice did (they) give to help you take your medication? 
 
Have you changed anything about the way you take your medicines because of 
what (they) said? 
 
If yes, what are you doing differently now? 
 
If only some actions have been implemented, try to ascertain the reasons for 
this. 
 
a) Did you find the review useful? 
 
Yes    No 
 
Why / why not? 
 
 
4) Have you been to see your GP since coming out of hospital? 
(Participant diary can be used as a prompt) 
 
Yes    No 
 
If yes:  Will you tell me about that?  
 
Prompts  How many times have you been? 
 
When was/were the visit(s)?   
 
If you don’t mind telling me, what was the reason for each visit? 
 
 
5) Have you been back into hospital since you agreed to take part in the 
study? (Participant diary can be used as a prompt) 
 
Yes    No 
 
If yes: Tell me about that 
 
Prompts:  How many times? 
 
When was/were the visit(s)?  
 
If you don’t mind telling me, what was the reason for each visit? 
 
 
6) Is there anything else about your medication that you’d like to talk 
about? 
 
 
Do you have any other questions for me?  
 
Thank-you very much for taking part in our study.  Terminate interview 
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Appendix 27: Follow up interview – Intervention Group 
 
Introduction  When you were in hospital a few weeks ago you agreed to take 
part in a research study called the Medicines Support Study.  We referred you 
to your usual community pharmacy for a review of how you were managing your 
medication after being in hospital.  Today I’d like to ask you a few questions to 
see how things are going with you and your medication.  Is that OK? 
 
 
1) Thinking back to when you first came out of hospital, how did you feel 
about the information you were given to help you manage your 
medicines? 
 
Prompts: Did you feel that you had enough information to take your 
medicines as the doctors intended? 
 
If yes: Why was that? 
 
Who gave you the information? 
 
What information did they give you? (e.g. that a medicine had been 
stopped or had its dose changed, name of new medicines, what they 
were for, how to take them, side effects) 
 
How did they give it to you? (Was it written, through talking to you or 
both?) 
 
When were you given the information? 
 
If no: What do you think could have been improved? 
 
 
2) Are you still managing your medication on your own at home (Prompt: 
or does someone else help you)? 
 
Yes    No 
 
If yes continue 
 
If no:  Who is helping you?  What do they do to help you with your medicines? 
Why did you decide you needed help? 
 
 
3) Have you had your medicines review with your community 
pharmacist? 
 
Yes    No 
 
This information should be available to the researcher prior to interview through 
liaison with the community pharmacist.  Prompts can be given to participant as 
below: 
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If No: Is there a reason for that? 
 
 
If the participant wishes to withdraw from the study, explore reasons.  If 
participant still does not wish to take part, thank them for their time and 
terminate interview.  If participant now decides to take up offer of MUR, 
terminate interview and liaise with community pharmacist to arrange MUR. 
 
If the participant has been unable to access the community pharmacy: Would 
you be interested in having a pharmacist come to your home or telephone you 
to talk about your medicines if this was available? 
 
Then thank them for their time and terminate interview. 
 
If yes, ask the participant to fetch their copy of the MUR action plan.  If the 
patient does not have an action plan, document this.  The researcher should 
also have a copy that has been returned by the community pharmacist.   
 
b) What advice did the pharmacist give to help you with your medicines? 
 
c) Have you changed anything about the way you take your medicines 
because of what the pharmacist said? 
 
If yes, what are you doing differently now? 
 
If only some actions have been implemented, try to ascertain the reasons for 
this. 
 
d) Did you find the review useful? 
 
Yes    No 
 
Why / why not? 
 
 
4) Since your talk with the pharmacist, how have you found managing 
your medicines? 
 
Prompt:  Easier?  The same? More difficult? 
 
Why do you think this is? 
 
 
5) Has anyone else been through your medication with you since you 
came out of hospital? 
 
Yes    No 
 
 
If yes: Tell me about that 
 
Prompts:  Who was this? 
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Did you ask them to look at your medication or did they offer? 
 
When did you have this review? 
 
What advice did (they) give to help you take your medication? 
 
Have you changed anything about the way you take your medicines because of 
what (they) said? 
 
If yes, what are you doing differently now? 
 
If only some actions have been implemented, try to ascertain the reasons for 
this. 
 
e) Did you find the review useful? 
 
Yes    No 
 
Why / why not? 
 
 
6) Have you been to see your GP since coming out of hospital? 
(Participant diary can be used as a prompt) 
 
Yes    No 
 
If yes:  Will you tell me about that?  
 
Prompts  How many times have you been? 
 
When was/were the visit(s)?  Before or after your medicines 
review with the community pharmacist? 
 
If you don’t mind telling me, what was the reason for each visit? 
 
 
7) Have you been back into hospital since you agreed to take part in the 
study? (Participant diary can be used as a prompt) 
 
Yes    No 
 
If yes: Tell me about that 
 
Prompts:  How many times? 
 
When was/were the visit(s)? Before or after your medicines review with the 
community pharmacist? 
 
If you don’t mind telling me, what was the reason for each visit? 
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8) Is there anything else about your medication that you’d like to talk 
about? 
 
 
I would like to leave this questionnaire with you.  Fill it in as soon as you are 
ready and return it to us using the stamped addressed envelope inside. 
 
Do you have any other questions for me?  
 
Thank-you very much for taking part in our study.  Terminate interview 
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Appendix 28: Hospital Pharmacist Focus Group Information Leaflet 
 
 
 
 
 
What is a focus group? 
A focus group is an in-depth, open-ended group discussion that explores a specific set of issues 
on a pre-defined topic.  The group is conducted under the guidance of a facilitator. 
 
What is the purpose of this focus group? 
Between one-third and half of all medicines for long term conditions are not taken as 
recommended.  Following a medication routine after being in hospital is particularly difficult as 
nearly two thirds of people have three or more medicines changed during a hospital stay and 
almost half experience an error with their medication on discharge. 
 
We are currently investigating the feasibility of setting up a referral process from hospital to 
community pharmacy for post discharge Medicines Use Reviews (MURs).   A key objective of 
this is the identification of patients who may benefit from the service, whilst they are still in 
hospital.  The aim of the transfer of care focus group is to explore the views of hospital 
pharmacists and technicians on issues such as: 
 The benefits and drawbacks of post-discharge MURs 
 How able you feel to identify and refer suitable patients 
 What would need to happen to take the service forward 
 What else could be done to improve medicines management on transfer of care 
 
Why should I take part? 
The Department of Health states that referral of suitable patients for post discharge MURs 
should be an integral part of the medicines pathway.   However no additional resources have 
been made available to hospitals to identify patients who may benefit from such a service, nor 
have any formal mechanisms for referral been established.  The MUR service as a whole has 
attracted criticism, with some claiming it is being used more for profit than for patient benefit.  
Focus groups with community pharmacists on the subject of transfer of care have been 
published but the views and experiences of hospital pharmacists seem to have been less widely 
studied. 
 
This session allows you to express in your own words what you think of the current transfer of 
care service provided at Southport And Ormskirk NHS Trust, exchange opinions and ideas for 
improvement with your collegues and hear other people’s experiences and suggestions.  This 
technique can be used to solve problems and improve services, with the overall objective of 
improving patient care. 
 
What will happen if I decide to take part? 
Participation in the focus group is entirely voluntary.  You will be asked to sign a consent form 
before the session begins.  The session will last about 45 minutes and will be facilitated by 
Helen Ramsbottom, clinical pharmacist and lead researcher on the study.  The topics mentioned 
above will be introduced by the facilitator and you will be encouraged to express your opinions 
and discuss them with the other participants in the session.  Personal experiences, suggestions 
and insights are welcome!  You are encouraged to respond to or challenge the views of other 
participants but we ask that you do so in a professional and respectful manner. 
 
The session will be audio-recorded, and quotes may be used in the written report.  However no-
one will be able to identify you from the report and all quotes will be anonymous.  If at any point 
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during the discussion you would like a break or wish to leave the group, you may do so without 
providing a reason.  If you do not want your data to be used, just tell the facilitator afterwards. 
 
What will happen to the data I provide? 
The recording of the session will be transcribed and analysed and the information used to 
improve the medicines support patients get on transfer of care.  The results will be included in 
the researcher’s PhD thesis and may also be made available to a peer reviewed journal. 
 
Contact for Further Information: 
 
If you have any questions about the study before deciding to take part, please contact the lead 
investigator, Helen Ramsbottom, or the university supervisors, who will be pleased to help you: 
 
Helen Ramsbottom    Professor Ray Fitzpatrick/ Dr Paul Rutter 
(Supervisors) 
Pharmacy Department    Pharmacy Practice Division 
Southport District General Hospital  Department of Pharmacy 
Town Lane     School of Applied Sciences 
Kew, Southport     University of Wolverhampton 
PR8 6PN     Wulfrana Street, WV1 1LY 
Tel: 01704 704161/07932506802  Tel: 01902 322173 
Email: helen.ramsbottom@nhs.net Email: ray.fitzpatrick@wlv.ac.uk / paul.rutter@wlv.ac.uk 
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Appendix 29: Hospital Pharmacist Focus Group Consent Form  
 
 
 
 
Study Number:2012/028 SISD 
Chief Researcher: Helen Ramsbottom 
 
Informed Consent Form: Transfer of Care Focus Group 31st July 2014 
 
If you have read the information about the session and are willing to participate please 
complete and sign this form, and return it to Helen Ramsbottom, focus group facilitator 
and lead researcher. 
Please initial each box 
I have read and understood parts the information sheet dated July 2014 
(version 1) for the Transfer of Care Focus Group. 
 
I have had the opportunity to ask questions about the study and have had them 
answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving a reason. 
 
I agree to the interview being audio recorded, and to anonymous quotes being 
used in the study report. 
 
I agree to take part in the focus group  
 
Name of participant: 
 
Date: Signature: 
Name of person taking consent: Date: Signature: 
When complete copy: 1 for participant, 1 (original) to be kept in study file 
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Appendix 30: Hospital Pharmacist Focus Group Topic Guide 
 
Transfer of Medicines Related care from hospital back into primary care 
What problems have you experienced with transfer of medicines related care 
from hospital back into community? 
Prompt: Could be before/after discharge or when patients are readmitted 
Communication with GP / community pharmacy / patient /carer 
 
Post Discharge MURs – Opinions of Hospital Pharmacy Staff 
What do you think are the benefits or drawbacks of post-discharge MURs? 
Prompt: For patient/community pharmacy/GP 
 
Is it a good idea for hospital pharmacy staff to refer patients for post-discharge 
MURs?  Why / why not? 
 
Barriers to Implementation of Service 
What factors make it harder to identify suitable patients to refer for a post 
discharge MUR? 
Prompt: Time/acute illness 
 
Enablers for Implementation of Service 
What makes or could make it easier to identify patients or get them referred? 
 
What do you think needs to happen to make referrals commonplace?  (If this is 
considered appropriate) 
Prompt: Manpower? / SOPs? /IT? 
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Appendix 31: Hospital Pharmacist Questionnaire 
 
 
Hospital Pharmacy - Post Discharge Medicines Use Review (DMUR) Questionnaire 
Your Views About the DMUR Referral Service 
I would like to ask for your help in my evaluation of the feasibility of a post discharge MUR 
referral service from hospital to community pharmacy.  The results of the questionnaire are 
confidential and will be used to help interpret the data collected during my feasibility study, 
which, if successful, could become a model for other hospitals to implement.  I am interested 
in your opinion of the service, particularly of your own involvement.  The questionnaire should 
take 10-15 minutes to complete.   When you have completed the questionnaire, please return 
it to me (Helen Ramsbottom) by placing it in my tray in the fishbowl. 
 
1. What is your current AfC banding at the hospital pharmacy? 
a. Band 6  ⃝ 
b. Band 7   ⃝ 
c. Band 8a  ⃝ 
d. Band 8b or above ⃝ 
 
2. What best describes your patient facing role? 
a. Non-specialist /rotational ⃝ 
b. Specialist   ⃝ 
c. Other (please specify)………………………………………………………………………………………………………. 
 
3. Approximately how many patients did you identify for a possible post discharge Medicines 
Use Review (DMUR) in a typical month? 
a. 0  ⃝ 
b. 1-5  ⃝ 
c. 6-10 ⃝ 
d. 11-15 ⃝ 
e. 16-20 ⃝ 
f. >20  ⃝ 
If you did not identify any patients, please can you tell us why? 
………………………………………………………………………………………………………………………………………………. 
………………………………………………………………………………………………………………………………………………. 
 
 
4. For what reasons did you refer patients to the DMUR service? (Please tick all that apply) 
a. Risk of poor adherence    ⃝ 
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b. High risk drug prescribed    ⃝ 
c. Specific patient groups (e.g. cardiac)  ⃝ 
d. Pre-admission medication stopped in hospital ⃝ 
e. New medication started in hospital   ⃝ 
f. Change of dose of medicine/s   ⃝ 
g. Patient request for information on medicines ⃝ 
h. Other (please specify) 
………………………………………………………………………………………………………………… 
 
 
5. Each of the issues below may represent a barrier to hospital pharmacy’s involvement in 
referring patients for DMURs.  For each, please tick the  box that most closely represents 
your view 
 
Key:  
1 = Not a barrier 
2 = Occasional barrier 
3 = A barrier about half of the time 
4 = Major barrier 
5 = Always a barrier  
1 2 3 4 5   
a. Difficulty identifying suitable patients ⃝ ⃝ ⃝ ⃝ ⃝           
 
b. Remembering to try to identify  ⃝ ⃝ ⃝ ⃝ ⃝                                               
patients to refer 
 
c. Patient  refusal to participate                    ⃝ ⃝ ⃝ ⃝ ⃝ 
 
d. Time pressures    ⃝ ⃝ ⃝ ⃝ ⃝ 
 
e. Patient stay in hospital too short to                ⃝ ⃝ ⃝ ⃝ ⃝                                                                                     
identify them as suitable 
        
f. Difficulty in identifying patients’ usual           ⃝ ⃝ ⃝ ⃝ ⃝                                                                                                      
community pharmacy  
  
g. Having to complete a referral form  ⃝ ⃝ ⃝ ⃝ ⃝ 
 
h. Lack of recognition for extra work                ⃝ ⃝ ⃝ ⃝ ⃝      
                                                                                                                 
i. Lack of IT infrastructure for communicating ⃝ ⃝ ⃝ ⃝ ⃝                                         
information to community pharmacy 
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6. Please state any other barriers you can think of that affected the delivery of the DMUR 
referral service 
…………………………………………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………………………………………… 
 
7. The list below contains some solutions to address the potential barriers to the delivery of a 
DMUR referral service.  For each, please tick the  box that most closely represents your 
view  
Key 
1 = Would not improve delivery   
2 = Slight improvement 
3 = Substantial improvement 
4 = Major improvement 
1 2 3 4    
a. Send discharge information electronically   ⃝ ⃝ ⃝ ⃝  
to community pharmacy 
 
b. Improve documentation of changes to medication ⃝ ⃝ ⃝ ⃝                                                            
on discharge summaries 
 
c. Greater promotion of DMURs to patients  ⃝ ⃝ ⃝ ⃝                                                    
while in hospital  
 
d. Greater promotion to patients in the   ⃝ ⃝ ⃝ ⃝                                   
community pharmacy 
 
e. Better communication of concept of DMUR  ⃝ ⃝ ⃝ ⃝                                                      
referral to hospital pharmacy staff 
 
f. Greater promotion of DMURs to ward  staff  ⃝ ⃝ ⃝ ⃝                                             
 
g. Investment in staff to free up time for  ⃝ ⃝ ⃝ ⃝  
pharmacists to do MUR referrals    
 
h. Focus on specific patient groups initially  ⃝ ⃝ ⃝ ⃝ 
 
i.  Feedback to hospital pharmacy about  ⃝ ⃝ ⃝ ⃝                                                 
actions arising from DMURs in community 
 
j. Compulsory patient registration with a  ⃝ ⃝ ⃝ ⃝          
named community pharmacy  
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8. Please state any other solutions you can think of 
………………..……………………………………………………….…………………………………………………………………
……………………………………………………………………………..………….…………………………………………………
……………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………... 
 
9. The list below contains some statements about DMUR referrals.  Please indicate your level 
of agreement/disagreement for each of the statements using the scale below: 
Key 
1 = Strongly disagree  
2 = Disagree 
3 = neither disagree nor agree  
4 = Agree  
5 = Strongly agree 
 1 2 3 4 5   
      
a. DMUR referrals will help patients to manage             ⃝ ⃝ ⃝ ⃝ ⃝                                                                                          
their medicines better after being in hospital   
 
b. DMURs will allow adherence problems and   ⃝ ⃝ ⃝ ⃝ ⃝       
medication errors to be identified and  
resolved sooner  
 
c. Time spent on the MUR referral process takes ⃝ ⃝ ⃝ ⃝ ⃝                                  
hospital pharmacists away from other patients 
 
d. The lack of reimbursement for hospital pharmacy ⃝ ⃝ ⃝ ⃝ ⃝                                        
puts me off  providing the service 
 
e. DMUR referrals help foster better working  ⃝ ⃝ ⃝ ⃝ ⃝                               
relationships with community pharmacies 
 
f. The service is not yet ingrained in the daily  ⃝ ⃝ ⃝ ⃝ ⃝               
work of a ward pharmacist 
 
g. The patient’s priority is to get home from  ⃝ ⃝ ⃝ ⃝ ⃝                                       
hospital; so it is hard to engage them in the                                               
DMUR scheme 
 
 5 
 
10. Please summarise your opinion of the pilot DMUR referral service at Southport and 
Ormskirk NHS Trust below 
 
…………………………………………………………………………………………………………………………………………… 
 
…………………………………………………………………………………………………………………………………………… 
 
…………………………………………………………………………………………………………………………………………… 
 
Thank you for completing this questionnaire.  Please return it to Helen Ramsbottom, 
Pharmacy department, Southport District General Hospital  
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Appendix 32: Community Pharmacist Questionnaire 
 
 
Community Pharmacy - Post Discharge Medicines Use Review (DMUR) Questionnaire 
Thank you for taking part in our study of a DMUR referral service.  To help us understand 
our results, we would be very grateful if you would take a few minutes to answer the 
questions below.  Completed forms should be returned using the details below. 
 
Question 1: Concerns the referrals sent to you by the hospital: 
a. They contained all the information I needed to conduct the MUR  ⃝ 
 
b. More information would have been useful regarding: (tick as many as apply) 
i) The discharge medication regimen    ⃝ 
ii) Reasons for changes made to pre-admission medication   ⃝ 
iii) Indications for new medications started     ⃝ 
iv) Adherence support needs of the patient post discharge   ⃝ 
v) Patient contact details                    ⃝ 
vi) Other (please specify below) 
……………………………………………………………………………………………………………………… 
c. I do not remember receiving any referrals (go straight to Question 4) ⃝ 
    
 
Question 2: Concerns the suitability of the patients 
a.  All patients referred to me were suitable for an MUR     ⃝ 
  
b. One or more patients were unable to engage fully in the MUR because: (tick 
as many as apply) 
 i) They were unable to attend in person     ⃝ 
ii) They were no longer self-administering their medication  ⃝ 
iii) They no longer wished to receive an MUR    ⃝ 
ii)  They were already fully informed regarding their medicines  ⃝  
v)  I was unable to contact them using the details available  ⃝ 
vi) They did not attend their arranged MUR    ⃝ 
vi) Other (please specify below) 
……………………………………………………………………………………………………………… 
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Question 3: How long, on average, did it take to conduct a DMUR as part of the study? 
a. Less than 20 minutes      ⃝  
b. 20 – 39 minutes      ⃝ 
c. 40 - 59 minutes      ⃝ 
d. 60 minutes or more      ⃝ 
 
Question 4: Have you done any DMURs since 6th April 2014 that were not a part of this 
study? 
 
a. No    ⃝ 
b. Yes, 1- 5   ⃝ 
c. Yes, 6-10   ⃝ 
d. Yes, 11-15   ⃝ 
e. Yes, 16-20   ⃝ 
f. Yes, more than 20  ⃝ 
 
If you have done any DMURs that were not a part of the study, please write a few words 
below about how you identified the patients involved. 
 
………………………………………………………………………………………………………………………………………… 
 
………………………………………………………………………………………………………………………………………… 
 
………………………………………………………………………………………………………………………………………… 
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Question 5: The list below contains some statements about DMUR referrals in general.  Please 
indicate your level of agreement/disagreement for each of the statements using the scale 
below: 
Key 
1 = Strongly disagree  
2 = Disagree 
3 = Neither disagree nor agree  
4 = Agree  
5 = Strongly agree 
 1 2 3 4 5   
      
a. DMUR referrals will help patients to manage             ⃝ ⃝ ⃝ ⃝ ⃝                                                                                          
their medicines better after being in hospital   
 
b. DMUR referrals will allow adherence problems  ⃝ ⃝ ⃝ ⃝ ⃝       
to be identified and resolved sooner  
 
c. DMUR referrals will allow medication errors  ⃝ ⃝ ⃝ ⃝ ⃝       
to be identified and resolved sooner  
 
d. DMUR referrals help foster better working  ⃝ ⃝ ⃝ ⃝ ⃝                               
relationships with hospital pharmacists 
 
e. DMURs are more complex than   ⃝ ⃝ ⃝ ⃝ ⃝               
other types of MUR 
 
f. It is hard to engage patients in DMURs  ⃝ ⃝ ⃝ ⃝ ⃝              
  
 
Please add any other comments regarding the referral process or post-discharge MURs 
in general 
 
………………………………………………………………………………………………………….……………………………… 
 
………………………………………………………………………………………………………………………………………… 
 
………………………………………………………………………………………………………….……………………………… 
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Thank you very much for completing this questionnaire.  Please return it to: 
 
Helen Ramsbottom     
Pharmacy Department     
Southport District General Hospital   
Town Lane      
Kew, Southport      
PR8 6PN      
Tel: 01704 704161 
Fax: 01704 704197     
Email: helen.ramsbottom@nhs.net 
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Appendix 33: Criteria Used During Case note Analysis of Readmissions  
Criteria used for assessing causality of suspected medication-related problems 
(61,62) 
1) Known adverse drug reaction, toxic reaction, response to omission of treatment or 
inadequate treatment 
2) Reasonable temporal relationship between commencement or cessation/omission 
of treatment and onset of problem 
3) Risk of further problems likely to be reduced by dose reduction or increase, 
discontinuation, closer monitoring or commencement of treatment 
4) Not explained by any other known condition of predisposition to the patient, or This 
condition/predisposition is likely to be exacerbated by the presence/absence of the 
drug 
5) For drug toxicity (1 out of): 
 Symptoms reappeared upon re-exposure 
 Laboratory tests showed toxic drug levels or drug-induced metabolic 
disturbances that explained the symptom 
 Symptoms resolved on dose reduction or discontinuation of the drug 
For drug omission: 
 Symptoms resolved upon re-introduction of the drug or dose increase 
If five criteria fulfilled, then definite.  
If four criteria fulfilled, then probable.  
If three criteria fulfilled, then possible.  
If two or fewer criteria fulfilled, then either not drug-related or unevaluable. 
 
Criteria used for classification of medication-related problems (61,215) 
Class Definition 
1 Inappropriate prescribing 
2 Inappropriate delivery (drug unavailable when needed, incorrect formulation, 
failure to administer, dispensing error) 
3 Non-compliance by patient 
4 Patient idiosyncrasy (response to drug, mistake or accident)  
5 Inappropriate monitoring 
6 Potentially preventable with interventions which are not standard care at 
present 
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Criteria used for assessing preventability of medication-related problems 
(61,215) 
1) Drug-related morbidity (DRM) preceded by a recognisable drug therapy problem 
(DRP) 
2) Given the DRP, the DRM would have been reasonably foreseeable 
3) The cause of DRM would have been identifiable with reasonable probability (above 
criteria probable or definite for causality) 
4) The cause of the DRM could have been reasonably controllable within the context 
and objectives of therapy 
 
Criteria used for assessing the contribution of medication-related problem to 
hospital admission (61,62) 
Score Category Definition 
3 Dominant The suspected symptoms were the main reason for   
admission, and no other symptoms contributed significantly 
2 Partly 
contributing 
The suspected symptoms played a substantial role in 
admission, but other factors also contributed 
significantly 
1 Less 
important 
The suspected symptoms played a minor or uncertain role, 
and the patient would probably have been admitted without 
them 
0 Not 
contributing 
Other symptoms/circumstances were the reason for 
hospitalisation 
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Appendix 34: Significance Scoring of Community Pharmacist 
Interventions during Post Discharge Medicines Use Reviews: Round 1 
Below is a list of 30 interventions made during post discharge Medicines Use 
Reviews (dMURs) by community pharmacists.  For the purposes of this 
exercise, an intervention is classed as any action taken or piece of advice given 
to the patient during the dMUR, as reported by the community pharmacists who 
undertook the dMURs. 
For each of the interventions described, please assign the score which you 
believe most closely represents the most likely outcome for the patient (not the 
best or worst case scenario).  Space is provided for any comments you wish to 
add regarding the reasons for your choice, or any other information you feel is 
relevant to the interpretation of the significance of the intervention. 
Note: An intervention scoring ‘3’ is one where a recommendation was made by 
the pharmacist to the patient’s GP but not actioned by the GP, and therefore did 
not make any difference to the patient’s care, whatever its potential significance 
may have been 
Intervention type Score 
Intervention which is detrimental to the patient’s well-being 1 
Intervention is of no significance to patient care 2 
Intervention is significant but does not lead to an 
improvement in patient care 
3 
Intervention is significant and results in an improvement in 
the standard of care 
4 
Intervention is very significant and prevents a major organ 
failure or adverse event of similar importance (e.g. 
hospitalisation for worsening clinical condition) 
5 
Intervention is potentially life-saving 6 
 
List of Interventions 
1. Patient discharged after acute coronary syndrome struggling to remember to 
take medicines as prescribed.  Community pharmacist organised blister 
packs 
 
Score:………………………………. 
 
Extra comments: 
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2. Patient having difficulty with co-ordination of metered dose inhaler device.  
Patient not keen on breath actuated device so community pharmacist 
requested spacer from GP (Unknown if spacer was actually provided) 
 
Score:………………………………. 
 
Extra comments: 
 
 
3. Patient discharged with atrial fibrillation newly prescribed antiarrythmics and 
warfarin. Struggling to remember if she has taken all medication so 
community pharmacist provided medicine administration record (MAR) sheet 
 
Score:………………………………. 
 
Extra comments: 
 
 
4. Community pharmacist explained to patient the system for obtaining future 
prescriptions following discharge after a stroke 
 
Score:………………………………. 
 
Extra comments: 
 
 
5. Patient had been buying antihistamine to help with skin itching.  Community 
pharmacist suggested GP add this to repeat prescription (Actioned by GP) 
 
Score:………………………………. 
 
Extra comments: 
 
 
6. Clopidogrel prescribed during admission for acute coronary syndrome for a 
patient already taking warfarin.  Patient unsure of indication, and whether 
clopidogrel will be long term.  Community pharmacist liased with hospital 
pharmacy to find answer (Clopidogrel to be discontinued after 12 months) 
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Score:………………………………. 
 
Extra comments: 
 
7. Community pharmacist discussed indication for new medication (betahistine) 
and how to obtain further supplies.   
 
Score:………………………………. 
 
Extra comments: 
 
8. Community pharmacist provided information on newly initiated furosemide - 
indication (heart failure) and how to take to manage side effects, for example 
can take at lunchtime instead of in morning if need to go out in morning, 
rather than skipping dose altogether to avoid polyuria (previous poor 
compliance) 
 
Score:………………………………. 
 
Extra comments: 
 
9. Community pharmacist explained indication for new medicine (finasteride 
5mg od). 
 
Score:………………………………. 
 
Extra comments: 
 
 
10.  Patient prescribed iron supplements during admission and noticed dark 
stools following discharge.  Community pharmacist reassured patient that 
darkened stools whilst taking iron supplements is normal 
 
Score:………………………………. 
 
Extra comments: 
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11. Community pharmacist reinforced counselling on apixaban (replacement for 
warfarin) as patient unsure of reason for switch and why blood tests no 
longer required 
 
Score:……………………………… 
 
Extra comments: 
 
12. Healthy living advice given re diet and physical activity to patient with angina 
 
Score:………………………………. 
 
Extra comments: 
 
13. Patient is a current smoker despite diagnosis of COPD.  Community 
pharmacist provided smoking cessation advice (unknown if acted on) 
 
Score:………………………………. 
 
Extra comments: 
 
14. Patient unsure of how to take some medicines and reasons for taking 
(patient has angina, diabetes and chronic kidney disease stage 3B).  
Community pharmacist reinforced times of day to take them and indications 
 
Score:………………………………. 
 
Extra comments: 
 
 
15. Patient taking simvastatin in the morning.  Community pharmacist explained 
rationale for evening dosing and patient changed time of dose 
 
Score:………………………………. 
 
Extra comments: 
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16. Lansoprazole removed from blister pack following discussion with patient to 
facilitate administration on empty stomach 
 
Score:………………………………. 
 
Extra comments: 
 
17.  Aspirin not being dispersed as blister packed and patient could not identify 
it.  Removed from blister pack by community pharmacy to aid identification 
 
Score:………………………………. 
 
Extra comments: 
 
18. Patient with osteoporosis not always taking Cacit due to forgetfulness. 
Community pharmacist discussed with patient and son, who will now help 
her remember to take it 
 
Score:………………………………. 
 
Extra comments: 
19. Patient not taking senna regularly but still 'very constipated'.  Pharmacist 
advised to try taking regularly 
 
Score:………………………………. 
 
Extra comments: 
 
 
20. Patient had restarted isosorbide mononitrate which had been stopped during 
admission due to low blood pressure.  This medicine was also still on repeat 
prescription.  Pharmacist liaised with GP and isosorbide was discontinued. 
 
Score:………………………………. 
 
Extra comments: 
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21. Gabapentin still on current record at pharmacy.  Community pharmacist 
ascertained that this had been discontinued and records updated to prevent 
re-ordering 
 
Score:………………………………. 
 
Extra comments: 
 
 
22. Colecalciferol increased during admission.  Community pharmacist updated 
their records accordingly 
 
Score:………………………………. 
 
Extra comments: 
 
23.  Bisoprolol stopped in hospital but no indication as to why.  Re-issued by 
GP.  Community pharmacist liaised with GP surgery to clarify situation.  
(Bisoprolol to continue) 
 
Score:………………………………. 
 
Extra comments: 
 
 
24. Patient presented prescription for pre-admission medication which was 
identified by community pharmacist due to information provided with dMUR 
referral from hospital pharmacy.  Prescription referred back to GP surgery.  
(Diuretic had been changed from bendrofluazide to furosemide, perindopril 
dose increased and warfarin and bisoprolol started) 
 
Score:………………………………. 
 
Extra comments: 
 
25.  Community pharmacist asked GP to consider whether patient appropriate 
for steroid inhaler due to recent discharge following exacerbation of COPD 
requiring antibiotics and steroids.  (Patient had been on no regular inhalers 
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prior to admission although reported having been on inhaled steroids in the 
past.  She had been discharged on salbutamol and tiotropium) 
 
Score:………………………………. 
 
Extra comments: 
 
26. Patient started on warfarin during recent admission.  Community pharmacist 
noticed INR had risen from 1.5 to 2.5 in 7 days with no dose change and 
patient had later seen blood after going to toilet.   Pharmacist arranged INR 
clinic appointment the next day. 
 
Score:………………………………. 
 
Extra comments: 
 
 
27. Pharmacist advised patient to consult GP if dizziness symptoms return, for 
review of blood pressure medicines (postural drop in blood pressure had 
been evident during admission) 
 
Score:………………………………. 
 
Extra comments: 
 
 
28. Blood pressure medicines reduced in hospital.  Community pharmacist re-
checked blood pressure and it was 80/44mmHg.  Pharmacist told patient to 
see GP. 
 
Score:………………………………. 
 
Extra comments: 
 
29. Amlodipine stopped in hospital as perindopril had been started and blood 
pressure controlled by this.  Patient started taking amlodipine again post-
discharge.  Pharmacist referred patient to GP. 
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Score:………………………………. 
 
Extra comments: 
 
 
30. Patient taking metformin and Novomix 30 insulin for diabetes was altering 
dose of metformin depending on blood sugars.  Pharmacist advised this is 
not the correct way to manage their readings and advised patient to ring 
diabetes nurse for review. 
 
Score:………………………………. 
 
Extra comments: 
 
Thank-you for completing this review of dMUR interventions.  Please email the 
completed document to helen.ramsbottom@nhs.net or post to Helen 
Ramsbottom, Pharmacy Department, Southport and Ormskirk NHS Trust, Town 
Lane, Kew, Southport PR8 6PN 
We will be back in touch in the next 2-3 weeks with some feedback on the 
results of this round of scoring and instructions for the next stage of the analysis 
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Appendix 35: Coding Framework Used During Analysis of Qualitative 
Participant Interviews 
 
1. Information / Advice re medication given in hospital 
a. Amount 
b. Nature 
c. Medium (e.g. written/verbal) 
d. Person(s) giving 
e. Timing 
f. Perceived utility 
g. Participant (pt) recall of advice 
h. General attitude of pt towards advice given and reasons for holding 
this view 
i. Offered by staff or requested by pt/family 
j. Person receiving (pt / family) 
k. Information deficits from hospital as perceived by pt 
i. Nature of deficit 
ii. Attitude towards this (e.g. in relation to expectations/perceived 
need) 
iii. Action taken (if any) since discharge to resolve deficit 
l. Reasons for different perceptions 
i. Prior level of knowledge 
ii. (Perceived) simplicity of changes 
iii. Nature of change e.g. greater information need perceived for 
addition of new medicines than over discontinuation of pre-
admission meds 
 
2. Transfer of care issues surrounding medicines 
a. Nature of problem 
b. Cause 
c. Preventability 
 
3. Contact with healthcare professionals (HCP) since discharge 
a. Initiation (pt/HCP) 
b. Location 
c. HCP involved 
d. Timing 
e. Reason (e.g. test/procedure, general review) 
f. Patient attitude (e.g. appointment fatigue) 
 
4. Medication support (other than dMUR) since discharge 
a. Medication review by HCP 
b. Advice re specific medicines (e.g. anticoagulant clinic) 
c. GP surgery medicines management staff 
d. Family 
e. Other contact with community pharmacy 
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5. Barriers to medication adherence 
a. Memory 
b. Manual dexterity 
c. Misunderstanding of complex dosing instructions 
d. Side effects 
e. Eyesight 
f. Pre-existing beliefs 
 
6. Medicines management systems at home 
a. Nature 
b. Initiation (e.g. by pt/family) 
 
7. Discharge Medicines Use Review (dMUR) 
a. Intervention group 
i. Completion (and reasons for non-completion) 
ii. Attendees (e.g. pt alone, pt and relative/carer) 
iii. Action plan 
iv. Method of organisation (e.g. arranged via telephone / 
‘opportunistic’ when pt in pharmacy) 
v. Content of consultation 
vi. Duration? 
vii. Supporting materials (e.g. written advice, compliance aids) 
viii. Pt / carer recall of consultation 
ix. Changes to medication/health related behaviour following 
dMUR 
x. Perceived utility to pt / carer 
xi. Factors influencing utility (e.g. level of information obtained 
from hospital) 
xii. Utility to community pharmacist e.g. information supplied by pt 
may be useful in updating PMR and reducing later prescribing / 
dispensing errors 
xiii. General attitude and reasons 
xiv. Changes to medication post discharge: timing in relation to 
dMUR (may cause confusion?) 
 
b. Control group 
i. Perception of whether dMUR would have been useful 
 
c. Both groups 
i. Barriers to dMUR 
 
8. General attitudes towards community pharmacy 
a. Positive/negative 
b. Reasons for holding this view 
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c. Knowledge of role of community pharmacist 
d. Reasons for using community pharmacy 
 
9. Residual information needs surrounding medication 
a. dMUR completers vs non-completers/controls 
b. Nature 
i. Specific to medication changes in hospital 
ii. Relating to pre-existing medication 
iii. Relating to subsequent medication changes 
iv. OTC medications 
 
Methodological Themes 
1. Difficulty in discussing particular topics 
a. Topic (e.g. medicines information given by hospital) 
b. How demonstrated 
i. Brief answers 
ii. Pauses 
c. Underlying reasons 
 
2. Digression of interviewer into HCP role 
a. Trigger/prompt 
i. In response to direct question or issue raised by patient 
b. Nature 
i. Supporting information re medicines 
ii. Management of side effects 
c. Participant subgroups where digression occurred (ie MUR vs non-
MUR completers vs control group pts) 
d. Possible effect on outcomes 
 
3. Difficulty of participants with completing questionnaire 
a. Comprehension in pts with mild cognitive impairment 
b. Eyesight (font size too small) 
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Appendix 36: Coding Index for Hospital Pharmacist Focus Group 
1. Problems with current procedure for transfer of medicines related care 
 
a. Poor documentation of medicines changes on current discharge 
prescriptions 
 Exacerbated by limitations of the e-prescribing system 
Leading to ambiguity over whether medicines have changes/what the 
changes are 
b. Timeliness of information transfer to primary care records 
 
2. Positive attitudes to / benefits of post discharge medicines use review 
(DMUR) referral 
 
a. General 
b. Picking up on side effects 
c. Promoting concordance in medicine taking 
d. Reinforcement of advice given in hospital 
e. Allow community pharmacists to pro-actively work with GPs to ensure 
changes are actioned, particularly for patients using monitored dosage 
systems (MDS) 
 
3. Barriers to DMUR referral service 
 
a. Lack of familiarity with community pharmacy services/potential 
b. Time taken to refer patients 
c. Funding 
d. Patient engagement/suitability 
e. Establishing a patient’s regular chemist 
f. Lack of integration of DMUR referrals with current practice in hospital 
pharmacy 
g. Rapid turnover of patients 
h. Negative attitudes towards extra work required to make DMUR referrals 
i. Consent/information governance issues 
j. Perceived barriers from community pharmacy 
 
4. Solutions for DMUR referral service 
 
a. Better use of IT 
b. Integration of referral process into established activities of hospital 
pharmacy 
 
5. Priority/Target groups for referral for DMUR 
 
a. Patients prescribed new medicines / high risk medicines 
b. Cardiac patients 
c. Pros and cons of targeting particular patient groups to refer 
 
 
